

# Reduction Potentials of One-Electron Couples Involving Free Radicals in Aqueous Solution

Peter Wardman

Gray Laboratory of the Cancer Research Campaign, Mount Vernon Hospital, Northwood Middlesex HA6 2JR, United Kingdom

Received July 18, 1988; revised manuscript received April 4, 1989

Reduction of an electron acceptor (oxidant),  $A$ , or oxidation of an electron donor (reductant),  $A^{2-}$ , is often achieved stepwise *via* one-electron processes involving the couples  $A/A\cdot^-$  or  $A\cdot^-/A^{2-}$  (or corresponding prototropic conjugates such as  $A/AH\cdot$  or  $AH\cdot/AH_2$ ). The intermediate  $A\cdot^-$  ( $AH\cdot$ ) is a free radical. The reduction potentials of such one-electron couples are of value in predicting the direction or feasibility, and in some instances the rate constants, of many free-radical reactions. Electrochemical methods have limited applicability in measuring these properties of frequently unstable species, but fast, kinetic spectrophotometry (especially pulse radiolysis) has widespread application in this area. Tables of *ca.* 1200 values of reduction potentials of *ca.* 700 one-electron couples in aqueous solution are presented. The majority of organic oxidants listed are quinones, nitroaryl and bipyridinium compounds. Reductants include phenols, aromatic amines, indoles and pyrimidines, thiols and phenothiazines. Inorganic couples largely involve compounds of oxygen, sulfur, nitrogen and the halogens. Proteins, enzymes and metals and their complexes are excluded.

Key words: aqueous solution; data compilation; electron transfer; equilibria; equilibrium constants; free radical; oxidation potential; radical; radiolysis; reduction potential; redox potential; review.

## Contents

1. Introduction .....	1639	3.9. Relative and Absolute Uncertainties Associated with Measurements .....	1643
2. Reduction Potential of Couples Involving Unstable Species .....	1639	4. Effects of Prototropic Equilibria Upon Reduction Potentials .....	1643
2.1. Stepwise Addition of Electrons .....	1639	4.1. Introduction .....	1643
2.2. Standard State, Reference Potentials and Sign Conventions .....	1640	4.2. Coupling of Electrons and Protons in the Reaction .....	1644
2.3. Ease of Reduction and Ease of Oxidation .....	1640	4.3. General Approach to Describing the pH-Dependence of Reduction Potentials .....	1644
3. Observation of One-Electron Transfer Equilibria .....	1640	4.4. Practical Application to One-Electron Reduction Potentials .....	1645
3.1. Generating the Couple $A/A\cdot^-$ by Reducing Radicals from Water Radiolysis .....	1640	4.5. Examples of the pH-Dependence of One-Electron Reduction Potentials and Suggestions for Symbols .....	1648
3.2. Generating the Couple $A\cdot^-/A^{2-}$ by Oxidizing Radicals from Water Radiolysis .....	1641	4.6. The Use of Mid-Point Potentials in Calculating Equilibrium Constants .....	1649
3.3. Generating Radicals by Flash Photolysis .....	1642	5. Calculation of One-Electron Reduction Potentials Using Radical Formation Constants .....	1650
3.4. Electrochemical Measurements of Reduction Potentials in Aqueous Solutions .....	1642	5.1. Introduction .....	1650
3.5. Establishing a Redox Equilibrium: Kinetic Constraints .....	1642	5.2. Derivation of Expressions .....	1650
3.6. Calculation of Reduction Potentials From Concentrations at Equilibrium .....	1642	5.3. Examples of Calculations .....	1651
3.7. Calculation of Reduction Potentials From the Kinetics of the Approach to Equilibrium .....	1642	5.4. Uncertainties in the Calculations .....	1651
3.8. Effects of Ionic Strength, Temperature and Solvent .....	1642	6. Recommended Redox Indicators and Their Potentials .....	1652
		6.1. Oxygen .....	1652
		6.2. Quinones .....	1652
		6.3. Bipyridinium Compounds (Viologens) .....	1652
		6.4. Hydroquinones and Phenols .....	1653
		6.5. Inorganic Indicators Other Than Oxygen .....	1653

©1989 by the U. S. Secretary of Commerce on behalf of the United States. This copyright is assigned to the American Institute of Physics and the American Chemical Society.

Reprints available from ACS; see Reprints List at back of issue.

7. Prediction of Reduction Potentials for Unknown Couples .....	1653	3.8. Symmetrical 1,1'-disubstituted 4,4'-bipyridinium compounds (viologens, $R_1 = R'_1$ ) without additional ring substituents .....	1680
7.1. Use of Polarographic and Cyclic Voltammetric Data Obtained Using Non-Aqueous Solvents .....	1653	3.9. Symmetrical 1,1'-disubstituted 4,4'-bipyridinium compounds (viologens, $R_1 = R'_1$ ) with additional ring substituents .....	1685
7.2. Correlations Between Reduction Potential and Rate Constants .....	1653	3.10. Asymmetrical 1,1'-disubstituted 4,4'-bipyridinium compounds (viologens, $R_1 = \text{CH}_3$ , $R'_1 = \text{variable}$ ) .....	1687
7.3. Correlations Between Reduction Potential and other Physico-Chemical Parameters ..	1654	3.11. Asymmetrical 1,1'-disubstituted 4,4'-bipyridinium compounds (viologens, $R_1 \neq R'_1 \neq \text{CH}_3$ ) .....	1688
8. Arrangement of the Data Tables and Indexes ...	1654	3.12. Quaternary derivatives of phenanthrolines, diazapyrenes and diazapentaphenes (see also 3.6) .....	1689
8.1. Content of the Tables .....	1654	4. Reduction potentials of miscellaneous organic compounds .....	1691
8.2. Alterations to Published Values .....	1654	4.1. Aldehydes and ketones .....	1691
8.3. Inorganic Couples: Standard States .....	1655	4.2. Disulfides (RSSR) .....	1691
9. Some Other Compilations of Reduction Potentials .....	1655	4.3. Amides .....	1691
10. List of Abbreviations and Symbols .....	1655	4.4. Pyridinium and related compounds .....	1691
11. Acknowledgments .....	1656	4.5. Phenothiazinium derivatives .....	1692
12. References to Text .....	1656	4.6. Flavins (isoalloxazines) and lumichrome derivatives (alloxazines) .....	1692
13. References to Tables .....	1717	4.7. Dioxathiadiazaheteropentalenes .....	1693
14. Compound Name Index .....	1724	4.8. Miscellaneous organic compounds .....	1694
15. Molecular Formula Index .....	1745	5. Reduction potentials of phenoxy radicals .....	1695

#### List of Tables


1. Reduction potentials of quinones .....	1658	5.1. Phenols .....	1695
1.1. Benzoquinones .....	1658	5.2. 1,2-Dihydroxybenzenes .....	1696
1.2. Naphthoquinones .....	1659	5.3. 1,3-Dihydroxybenzenes .....	1696
1.3. Anthraquinones .....	1660	5.4. 1,4-Dihydroxybenzenes (1,4-hydroquinones) .....	1697
1.4. Isoindole-4,7-iones .....	1660	5.5. Trihydroxybenzenes .....	1697
1.5. Miscellaneous quinones .....	1661	6. Reduction potentials of amine, indole, pyrimidine and purine radicals .....	1699
2. Reduction potentials of nitroaryl compounds .....	1663	6.1. Aminobenzenes and phenylene diamines ..	1699
2.1. Nitrobenzenes .....	1663	6.2. Indoles .....	1699
2.2. Nitrofurans .....	1664	6.3. Pyrimidines .....	1701
2.3. 2-Nitroimidazoles .....	1664	6.4. Purines .....	1702
2.4. 4-Nitroimidazoles .....	1668	7. Reduction potentials of phenothiazine radicals ...	1703
2.5. 5-Nitroimidazoles .....	1670	7.1. 10 <i>H</i> -Phenothiazine .....	1703
2.6. Nitroazaindoles .....	1672	7.2. 10 <i>H</i> -Phenothiazines with one ring carbon substituent .....	1703
2.7. Nitroacridines .....	1672	7.3. 10 <i>H</i> -Phenothiazines with two ring carbon substituents .....	1703
2.8. Miscellaneous nitroaryl compounds .....	1673	7.4. <i>N</i> -Substituted phenothiazines without ring carbon substitution .....	1704
3. Reduction potentials of bipyridinium and related compounds .....	1675	7.5. <i>N</i> -Substituted phenothiazines with one ring carbon substituent .....	1705
3.1. Unbridged 2,2'-bipyridinium compounds .	1675	7.6. Benzophenothiazines .....	1706
3.2. Bridged 2,2'-bipyridinium compounds: derivatives of dipyrdo [1,2- <i>a</i> :2',1'- <i>c</i> ]pyrazinediium .....	1675	7.7. Phenothiazines with oxidized sulfur .....	1707
3.3. Bridged 2,2'-bipyridinium compounds: derivatives of 6,7-dihydrodipyrdo[1,2- <i>a</i> :2',1'- <i>c</i> ]pyrazinediium ('diquat') .....	1675	8. Reduction potentials of radicals from miscellaneous organic compounds .....	1708
3.4. Bridged 2,2'-bipyridinium compounds: derivatives of 7,8-dihydro-6 <i>II</i> -dipyrdo[1,2- <i>a</i> :2',1'- <i>c</i> ][1,4]diazepinediium ('triquat') .	1677	8.1. Hydroxy compounds .....	1708
3.5. Bridged 2,2'-bipyridinium compounds: derivatives of 6,7,8,9-tetrahydrodipyrdo[1,2- <i>a</i> :2',1'- <i>c</i> ][1,4]diazocinediium ('tetraquat') .....	1678	8.2. Dihydrocinotinamides .....	1709
3.6. Miscellaneous 2,2'-bipyridinium compounds .....	1679	8.3. Thiols .....	1709
3.7. 2,4'-Bipyridinium compounds .....	1680	8.4. Pyrazolinones .....	1710
		8.5. Peroxy radicals .....	1710
		9. Reduction potentials of inorganic couples .....	1711

## List of Figures

1. Variation of the mid-point potential,  $E_m$  with pH of the one-electron couple: quinone/semiquinone for 1,4-benzoquinone..... 1648
2. Variation of the mid-point potential,  $E_m$  with pH of the one-electron couple: semiquinone/hydroquinone for 1,4-benzoquinone..... 1648
3. Variation of the mid-point potential,  $E_m$  with pH of the one-electron reduction potential of 1-(2-piperidinylolethyl)-2-nitroimidazole ( $ArNO_2$ ) ..... 1649
4. Variation of the mid-point potential,  $E_m$  with pH of the one-electron couples of two hypothetical oxidants A and B (see text) and the logarithm of the effective equilibrium constant  $K_1$  for the one-electron transfer equilibrium between these oxidants and their electron-adducts..... 1649

## 1. Introduction

Many reactions of free radicals involve one-electron transfer. If an electron acceptor, A is reduced to a radical,  $A\cdot^-$  then the possibility of further or competing reactions involving other electron acceptors, B, C etc.:



can be calculated if the one-electron reduction potentials  $E^\circ(A/A\cdot^-)$ ,  $E^\circ(B/B\cdot^-)$  etc. are known. Thus the equilibrium constant,  $K_1$  for reaction 1 is related to the difference  $\Delta E_1^\circ$  between the couples:

$$\Delta E_1^\circ = E^\circ(B/B\cdot^-) - E^\circ(A/A\cdot^-) \quad (1)$$

by the expression

$$\Delta G_1^\circ = -nF\Delta E_1^\circ = -RT\ln K_1 \quad (2)$$

where  $K_1$  is the ratio of activities

$$K_1 = \frac{(a_A a_{B\cdot^-})}{(a_B a_{A\cdot^-})} \quad (3)$$

Except at high ionic strengths (see below, Sec. 3.8) we can replace activities by concentration so that

$$K_1 \approx \left( \frac{[A][B\cdot^-]}{[B][A\cdot^-]} \right) \quad (4)$$

At 298 K from Eq. (2) we have

$$\Delta E_1^\circ/\text{mV} \approx 59.1 \log K_1 \quad (5)$$

and differences of ca. 60 mV in reduction potential correspond to an order of magnitude change in equilibrium constant.

Even when reactions are irreversible and equilibria are not achieved, there are many instances where the rate constants for the reaction are reflected in the reduction potentials of electron donor or acceptor (see below, Sec. 7.2). Current interest in reactions of excited states with electron donors or acceptors, often involving electron transfer, is aided by the relative ease by which reduction potentials of many substances can be measured electrochemically in the aprotic solvents often used in such experiments. In water, however, free radicals are often too short-lived for conventional electrochemical methods to be used. The ability to observe directly the lifetimes and reactions of unstable intermediates using kinetic spectrophotometry offers obvious advantages. Detailed descriptions of electrochemical techniques can be readily found in the literature, and this introduction therefore concentrates on the more recent application of fast, kinetic methods to derive electrochemical potentials. As outlined below, pulse radiolysis and flash photolysis techniques can be used to measure equilibrium constants of redox reactions before transient species can decay. Neta<sup>1</sup> has summarized some early studies of redox properties of free radicals using the pulse radiolysis technique.

Dorfman and colleagues<sup>2</sup> used pulse radiolysis to observe electron-transfer equilibria of arene radicals in ethanol, and Patel and Willson<sup>3</sup> measured equilibrium constants for electron transfer between semiquinones and oxygen in water. The latter data and approach enabled Wood,<sup>4</sup> Ilan et al.<sup>5</sup> and Meisel and Czapski<sup>6</sup> to obtain the definitive value of the important couple  $E^\circ(O_2/O_2\cdot^-)$ . Meisel and Neta<sup>7</sup> extended the method to include reversible electron transfer between quinones and nitroaromatic compounds, and Steenken and Neta<sup>8</sup> measured equilibria between phenoxyl radicals and hydroquinones or phenoxides at high pH. As a result of these pioneering studies, there are now many reliable values of thermodynamically-reversible one-electron reduction potentials of couples involving unstable free radicals in aqueous solution.

## 2. Reduction Potentials of Couples Involving Unstable Species

## 2.1. Stepwise Addition of Electrons

Many reactions formally involving two-electron couples  $A/A^{2-}$  are known to proceed in two one-electron steps,  $A/A\cdot^-$  and  $A\cdot^-/A^{2-}$ . (For simplicity we presently ignore protonation here, but recognize that e.g.  $A\cdot^-$  or  $A^{2-}$  may exist as conjugate acids at the pH of interest.)

The intermediate  $A\cdot^-$ , generally a free radical in most of the cases tabulated here, may be produced *either* by reduction of  $A$  or by oxidation of  $A^{2-}$  (see below, Sec. 3.1, 3.2). The two-electron potential,  $E^\circ(A/A^{2-})$  is related to the one-electron couples by

$$2E^\circ(A/A^{2-}) = E^\circ(A/A\cdot^-) + E^\circ(A\cdot^-/A^{2-}). \quad (6)$$

Various alternative symbols are used for reduction potential, e.g. we can recognise the first- and second- one-electron potentials by denoting  $E(A/A\cdot^-)$  as  $E^1$  and  $E(A\cdot^-/A^{2-})$  as  $E^2$  with subscripts for pH, e.g.  $E_7^1$ ,  $E_{13.5}^2$ . The standard reduction potential is usually denoted by  $E^\circ$ . The distinction between standard potentials and measured quantities is not always clear, and is a particular problem where either ground state or radical species are protonated or dissociate in prototropic equilibria. A discussion of this point and recommendations for symbolism and description of reduction potentials is postponed to Sec. 4 when prototropic equilibria will have been considered in more detail.

## 2.2. Standard States, Reference Potentials and Sign Conventions<sup>9-11</sup>

The standard states of unit activity (approximately 1 mol dm<sup>-3</sup> concentration) for solids and liquids and unit fugacity (approximately 1 atmosphere partial pressure) for gases are used. *The latter convention frequently leads to errors in calculation*, particularly in reactions involving the important  $O_2/O_2\cdot^-$  couple. Thus the standard potential is  $E^\circ(O_2/O_2\cdot^-) \approx -325$  mV whereas the potential of the couple  $E(O_2(1 \text{ mol dm}^{-3})/O_2\cdot^-) \approx -155$  mV.<sup>4-6</sup> The difference can be appreciated by application of the Nernst equation (see Sec. 4.2, eq. (14), below) with the oxygen concentration of  $\sim 1.3$  mmol dm<sup>-3</sup>. The standard state pressure was defined as 101.325 kPa; changing to a new standard state of 100 kPa = 1 bar alters potentials by only 0.17 mV, negligible in the present context. The convention of the standard state of pure elements being the normal physical state existing at 1 atmosphere and 298 K introduces another complication; thus the standard potential  $E^\circ(I_2/I_2\cdot^-)$  refers to solid elemental iodine and not  $\sim 1$  mol dm<sup>-3</sup> in aqueous solution.

The reference potential throughout these tables is the normal or standard hydrogen electrode (s.h.e.). Many electrochemical measurements are originally referred to the saturated calomel electrode (s.c.e.); these have been converted to s.h.e. by adding 244 mV if the measurements were at  $\sim 298$  K (241 mV at 303 K). A few measurements originally referred to the calomel electrode at 1 mol dm<sup>-3</sup> KCl (normal), n.c.e.; the correction in this case is 280 mV. The Ag/AgCl electrode is 222 mV lower than s.h.e. at 298 K.

The IUPAC convention of writing couples as *reduc-*

*tion* potentials is followed exclusively. Thus for the reduction of  $A$  to  $A\cdot^-$  the couple is  $E(A/A\cdot^-)$ ; an obsolete convention of describing couples as *oxidation* potentials is to be discouraged. Even though the conversion of  $A^{2-}$  to  $A\cdot^-$  involves oxidation, it is preferable to write all couples as reduction potentials: the ease of oxidation of  $A^{2-}$  to  $A\cdot^-$  is characterized as the reduction potential of the radical  $A\cdot^-$ , i.e.  $E(A\cdot^-/A^{2-})$ . The standard use of the term 'reduction potential', exclusion of the obsolete 'oxidation potential' and avoidance of the ambiguous 'redox potential' serves not only to clarify the definition of the couples but also aids information retrieval in computer systems. Further discussion of the definitions, and use of symbols for reduction potentials is postponed until Sec. 4 (below), when their application should be more apparent.

## 2.3. Ease of Reduction and Ease of Oxidation

With these conventions, substances  $A$  with more positive reduction potentials for the couple  $A/A\cdot^-$  are more powerful oxidants ( $A$  easier to reduce). Substances  $A^{2-}$  with more negative reduction potentials for the couple  $A\cdot^-/A^{2-}$  are more powerful reductants (oxidation of  $A^{2-}$  more favorable). Thus 1,4-benzoquinone (Q) with  $E^\circ(Q/Q\cdot^-) = 78$  mV is a more powerful oxidant than its 2,3,5,6-tetramethyl derivative, duroquinone (DQ) with  $E^\circ(DQ/DQ\cdot^-) = -244$  mV. The semiquinone  $DQ\cdot^-$  of duroquinone will tend to be oxidized by benzoquinone, forming benzosemiquinone, depending on the relative concentrations of the reactants as described by equilibrium 1. These differences can be readily understood because of the electron-donating influence of the methyl groups. Phenols, such as 1,4-dihydroxybenzene (hydroquinone) are fully dissociated to phenoxide ions,  $PhO^-$  at high pH (highest  $pK_a$  in this case  $\sim 11.4$ ). Reduction potentials at pH  $\sim 13.5$  for the phenoxyl radical/phenoxide couple,  $E(PhO\cdot/PhO^-)$  of  $\sim 23$  and 700 mV have been calculated or measured for hydroquinone and phenol, respectively. Hence hydroquinone is much more easily oxidized than phenol. The phenoxyl radical obtained upon one-electron oxidation of phenol is thermodynamically capable of oxidizing hydroquinone unless there is a hugely unrealistic excess of phenol to hydroquinone to modify the position of the electron-transfer equilibrium. The phenoxyl radical derived from phenol is a more powerful oxidant than that derived from hydroquinone; the *reduction* potential of the former radical is more positive than that from the latter.

## 3. Observation of One-Electron Transfer Equilibria

### 3.1. Generating the Couple $A/A\cdot^-$ by Reducing Radicals From Water Radiolysis<sup>12-15</sup>


The radiolysis of water produces  $e_{aq}^-$ ,  $H\cdot$  and  $\cdot OH$  radicals. The hydrated electron,  $e_{aq}^-$ , will generally reduce  $A$

to  $A^{\cdot-}$ , often in a diffusion-controlled reaction. The hydroxyl radical,  $\cdot\text{OH}$ , is oxidizing and can be prevented from reacting with A:




by several methods:

a. *tert*-Butyl alcohol is added, which reacts with  $\cdot\text{OH}$  to yield a radical which is of only moderate reactivity and *may* not react with A or other solutes on the timescale of interest:



Not infrequently, however,  $A^{\cdot-}$  does react with the alcohol radical from reaction 5. Loss of  $A^{\cdot-}$  via this unwanted route can be avoided by alternatives b and c (below) or by using minimal dose (radical concentration).

b. 2-Propanol is added which reacts with  $\cdot\text{OH}$  to yield *predominantly* an  $\alpha$ -hydroxyalkyl radical which will *usually* produce the desired species  $A^{\cdot-}$  by electron-transfer:




The fraction of  $\cdot\text{OH}$  attack on  $-\text{CH}_3$  to yield a  $\beta$ -hydroxyalkyl radical, with similar properties to that produced in reaction 5 is  $\sim 15\%$ .<sup>16</sup> Hence a fraction of  $A^{\cdot-}$  may be lost via this unwanted reaction, albeit on a timescale often too slow to interfere with electron-transfer equilibration (see below, Sec. 3.5).

c. The  $\cdot\text{OH}$  scavenger of choice when the longest 'natural' lifetime of  $A^{\cdot-}$  is sought is formate (usually the sodium salt). The  $\text{CO}_2^{\cdot-}$  radical formed upon scavenging  $\cdot\text{OH}$  with  $\text{HCO}_2^-$ :



will *generally* produce the same species  $A^{\cdot-}$  produced by reduction with  $e_{\text{aq}}^-$ :




although a high ionic strength usually results (see below, Sec. 3.8).

One aims to have the rate of reactions 5, 6 or 8 much greater than the rate of reaction 4. Rate constants for reaction of  $\cdot\text{OH}$  with many substances are known<sup>17</sup> or can be estimated with sufficient accuracy for this inequality to be satisfied. Usually the  $\cdot\text{OH}$  scavenger will

be used at concentrations of 0.1-0.2 mol dm<sup>-3</sup>. Hydrogen atoms comprise ca. 10% of the total radicals and a fraction may react with e.g.  $(\text{CH}_3)_2\text{CHOH}$  or  $\text{HCO}_2^-$  (*tert*-butyl alcohol is less reactive) depending on the solute reactivity. It cannot be assumed that H $\cdot$  will react with A to yield  $A^{\cdot-}$ . Especially with oxidants A of very low electron affinity it may not be safe to assume that reactions 7 and even 9 will yield  $A^{\cdot-}$  and alternative (a) may be preferred in spite of the disadvantages noted.


### 3.2. Generating the Couple $A^{\cdot-}/A^{2-}$ by Oxidizing Radicals From Water Radiolysis<sup>12-15</sup>

Removing the reducing radical  $e_{\text{aq}}^-$  is simple:




and saturation with  $\text{N}_2\text{O}$  ( $[\text{N}_2\text{O}] \approx 25 \text{ mmol dm}^{-3}$ ) will prevent effectively the now unwanted reaction 10 if  $k_{11}[\text{N}_2\text{O}] \gg k_{10}[\text{A}]$ . Numerous values for  $k_{10}$  are tabulated.<sup>17</sup> The H $\cdot$  atoms are usually ignored but could be a source of error if the product(s) of  $\text{H}\cdot + A^{2-}$  absorb significantly compared to  $A^{\cdot-}$ .



With  $A^{2-} = \text{phenoxide ion}$ , reaction 13 rapidly follows reaction 12 to yield the desired phenoxyl radical  $A^{\cdot-}$  in basic solution:



However, the lack of selectivity in reactions of  $\cdot\text{OH}$  has led to the practice of converting it to a more selective oxidizing radical, e.g.  $\dot{\text{C}}\text{H}_2\text{CHO}$ :<sup>18</sup>




Alternative oxidizing systems more selective than  $\cdot\text{OH}$  are the halogen or pseudohalogen radicals  $X_2^{\cdot-}$  (X = halogen or thiocyanate etc.) and  $\text{N}_3^{\cdot-}$ :




Rate constants of many one-electron oxidation reactions of these species have been tabulated:<sup>19</sup>







Another useful system involves  $\text{SO}_4 \cdot^-$  (via  $e_{\text{aq}}^- + \text{S}_2\text{O}_8^{2-}$ )<sup>19</sup>



Since  $k_4 \approx k_{14} \approx k_{17} \approx k_{18}$  we use [glycol],  $[\text{X}^-]$ ,  $[\text{N}_3^-]$  etc.  $\gg$  [A], e.g. 1 mol  $\text{dm}^{-3}$  glycol or 0.1 mol  $\text{dm}^{-3}$   $\text{Br}^-$ .

### 3.3. Generating Radicals by Flash Photolysis

The triplet state  $\text{A}^*$  (e.g. of nitroaromatic compounds)<sup>20,21</sup> may be quenched by electron donors, D to yield radical-anions:



although little application of this method to measuring reduction potentials has been reported.<sup>20</sup>

### 3.4. Electrochemical Measurements of Reduction Potentials in Aqueous Solution

Clark's classical text<sup>22</sup> includes methods by which one-electron potentials may be derived from electrochemical measurements, and Bard<sup>23</sup> has described general electrochemical methods. Some electrochemical methods require the intermediate  $\text{A} \cdot^-$  to be relatively stable; this condition is easily met for  $\text{A} =$  bipyridinium dication<sup>22</sup> (viologens), some quinones at high pH<sup>24</sup>, etc., and for  $\text{A}^{2-} =$  some phenylenediamines, and phenothiazines in acidic solution. Polarography with a time resolution compatible with pulse radiolysis<sup>25</sup> offers obvious advantages over conventional methods, but protonation of radicals is frequently accompanied by irreversibility of the reduction process. More recently, cyclic voltammetry has had some success<sup>26-29</sup> in determining reduction potentials involving both inorganic and organic radicals in aqueous solution; in this case, the theoretical treatment requires rapid loss of the radical<sup>26,30,31</sup>.


### 3.5. Establishing a Redox Equilibrium: Kinetic Constraints

Many of the radiolytic reactions useful for generating radicals  $\text{A} \cdot^-$  (7,9,10,16,19-21) are so rapid that at practical concentrations of A of the order 10  $\mu\text{mol dm}^{-3}$  - 10  $\text{mmol dm}^{-3}$ , the production of radicals  $\text{A} \cdot^-$  and/or  $\text{B} \cdot^-$  for the desired equilibrium 1 is complete a few microseconds after a radiation pulse. The rate of approach to equilibrium 1 is then controlled by  $k_1$  and  $k_{-1}$ :

$$k_{1,\text{obs}} \approx k_1[\text{B}] + k_{-1}[\text{A}]. \quad (7)$$

This approximation is usually valid if pulse radiolysis or flash photolysis involves generation of ca. 1 - 10  $\mu\text{mol}$

$\text{dm}^{-3}$   $\text{A} \cdot^-$  and/or  $\text{B} \cdot^-$  and  $[\text{A} \cdot^-], [\text{B} \cdot^-] \ll [\text{A}], [\text{B}]$ . Here  $k_{1,\text{obs}}$  is the first-order rate constant (units  $\text{s}^{-1}$ ) obtained by plotting the appropriate function of absorbance vs. time. As equilibrium 1 is approached, significant loss of  $\text{A} \cdot^-$ ,  $\text{B} \cdot^-$  (e.g. by disproportionation):



must be negligible if  $K_1$  is to be estimated reliably. While  $k_1$  and/or  $k_{-1}$  may be of the order of  $10^8 \text{ dm}^3 \text{ mol}^{-1} \text{ s}^{-1}$  for many electron-transfer reactions, it is frequently observed that protonation of A,  $\text{A} \cdot^-$ , or  $\text{A}^{2-}$  slows down electron-transfer rate constants by orders of magnitude, and then equilibrium 1 may not be achieved in competition with reaction 24 etc. Thus deprotonation of hydroquinones, phenols, ascorbate etc. is often necessary to observe reversible electron-transfer reactions of these substrates.<sup>8</sup>

### 3.6. Calculation of Reduction Potentials From Concentrations at Equilibrium

By making the assumption that as [A], [B] is varied the radiolytic yield ( $[\text{A} \cdot^-] + [\text{B} \cdot^-]$ ) remains constant, then<sup>7</sup>

$$K_1 \approx \frac{(A_{\text{obs}} - A_{\text{A} \cdot^-}) \cdot [\text{A}]}{(A_{\text{B} \cdot^-} - A_{\text{obs}}) \cdot [\text{B}]} \quad (8)$$

$A_{\text{obs}}$  is the absorbance at a constant dose (constant total radical concentration) in the solution containing A and B, and  $A_{\text{A} \cdot^-}$ ,  $A_{\text{B} \cdot^-}$  are the absorbances at the selected wavelength of  $\text{A} \cdot^-$  and  $\text{B} \cdot^-$  alone. Alternative algebraic routes to  $K_1$  have been used.<sup>3,6</sup> Under some circumstances a significant fraction of A, B may be converted to  $\text{A} \cdot^-$ ,  $\text{B} \cdot^-$  and calculation by an iterative procedure for the concentrations of A, B at equilibrium may be necessary.

### 3.7. Calculation of Reduction Potential From the Kinetics of the Approach to Equilibrium

From Eq. (7) we have:

$$\frac{k_{1,\text{obs}}}{[\text{B}]} \approx k_1 + k_{-1} \frac{[\text{A}]}{[\text{B}]} \quad (9)$$

A plot of  $k_{1,\text{obs}}/[\text{B}]$  vs.  $[\text{A}]/[\text{B}]$  yields an estimate of  $K_1$  from the ratio (intercept/slope). Again, the kinetics must reflect only the approach to equilibrium 1 and there must be insignificant loss of  $\text{A} \cdot^-$ ,  $\text{B} \cdot^-$  by other routes.


### 3.8. Effects of Ionic Strength, Temperature and Solvent

If either both reactants or both products of reaction 1 are charged then  $K_1$  defined by Eq. (4) will vary with ionic strength,  $I$ . We can either plot several measured values of  $\Delta E_1$  against (say)  $I^{1/2}$  to extrapolate to zero ionic strength or use the Debye-Hückel equation to calculate

activity coefficient ratios.<sup>32</sup> The limitations of such treatments to ionic strengths much lower than those used in many radiolysis experiments are well known. An alternative approach uses the Debye-Hückel-Brønsted-Davies expression for the primary kinetic salt effect:<sup>33</sup>

$$\log k = \log k^0 + 2z_A z_B A (I^{\frac{1}{2}}(1 + I^{\frac{1}{2}})^{-1} - BI) \quad (10)$$

where the constants  $A$ ,  $B$  vary with solvent and ions but are close to 0.5 and 0.2 respectively for water and typical ions. If for simplicity we abbreviate  $z_A$ ,  $z_B$  to  $a, b$  (the charges on A, B) then reaction  $I$  may be written:



It is readily shown that

$$\Delta E_0 = \Delta E_I + \Delta E_{\text{corr}} \quad (11)$$

where the correction term to be added to the value  $\Delta E_I$  measured at an ionic strength  $I$  is:

$$\Delta E_{\text{corr}}/\text{mV} \approx 59.1(b - a)f(I). \quad (12)$$

The function  $f(I)$  appropriate for many reactions in water at 298 K can be approximated to:

$$f(I) \approx 1.02(I^{\frac{1}{2}}(1 + I^{\frac{1}{2}})^{-1} - 0.2I). \quad (13)$$

If e.g. A = a bipyridinium dication and B = a quinone sulfonate monoanion then  $(b - a) = -3$  and  $\Delta E_{\text{corr}} \approx -16$  and  $-49$  mV at  $I = 0.01$  and  $0.2$  respectively. At a given pH we may see  $A^{\cdot-}$  protonated but A not and the salt effect then requires more careful consideration; with complex molecules the effective charge may differ from the nominal net charge,<sup>34</sup> and experiments at several ionic strengths are desirable. Some other effects of ionic strength are considered in Sec. 5.

Little work has been done on the effects of temperature and solvent. The author has used data<sup>35</sup> for the temperature-variation of the reduction potential of 1,1'-dimethyl-4,4'-bipyridinium dication and its benzyl analogue to show that  $E(A/A^{\cdot-})$  for A = the 2-nitroimidazole, misonidazole varies with temperature at pH 7 in aqueous solution with  $dE/dT \approx -1.1$  to  $-1.8$  mV K<sup>-1</sup> depending on the viologen data used (unpublished work). Solvent effects (mixed aqueous: organic solutions) will vary widely, depending especially upon the net charges involved; illustrations of these effects have been presented.<sup>36,37</sup> Entropy changes can, of course, be estimated from  $dE/dT$ . Typical values of  $dE/dT$  for viologen reference compounds are  $-0.4$  to  $-0.9$  mV K<sup>-1</sup>,<sup>35</sup> and for simple nitroaryl compounds are  $-1$  to  $-2$  mV K<sup>-1</sup>. Thus the common practice of ignoring variations in experimental temperatures may introduce systematic errors in estimates of  $E^\circ$  of several mV, aside from other uncertainties noted below.

### 3.9. Relative and Absolute Uncertainties Associated With Measurements

From Eq. (5) an uncertainty of  $\pm 10\%$  in  $K_I$  corresponds to ca.  $\pm 2.6$  mV in  $\Delta E_I^\circ$ . The lack of, or uncertainties in ionic strength corrections (where needed) may be at least of this order and in general values of  $\Delta E_I^\circ$  are unlikely to be more accurate than  $\pm 5$  mV. The potentials of most redox indicators (see below, Sec. 5,6) are certainly not known to better than  $\pm 5$ - $10$  mV and a realistic uncertainty in  $E^\circ(A/A^{\cdot-})$  of  $\pm 10$  mV is probably the *minimum* associated with the data given in Tables 1-4. For couples of the form  $A^{\cdot-}/A^{2-}$  (Tables 5-8)  $\Delta E_I^\circ$  may often be measurable to  $\pm 10$  mV or so<sup>3</sup> but ionic strength effects, where present (either  $a \neq 0$ ,  $b \neq 0$  or  $a \neq b$ ) in e.g.  $0.5$  mol dm<sup>-3</sup> KOH may lead to treble this uncertainty in values of reduction potentials.

The potentials in the Tables are presented in integer millivolts mainly to minimize rounding errors where several values may be coupled together to facilitate calculations, or to facilitate calculation of equilibrium constants from which the potentials were derived. The *absolute* values of the potentials are seldom reliable to better than  $\pm 10$  mV, and many may be uncertain by  $\pm 20$  mV.

Couples involving protons (see below) introduce further uncertainties since thermodynamic  $pK_a$ 's are frequently unavailable. The effects of these possible systematic errors are discussed further below.

## 4. Effects of Prototropic Equilibria Upon Reduction Potentials

### 4.1. Introduction

Reduction potentials refer to reactions of the form:



The couples  $A/A^{2-}$ ,  $A/A^{\cdot-}$  and  $A^{\cdot-}/A^{2-}$  may represent the reactions involved in the two-electron reduction of A to  $A^{2-}$ , or the two individual one-electron steps, as described above. In the latter case, the radical species  $A^{\cdot-}$  is involved as reductant in the couple  $A/A^{\cdot-}$ , and as oxidant in the couple  $A^{\cdot-}/A^{2-}$ . If protons are involved in the reaction:



then the reduction potential of the 'half-cell' describing the reaction varies with pH. However, the *standard potential* does *not* vary with pH, since it is defined as the potential referred to the hydrogen standard when each species in the reaction, including  $H^+$  if present, is at unit activity. This obviously includes the condition pH = 0 if  $H^+$  is a reactant, and leads to considerable confusion. Symbols for standard potentials include  $E^\ominus$  and  $E^\circ$ ; the latter is often typeset as  $E^\circ$  and frequently also expressed as  $E_0$  even though the subscripted symbol does not refer

to a standard potential. Obviously, in verbal discussion the opportunities for confusion of  $E^\circ$  and  $E_0$  are even greater.

The symbol  $E_0$  is best restricted to denote a *formal* rather than *standard* potential; this distinction should become clear later. Unfortunately, such formal potentials can have rather variable definitions, and care needs to be taken to ascertain just which constants are included in  $E_0$ . This point is not always clear even in well-known texts, e.g. Clark's book,<sup>22</sup> and is discussed further below.

#### 4.2. Coupling of Electrons and Protons in the Reaction


Suppose the reductant, formally represented by  $A^{2-}$  previously, can be involved in prototropic equilibria, e.g.:



as can the radical intermediate,  $A^{\cdot-}$  or the oxidant, A:



(It is important to recognise that free radicals may have dissociation constants for such equilibria which differ by several orders of magnitude from the corresponding dissociation in the ground state; thus for simple benzoquinones,  $pK_{29} \gg pK_{30}$ .<sup>3,38</sup>) The two-electron reduction of A to  $A^{2-}$  can be represented *either* as 31a, excluding protons in the equation, *or* as 31b, which includes protons:



The *standard* potentials,  $E^\circ(\text{A}/\text{A}^{2-})$  and  $E^\circ(\text{A}, 2\text{H}^+/\text{AH}_2)$  have quite distinct definitions and values, and when discussing the reduction of A to  $A^{2-}$  or its protonated conjugates  $\text{AH}^-$ ,  $\text{AH}_2$  we should take care always to qualify  $E^\circ$  as shown above with the oxidant/reductant couple in parentheses.

The electrode potential (reduction potential) of a system or couple is the e.m.f. of a cell in which the couple forms the right-hand electrode and the standard hydrogen electrode (s.h.e.) forms the left.<sup>9</sup> If  $A^{2-}$  is involved in prototropic equilibria (reactions 27,28) of any significance over the pH range of practical interest — say 0 to 14 — then the potential of the half-cell in which A is reduced can be assigned the symbol  $E_h$ . This is defined in the Nernst relationship:

$$E_h = E^\circ + \frac{RT}{nF} \ln \left\{ \frac{(\text{product of activities of oxidant})}{(\text{product of activities of reductant})} \right\} \quad (14)$$

where  $E^\circ$  is the standard potential of the oxidant/reductant couple *as defined in the half-cell equation*. The relationship can be expressed *either* using the half-cell reaction 31a:

$$E_h = E^\circ(\text{A}/\text{A}^{2-}) + \frac{RT}{nF} \ln \frac{(\text{A})}{(\text{A}^{2-})} \quad (15)$$

*or* in terms of the half-cell reaction 31b, including protons:

$$E_h = E^\circ(\text{A}, 2\text{H}^+/\text{AH}_2) + \frac{RT}{nF} \ln \frac{(\text{A})(\text{H}^+)^2}{(\text{AH}_2)} \quad (16)$$

whichever is most convenient (see below). (We generally follow the symbols used by Clark,<sup>22</sup> except in the more restrictive use of  $E_0$  as shown below; activities are denoted by parentheses, (A) etc., while concentrations are represented by square brackets, [A] etc.) For simplicity we ignore, for the present, protonation of oxidant (reaction 30), i.e.  $pK_{30} \ll 0$ .  $E_h$  is *not* a standard potential, but merely the potential of a half-cell in which A is being reduced (in this case by two electrons, ignoring the individual one-electron couples). We *could* use the symbol  $E_h(\text{A}, 2\text{H}^+/\text{AH}_2)$  to remind ourselves that the reduction is coupled to protons at some pH values of interest, but the reductant is really a mixture of all three prototropic conjugates.

#### 4.3. General Approach to Describing the pH-Dependence of Reduction Potentials

As noted above, the standard potential  $E^\circ(\text{A}, 2\text{H}^+/\text{AH}_2)$  is pH-invariant since the condition  $(\text{H}^+) = 1$  applies. However,  $E_h$  will vary with pH since in Eq. (15) the activity of  $A^{2-}$  will depend on equilibrium 28 conjugating  $A^{2-}$  with  $\text{H}^+$ . In Eq. (16) not only will  $(\text{AH}_2)$  be controlled by equilibrium 27, but  $(\text{H}^+)$  is also incorporated in the Nernst relationship. The general approach to deriving an expression relating  $E_h$  to  $(\text{H}^+)$  may be summarized: (i) Write down the reaction as a reduction of an oxidant to a reductant, reading left to right, in any form in which protons and electrons balance (e.g. reactions 25 or 26; 31a or 31b). (ii) Write down the Nernst expression for the reaction as written, with  $E^\circ$  clearly defined in parentheses after the symbol (e.g. Eqs. (15) or (16)). (iii) Derive expressions for the fraction of total oxidant and/or total reductant which are in the prototropic forms shown in the reaction as written, i.e. in the definition of  $E^\circ$ . (iv) Substitute these terms in the Nernst expression, and separate out the term for the ratio of total activities (or concentrations, see below) of oxidants and reductants to define a mid-point potential,  $E_m$  when this ratio is unity. (v) A formal (*not* standard) potential,  $E_0$  can then



be defined to separate out the constants and present a relationship between  $E_m$  and pH which includes the dissociation constants for the prototropic equilibria involved. The standard potential  $E^\circ$  is included in the constant  $E_0$  but the latter may, or may not, approximate to  $E^\circ$ , as discussed below.

Restricting ourselves for the present to defining  $E_h$  for the two-electron reduction of the oxidant A, and ignoring prototropic equilibria such as 30 involving the oxidant, we have already accomplished steps (i) and (ii) above to arrive at Eqs. (15) and (16). Using Eq. (16), for step (iii) we have to derive the proportion of total reductant in the form  $AH_2$ . Following Clark,<sup>22</sup> we define the symbol  $S_r$  to denote the sum of reductants:

$$S_r = AH_2 + AH^- + A^{2-} \quad (17)$$

and define equilibrium constants for the dissociation of the reductant in decreasing numerical value:

$$K_{r1} = \frac{(AH^-)(H^+)}{(AH_2)} \quad (=K_{27}) \quad (18)$$

$$K_{r2} = \frac{(A^{2-})(H^+)}{(AH^-)} \quad (=K_{28}) \quad (19)$$

We can then express  $(AH_2)$  in terms of  $(S_r)$ ,  $K_{r1}$  and  $K_{r2}$ :

$$(S_r) = (AH_2) + (AH^-) + (A^{2-}) \quad (20)$$

$$(S_r) = (AH_2) \left( 1 + \frac{K_{r1}}{(H^+)} + \frac{K_{r2}}{(H^+)^2} \right) \quad (21)$$

$$(AH_2) = (S_r) \left( \frac{(H^+)^2}{K_{r1}K_{r2} + K_{r1}(H^+) + (H^+)^2} \right) \quad (22)$$

To progress to step (iv) we define, for consistency,  $S_o$  as the sum of the oxidants (only A if we ignore  $AH^+$  formation, reaction 30). Eq. (16) then becomes:

$$E_h = E^\circ(A, 2H^+/AH_2) + \frac{RT}{2F} \ln \frac{(S_o)}{(S_r)} + \frac{RT}{2F} \ln \frac{(K_{r1}K_{r2} + K_{r1}(H^+) + (H^+)^2)(H^+)^2}{(H^+)^2} \quad (23)$$

if we separate out the term with  $(S_o)/(S_r)$  since  $(S_o) = (A)$ . When  $(S_o) = (S_r)$ ,  $E_h$  can be described as a 'mid-point' potential with symbol  $E_m$ :

$$E_m = E^\circ(A, 2H^+/AH_2) + \frac{RT}{2F} \ln (K_{r1}K_{r2} + K_{r1}(H^+) + (H^+)^2) \quad (24)$$

Beginning with the alternative 'orienting reaction' 31a and its corresponding Nernst relationship Eq. (15), we have to derive an expression for  $(A^{2-})$  analogous to Eq. (22), in a similar fashion:

$$(A^{2-}) = (S_r) \left( \frac{K_{r1}K_{r2}}{K_{r1}K_{r2} + K_{r1}(H^+) + (H^+)^2} \right) \quad (25)$$

We then obtain the alternative expression for  $E_m$ :

$$E_m = E^\circ(A/A^{2-}) + \frac{RT}{2F} \ln \frac{(K_{r1}K_{r2} + K_{r1}(H^+) + (H^+)^2)}{K_{r1}K_{r2}} \quad (26)$$

Equations (24) and (26) describe the same parameter,  $E_m$ , the potential of the half-cell in which A is reduced by 2 electrons when the sum of the activities of the oxidant equals the sum of the activities of the reductant. Equating these expressions, the relationship between the two standard potentials is:

$$E^\circ(A, 2H^+/AH_2) = E^\circ(A/A^{2-}) - \frac{RT}{2F} \ln (K_{r1}K_{r2}) \quad (27)$$

If potentials are in mV and  $T \approx 298$  K:

$$E^\circ(A, 2H^+/AH_2) \approx E^\circ(A/A^{2-}) + 29.6(pK_{r1} + pK_{r2}) \quad (28)$$

To obtain a more convenient expression for fitting data of  $E_m$  vs. pH to the appropriate function, Eq. (26) could be modified by incorporating the pH-independent term,  $K_{r1}K_{r2}$  in the denominator, with the standard potential to yield a new constant,  $E_0$ :


$$E_0 = E^\circ(A/A^{2-}) - \frac{RT}{2F} \ln (K_{r1}K_{r2}) \quad (29)$$

$$E_m = E_0 + \frac{RT}{2F} \ln (K_{r1}K_{r2} + K_{r1}(H^+) + (H^+)^2) \quad (30)$$

Clark<sup>22</sup> uses this procedure extensively. However, the definition of  $E_0$  is often not immediately apparent in some more complex situations, and the symbol is very frequently used for a formal potential with a specific definition; this introduces an ambiguity which is discussed below.

#### 4.4. Practical Application to One-Electron Reduction Potentials

Both equilibrium constants and mid-point potentials are usually measurable only in terms of concentrations rather than activities, and the expressions for the pH-dependence of  $E_m$  for one-electron couples will be derived in terms of these measurable quantities. Consider first the one-electron reduction of A, which can be represented by the two alternative equations:



These are linked by the prototropic equilibrium 29. The practical ionization constant for dissociation of AH· will mix concentrations and activities:

$$K'_r = \frac{[A^{\cdot-}](H^+)}{[AH\cdot]} (=K'_{29}). \quad (31)$$

The use of  $K'$  rather than  $K$  denotes the use of concentrations for all species except  $H^+$  (activities of  $H^+$  are measured with the glass electrode or calculated using standard buffers). The subscript  $r$  with  $K'$  is used since  $A$  is the oxidant and  $AH\cdot/A^{\cdot-}$  the reductant. Since there is only one ionization of the reductant considered,  $K'_r$  rather than  $K'_{r1}$  can be used.

The Nernst expression corresponding to the simpler alternative reaction 32a is:

$$E_h = E^\circ(A/A^{\cdot-}) + \frac{RT}{F} \ln \frac{(A)}{(A^{\cdot-})}. \quad (32)$$

When modified to include activity coefficients,  $f$  defined by:

$$(A) = f_A[A] \quad (33)$$

etc., this yields:

$$E_h = E^\circ(A/A^{\cdot-}) + \frac{RT}{F} \ln \frac{f_A}{f_{A^{\cdot-}}} + \frac{RT}{F} \ln \frac{[A]}{[A^{\cdot-}]}. \quad (34)$$

Representing  $A$  by  $S_o$  and the sum of  $A^{\cdot-}$  and  $AH\cdot$  by  $S_r$  as before, and following the general approach described above:

$$[A^{\cdot-}] = [S_r] \left( \frac{K'_r}{K'_r + (H^+)} \right) \quad (35)$$

$$E_h = E^\circ(A/A^{\cdot-}) + \frac{RT}{F} \ln \frac{f_A}{f_{A^{\cdot-}}} + \frac{RT}{F} \ln \frac{[S_o]}{[S_r]} + \frac{RT}{F} \ln \left( \frac{K'_r + (H^+)}{K'_r} \right). \quad (36)$$

If a formal potential,  $E_0$  is now defined as the mid-point potential when the ratio of the total concentrations of oxidized and reduced species is unity, and  $H^+$  is at unit activity ( $pH = 0$ ), then from Eq. (36):

$$E_0 = E^\circ(A/A^{\cdot-}) + \frac{RT}{F} \ln \frac{f_A}{f_{A^{\cdot-}}} + \frac{RT}{F} \ln \left( \frac{K'_r + 1}{K'_r} \right). \quad (37)$$

$$E_m = E_0 + \frac{RT}{F} \ln \left( \frac{K'_r + (H^+)}{K'_r + 1} \right). \quad (38)$$

For many species of interest, such as semiquinones,  $K'_r \ll 1$  so that:

$$E_0 \approx E^\circ(A/A^{\cdot-}) + \frac{RT}{F} \ln \frac{f_A}{f_{A^{\cdot-}}} - \frac{RT}{F} \ln K'_r \quad (39)$$

$$E_m \approx E_0 + \frac{RT}{F} \ln (K'_r + (H^+)). \quad (40)$$

The latter two equations also result if  $E_0$  has no specific definition but merely represents taking out the pH-independent terms in the expressions for  $E_h$  or  $E_m$ . The values of  $E_0$  calculated from Eq. (39) rather than Eq. (37) may differ by negligibly small amounts, e.g. by 0.3 mV if  $pK'_r > 2$ ; however, it is recommended that  $E_0$  is defined clearly as the formal potential described above even though it introduces extra terms such as  $(K'_r + 1)$  in the equations. We can then use consistently subscripts with  $E_m$  to denote pH and by definition,  $E_{m0} = E_0$ .

Equation (38) may also be derived starting from the alternative Nernst relationship corresponding to reaction 32b:

$$E_h = E^\circ(A, H^+/AH\cdot) + \frac{RT}{F} \ln \frac{(A)(H^+)}{(AH\cdot)}. \quad (41)$$

An expression is derived for  $[AH\cdot]$  in terms of  $[S_r]$ , etc., except that  $E_0$  in Eq. (38) now becomes (using the defined formal potential as before):

$$E_0 = E^\circ(A, H^+/AH\cdot) + \frac{RT}{F} \ln \frac{f_A}{f_{AH\cdot}} + \frac{RT}{F} \ln (K'_r + 1). \quad (42)$$

At constant ionic strength, Eqs. (37) and (42) equate, so that

$$E^\circ(A/A^{\cdot-}) = E^\circ(A, H^+/AH\cdot) + \frac{RT}{F} \ln \frac{f_A}{f_{AH\cdot}} - \frac{RT}{F} \ln K'_r. \quad (43)$$

Since:

$$K'_r = K'_r \frac{f_{A^{\cdot-}}}{f_{AH\cdot}} \quad (44)$$

$$E^\circ(A/A^{\cdot-}) = E^\circ(A, H^+/AH\cdot) + \frac{RT}{F} \ln K'_r. \quad (45)$$

This relationship may be re-arranged in the same form as Eq. (28):

$$E^\circ(A, H^+/AH\cdot) \approx E^\circ(A/A^{\cdot-}) + 59.2 \text{ p}K'_r. \quad (46)$$

Obviously, Eq. (45) may also be derived more directly in the same way as was Eq. (27), using activities rather than concentrations, or by simply considering the free-energy changes in the reactions concerned.




Note that  $E_0$  as defined by Eq. (42) does not equate to  $E^\circ(A, H^+/AH\cdot)$ , but if  $K'_r \ll 1$  it approximates to it at low ionic strength. These formal potentials may be defined to include not only activity coefficients, but also e.g. complexation with counter-ions in the supporting electrolyte. Thus for the Fe(III)/Fe(II) couple,  $E_0$  is dependent upon the nature of the acid as well as ionic strength. An exten-

sion of this approach is to define the formal potential to have some other 'standard' condition (really, non-standard!). For example, in biochemical systems ( $H^+$ ) may be redefined with  $pH = 7$  as the 'standard' state; a symbol such as  $E'_0$  may then be used.

Regardless of the definition of  $E_0$ , at any two pH values,  $i$  and  $j$ , Eq. (38) yields:

$$E_{mi} = E_{mj} + \frac{RT}{F} \ln \left( \frac{K'_i + 10^{-i}}{K'_i + 10^{-j}} \right). \quad (47)$$

For the radical/reductant one-electron couple, the half-cell may be written in several forms:



The Nernst expression for reaction 33a is:

$$E_h = E^\circ(A \cdot^-/A^{2-}) + \frac{RT}{F} \ln \frac{[A \cdot^-]}{[A^{2-}]} \quad (48)$$

The radical species  $AH \cdot/A \cdot^-$  is now the oxidant, rather than the reductant as in the example immediately preceding. Thus we denote:

$$K'_0 = \frac{[A \cdot^-](H^+)}{[AH \cdot]} \quad (= K'_{29}) \quad (49)$$

(cf. (Eq. 31)), and

$$[A \cdot^-] = [S_0] \left( \frac{K'_0}{K'_0 + (H^+)} \right) \quad (50)$$

(cf. (Eq. 35)). The reductant concentration,  $[A^{2-}]$  is defined by Eq. (22) except that concentrations replace activities and practical ionization constants  $K'_{r1}$ ,  $K'_{r2}$  are used. We then obtain:

$$E_0 = E^\circ(A \cdot^-/A^{2-}) + \frac{RT}{F} \ln \frac{f_{A \cdot^-}}{f_{A^{2-}}} + \frac{RT}{F} \ln \left( \frac{K'_0}{K'_0 + 1} \right) + \frac{RT}{F} \ln \left( \frac{K'_{r1}K'_{r2} + K'_{r1}(H^+) + (H^+)^2}{K'_{r1}K'_{r2}} \right) \quad (51)$$

If the formal potential,  $E_0$  is defined strictly as before, with unit ratio of total concentrations of oxidant to reductant, and  $(H^+) = 1$ , then:

$$E_0 = E^\circ(A \cdot^-/A^{2-}) + \frac{RT}{F} \ln \frac{f_{A \cdot^-}}{f_{A^{2-}}} + \frac{RT}{F} \ln \left( \frac{K'_0}{K'_0 + 1} \right) + \frac{RT}{F} \ln \left( \frac{K'_{r1}K'_{r2} + K'_{r1} + 1}{K'_{r1}K'_{r2}} \right) \quad (52)$$

$$E_m = E_0 + \frac{RT}{F} \ln \left( \frac{K'_{r1}K'_{r2} + K'_{r1}(H^+) + (H^+)^2}{K'_0 + (H^+)} \right) + \frac{RT}{F} \ln \left( \frac{K'_0 + 1}{K'_{r1}K'_{r2} + K'_{r1} + 1} \right) \quad (53)$$

The last term in Eq. (53) will be negligible if  $K'_0$ ,  $K'_{r1}$ ,  $K'_{r2} \ll 1$ . Indeed, as noted above, it would be omitted if  $E_0$  was simply defined by combining the pH-independent terms in Eq. (51).

Corresponding pairs of expressions for  $E_0$  and  $E_m$  are derived setting out from the alternative orienting reactions 33b-d. The standard potentials are related by:

$$E^\circ(A \cdot^-/A^{2-}) = E^\circ(A \cdot^-, H^+/AH^-) + \frac{RT}{F} \ln K_{r2} \quad (54a)$$

$$= E^\circ(A \cdot^-, 2H^+/AH_2) + \frac{RT}{F} \ln K_{r1}K_{r2} \quad (54b)$$

$$= E^\circ(AH \cdot, H^+/AH_2) + \frac{RT}{F} \ln \frac{K_{r1}K_{r2}}{K'_0} \quad (54c)$$

These relationships, and also Eqs. (27) and (45) can be most simply obtained by writing down the appropriate equations and summing the free energy changes involved.

Again, for any two pH values,  $i$  and  $j$ , Eq. (51) or Eq. (53) yields:

$$E_{mi} = E_{mj} + \frac{RT}{F} \ln \left( \frac{K'_{r1}K'_{r2} + K'_{r1}(10^{-i}) + 10^{-2i}}{K'_{r1}K'_{r2} + K'_{r1}(10^{-j}) + 10^{-2j}} \right) + \frac{RT}{F} \ln \left( \frac{K'_0 + 10^{-i}}{K'_0 + 10^{-j}} \right) \quad (55)$$

We neglected earlier the possibility of protonation of the oxidant, A as in equilibrium 30. Returning to the one-electron reduction of A, to incorporate this equilibrium we define:

$$K'_0 = \frac{[A](H^+)}{[AH^+]} \quad (= K'_{30}) \quad (56)$$

Following the usual approach we obtain, for example:

$$E_i = E_j + \frac{RT}{F} \ln \left( \frac{K'_r + 10^{-i}}{K'_r + 10^{-j}} \right) \left( \frac{K'_o + 10^{-j}}{K'_o + 10^{-i}} \right) \quad (57)$$

This describes the variation with pH of the mid-point potential of the oxidant/radical one-electron couple, in place of Eq. (47).

#### 4.5. Examples of the pH-Dependence of One-Electron Reduction Potentials and Suggestions for Symbols

The quinone/semiquinone and semiquinone/hydroquinone one-electron couples are illustrated in Figs. 1 and 2 respectively. The mid-point potentials,  $E_m$  are plotted vs. pH for 1,4-benzoquinone. (The numerical values used are those calculated in Sec. 5.5, below). The pH range 0-14 is separated into regions with  $pK$  values defining the 'break points'. In each region, the prototropic forms of the species *predominating* are shown in a box: oxidant, upper species; reductant, lower. The positions of the various standard potentials,  $E^\circ$  are also given. It should be stressed that the apparent coincidence of some standard potentials with intercepts (pH 0) or asymptotes (pH  $\approx$  14) in the curves of  $E_m$  vs. pH arises because of the identity:  $0 \ll (pK_s, pK_{r1}, pK_{r2}) \ll 14$  in this example, and not by definition ( $pK_s = pK_a$  for dissociation of the semiquinone species, QH $^\cdot$ ).

It has been stressed already that  $E^\circ$  should always be qualified with the half-cell reaction in parenthesis, as shown in Figs. 1 and 2, and that  $E_0$  is to be preferred as a defined, formal potential rather than a collection of constants. However, convenient abbreviations to qualify  $E_m$  are not so simply defined; perhaps it is reasonable to use the prototropic forms predominating over the pH range of most interest. Thus the abscissae in Figs. 1 and 2 might be labeled:  $E_m(A/A^\cdot)$  and  $E_m(Q^\cdot, 2H^+/QH_2)$  respectively. We stress again that  $E^\circ$  does *not* vary with pH.

It has been common practice to use superscripts to qualify symbols for first and second one-electron reduction potentials, with subscripts for pH, e.g.  $E_1^\circ(A/A^\cdot)$  or  $E_{13.5}^{2-}(A^\cdot/A^{2-})$ . This now seems superfluous and possibly confusing. On the other hand, if results are described as

mid-point potentials throughout (except where standard potentials are clearly denoted), it seems reasonable to use  $E_i$  for simplicity rather than  $E_{mi}$ , where the subscript  $i$  is the pH.




FIG. 1. Variation of the mid-point potential,  $E_m$  with pH of the one-electron couple: quinone/semiquinone for 1,4-benzoquinone.





FIG. 2. Variation of the mid-point potential,  $E_m$  with pH of the one-electron couple: semiquinone/hydroquinone for 1,4-benzoquinone.

The variation of  $E_m$  with pH may be influenced by prototropic functions not closely associated with the redox center, if the  $pK_a$  of the function differs in oxidant and reductant. Figure 3 shows an example of the effect of a basic function in the substituent in a nitroaryl compound. The unsubstituted imidazolyl nitrogen has  $pK_a \leq 0$  in the ground state and may be ignored. However, this site is protonated in the electron adduct (radical), with  $pK_{r1} \approx 5.0$ . The piperidino nitrogen in the substituent protonates with  $pK_0' \approx 7.6$  in the ground state, but the inductive effect of the nitroaryl group is reduced in the electron-adduct:  $pK_{r2}' \approx 8.5$  fits the experimental data. This shift in  $pK_a$  of  $\sim 0.9$  is observed in spite of an 'insulating' saturated carbon chain separating the basic site and the redox center. (In this example, the nitro group will be protonated in the radical, but this occurs at pH values lower than those shown.)

Similarly, other unpublished work by the author indicates the carboxylate function in 4-nitrobenzoic acid dissociates with a  $pK_a$  about 0.9 higher in the radical-ion than the ground state. Such effects, if ignored, result in significant errors in extrapolating to lower pH values. They may be present to some extent, although as yet undetected, in biologically-important redox couples involving tryptophan and tyrosine, for example.

#### 4.6. The Use of Mid-Point Potentials in Calculating Equilibrium Constants

The Introduction (Sec. 1) showed how reduction potentials were related to electron-transfer equilibria such as 1:



If A, B and/or the radicals,  $A^{\cdot-}$ ,  $B^{\cdot-}$  are involved in prototropic equilibria, then the measured mid-point potentials  $E_m$ , will yield, via Eq. (5), an apparent or effective equilibrium constant,  $K_i$  where:

$$K_i \approx \left( \frac{[S_A][S_{B^{\cdot-}}]}{[S_B][S_{A^{\cdot-}}]} \right) \quad (4')$$

This is a modification of Eq. (4) where, following previous use, we replace [A],  $[A^{\cdot-}]$ , etc. by the sums of the concentrations of related prototropic conjugates:  $[S_{A^{\cdot-}}] = ([A^{\cdot-}] + [AH^{\cdot-}])$ , etc. Such an effective equilibrium constant is most useful in predicting the overall equilibrium, or direction of electron flow, as illustrated in Fig. 4.

This figure represents an equilibrium 1 in which, like semiquinones for example, the reductant species  $A^{\cdot-}$ ,  $B^{\cdot-}$  participate in prototropic equilibria, with  $E^\circ(A/A^{\cdot-})$  and  $E^\circ(B/B^{\cdot-}) = -400$  and  $-300$  mV respectively but with  $pK_a$  for the dissociation of the protonated conju-

gates,  $AH^{\cdot-}$  and  $BH^{\cdot-} = 8$  and 5 respectively. At  $pH \geq 9$ ,  $K_i$  can be calculated from Eqs. (1) and (5) to be  $\approx 49$ . However, because  $E_m$  increases more rapidly with decreasing pH for the oxidant A compared to B, the effective position of the equilibrium reverses at  $pH \leq 6$ . At  $pH \leq 4$ ,  $K_i$  is approximately constant at  $\approx 0.05$ .

It is preferable to treat such pH-dependent equilibria in this way rather than add protons to equilibrium 1 and work with complex equilibrium expressions. There is, however, an important kinetic consequence of these prototropic equilibria in many instances. It is commonly observed that protonation (or absence of ionization) of




FIG. 3. Variation of the mid-point potential,  $E_m$  with pH of the one-electron reduction potential of 1-(2-piperidylethyl)-2-nitroimidazole ( $ArNO_2$ )




FIG. 4. Variation of the mid-point potentials,  $E_m$  with pH of the one-electron couples of two hypothetical oxidants A and B (see text) and the logarithm of the effective equilibrium constant  $K_i$  for the one-electron transfer equilibrium between these oxidants and their electron-adducts

basic (or acidic) functions slows down the rates of electron transfer reactions, often dramatically, as noted in Sec. 3.5. The rate of approach to equilibrium 1 may depend, for example, on the fraction of radicals from A present in the form  $A^{\cdot-}$  rather than the much less reactive AH. Thus the electron-transfer equilibrium 1 may not be kinetically achievable under practicable conditions even though calculation readily establishes the thermodynamic feasibility. In general, prototropic equilibria are established so rapidly that the kinetics of proton transfer are seldom rate-determining.

Other, some more complex, illustrations of the effects of prototropic equilibria on reduction potentials have been discussed, e.g. for quinones,<sup>6,39-42</sup> nitroaromatic compounds,<sup>7</sup> flavins,<sup>43</sup> phenoxyl radicals,<sup>8</sup> etc. The principles of the calculations are simply as outlined above in Sec. 4.3. In some instances, however, the formulae given represent approximations to those derived herein. In almost every case the practical implications of such differences are negligible.

## 5. Calculation of One-Electron Reduction Potentials Using Radical Formation Constants

### 5.1. Introduction

Radicals, e.g.  $A^{\cdot-}$  may be present in equilibrium with oxidant, A and reductant,  $A^{2-}$  or their protonated conjugates:



and a radical formation constant can be defined:

$$K_f = \frac{(A^{\cdot-})^2}{(A)(A^{2-})} \quad (58)$$

The value of  $K_f$  is obviously a measure of the steady-state concentrations of radicals,  $A^{\cdot-}$  obtained on mixing oxidant A with reductant,  $A^{2-}$ . When experimental conditions result in sufficiently high concentrations of radicals to be measured, estimates of  $K_f$  can be used in conjunction with the two-electron potentials,  $E^\circ(A/A^{2-})$  or  $E^\circ(A, 2H^+/AH_2)$  to obtain estimates of the one-electron couples,  $E^\circ(A/A^{\cdot-})$ , etc.

### 5.2. Derivation of Expressions

Reaction 34 (above) can be obtained by subtracting 33a from 32a:



Eq. (59) is obtained by subtracting the corresponding free-energy changes:

$$E^\circ(A/A^{\cdot-}) - E^\circ(A^{\cdot-}/A^{2-}) = \frac{RT}{F} \ln K_f \quad (59)$$

If we add reaction 32a to reaction 33a we obtain reaction 31a. Noting that  $n = 2$  in the conversion of free energy to potential, Eq. (2), in the latter reaction:

$$E^\circ(A/A^{\cdot-}) + E^\circ(A^{\cdot-}/A^{2-}) = 2 E^\circ(A/A^{2-}) \quad (60)$$

(cf. Eq. (6)). Adding Eqs. (59) and (60) yields:

$$E^\circ(A/A^{\cdot-}) = E^\circ(A/A^{2-}) + \frac{RT}{2F} \ln K_f \quad (61)$$

while subtraction gives:

$$E^\circ(A^{\cdot-}/A^{2-}) = E^\circ(A/A^{2-}) - \frac{RT}{2F} \ln K_f \quad (62)$$

Using Eq. (28) with potentials in mV and  $T \approx 298$  K:

$$E^\circ(A/A^{\cdot-}) \approx E^\circ(A, 2H^+/AH_2) - 29.6(pK_{r1} + pK_{r2} + pK_f) \quad (63)$$

$$E^\circ(A^{\cdot-}/A^{2-}) \approx E^\circ(A, 2H^+/AH_2) - 29.6(pK_{r1} + pK_{r2} - pK_f) \quad (64)$$

where  $K_{r1}$ ,  $K_{r2}$  are the dissociation constants for  $AH_2$  and  $AH^-$  respectively as defined in Eqs. (18) and (19).

It may be difficult to measure  $K_f$  directly, e.g. because very high pH values may be required to ionize completely the reductant to  $A^{2-}$ . It is much more convenient to define an apparent formation constant,  $K_{fi}$  at an experimentally accessible pH,  $i$ :

$$K_{fi} = \frac{(S_s)^2}{(S_o)(S_r)} \quad (65)$$

We follow previous symbolism and define  $S_o$  and  $S_r$  as the sums of the oxidant (only A) and reductant ( $AH_2 + AH^- + A^{2-}$ ) respectively, as before, and use  $S_s$  to represent the sum of the radical intermediate species. The subscript  $s$  is convenient because the radical will be a semiquinone in many examples. It is easily shown, using the approach already used in Sec. 4.3, that:

$$K_f = K_{fi} \left( \frac{K_s}{K_s + (H^+)} \right) \left( \frac{K_{r1}K_{r2} + K_{r1}(H^+) + (H^+)^2}{K_{r1}K_{r2}} \right) \quad (66)$$

where  $K_{r1}$ ,  $K_{r2}$  are defined in Eqs. (18) and (19) as before and  $K_s = K_{29}$ .

As noted earlier, in practice, concentrations rather than activities are generally measured. We will usually obtain an estimate of  $K_f$  or  $K_{fi}$  at some ionic strength,  $I$ . Using  $K'_f$ ,  $K'_{fi}$  as before to denote the apparent formation constants thus defined in concentration terms except for  $(H^+)$ , together with the mid-point potentials  $E_{mi}$  measured at the same ionic strength, it can be shown that:

$$E_{mi}(A/A\cdot^-) = E_{mi}(A/A^{2-}) + \frac{RT}{2F} \ln K'_{fi} \quad (67)$$

$$E_{mi}(A\cdot^-/A^{2-}) = E_{mi}(A/A^{2-}) - \frac{RT}{2F} \ln K'_{fi} \quad (68)$$

The mid-point condition now refers to the sum of the concentrations of oxidant being equal to the sum of the concentrations of reductant. (The activity coefficient terms in Eqs. (36) and (51) cancel out the terms in Eq. (69)).

$$K'_f = K_f \frac{f_{A\cdot^-}}{f_{A^{2-}}} \quad (69)$$

### 5.3. Examples of Calculations

The one-electron reduction potential of the oxidant, duroquinone (DQ) can be estimated using electrochemical data for the reduction potential of the two-electron couple: duroquinone/durohydroquinone, and spectrophotometric measurement of the semiquinone concentration present in mixtures of the quinone and hydroquinone at high pH. Interpolating Baxendale and Hardy's data<sup>44,45</sup> to yield values at 298 K give:  $pK'_{r1} = 11.24$ ,  $pK'_{r2} = 12.83$  and  $pK'_f = 0.11$  at  $I = 0.65$ . Conant and Fieser<sup>47</sup> indicate  $E^\circ(\text{DQ}, 2\text{H}^+/\text{DQH}_2) = 480$  mV (but used 50% ethanol). Equation (63) then yields an estimate of  $E^\circ(\text{DQ}/\text{DQ}\cdot^-) = -236$  mV, ignoring the use of practical rather than thermodynamic equilibrium constants. Alternatively, Michaelis et al.<sup>48</sup> estimated  $E_{m7}$ (duroquinone/durohydroquinone) using 20% pyridine in water at 303 K, for pH ( $i$ ) = 7.4 to 13.5; a value of  $E_{m7} = 41$  mV is interpolated. Baxendale and Hardy's data,<sup>44,45</sup> and  $pK'_s = 5.1$  from pulse radiolysis,<sup>3</sup> yields  $K'_f = 1.1 \times 10^{-10}$ . Using Eq. (67),  $E_f(\text{DQ}/\text{DQ}\cdot^-) = -254$  mV is estimated. These values are similar to those obtained quite independently by Wardman and Clarke<sup>32</sup> using pulse radiolysis.

(A number of authors have used  $pK'_{r2} = 13.2$  for duroquinone, as tabulated from Bishop and Tong<sup>46</sup> from Baxendale and Hardy's measurements. The original data<sup>44</sup> clearly show  $pK'_{r2}$  varying between 13.17 at 14.9 °C to 12.70 at 29.8 °C, from which the present author interpolates a value of 12.83 at 298 K).

Electron spin resonance measurements<sup>49</sup> of the steady-state concentrations of ascorbyl radicals produced on mixing the reductant, ascorbic acid with the corresponding oxidant, dehydroascorbic acid gave estimates of  $K'_f$  between pH 4.0 and 6.4. An estimate of  $K'_f = 1.2 \times 10^{-3}$  is obtained using Eq. (66) and  $pK'_{r1} = 4.21$ ,  $pK'_{r2} = 11.52$  (representative literature values) and  $pK'_s = -0.45$ .<sup>50</sup> A value of  $E_{m0} = 400$  mV for the two-electron reduction (see Clark,<sup>22</sup> p.470), will be close to  $E^\circ(A, 2\text{H}^+/\text{AH}_2)$ , from Eq. (24). Eq. (64) yields  $E^\circ(A\cdot^-/A^{2-}) \approx 19$  mV for  $A^{2-}$  = ascorbic acid. Steenken and Neta,<sup>8</sup> using the pulse radiolysis redox equilibrium method, estimated  $E_{13.5}(A\cdot^-/A^{2-}) = 15$  mV. This is well within the uncer-

tainty of the independent calculation. (Because  $pK'_{r2} \approx 11.5$ ,  $E_{13.5}(A\cdot^-/A^{2-}) \approx E^\circ(A\cdot^-/A^{2-})$ ).

### 5.4. Uncertainties In the Calculations

As an example, consider the calculation for  $E^\circ(A/A\cdot^-)$  for A = simple quinones. Clark's tables<sup>22</sup> of values of  $E_0$  for the two-electron reduction of many quinones indicate random uncertainties of 5-15 mV, the higher values including measurements in partly non-aqueous solvents. In these cases  $E_0$  approximates to  $E^\circ(A, 2\text{H}^+/\text{AH}_2)$ . To calculate the uncertainty in the estimate of  $E^\circ(A/A\cdot^-)$ , for example, we also need to consider the uncertainty in the sum:  $pK'_{r1} + pK'_{r2} + pK'_f$ , as indicated in Eq. (63). Estimates<sup>44,46</sup> of  $pK'_{r1}$ ,  $pK'_{r2}$  and  $pK'_f$  refer to ionic strengths of 0.65 or 0.375, and the substitution of these practical constants for the thermodynamic constants required in Eq. (63) introduces systematic errors.

Perrin et al.<sup>51</sup> derived a formula to correct practical ionization constants. For dissociation of the weak acid  $\text{HA}^{(n-1)-}$ :



$$pK \approx pK' + [(2n - 1)/2]f(I). \quad (70)$$

We have adapted his formula to use the ionic strength function,  $f(I)$  previously defined:

$$f(I) \approx 1.02(I^{\frac{1}{2}}(1 + I^{\frac{1}{2}})^{-1} - 0.2I). \quad (13)$$

At high ionic strengths,  $I \approx 0.4$ -0.6, reliable use of Eq. (70) is doubtful. However, we see that for uncharged quinones (e.g. duroquinone),  $pK'_{r1}$  and  $pK'_{r2}$  may underestimate the thermodynamic values by ca. 0.1-0.2 and 0.5 respectively. It can be shown that

$$pK_f \approx pK'_f - f(I) \quad (71)$$

for uncharged oxidants A, i.e. for uncharged quinones. The semiquinone formation constant decreases with increasing  $I$  so that  $pK'_f$  overestimates  $pK_f$  by ca. 0.3 at  $I \approx 0.4$ -0.6. There is thus partial canceling-out of these systematic errors in the application of Eq. (63). The systematic error introduced into the calculation of  $E^\circ(A/A\cdot^-)$  will still amount to the estimate being ca. 10 mV more positive than the true value.

Even for these simple quinones, generally only one estimate<sup>44,46</sup> of the ionization and formation constants required is available. Even discounting random errors in their determination, the calculations of one-electron reduction potential as described in this section must involve uncertainties of at least 10-20 mV is general. Similar consideration may be given to other applications of the formulae derived.

These illustrations may be used, in turn, to refine calculations of standard potentials using experimental measurements of ionization and formation constants. Thus

the literature data<sup>4,5,6,42</sup> for 1,4-benzoquinone may be corrected to yield estimates of the thermodynamic constants  $pK_{a1}$ ,  $pK_{a2}$ ,  $pK_1$  and  $pK_2$  of 10.0, 11.9, 4.0 and -0.97 respectively. Using the well-established<sup>22</sup>  $E^\circ(Q,2H^+/QH_2) = 699$  mV yields estimates of  $E^\circ(Q,Q\cdot^-) = 78$  mV and  $E^\circ(Q\cdot^-,Q^{2-}) = 24$  mV, the former some 20 mV lower than previous estimates.<sup>42</sup> In fact, such corrections are not so straight-forward, since Baxendale and Hardy<sup>44</sup> included some activity coefficients (of the buffers used) in defining  $K'_1$ ,  $K'_2$ . The simple application of Eqs. (70) or (71) may be inappropriate in some instances.

## 6. Recommended Redox Indicators and Their Potentials

The choice of redox indicators B with which to establish and measure the position of the desired equilibrium I with the unknown A is influenced by several factors. Ideally, determinations of  $K_I$  with two indicators — one higher than the unknown by (say) 50-100 mV, one lower — will lead to the most reliable value. In practice, the choice depends on solubilities, absorption spectra of reactants and products,  $pK_a$ 's, kinetic constraints, (especially the need for fast electron transfer, see above, Sec. 3.5) and ready availability with adequate purity.

### 6.1. Oxygen

Oxygen is an important reactant with many radicals, although electron-transfer rather than radical-addition is a pre-requisite and it is somewhat inconvenient to vary the concentration of oxygen over a wide range. It is useful to draw attention again to the standard definition:  $E^\circ(O_2(1 \text{ atm.})/O_2\cdot^-) = -325$  mV whereas  $E(O_2(1 \text{ mol dm}^{-3})/O_2\cdot^-) = -155$  mV.

### 6.2. Quinones


Reduction potentials for the couples  $A/A\cdot^-$  and  $A\cdot^-/A^{2-}$  for A = quinones may be calculated<sup>4,5,6,42</sup> from the ionization constants of  $AH_2$  and the semiquinone formation constants, as described above (Sec. 5). Completely independent estimates of  $E^\circ(A/A\cdot^-)$  for A = duroquinone are provided by the measurements of  $\Delta E_1$  corrected to  $I = 0$  for A = duroquinone and B = 1,1'-dibenzyl-4,4'-bipyridinium dication.<sup>32</sup> Values of  $\Delta E_1$  of  $110 \pm 4$ <sup>32</sup>,  $113 \pm 4$ <sup>32</sup>, and  $107 \pm 3$ <sup>33</sup> mV together with  $E^\circ(B/B\cdot^-) = -354$  mV (but see below, Sec. 6.3) yield  $E^\circ(A/A\cdot^-) = -244$  mV for duroquinone, in good agreement with the values calculated<sup>4,5,6,42</sup> from dissociation constants (see also Sec. 5.3). A value of  $E^\circ(A/A\cdot^-) = -375$  mV for 9,10-anthraquinone-2-sulfonate is a reasonable mean of estimates based on equilibria involving duroquinone<sup>7,32,52</sup>, and two bipyridinium indicators<sup>32,52,53</sup> and is quite close to the value -360 mV obtained polarographically at high pH.<sup>24</sup> The more negative potential now recommended for benzyl viologen (see below) will

result in corresponding alterations to the values for the quinone couples, e.g. to -260 mV for duroquinone and -390 mV for 9,10-anthraquinone-2-sulfonate.

Reduction potentials for other quinone couples have been calculated<sup>4,5,6,42</sup> from literature data and experimentally derived<sup>43</sup> from equilibrium measurements. They can be relied upon when confirmed by independent routes, e.g. when the values are consistent with measurements of the  $A\cdot^-/O_2$  equilibrium.<sup>5,6,43</sup> 1,4-Benzoquinone (Q) is a recommended standard, with  $E^\circ(Q/Q\cdot^-) = 78$  mV and  $E^\circ(Q\cdot^-/Q^{2-}) = 24$  mV, as calculated in Sec. 5.4.

### 6.3. Bipyridinium Compounds (Viologens)

While these viologens are, in principle, excellent redox indicators because the radicals  $A\cdot^-$  are essentially stable in aqueous solution and have a high extinction coefficient at wavelengths where interfering absorptions are seldom a problem, a note of caution is appropriate. Not only is variable water of hydration a problem (relatively minor in this context) with the dimethyl derivative (paraquat), but variable purity of commercial samples of both viologens has been noted. Note, however, that the spectra of the viologen radical cations are concentration-, temperature- and time-dependent<sup>32,54-59</sup> and that electrochemical measurements may involve higher concentrations of these cations than are utilized in pulse radiolysis measurements. The spectral changes arise because the radical cations  $V\cdot^+$  obtained on one-electron reduction of viologens,  $V^{2+}$  dimerize:



Estimates of the apparent dimer dissociation constant,  $K'_D$  have been made. These vary from  $\sim 1.5 \times 10^{-3}$  mol  $\text{dm}^{-3}$  for methyl viologen<sup>55-57</sup> to  $\sim 2.7 \times 10^{-3}$  (ethyl viologen)<sup>58</sup> and  $2 \times 10^{-5}$  mol  $\text{dm}^{-3}$  (benzyl viologen),<sup>59</sup> under the experimental conditions used ( $K'_D$  is ionic strength dependent). If  $x$  is the fraction of radicals in the monomeric form and  $S$ , is the total concentration of reductant ( $[V\cdot^+] + 2[(V\cdot^+)_2]$ ), then:

$$K'_D = \frac{2Sx^2}{(1-x)} \quad (72)$$

The  $\sim 100$ -fold lower value of  $K'_D$  for benzyl viologen compared to its methyl analogue has serious implications in using the former as a redox indicator, since it is seen that if e.g.  $S_i = 10^{-5}$  mol  $\text{dm}^{-3}$ ,  $x \approx 0.6$  with benzyl viologen. By application of the Nernst relationship in a similar manner to that used in Sec. 4, it can be shown that:

$$E_m = E^\circ(V^{2+}/V\cdot^+) - \frac{RT}{F} \ln \left\{ \frac{K'_D}{4S_i} ([1 + (8S_i/K'_D)]^{\frac{1}{2}} - 1) \right\} \quad (73)$$




If, e.g.  $K_D = 5 \times 10^{-5} \text{ mol dm}^{-3}$  and  $S_r = 2.5 \times 10^{-4} \text{ mol dm}^{-3}$ ,  $E_m$  is *ca.* 30 mV more positive than  $E^\circ(V^{2+}/V^{\cdot+})$ .

Concentration-dependent mid-point potentials for benzyl viologen ( $BV^{2+}$ ) have been reported<sup>60,61</sup> and it seems likely that the value of this reference potential is more negative than the electrochemical data suggest.<sup>61</sup> A provisional value of  $-370 \text{ mV}$  would be reasonable, pending further investigation; such a value is also consistent with unpublished work by the author with Mr. E.D. Clarke. Experiments determining  $\Delta E$  for nitroaryl compounds vs. both benzyl and methyl viologen indicated either  $E^\circ(V^{2+}/V^{\cdot+})$  for the benzyl analogue was lower than  $-354 \text{ mV}$  (previously assumed) or the value for methyl viologen was higher than the well-established value of  $-448 \text{ mV}$ . The apparent correction necessary was usually  $\sim 16 \text{ mV}$ , in agreement with the new recommendation for  $E^\circ(BV^{2+}/BV^{\cdot+}) = -370 \text{ mV}$ .

This problem of dimerization of viologen radical-cations has serious implications in estimating the value of  $E^\circ(BV^{2+}/BV^{\cdot+})$  from electrochemical measurements. It is much less of a problem when electron-transfer equilibria with  $BV^{\cdot+}$  as reactant are studied by pulse radiolysis, since  $[BV^{\cdot+}]$  is typically  $\leq 1 \mu\text{mol dm}^{-3}$  at equilibrium, and the equilibrium point may well be established before significant dimerization (reverse of reaction 36) can occur. Dimerization is also much less of a problem with methyl viologen ( $MV^{2+}$ ), and there are so many values published (see Table 3, compound 3.8.2) that outliers can be clearly identified. A value of  $E^\circ(MV^{2+}/MV^{\cdot+}) = -448 \text{ mV}$  is recommended. The usefulness of low potential viologens in particular, outweigh these uncertainties. The reported<sup>62</sup> protonation of the methyl viologen radical cation with  $pK_a = 1$  seems more likely ascribable to other reactions<sup>63</sup>, and the pH-independence of these couples is a further advantage.

#### 6.4. Hydroquinones and Phenols

The studies of Steenken and Neta<sup>8,64</sup> of equilibria of the form:




with  $A^{\cdot-}$ ,  $B^{2-} =$  hydroxy- and amino-phenols, phenylenediamines, etc. have provided values of  $E_{13.5}(A^{\cdot-}/A^{2-}) = 23, 43$  and  $174 \text{ mV}$  for  $A^{2-} =$  hydroquinone, 1,2-dihydroxybenzene (catechol) and 4-(*N,N*-dimethylamino)phenol respectively. These are supported by internal consistency of measured values of  $K_{37}$ . Their value of  $E_{13.5}(A^{\cdot-}/A^{2-}) = 266 \text{ mV}$  for  $A^{2-} =$  *N,N,N',N'*-tetramethyl-*p*-phenylenediamine is similarly supported by other redox equilibria,<sup>64</sup> and by earlier electrochemical measurements<sup>65</sup> so that an estimate<sup>8</sup> of 88 mV may be discounted. All the equilibria were measured at  $I \approx 0.5$ . It is worth stressing again that values of reduction potentials enable the *thermodynamic feasibility* of reactions to be calculated, not the *likelihood*; deprotonation of reactants may be necessary before the *rates* of

reaction become sufficiently fast for the reaction to proceed. The lack of reversibility of the NAD<sup>+</sup>/NADH couple for nicotinamide adenine dinucleotide has been discussed.<sup>66</sup>

#### 6.5. Inorganic Indicators Other Than Oxygen

Reference to Table 9 indicates the high reliability of  $E^\circ(\text{ClO}_2/\text{ClO}_2^-) = 934 \text{ mV}$ . More powerful oxidants include halogen- and pseudohalogen radical-anions, e.g.  $(\text{SCN})_2^{\cdot-}$  or  $\text{Br}_2^{\cdot-}$ ; the reduction potentials of these radicals are established to *ca.*  $\pm 30 \text{ mV}$ ; values of  $E^\circ((\text{SCN})_2^{\cdot-}/2\text{SCN}^-) = 1330 \text{ mV}$  and  $E^\circ(\text{Br}_2^{\cdot-}/2\text{Br}^-) = 1660 \text{ mV}$  are presently recommended.

A useful, very low potential inorganic oxidant is  $\text{TI}^+$ , the reduced form of which is in equilibrium with  $\text{TI}_2^+$ :



The equilibrium constant  $K_{38} = 140 \text{ dm}^3 \text{ mol}^{-1}$  and under certain conditions equilibrium 38 may be attained faster than electron transfer between  $\text{TI}^+$  and reductants.<sup>67</sup> Hence providing account is taken of the equilibrium 38, the reduction potential of very low potential oxidants may be derived using  $\text{TI}^+$  as indicator and  $E^\circ(\text{TI}^+/\text{TI}_{\text{aq}}^0) = -1.94 \text{ V}$ .<sup>67</sup>

### 7. Prediction of Reduction Potentials for Unknown Couples

#### 7.1. Use of Polarographic and Cyclic Voltammetric Data Obtained Using Non-Aqueous Solvents

The literature of electrochemical measurements of  $E(A/A^{\cdot-})$ ,  $E(A^{\cdot-}/A^{2-})$  in aprotic solvents is voluminous. Such measurements will generally differ considerably in absolute terms (when corrected to s.h.e., see above, Sec. 2.2) from corresponding values for water. However, relative effects in aprotic solvents, e.g. the influence of substituents<sup>68</sup> in a molecule of known potential in aqueous solution, may be useful. Measurements in water using cyclic voltammetry correlate<sup>69</sup> but do not necessarily equate with the reversible potentials  $E(A/A^{\cdot-})$  (but see Sec. 3.4, above). The greatest discrepancies will be where molecules have substituents with prototropic functions.

#### 7.2. Correlations Between Reduction Potentials and Rate Constants

There are several correlations of  $k_1$ ,  $k_{-1}$  with  $\Delta E_1$  of the form based upon the Marcus theory (e.g. with radiation-produced radicals<sup>64,70,71</sup>). Values of  $E(A/A^{\cdot-})$ , for example, may sometimes be estimated from other rate constants providing they are well below the diffusion-controlled limits. Values of  $k_1$  were correlated with the e.s.r. characteristics (see below) of  $A^{\cdot-}$  for  $A =$  nitrobenzenes,<sup>72</sup> and are therefore linked to reduction potentials.

### 7.3. Correlations Between Reduction Potential and Other Physico-Chemical Parameters

The correlations well established for polarographic potentials,<sup>66</sup> provide a guide to other useful parameters which may be used to predict values for unknown couples. Hammett substituent constants ( $\sigma$  values) are the most useful, e.g. for 5-substitution of 1-methyl-2-nitroimidazole we have:<sup>73</sup>

$$E(A/A\cdot^-)/mV = -(406 \pm 5) + (146 \pm 8)\sigma_p^- \quad (74)$$

Hammett constants are well known to correlate with hyperfine splittings (h.f.s.) in the electron spin resonance spectra of radical-anions of series of derivatives and a useful correlation between the N ( $\text{NO}_2$ ) h.f.s. and  $E(A/A\cdot^-)$  has been made.<sup>7</sup> Variations between mono- and dinitrosubstituted series were noted.<sup>74</sup> Of course, relationships such as Eq. (74) will only be reliable predictors *either* when prototropic functions which could modulate  $E_m$  are absent, *or* when the pH is sufficiently high that  $E_m$  is unaffected by further increases in pH (all groups ionized or deprotonated). Since  $\sigma$  values are a measure of  $\text{p}K_a$  shifts, it would be theoretically possible to modify relationships between  $E_m$  and pH to incorporate  $\sigma$  as a predictor, but the relationships would be complex.

## 8. Arrangement of the Data Tables and Indexes

### 8.1. Content of the Tables

The Tables fall into 3 distinct groups. Tables 1 to 4 present reduction potentials of organic oxidants, in the form  $E(A/A\cdot^-)$  where A is a stable ground state and  $A\cdot^-$  the radical produced on one-electron reduction. Tables 5 to 8 present reduction potentials of the radicals obtained upon one-electron oxidation of organic reductants, in the form  $E(A\cdot^-/A^{2-})$  where  $A^{2-}$  represents a stable reductant and  $A\cdot^-$  the radical (disregarding prototropic state, of course). Table 9 presents reduction potentials of inorganic species, but without separation into groups where the radical is either reductant or oxidant.

The systematic names for many of the compounds are complex, and (except for inorganic couples) rather than arrange alphabetically, compounds in Tables 1 to 8 are subdivided into related groups. Within each group, compounds are generally listed in related sub-groups with increasing element count (C,H,N etc.) in substituents defining order where appropriate. With the structures at the foot of appropriate pages, the various groupings should be reasonably clear. Multiple entries for any one couple appear in order of publication year.

Each table contains 10 main columns: (1) A compound reference number. (2) The reduction potential of ground state or radical, as appropriate, all referring to one-electron reduction and all vs. the standard hydrogen electrode. These potentials are all mid-point potentials,

$E_m$  and in many, although not all cases, may be used as estimates for standard potentials,  $E^\circ$ . Whether a measured or calculated value for  $E$  as tabulated equates or approximates to a standard potential depends largely upon the possible or known occurrence of prototropic equilibria involving either reductant, or oxidant, as discussed in Sec. 4. Column (3) gives the pH of measurement (or to which the calculation refers, where appropriate). Except where electrochemical methods were used most of the values were obtained by measurement of the concentrations of radicals and ground states at equilibrium, as outlined in Secs. 1 and 3. These have the symbol C (for concentrations) in column (9). A minority were determined from the kinetics of approach to equilibrium (Sec. 3.7). In this case K (for kinetics) appears in column (9). Either C or K may appear in parentheses where the data were secondary to, i.e. merely supported, the calculation of  $\Delta E$ . Column (4) gives the reference compound used in the electron-transfer equilibrium, and (5) the reference potential *assumed* in the calculation of  $E$  (see below).

Since many values were derived from radiation-chemical experiments in which *either* one-electron oxidation *or* reduction was selected by using scavengers as described in Secs. 3.1, 3.2, in column (6) the co-solute (scavenger) is given, to help describe the experiment. As described in Sec. 3.8, ionic strength frequently influences measured equilibrium constants or kinetics, and column (7) gives an approximate ionic strength to which the experiments relate. The expression:  $\rightarrow 0$  appears in column (7) if the experimental values were extrapolated to zero ionic strength. Column (8) notes the experimental method used: if only C and/or K appears, as described above, then the method involved monitoring fast electron-transfer equilibria following generation of radicals by pulse radiolysis, before the radical species disappear by other routes. The final column, (10) gives the reference number of the study, using the number assigned by the Radiation Chemistry Data Center of the University of Notre Dame and is common to the many publications of the Center and its online databases.

### 8.2. Alterations to Published Values

In general, only correction to s.h.e. (where appropriate) has been made to the original data. Where a value seems questionable, this is indicated by a dagger alongside the value, usually with an explanatory note in the Comments/method column. A recommended value is indicated by an asterisk. Many of the values may be immediately corrected by the reader using new recommendations or new values for reference potentials as they become available, since the Table indicates the reference couple and value assumed in the original work. Such corrections will be relatively minor and presentation of original data seemed preferable to making minor changes which will themselves be subject to revision as refinements to reference potentials are published.

## 8.3. Inorganic Couples: Standard States

The user is reminded that the standard state for a substance is that existing in its normal state at standard temperature and pressure (Sec. 2.2.), i.e. for gases such as oxygen it is 1 atmosphere partial pressure. For calculations of equilibrium constants where concentrations are appropriate, the Nernst equation should be used to calculate a reduction potential corresponding to unit concentration. More detailed discussion of numerous inorganic couples is given in Stanbury's recent compilation,<sup>75</sup> but the reader is warned that the latter author presents data uniformly using a standard state of 1 mol dm<sup>-3</sup>, including couples involving gases.

## 9. Some Other Compilations of Reduction Potentials

Clark's classical text<sup>22</sup> includes compilations of many reduction potentials of organic substances. The volume by Bard et al.<sup>11</sup> supersedes an earlier compilation<sup>10</sup> of reduction potentials of inorganic substances in aqueous solution. Stanbury's review<sup>75</sup> discusses inorganic couples involving free radicals in more detail (note the comment about standard states in Sec. 8.3). Steenken<sup>76</sup> presents comprehensive information concerning electron transfer equilibria involving radicals and radical ions in aqueous solution. This includes values of reduction potentials as well as data characterizing the kinetics of electron-transfer equilibria involving radicals. Koppenol and Butler have discussed the energetics of interconversion of oxyradicals.<sup>77</sup>

## 10. List of Abbreviations and Symbols

A	General symbol for oxidant or electron acceptor
A*	Triplet excited state of species A
A <sup>2-</sup>	General symbol for fully dissociated form of reductant AH <sub>2</sub>
A <sub>i</sub>	Absorbance of species <i>i</i>
a <sub>A</sub>	Activity of species A
AcOH	Acetic acid
AH <sup>-</sup>	General symbol for partially dissociated form of reductant AH <sub>2</sub>
AH <sub>2</sub>	General symbol for reductant or electron donor
Approx.	Approximate
AQS <sup>-</sup>	9,10-Anthraquinone-2-sulfonate (Tables, 1.3.1)
Au.	This author (PW)
bpy	2,2'-Bipyridine
<i>t</i> -BuOH	<i>tert</i> -Butyl alcohol (2-Methylpropan-2-ol)
BV <sup>2+</sup>	Benzyl viologen (1,1'-Dibenzyl-4,4'-bipyridinium) (Tables, 3.8.39)

C (in Methods column)	Concentrations used to estimate equilibrium constant (Introduction, Sec. 8.1)
CAT	Catechol (1,2-Dihydroxybenzene) (Tables, 5.2.1)
Calc.	Calculated
Calc. data	Calculated by the present author from data in reference shown
Calc. lit.	Calculated by the authors in the reference shown from literature data
Calc.	Calculation
Consts.	Constants
Cyc. v.	Cyclic voltammetry
Diff. pulse volt.	Differential pulse voltammetry
DMAP	4-(Dimethylamino)phenol (Tables, 5.1.8)
DQ	Duroquinone (2,3,5,6-Tetramethyl-1,4-benzoquinone) (Tables 1.1.7)
<i>E</i>	General symbol for reduction potential
<i>E</i> <sup>o</sup>	Standard reduction potential (Introduction, Sec. 4.2)
<i>E</i> <sub>0</sub>	Formal reduction potential (Introduction, Secs. 4.3, 4.4)
<i>E</i> <sub>h</sub>	Reduction potential of half-cell relative to s.h.e. (Introduction, Sec. 4.2)
<i>E</i> <sub>m</sub>	Mid-point potential of half-cell (Introduction, Sec. 4.3)
<i>E</i> <sub>mi</sub>	Mid-point potential of half-cell at pH = <i>i</i> (Introduction, Sec. 4.4)
Eq.	Equation
Extrap.	Extrapolated
<i>F</i>	The Faraday constant = 9.649 × 10 <sup>4</sup> C mol <sup>-1</sup>
<i>f</i> <sub>A</sub>	Activity coefficient of species A
<i>f</i> ( <i>I</i> )	Ionic strength function (Introduction, Sec. 3.8)
Fp	Flash photolysis
Glycol	Ethylene glycol (1,2-Ethanediol)
GlyTyr	Glycyl-L-tyrosine
<i>h</i>	Planck's constant = 6.626 × 10 <sup>-34</sup> J s
HQ	Hydroquinone (1,4-Dihydroxybenzene) (Tables, 5.4.1)
<i>I</i>	Ionic strength
<i>k</i>	Rate constant
<i>K</i>	Equilibrium constant (expressed in terms of activities)
<i>K</i> '	Equilibrium constant (expressed in terms of concentrations)
<i>K</i> <sub>a</sub>	Dissociation constant of an acid or the conjugate acid of a base
<i>K</i> <sub>D</sub>	Equilibrium constant for dissociation of dimer (Introduction, Sec. 6.3)
<i>K</i> <sub>f</sub>	Equilibrium constant of semiquinone formation equilibrium (Introduction, Sec. 5.1)

$k_{\text{app}}$	Apparent semiquinone formation constant at pH = 7 (Introduction, Sec. 5.2)
$k_{\text{in}}$ (Method column)	Kinetics used to estimate equilibrium constant (Introduction, Sec. 8.1)
Kin.	Kinetics
$MV^{2+}$	Methyl viologen (1,1'-Dimethyl-4,4'-bipyridinium) (Tables, 3.8.2)
$n$	Number of electrons transferred in the oxidant/reductant couple
$NAD^+$	Nicotinamide-adenine dinucleotide (Tables, 4.4.6)
$NADH$	Nicotinamide-adenine dinucleotide, reduced form (Tables, 8.2.1)
n.c.e.	Normal calomel electrode (1 mol $dm^{-3}$ KCl)
Pol.	Polarography
Pot.	Potentiometry
Potl.	Potential
2-PrOH	<i>iso</i> Propyl alcohol (Propan-2-ol)
Q	General symbol for quinones
$QH_2$	General symbol for hydroquinones
R	The gas constant = 8.314 J K <sup>-1</sup> mol <sup>-1</sup>
Rad.	Radiolysis
Rec.	Recommended
Reduct.	Reduction
Ref.	Reference
$S_o$	Sum of all oxidant species (Introduction, Sec. 4.3)
$S_r$	Sum of all reductant species (Introduction, Sec. 4.3)
s.c.e.	Saturated calomel electrode
Sec.	Section
s.h.e.	Standard (normal) hydrogen electrode
Spect.	Spectrophotometry
T	Absolute temperature
TMP	3,4,7,8-Tetramethylphenanthroline
TMPD	<i>N,N,N',N'</i> -Tetramethyl- <i>p</i> -phenylenediamine (Tables, 6.1.5)
$TQ^{2+}$	Triquat (7,8-Dihydro-6 <i>H</i> -dipyrido[1,2- <i>a</i> :2',1'- <i>c</i> ]diazapinediium) (Tables, 3.4.1)
v/v	Parts by volume
$z_A$	Net charge (valency) on ion A
$\nu$	Frequency
$\sigma_p^-$	Hammett sigma substituent constant (from <i>para</i> substituted phenols)
$\Delta E$	Difference in reduction potentials (Introduction, Sec. 1)
$\Delta G$	Free energy change accompanying reaction

## 11. Acknowledgments

The Radiation Laboratory at the University of Notre Dame is operated under contract DE-AC02-76ER0038 with the Department of Energy. The Radiation Chemistry Data Center is supported jointly by the Office of Basic Energy Sciences of the Department of Energy and the National Bureau of Standards, Office of Standard Reference Data. This is Radiation Laboratory Document No. NDRL-3098. Peter Wardman is supported by the Cancer Research Campaign. The author would like to acknowledge the continual assistance and encouragement of Dr. Alberta B. Ross during this project, Dr. W. Phillip Helman and Ms. Christa Wardlow for help with the text processing, and all their colleagues in the Data Center for invaluable assistance: their help is gratefully acknowledged.


## 12. References to Text

- Neta, P., *J. Chem. Educ.* **58**, 110-3 (1981).
- Arai, S., Dorfman, L.M., *Adv. Chem. Ser.* **82**, 378-86 (1968).
- Patel, K.B., Willson, R.L., *J. Chem. Soc., Faraday Trans. 1* **69**, 814-25 (1973).
- Wood, P.M., *FEBS Lett.* **44**, 22-4 (1974).
- Ilan, Y.A., Meisel, D.; Czapski, G., *Isr. J. Chem.* **12**, 891-5 (1974).
- Meisel, D., Czapski, G., *J. Phys. Chem.* **79**, 1503-9 (1975).
- Meisel, D., Neta, P., *J. Am. Chem. Soc.* **97**, 5198-203 (1975).
- Steenken, S., Neta, P., *J. Phys. Chem.* **83**, 1134-7 (1979).
- Atkins, P.W., *Physical Chemistry*, 2nd ed., (Oxford Univ. Press, 1982), p. 346-58.
- Charlot, G., Collumeau, A., Marchon, J.C., *Selected Constants: Oxidation-Reduction Potentials of Inorganic Substances in Aqueous Solution*, (Butterworths, London, 1971).
- Bard, A.J., Parsons, R., Jordan, J. (eds.), *Standard Potentials in Aqueous Solution*, (Marcel Dekker, New York, 1985).
- Swallow, A.J., *Radiation Chemistry* (John Wiley and Sons, New York, 1973).
- Farhatziz, Rodgers, M.A.J. (eds.), *Radiation Chemistry: Principles and Applications*, (Verlag Chemie, 1987).
- Buxton, G.V., In *The Study of Fast Processes and Transient Species by Electron Pulse Radiolysis*, J.H. Baxendale and F. Busi (eds.), (D. Reidel, Dordrecht, Holland, 1982), p.241-66.
- Swallow, A.J., In *The Study of Fast Processes and Transient Species by Electron Pulse Radiolysis*, J.H. Baxendale and F. Busi (eds.), (D. Reidel, Dordrecht, Holland, 1982), p.289-315.
- Asmus, K.-D., Moeckel, H., Henglein, A., *J. Phys. Chem.* **77**, 1218-21 (1973).
- Buxton, G.V., Greenstock, C.L., Helman, W.P., Ross, A.B., *J. Phys. Chem. Ref. Data* **17**, 513-886 (1988).
- Steenken, S., *J. Phys. Chem.* **83**, 595-9 (1979).
- Neta, P., Huie, R.E., Ross, A.B., *J. Phys. Chem. Ref. Data* **17**, 1027-284 (1988).
- Khudyakov, I.V., Kuzhkov, V.B., Kuz'min, V.A., *Dokl. Phys. Chem.* **246**, 424-6 (1979) Translated from: *Dokl. Akad. Nauk SSSR* **246**, 397-400 (1979).
- Martins, L.J.A., *J. Chem. Soc., Faraday Trans. 1* **78**, 533-43 (1982).
- Clark, W.M., *Oxidation-Reduction Potentials of Organic Systems*, (Williams and Wilkins, Baltimore, 1960).


- <sup>23</sup>Bard, A.J., *Electrochemical Methods: Fundamentals and Applications*, (Wiley, New York, 1980).
- <sup>24</sup>Gill, R., Stonehill, H.I., *J. Chem. Soc.* 1845 (1952).
- <sup>25</sup>Henglein, A., *Electroanal. Chem.* 9, 163-244 (1976).
- <sup>26</sup>Samec, Z., Bresnahan, W.T., Elving, P.J., *J. Electroanal. Chem.* 133, 1-23 (1982).
- <sup>27</sup>Alfassi, Z.B., Harriman, A., Huie, R.E., Mosseri, S., Neta, P., *J. Phys. Chem.* 91, 2120-2 (1987).
- <sup>28</sup>Neta, P., Huie, R.E., Harriman, A., *J. Phys. Chem.* 91, 1606-11 (1987).
- <sup>29</sup>Harriman, A., *J. Phys. Chem.* 91, 6102-4 (1987).
- <sup>30</sup>Nicholson, R.S., Shain, I., *Anal. Chem.* 36, 706-23 (1964).
- <sup>31</sup>Andrieux, C.P., Nadjo, L., Saveant, J.M., *J. Electroanal. Chem.* 26, 147-86 (1970).
- <sup>32</sup>Wardman, P., Clarke, E.D., *J. Chem. Soc., Faraday Trans. 1* 72, 1377-90 (1976).
- <sup>33</sup>Perlmutter-Hayman, B., *Prog. Reaction Kinetics* 6, 239-67 (1971).
- <sup>34</sup>Anderson, R.F., *Biochim. Biophys. Acta* 723, 78-82 (1983).
- <sup>35</sup>Watt, G.D., Burns, A., *Biochem. J.* 152, 33-7 (1975).
- <sup>36</sup>Ledwith, A., In *Biochemical Mechanisms of Paraquat Toxicity*, A.P. Autor (ed.), (Academic Press, New York, 1977), p.21-37.
- <sup>37</sup>Wardman, P., Clarke, E.D., *Br. J. Cancer* 55, Suppl. VIII, 172-7 (1987).
- <sup>38</sup>Hayon, E., Simic, M., *Acc. Chem. Res.* 7, 114-21 (1974).
- <sup>39</sup>Land, E.J., Mukherjee, T., Swallow, A.J., Bruce, J.M., *J. Chem. Soc., Faraday Trans. 1* 79, 391-404 (1983).
- <sup>40</sup>Land, E.J., Mukherjee, T., Swallow, A.J., Bruce, J.M., *Arch. Biochem. Biophys.* 255, 116-121 (1983).
- <sup>41</sup>Mukherjee, T., *Radiat. Phys. Chem.* 29, 455-62 (1987).
- <sup>42</sup>Ilan, Y.A., Czapski, G., Meisel, D., *Biochim. Biophys. Acta* 430, 209-24 (1976).
- <sup>43</sup>Meisel, D., Neta, P., *J. Phys. Chem.* 79, 2459-61 (1975).
- <sup>44</sup>Baxendale, J.H., Hardy, H.R., *Trans. Faraday Soc.* 49, 1140-4 (1953).
- <sup>45</sup>Baxendale, J.H., Hardy, H.R., *Trans. Faraday Soc.* 49, 1433-7 (1953).
- <sup>46</sup>Bishop, C.A., Tong, L.K.J., *J. Am. Chem. Soc.* 87, 501-5 (1965).
- <sup>47</sup>Conant, J.B., Fieser, L.F., *J. Am. Chem. Soc.* 45, 2194-218 (1923).
- <sup>48</sup>Michaelis, L., Schubert, M.P., Reber, R.K., Kuck, J.A., Graniak, S., *J. Am. Chem. Soc.* 60, 1678-83 (1938).
- <sup>49</sup>von Foerster, G., Weis, W., Staudinger, H., *Ann. Chem.* 690, 166-9 (1965).
- <sup>50</sup>Laroff, G.P., Fessenden, R.W., Schuler, R.H., *J. Am. Chem. Soc.* 94, 9062-73 (1972).
- <sup>51</sup>Perrin, D.D., Dempsey, B., Serjeant, E.P., *pK<sub>a</sub> Prediction for Organic Acids and Bases*, (Chapman and Hall, London, 1981), p.5-7.
- <sup>52</sup>Wold, E., Kaalhus, O., Johansen, E.S., Ekse, A.T., *Int. J. Radiat. Biol. Relat. Stud. Phys., Chem. Med.* 38, 599-611 (1980).
- <sup>53</sup>Anderson, R.F., *Biochim. Biophys. Acta* 722, 158-62 (1982).
- <sup>54</sup>Michaelis, L., Hill, E.S., *J. Gen. Physiol.* 16, 859-73 (1933).
- <sup>55</sup>Thorneley, R.N.F., *Biochim. Biophys. Acta* 333, 487-96 (1974).
- <sup>56</sup>Stargardt, J.F., Hawkridge, F.M., *Anal. Chim. Acta* 146, 1-8 (1983).
- <sup>57</sup>Van Dijk, C., Mayhew, S.G., Grande, H.J., Veeger, C., *Eur. J. Biochem.* 102, 317-30 (1979).
- <sup>58</sup>Schwarz, W.M., Jr., *Investigation of Stable Free Radicals Formed by Electroreduction of N-Alkylpyridinium Salts*, (Ph.D. Thesis, Univ. Wisconsin, 1961).
- <sup>59</sup>Mayhew, S.G., Mueller, F., *Biochem. Soc. Trans.* 176-7 (1982).
- <sup>60</sup>Stombaugh, N.A., Sundquist, J.E., Burris, R.H., Orme-Johnson, W.H., *Biochemistry* 15, 2663-41 (1976).
- <sup>61</sup>Van Leeuwen, J.W., Van Dijk, C., Veeger, C., *Eur. J. Biochem.*, 135, 601-7 (1983).
- <sup>62</sup>Solar, S., Solar, W., Getoff, N., Holcman, J., Sehested, K., *J. Chem. Soc., Faraday Trans. 1* 78, 2467-77 (1982).
- <sup>63</sup>Venturi, M., Mulazzani, Q.G., Hoffman, M.Z., *Radiat. Phys. Chem.* 23, 229-36 (1984).
- <sup>64</sup>Steenken, S., Neta, P., *J. Phys. Chem.* 86, 3661-7 (1982).
- <sup>65</sup>Friend, J.A., Roberts, N.K., *Aust. J. Chem.* 11, 104-19 (1958).
- <sup>66</sup>Grodzowski, J., Neta, P., Carlson, B.W., Miller, L., *J. Phys. Chem.* 87, 3135-8 (1983).
- <sup>67</sup>Schwartz, H.A., Dodson, R.W., *J. Phys. Chem.* 93, 409-14 (1989).
- <sup>68</sup>Zuman, P., *Substituent Effects in Organic Polarography*, (Plenum Press, New York, 1967).
- <sup>69</sup>Breccia, A., Berrilli, G., Roffia, S., *Int. J. Radiat. Biol. Relat. Stud. Phys., Chem. Med.* 36, 85-9 (1979).
- <sup>70</sup>Meisel, D., *Chem. Phys. Lett.* 34, 263-6 (1975).
- <sup>71</sup>Wardman, P., Clarke, E.D., *Biochem. Biophys. Res. Commun.* 69, 942-9 (1976).
- <sup>72</sup>Neta, P., Meisel, D., *J. Phys. Chem.* 80, 519-24 (1976).
- <sup>73</sup>Wardman, P., In *Advanced Topics on Radiosensitizers of Hypoxic Cells*, A. Breccia, C. Rimondi and G.E. Adams (eds.), (Plenum Press, New York, 1982), p.49-75.
- <sup>74</sup>Neta, P., Simic, M.G., Hoffman, M.Z., *J. Phys. Chem.* 80, 2018-23 (1976).
- <sup>75</sup>Stanbury, D. M., *Adv. Inorg. Chem.* 33, 69-138 (1989).
- <sup>76</sup>Steenken, S., *Landolt-Boernstein* 13e, 147-293 (1985).
- <sup>77</sup>Koppenol, W.H., Butler, J., *Adv. Free Radical Biol. Med.* 1, 91-131 (1985).

TABLE I. Reduction potentials of quinones (Q/Q<sup>•-</sup>)

No.	Compound or couple	E/mV	pH	Ref. compound	Ref. E /mV	Co-solute	I	Method/ comments	Ref.
<b>1.1. Benzoquinones (1a)</b>									
1.1.1	1,4-Benzoquinone	78	* 7					Rec. value; calc.; see Introduction (Sec. 5.4)	
		104	~7					Calc. from semiquinone formation consts. measured pH 6-7.	66C003
		99	7					Calc. lit.	761063
		399	0						
1.1.2	Methyl-1,4-benzoquinone	23	7					Calc. lit.	761063
1.1.3	2,3-Dimethyl-1,4-benzoquinone	-74	7					Calc. lit.	761063
1.1.4	2,5-Dimethyl-1,4-benzoquinone	-67	7					Calc. lit.	761063
		210	0						
1.1.5	2,6-Dimethyl-1,4-benzoquinone	-80	7					No details	765319
1.1.6	2,3,5-Trimethyl-1,4-benzoquinone	-165	7					Calc. lit.	761063
1.1.7	2,3,5,6-Tetramethyl-benzoquinone	-260	* 7					Rec. value; see Introduction (Sec. 6.2)	
		-250	7					Calc. lit.	74C001
		65	0					Calc. lit.	741141
		-235	7					Calc. lit.	751090
		-240	7					Calc. lit.	761063
		65	0						
		-244	7	BV <sup>2+</sup>	-354	2-PrOH	-0	C (K)	761070
		-242	7	BV <sup>2+</sup>	-355		-0	C; calc. data	80A349
		-247	7	BV <sup>2+</sup>	-354	2-PrOH	-0	C	83C002
1.1.8	2,5-Diaziridinyl-3,6-bis(2-hydroxyethylamino)-1,4-benzoquinone (BZQ) (1b, R <sup>2</sup> = R <sup>5</sup> = NHCH <sub>2</sub> CH <sub>2</sub> OH)	-383	7	MV <sup>2+</sup>	-450	HCO <sub>2</sub> <sup>-</sup>	0.12	C	87A269
		-370	7	3.8.31	-290	HCO <sub>2</sub> <sup>-</sup>	0.12	C	87A269
1.1.9	2,5-Diaziridinyl-3,6-bis(carbethoxyamino)-1,4-benzoquinone (AZQ) (1b, R <sup>2</sup> = R <sup>5</sup> = NHCO <sub>2</sub> Et)	-168	† 7	DQ	-244	<i>t</i> -BuOH	~0.010	K	81C031
		-65	7	1.2.5	-110	HCO <sub>2</sub> <sup>-</sup>	0.12	C	87A269
		-70	7	1.1.4	-66	HCO <sub>2</sub> <sup>-</sup>	0.12	C	87A269
		-73	7	O <sub>2</sub> (1 mol dm <sup>-3</sup> )	-155	HCO <sub>2</sub> <sup>-</sup>	0.12	K	87A269




(1a)




(1b)

TABLE I. Reduction potentials of quinones (Q/Q<sup>-</sup>)—Continued


No.	Compound or couple	E/mV	pH	Ref. compound	Ref. E /mV	Co-solute	I	Method/ comments	Ref.
<b>1.2. Naphthoquinones</b>									
1.2.1	1,2-Naphthoquinone	-89	7.8			HCO <sub>2</sub> <sup>-</sup>	0.11	C	86R230
1.2.2	1,4-Naphthoquinone (1c)	-140	7.8			HCO <sub>2</sub> <sup>-</sup>	0.11	C	86R230
1.2.3	5-Hydroxy-1,4-naphthoquinone (juglone)	-93	7	O <sub>2</sub> (1 mol dm <sup>-3</sup> )	-155	HCO <sub>2</sub> <sup>-</sup>	~0.1	C; data at other pH values, also with 1.1.5	87A234
1.2.4	5,8-Dihydroxy-1,4-naphthoquinone	-110	7	1.1.5	-80	HCO <sub>2</sub> <sup>-</sup>		C	83A039
		-103	5.5			HCO <sub>2</sub> <sup>-</sup>		C; other values pH 5.5-11	83A039
1.2.5	1,4-Naphthoquinone-2-sulfonate ion (1d, R <sup>2</sup> = SO <sub>3</sub> <sup>-</sup> )	-60	7	O <sub>2</sub> (1 atm.)	-330	HCO <sub>2</sub> <sup>-</sup>	0.1	C	761063
1.2.6	2-Methyl-1,4-naphthoquinone (1d, R <sup>2</sup> = CH <sub>3</sub> )	-203	7	O <sub>2</sub> (1 atm.)	-325	HCO <sub>2</sub> <sup>-</sup>	~0.02	C	751090
		-206	7	DQ	-235	2-PrOH	~0.01	C; calc. data	751090
		-203	7.67	O <sub>2</sub> (1 mol dm <sup>-3</sup> )	-155	2-PrOH	<0.01	C	86B096
		-199	7.67	BV <sup>2+</sup>	-354	2-PrOH	→0	C	86B096
1.2.7	(1d, R <sup>2</sup> = CH <sub>2</sub> OH)	-152	7.67	O <sub>2</sub> (1 mol dm <sup>-3</sup> )	-155	2-PrOH	<0.01	C	86B096
1.2.8	(1d, R <sup>2</sup> = CH <sub>2</sub> OCH <sub>3</sub> )	-129	7.67	O <sub>2</sub> (1 mol dm <sup>-3</sup> )	-155	2-PrOH	<0.01	C	86B096 761063
1.2.9	(1d, R <sup>2</sup> = CH <sub>2</sub> OCOCH <sub>3</sub> )	-100	7.07	O <sub>2</sub> (1 mol dm <sup>-3</sup> )	-155	2-PrOH	<0.01	C	86B090
1.2.10	(1d, R <sup>2</sup> = CH <sub>2</sub> OCONHCH <sub>2</sub> CH <sub>2</sub> Cl)	-122	7.67	O <sub>2</sub> (1 mol dm <sup>-3</sup> )	-155	2-PrOH	<0.01	C	86B096
1.2.11	(1e, R <sup>6</sup> = CH <sub>2</sub> Br)	-92	7.67	O <sub>2</sub> (1 mol dm <sup>-3</sup> )	-155	2-PrOH	<0.01	C	86B096
1.2.12	(1e, R <sup>6</sup> = CH <sub>2</sub> Cl)	-94	7.67	O <sub>2</sub> (1 mol dm <sup>-3</sup> )	-155	2-PrOH	<0.01	C	86B096
1.2.13	(1e, R <sup>6</sup> = CH <sub>2</sub> OCOCH <sub>3</sub> )	-94	7.67	O <sub>2</sub> (1 mol dm <sup>-3</sup> )	-155	2-PrOH	<0.01	C	86B096
1.2.14	(1e, R <sup>6</sup> = CH <sub>2</sub> OCONHCH <sub>3</sub> )	-99	7.67	O <sub>2</sub> (1 mol dm <sup>-3</sup> )	-155	2-PrOH	<0.01	C	86B096
1.2.15	2,3-Dimethyl-1,4-naphthoquinone (1f, R <sup>3</sup> = CH <sub>3</sub> )	-240	7	O <sub>2</sub> (1 atm.)	-330	HCO <sub>2</sub> <sup>-</sup>	0.1	Calc. lit.	761063




(1c)




(1d)



(1e)



(1f)



(1g)

TABLE I. Reduction potentials of quinones (Q/Q<sup>-</sup>)—Continued




No.	Compound or couple	E/mV	pH	Ref. compound	Ref. E /mV	Co-solute	I	Method/ comments	Ref.
<b>1.2. Naphthoquinones—Continued</b>									
1.2.16	(1f, R <sup>3</sup> = S-glutathionyl)	-192	7.67	O <sub>2</sub> (1 mol dm <sup>-3</sup> )	-155	2-PrOH	<0.01	C	86B096
1.2.17	2-Methyl-3-phytyl-1,4-naphthoquinone (1g)	-170	7					Calc. lit.	761063
<b>1.3. Anthraquinones</b>									
1.3.1	9,10-Anthraquinone-2-sulfonate ion (1h, R <sup>2</sup> = SO <sub>3</sub> <sup>-</sup> , R <sup>1</sup> = R <sup>4</sup> = R <sup>6</sup> = H)	-390 *						Rec. value; see Introduction (Sec. 6.2)	
		-380	7	DQ	-235	2-PrOH	~0.010	C	751117
		-375	7	BV <sup>2+</sup>	-354	2-PrOH	→0	C	761070
		-377	7	DQ	-244	2-PrOH	→0	C; calc. data	761070
		-375	7	DQ	-244	2-PrOH	→0	C; calc. data	80A349
		-373	7	BV <sup>2+</sup>	-355	2-PrOH	→0	C; calc. data	80A349
		-366	7	BV <sup>2+</sup>	-354	2-PrOH	→0	C	83C002
		-381	7	TQ <sup>2+</sup>	-548	2-PrOH	→0	C	83C002
1.3.2	1,4-Dihydroxy-9,10-anthraquinone-2-sulfonate ion (1h, R <sup>1</sup> = R <sup>4</sup> = OH, R <sup>2</sup> = SO <sub>3</sub> <sup>-</sup> , R <sup>6</sup> = H)	-270	7	3.3.1	-350	HCO <sub>2</sub> <sup>-</sup>	0.1	C; other data pH 6-11	88A901
1.3.3	1,4-Dihydroxy-9,10-anthraquinone-6-sulfonate ion (1h, R <sup>1</sup> = R <sup>4</sup> = OH, R <sup>2</sup> = H, R <sup>6</sup> = SO <sub>3</sub> <sup>-</sup> )	-249	7	3.3.1	-350	HCO <sub>2</sub> <sup>-</sup>	0.1	C; other data pH 7-11	88A901
1.3.4	1,4-Dihydroxy-5,8-bis[(2-hydroxyethylamino)ethyl]amino-9,10-anthraquinone (1i, R <sup>1</sup> = R <sup>4</sup> = OH, R <sup>5</sup> = R <sup>8</sup> = NHCH <sub>2</sub> CH <sub>2</sub> NHCH <sub>2</sub> CH <sub>2</sub> OH)	-527	7					C; no details	87R257
1.3.5	1,4-Bis[(2-hydroxyethylamino)ethyl]amino-9,10-anthraquinone diacetate (1i, R <sup>1</sup> = R <sup>4</sup> = NHCH <sub>2</sub> CH <sub>2</sub> NHCH <sub>2</sub> CH <sub>2</sub> OAc, R <sup>5</sup> = R <sup>8</sup> = H)	-348	7	BV <sup>2+</sup>	-354			K	81C031
<b>1.4. Isoindole-4,7-diones</b>									
1.4.1	(1j, R <sup>1</sup> = R <sup>2</sup> = CH <sub>3</sub> , R <sup>3</sup> = C <sub>6</sub> H <sub>5</sub> )	-440	7	AQS <sup>-</sup>	-380	2-PrOH	~0.002	C	84R027
1.4.2	(1j, R <sup>1</sup> R <sup>2</sup> = -CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> <sup>-</sup> , R <sup>5</sup> (R <sup>6</sup> ) = CH <sub>3</sub> )	-420	7	AQS <sup>-</sup>	-380	2-PrOH	~0.002	C; mixture of isomers.	84R027
									
	(1h)								
									
	(1i)								
									
	(1j)								



TABLE 1. Reduction potentials of quinones (Q/Q<sup>-</sup>)—Continued

No.	Compound or couple	E/mV	pH	Ref. compound	Ref. E /mV	Co-solute	I	Method/ comments	Ref.
<b>1.4. Isoindole-4,7-diones—Continued</b>									
1.4.3	(1j), R <sup>1</sup> = CH <sub>3</sub> , R <sup>2</sup> = CH <sub>3</sub> , R <sup>3</sup> = C <sub>6</sub> H <sub>5</sub> , R <sup>5</sup> (R <sup>6</sup> ) = CH <sub>3</sub> )	-423	7	AQS <sup>-</sup>	-380			C	82A329
1.4.4	(1j), R <sup>1</sup> = C <sub>6</sub> H <sub>5</sub> , R <sup>2</sup> R <sup>3</sup> = -CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> -)	-427	7	AQS <sup>-</sup>	-380				
1.4.5	(1j), R <sup>2</sup> = CH <sub>3</sub> , R <sup>3</sup> = C <sub>6</sub> H <sub>5</sub> )	-419	7	AQS <sup>-</sup>	-380				
1.4.6	(1j), R <sup>1</sup> = CH <sub>3</sub> , R <sup>2</sup> R <sup>3</sup> = -CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> -)	-438	7	AQS <sup>-</sup>	-380				
1.4.7	(1j), R <sup>1</sup> R <sup>2</sup> = -CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> -, R <sup>3</sup> = C <sub>6</sub> H <sub>5</sub> , R <sup>5</sup> = R <sup>6</sup> = CH <sub>3</sub> )	-435	7	AQS <sup>-</sup>	-380	2-PrOH	~0.002	C	84R027
1.4.8	(1j), R <sup>1</sup> = R <sup>2</sup> = R <sup>5</sup> = R <sup>6</sup> = CH <sub>3</sub> , R <sup>3</sup> = C <sub>6</sub> H <sub>5</sub> )	-452	7	AQS <sup>-</sup>	-380	2-PrOH	~0.002	C	84R027
1.4.9	(1j), R <sup>1</sup> = CO <sub>2</sub> C <sub>2</sub> H <sub>5</sub> , R <sup>2</sup> R <sup>3</sup> = -CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> -, R <sup>5</sup> (R <sup>6</sup> ) = CH <sub>3</sub> )	-368	7	AQS <sup>-</sup>	-380	2-PrOH	~0.002	C; mixture of isomers.	84R027
1.4.10	(1j), R <sup>1</sup> = CO <sub>2</sub> C <sub>2</sub> H <sub>5</sub> , R <sup>2</sup> = R <sup>5</sup> (R <sup>6</sup> ) = CH <sub>3</sub> , R <sup>3</sup> = C <sub>6</sub> H <sub>5</sub> )	-366	7	2.1.9	-437	2-PrOH	~0.002	C; mixture of isomers.	84R027
1.4.11	(1j), R <sup>1</sup> = CO <sub>2</sub> C <sub>2</sub> H <sub>5</sub> , R <sup>2</sup> R <sup>3</sup> = -CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> -, R <sup>5</sup> (R <sup>6</sup> ) = CH <sub>3</sub> , R <sup>6</sup> (R <sup>5</sup> ) = OCH <sub>3</sub> )	-383	7	2.1.9	-437	2-PrOH	~0.002	C; mixture of isomers.	84R027
		-378	7	2.1.10	-352	2-PrOH	~0.002	C	84R027
<b>1.5. Miscellaneous quinones</b>									
1.5.1	Adrenochrome (1k)	-253	7	BV <sup>2+</sup>	-354			K	81C031
1.5.2	5-Aminophthalazine-1,4-dione (1l)	240	~10.6	O <sub>2</sub> (1 mol dm <sup>-3</sup> )	-155	HCO <sub>3</sub> <sup>-</sup>		Chemiluminescence; ± 20 mV.	84C026
1.5.3	9,10-Phenanthrene-quinone (1m)	-124	7.8			HCO <sub>2</sub> <sup>-</sup>	0.11	C	86R230
1.5.4	Adriamycin (1n, R = COCH <sub>2</sub> OH)	-292	7	DQ	-244			K. Eq. vs. O <sub>2</sub> mis-calc., inconsistent (see 83C018)	81C031
		-328	7	DQ	-240	HCO <sub>2</sub> <sup>-</sup>	0.1	C; other values, pH 6-12.	83C018
		-341 *	7	several		HCO <sub>2</sub> <sup>-</sup>	0.1	Rec.; C	88A901













TABLE I. Reduction potentials of quinones (Q/Q<sup>-</sup>)—Continued

No.	Compound or couple	E/mV	pH	Ref. compound	Ref. E /mV	Co-solute	I	Method/ comments	Ref.
<b>1.5. Miscellaneous quinones—Continued</b>									
1.5.5	Daunomycin (1n, R = COCH <sub>3</sub> )	-305	7	DQ	-244			K	81C031
		-430 †	7	Q/QH <sub>2</sub>	-410			Semiquinone formation const. + E(Q/QH <sub>2</sub> ).	85A001
1.5.6	Indigodisulfonate ion (1o)	-247	7						59C002
1.5.7	Mitomycin C (1p)	-271	7	DQ	-244			K	81C031
		-238	7	BV <sup>2+</sup>	-354			K	
		-310 *	7					Rec.; C	85R016
1.5.8	3,3',5,5'-Tetrabromodiphenoquinone (1q, X = Br)	260	7	BQ	99	HCO <sub>2</sub> <sup>-</sup> CH <sub>3</sub> CN (50% v/v)	~0.02	C (K), (fp)	81A405, 82B068
1.5.9	3,3',5,5'-Tetrachlorodiphenoquinone (1q, X = Cl)	260	7	BQ	99	CH <sub>3</sub> CN (50% v/v)	~0.02	C (K), (fp)	81A405, 82B068
1.5.10	Methoxatine (1r)	-114	7.3	O <sub>2</sub> (1 mol dm <sup>-3</sup> )	-155	HCO <sub>2</sub> <sup>-</sup>	0.11	C + K	86A520
1.5.11	CI941 (1s)	-538	7.0	MV <sup>2+</sup>		HCO <sub>2</sub> <sup>-</sup>	0.12	C	87R243
1.5.12	(1t, R = OCH <sub>3</sub> )	(+)85	7.4	BQ	99	2-PrOH		C	88A125
		85	7.4	1.1.4	-66	N <sub>3</sub> <sup>-</sup>		C	88A125
1.5.13	(1t, R = N(CH <sub>3</sub> ) <sub>2</sub> )	-10	7.4	BQ	99	2-PrOH		C	88A125
		-40	7.4	1.1.4	-66	2-PrOH		C	88A125




\* Recommended value.


† Questionable or superseded value.

TABLE 2. Reduction potentials of nitroaryl compounds ( $RNO_2/R\dot{N}O_2^-$ )


No.	Compound or couple	$E/mV$	pH	Ref. compound	Ref. $E/mV$	Co-solute	$I$	Method/ comments	Ref.
<b>2.1. Nitrobenzenes</b>									
2.1.1	1,2-Dinitrobenzene	-287	7	DQ	-235	2-PrOH		C(K)	761111
2.1.2	1,3-Dinitrobenzene	-345	7	DQ	-235	2-PrOH		C(K)	761111
2.1.3	1,4-Dinitrobenzene	-257	7	DQ	-235	2-PrOH		C(K)	761111
2.1.4	2,4-Dinitrobenzoic acid	-345	7	DQ	-235	2-PrOH		C(K)	761111
2.1.5	2,5-Dinitrobenzoic acid	-272	7	DQ	-235	2-PrOH		C	761111
2.1.6	3,4-Dinitrobenzoic acid	-271	7	DQ	-235	2-PrOH		C	761111
2.1.7	3,5-Dinitrobenzoic acid	-344	7	DQ	-235	2-PrOH		C(K)	761111
2.1.8	2,4-Dinitrophenol	-500	7			2-PrOH	$\rightarrow 0$	C	82R118
2.1.9	3-Nitroacetophenone	-437	7	AQS <sup>-</sup>	-380	2-PrOH	$-0.010$	C	751117
2.1.10	4-Nitroacetophenone	-358	7	DQ	-235	2-PrOH	$\sim 0.010$	C	751117
		-353	7	AQS <sup>-</sup>	-380	2-PrOH	$\sim 0.010$	C	751117
2.1.11	Nitrobenzene	-486	7	AQS <sup>-</sup>	-380	2-PrOH	$\sim 0.010$	C	751117
		-486	7	AQS <sup>-</sup>	-375	<i>t</i> -BuOH	$\rightarrow 0$	C	80C024
2.1.12	2-Nitrobenzaldehyde	-355	7	DQ	-244	<i>t</i> -BuOH	$\rightarrow 0$	C	80C024
2.1.13	4-Nitrobenzaldehyde	-322	7	DQ	-244	<i>t</i> -BuOH	$\rightarrow 0$	C	80C024
2.1.14	2-Nitrobenzoic acid	-412	7	DQ	-235	2-PrOH		C(K)	761111
2.1.15	3-Nitrobenzoic acid	-433	7	DQ	-235	2-PrOH		C(K)	761111
2.1.16	4-Nitrobenzoic acid	-396	7	DQ	-235	2-PrOH		C(K)	761111
		-425	7	AQS <sup>-</sup>	-375	2-PrOH	$\rightarrow 0$	C	80R182
2.1.17	2-Nitrobenzotrile	-308	7	DQ	-244	<i>t</i> -BuOH	$\rightarrow 0$	C	80C024
2.1.18	4-Nitrobenzyl alcohol	-477	7						79R017
		-469	7	AQS <sup>-</sup>	-375	2-PrOH	$\rightarrow 0$	C	79R017
		-487	7	MV <sup>2+</sup>	-447	2-PrOH	$\rightarrow 0$	C	79R017
2.1.19	4-Nitro-(3'-dimethylamino)-propiophenone ( <b>2a</b> , $R^1 = CO(CH_2)_2N(CH_3)_2$ )	-315	7	AQS <sup>-</sup>	-375	2-PrOH	$\rightarrow 0$	C	761037
2.1.20	( <b>2b</b> , $R^6 = CONH_2$ )	-385	7						87R083
2.1.21	( <b>2b</b> , $R^6 = CONHCH_3$ )	-387	7						87R083
2.1.22	( <b>2b</b> , $R^6 = CON(CH_3)_2$ )	-377	7						87R083
2.1.23	( <b>2b</b> , $R^6 = CONHCH_2CH(OCH_3)_2$ )	-384	7						87R083
2.1.24	( <b>2c</b> , $R^4 = NH_2$ )	-460	7						87R083
2.1.25	( <b>2c</b> , $R^4 = N(CH_3)_2$ )	-464	7						87R083
2.1.26	( <b>2d</b> , $R^4 = CONH_2$ , $R^6 = -N$ -aziridinyI)	-515	7						87R083
2.1.27	( <b>2d</b> , $R^4 = -N$ -aziridinyI, $R^6 = -N(CH_3)_2$ )	-431	7						87R083



(2a)



(2b)




(2c)




(2d)

TABLE 2. Reduction potentials of nitroaryl compounds ( $\text{RNO}_2/\text{RNO}_2^-$ )—Continued


No.	Compound or couple	$E/\text{mV}$	pH	Ref. compound	Ref. $E/\text{mV}$	Co-solute	$I$	Method/comments	Ref.
<b>2.2. Nitrofurans</b>									
2.2.1	5-Nitro-2-furoic acid (2e, $\text{R}^2 = \text{CO}_2\text{H}$ )	-317	7	DQ	-235	2-PrOH	~0.010	C	751117
2.2.2	Nifuroxime (2e, $\text{R}^2 = \text{CH}=\text{NOH}$ ( <i>anti</i> ))	-253	7	DQ	-235	2-PrOH	~0.010	C	751117
2.2.3	2-Methoxymethyl-5-nitrofuran (2e, $\text{R}^2 = \text{CH}_2\text{OCH}_3$ )	-338	7	BV <sup>2+</sup>	-354	2-PrOH	→0	C	79R017
2.2.4	Nitrofurazone (2e, $\text{R}^2 = \text{CH}=\text{NNHCONH}_2$ )	-257	7	BV <sup>2+</sup>	-354	2-PrOH	→0	C	761037
2.2.5	Nitrofurantoin (2e, $\text{R}^2 = 2\text{f}$ )	-264	7	BV <sup>2+</sup>	-354	2-PrOH	→0	C	80R185
2.2.6	Nifurpipone (2e, $\text{R}^2 = 2\text{g}$ )	-214	7	BV <sup>2+</sup>	-354	2-PrOH	→0	C	761037
2.2.7	(2e, $\text{R}^2 = -\text{CH}=\text{CH}$ - (2-quinolyl))	-276 -263	7 7	DQ 1.2.6	-245 -203	2-PrOH (50% v/v)	~0.10	K (fp)	79C021
2.2.8	(2e, $\text{R}^2 = -\text{CH}=\text{CH}$ - $\text{CH}=\text{CH}$ -(2-quinolyl))	-265 -256	7 7	DQ 1.2.6	-245 -203	2-PrOH (50% v/v)	~0.10	K (fp)	79C021
2.2.9	(2e, $\text{R}^2 =$ -CH=C(CONH <sub>2</sub> )(2- furyl) = <i>cis</i> -AF-2)	-242	7	BV <sup>2+</sup>	-354	2-PrOH	→0	C	84A208
2.2.10	(2e, $\text{R}^2 =$ -CH=C(CONH <sub>2</sub> )(2- furyl) = <i>trans</i> -AF-2)	-276	7	BV <sup>2+</sup>	-354	2-PrOH	→0	C	84A208
2.2.11	<i>N</i> -Butyl-5-nitro-2- furamide (2e, $\text{R}^2 =$ CONHnC <sub>4</sub> H <sub>n</sub> )	-230	7	BV <sup>2+</sup>	-354	2-PrOH	→0	C	84A263
<b>2.3. 2-Nitroimidazoles</b>									
2.3.1	2-Nitroimidazole (2h, $\text{R}^1 = \text{H}$ )	-418 -508	7 9.2	AQS <sup>-</sup>	-375	2-PrOH	→0	C	761070
2.3.2	2,4-Dinitroimidazole (2h, $\text{R}^1 = \text{NO}_2$ (4/5- nitro))	-445 -305 -265	6.93 4.1 3.26	BV <sup>2+</sup> BV <sup>2+</sup> BV <sup>2+</sup>	-354 -354 -354	2-PrOH 2-PrOH 2-PrOH	→0 ~0.005 ~0.002	C	79R037
2.3.3	5-Cyano-1-methyl-2- nitroimidazole (2i, $\text{R}^5 =$ CN)	-267	7	DQ	-244	2-PrOH	→0	C	80R187
2.3.4	1-Methyl-2- nitroimidazole-5- carboxaldehyde (2i, $\text{R}^5 =$ CHO)	-243	7	DQ	-244	2-PrOH	→0	C	761070
2.3.5	1-Methyl-2- nitroimidazole-5- carboxylate ion (2i, $\text{R}^5 =$ CO <sub>2</sub> <sup>-</sup> )	-385	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	773087
2.3.6	1-Methyl-2- nitroimidazole-5- carboxamide (2i, $\text{R}^5 =$ CONH <sub>2</sub> )	-321	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R187
2.3.7	(2i, $\text{R}^5 = \text{CH}_2\text{OH}$ )	-400	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	79R017




(2e)




(2f)



(2g)




(2h)



(2i)

TABLE 2. Reduction potentials of nitroaryl compounds ( $RNO_2/R\dot{N}O_2^-$ )—Continued

No.	Compound or couple	$E/mV$	pH	Ref. compound	Ref. $E/mV$	Co-solute	$I$	Method/comments	Ref.
<b>2.3. 2-Nitroimidazoles—Continued</b>									
2.3.8	5-Ethenyl-1-methyl-2-nitroimidazole ( <b>2i</b> , $R^5 = CH=CH_2$ )	-392	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	79R017
		-398	7	BV <sup>2+</sup>	-354	2-PrOH	→0	C	85R035
2.3.9	( <b>2i</b> , $R^5 = CO_2CH_3$ )	-300	7	DQ	-244	2-PrOH	→0	C	79R017
2.3.10	( <b>2i</b> , $R^5 = CH=N^+(-O^-)CH_3$ )	-282	7	BV <sup>2+</sup>	-354	2-PrOH	→0	C	79R017
2.3.11	( <b>2i</b> , $R^5 = CH(OH)CH_2OH$ )	-396	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	79R017
2.3.12	( <b>2i</b> , $R^5 = CH(CH_3)_2$ )	-439	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	79R017
2.3.13	( <b>2i</b> , $R^5 = C(CH_3)_2(OH)$ )	-412	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	79R017
2.3.14	( <b>2i</b> , $R^5 = CH=N-N(CH_3)_2$ )	-386	7	BV <sup>2+</sup>	-354	2-PrOH	→0	C	80R184
2.3.15	( <b>2i</b> , $R^5 = CH=C(CN)_2$ )	-240	7	BV <sup>2+</sup>	-354	2-PrOH	→0	C	80R184
2.3.16	( <b>2i</b> , $R^5 = CH(OCOCH_3)_2$ )	-350	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	79R017
2.3.17	( <b>2i</b> , $R^5 = CH=N-(N-morpholino)$ )	-366	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R184
2.3.18	( <b>2i</b> , $R^5 = CH=N-(N-piperazino)$ )	-354	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R184
2.3.19	( <b>2i</b> , $R^5 = CH=N-(N-piperidino)$ )	-376	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R184
2.3.20	2-Nitroimidazole-1-acetic acid ( <b>2j</b> , $R^1 = CH_2CO_2H$ )	-447	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R185
2.3.21	1-(2-Hydroxyethyl)-2-nitroimidazole ( <b>2j</b> , $R^1 = CH_2CH_2OH$ )	-398	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	761070
2.3.22	( <b>2j</b> , $R^1 = CH_2CH_2OH$ , $R^4 = NO_2$ )	-238	7	BV <sup>2+</sup>	-354	2-PrOH	→0	C	79R037
2.3.23	1-(2-Hydroxyethyl)-5-methyl-2-nitroimidazole ( <b>2j</b> , $R^1 = CH_2CH_2OH$ , $R^5 = CH_3$ )	-423	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	761070
2.3.24	2-Nitro-1-(2-oxopropyl)imidazole ( <b>2j</b> , $R^1 = CH_2COCH_3$ )	-358	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	79R017
2.3.25	( <b>2j</b> , $R^1 = CH_2CO_2CH_3$ )	355	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	79R017
2.3.26	( <b>2j</b> , $R^1 = CH_2CH(OH)CH_2Cl$ )	-384	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	79R017
2.3.27	( <b>2j</b> , $R^1 = CH_2CH(OH)CH_2F$ )	-383	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	79R017




(2j)

2.3.30-3. Benzimidazole, pyrazole, and nitroaryl compounds (HNO<sub>2</sub>/RNO<sub>2</sub><sup>-</sup>)—Continued


Ref.	Structure	E/mV	pH	Ref. compound	Ref. E/mV	Co-solute	I	Method/ comments	Ref.
<b>2.3. Nitroimidazoles—Continued</b>									
2.3.28	1-(2-Methoxyethyl)-2-nitroimidazole (2j, R <sup>1</sup> = CH <sub>2</sub> CH <sub>2</sub> OCH <sub>3</sub> )	-393	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	79R017
2.3.29	(2j, R <sup>1</sup> = CH <sub>2</sub> CH(OH)CH <sub>2</sub> OH)	-389	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	761070
2.3.30	(2j, R <sup>1</sup> = CH <sub>2</sub> CH <sub>2</sub> SO <sub>2</sub> CH <sub>3</sub> )	-368	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	79R017
2.3.31	(2j, R <sup>1</sup> = CH <sub>2</sub> CH <sub>2</sub> OCOCH <sub>3</sub> )	-420	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	761070
2.3.32	(2j, R <sup>1</sup> = CH <sub>2</sub> CONHCH <sub>2</sub> CH <sub>2</sub> OH)	-388						C	80R193
2.3.33	(2j, R <sup>1</sup> = CH <sub>2</sub> CO <sub>2</sub> C <sub>2</sub> H <sub>5</sub> , R <sup>5</sup> = C <sub>2</sub> H <sub>5</sub> )	-388	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	761070
2.3.34	1-(2-Ethoxyethyl)-2-nitroimidazole (2j, R <sup>1</sup> = CH <sub>2</sub> CH <sub>2</sub> OC <sub>2</sub> H <sub>5</sub> )	-400	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	79R017
2.3.35	Misonidazole (2j, R <sup>1</sup> = CH <sub>2</sub> CH(OH)CH <sub>2</sub> OCH <sub>3</sub> )	-389 *						Rec.	
		-363	7	DQ	-235	2-PrOH	~0.010	C	751117
		-398	7	AQS <sup>-</sup>	-380	2-PrOH	~0.010	C	751117
		-389	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	761070
		-389	7	AQS <sup>-</sup>	-375	t-BuOH	→0	C (K)	761070
		-389	7	AQS <sup>-</sup>	-375	HCO <sub>2</sub> <sup>-</sup>	→0	C, calc. data	761070
		-388	7	BV <sup>2+</sup>	-354	2-PrOH	→0	C (K)	761070
2.3.36	1-[(2-Ethylsulfonyl)ethyl]-2-nitroimidazole (2j, R <sup>1</sup> = CH <sub>2</sub> CH <sub>2</sub> SO <sub>2</sub> C <sub>2</sub> H <sub>5</sub> )	-368	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	79R017
2.3.37	(2j, R <sup>1</sup> = CH <sub>2</sub> CONH-CH <sub>2</sub> CHOHCH <sub>2</sub> OH)	-392						C	80R193
2.3.38	(2j, R <sup>1</sup> = CH <sub>2</sub> CH(OH)-CH <sub>2</sub> OCH <sub>2</sub> CH=CH <sub>2</sub> )	-391	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	79R017
2.3.39	(2j, R <sup>1</sup> = CH <sub>2</sub> CON(CH <sub>2</sub> CH <sub>2</sub> OH) <sub>2</sub> )	-398						C	80R193
2.3.40	(2j, R <sup>1</sup> = CH <sub>2</sub> CH <sub>2</sub> OC <sub>6</sub> H <sub>5</sub> )	-391	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	79R017
2.3.41	(2j, R <sup>1</sup> = CH <sub>2</sub> CH <sub>2</sub> SO <sub>2</sub> C <sub>6</sub> H <sub>5</sub> )	-367	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	79R017
2.3.42	Benznidazole (2j, R <sup>1</sup> = CH <sub>2</sub> CONHCH <sub>2</sub> C <sub>6</sub> H <sub>5</sub> )	-380	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	761070
2.3.43	(2j, R <sup>1</sup> = (CH <sub>2</sub> ) <sub>3</sub> OC <sub>6</sub> H <sub>5</sub> )	-409	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	79R017
2.3.44	(2j, R <sup>1</sup> = CH <sub>2</sub> CHOHCH <sub>2</sub> O-CH(CH <sub>2</sub> Cl)CH <sub>2</sub> OCHMe <sub>2</sub> )	-395	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	82R117
2.3.45	(2k, n = 2, NR'R'' = N-morpholino)	-390	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	79R017
2.3.46	(2k, n = 2, NR'R'' = N-morpholino methiodide)	-318	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R184
2.3.47	(2k, n = 3, NR'R'' = N-morpholino)	-386	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R184

TABLE 2. Reduction potentials of nitroaryl compounds ( $RNO_2/R\dot{N}O_2^-$ )—Continued

No.	Compound or couple	E/mV	pH	Ref. compound	Ref. E /mV	Co-solute	I	Method/ comments	Ref.
<b>2.3. 2-Nitroimidazoles—Continued</b>									
2.3.48	(2k, n = 4, NR'R'' = N-morpholino)	-396	7	MV <sup>2+</sup>	-447	2-PrOH	→0	C	80R184
2.3.49	(2k, n = 4, NR'R'' = N-morpholino methiodide)	-379	7	MV <sup>2+</sup>	-447	2-PrOH	→0	C	80R184
2.3.50	(2k, n = 5, NR'R'' = N-morpholino)	-399	7	MV <sup>2+</sup>	-447	2-PrOH	→0	C	80R184
2.3.51	(2k, n = 6, NR'R'' = N-morpholino)	-379	7	MV <sup>2+</sup>	-447	2-PrOH	→0	C	80R184
2.3.52	(2k, n = 8, NR'R'' = N-morpholino)	-388	7	MV <sup>2+</sup>	-447	2-PrOH	→0	C	80R184
2.3.53	(2k, n = 11, NR'R'' = N-morpholino)	-403	7	MV <sup>2+</sup>	-447	2-PrOH	→0	C	80R184
2.3.54	(2k, n = 2, NR'R'' = N-pyrrolidino)	-334	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R184
2.3.55	(2k, n = 4, NR'R'' = N-pyrrolidino)	-389	7	MV <sup>2+</sup>	-447	2-PrOH	→0	C	80R184
2.3.56	(2k, n = 2, NR'R'' = N-piperidino)	-325	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R184
		-316	6						82Z198
		-345	8						
2.3.57	(2k, n = 3, NR'R'' = N-piperidino)	-353	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R184
2.3.58	(2k, n = 4, NR'R'' = N-piperidino)	-386	7	MV <sup>2+</sup>	-447	2-PrOH	→0	C	80R184
2.3.59	(2k, n = 6, NR'R'' = N-piperidino)	-399	7	MV <sup>2+</sup>	-447	2-PrOH	→0	C	80R184
2.3.60	(2k, n = 2, NR'R'' = 2-pyridyl)	-395	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R184
2.3.61	(2k, n = 2, NR'R'' = N-anilino)	-398	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R184
2.3.62	(2k, n = 2, NR'R'' = N(CH(CH <sub>3</sub> ) <sub>2</sub> ) <sub>2</sub> )	-272	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R184
2.3.63	(2l, NR'R'' = N-aziridino)	-398	7					C	84R149
2.3.64	(2l, NR'R'' = N(CH <sub>3</sub> ) <sub>2</sub> )	-351	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R186
2.3.65	(2l, NR'R'' = N(C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> )	-349	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R186
2.3.66	(2l, NR'R'' = N(CH <sub>2</sub> CH <sub>2</sub> OH) <sub>2</sub> )	-369	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R186
2.3.67	(2l, NR'R'' = NHC(CH <sub>3</sub> ) <sub>3</sub> )	-348	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R186
2.3.68	(2l, NR'R'' = NHCH <sub>2</sub> C <sub>6</sub> H <sub>5</sub> )	-353	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R186
2.3.69	(2l, NR'R'' = NHC <sub>6</sub> H <sub>4</sub> OCH <sub>3</sub> (p))	-391	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R186




(2k)




(2l)

TABLE 2. Reduction potentials of nitroaryl compounds ( $\text{RNO}_2/\text{RNO}_2^-$ )—Continued


No.	Compound or couple	$E/\text{mV}$	pH	Ref. compound	Ref. $E/\text{mV}$	Co-solute	$I$	Method/comments	Ref.
<b>2.3. 2-Nitroimidazoles—Continued</b>									
2.3.70	(2l, $\text{NR}'\text{R}'' = \text{NHCH}_2\text{C}_6\text{H}_4\text{OCH}_3(p)$ )	-350	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R186
2.3.71	(2l, $\text{NR}'\text{R}'' = 2m$ )	-355	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R186
2.3.72	(2l, $\text{NR}'\text{R}'' = 2n$ )	-361	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R186
2.3.73	1-(3- <i>N</i> -Pyrrolidinyl-2-hydroxypropyl)-2-nitroimidazole (2o, X = absent)	-352	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R186
2.3.74	(2o, X = $\text{CH}_2$ )	-346	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R186
2.3.75	(2o, X = $\text{CH}_2$ , R' = OH)	-357	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R186
2.3.76	1-[3-(4-Morpholino)-2-hydroxypropyl]-2-nitroimidazole (2o, X = O)	-380	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R186
2.3.77	(2o, X = $\text{NCH}_3$ )	-370	7	AQS <sup>-</sup>	-375	2-PrOH	→0	C	80R186
<b>2.4. 4-Nitroimidazoles</b>									
2.4.1	4-Nitroimidazole (2p, R <sup>2</sup> = R <sup>5</sup> = H)	≤-527	7	AQS <sup>-</sup>	-375	<i>t</i> -BuOH	→0	C	761070
2.4.2	5-Iodo-4-nitroimidazole (2p, R <sup>5</sup> = I)	-503	7	AQS <sup>-</sup>	-380	2-PrOH	~0.010	C (K)	85A303
2.4.3	2-Methyl-4-nitroimidazole (2q, R <sup>2</sup> = $\text{CH}_3$ )	-542	7	AQS <sup>-</sup>	-380	2-PrOH	~0.010	C	751117
		-492	7	AQS <sup>-</sup>	-375	<i>t</i> -BuOH	→0	C	771044
2.4.4	5-Bromo-1-methyl-4-nitroimidazole (2q, R <sup>5</sup> = Br)	-523	7	MV <sup>2+</sup>	-447	2-PrOH	→0	C	82A033
2.4.5	5-Chloro-1-methyl-4-nitroimidazole (2q, R <sup>5</sup> = Cl)	~517	7	AQS <sup>-</sup>	-375	<i>t</i> -BuOH	→0	C	761070
		-534	7	MV <sup>2+</sup>	-447	<i>t</i> -BuOH	→0	C	80A136
2.4.6	5-Iodo-1-methyl-4-nitroimidazole (2q, R <sup>5</sup> = I)	-529	7	MV <sup>2+</sup>	-447	2-PrOH	→0	C	82A033
		-505	7	AQS <sup>-</sup>	-380			C	85A303
2.4.7	5-Mercapto-1-methyl-4-nitroimidazole (2q, R <sup>5</sup> = SH)	-538	7		-486	2-PrOH	→0	C	80R183
2.4.8	1-Methyl-4-nitroimidazole-5-sulfonamide (2q, R <sup>5</sup> = $\text{SO}_2\text{NH}_2$ )	-395	7	MV <sup>2+</sup>	-447	2-PrOH	→0	C	80R183
2.4.9	(2q, R <sup>5</sup> = $\text{SO}_2\text{CH}_3$ )	-355	7						81R072
2.4.10	(2q, R <sup>5</sup> = $\text{SCH}_2\text{CO}_2\text{H}$ )	-545	7	MV <sup>2+</sup>	-447	2-PrOH	→0	C	80R183
2.4.11	(2q, R <sup>5</sup> = $\text{SO}_2\text{N}(\text{CH}_3)_2$ )	-409	7	MV <sup>2+</sup>	-447	2-PrOH	→0	C	80R183




(2m)




(2n)



(2o)



(2p)



(2q)



TABLE 2. Reduction potentials of nitroaryl compounds ( $\text{RNO}_2/\text{RNO}_2^-$ )—Continued

No.	Compound or couple	$E/\text{mV}$	pH	Ref. compound	Ref. $E/\text{mV}$	Co-solute	$I$	Method/ comments	Ref.
<b>2.4. 4-Nitroimidazoles—Continued</b>									
2.4.12	( <b>2q</b> , $\text{R}^5 = \text{SO}_2\text{NHCOCCH}_3$ )	-523	7					C	81R072
2.4.13	( <b>2q</b> , $\text{R}^5 = \text{SO}_2\text{NHCH}_2\text{N}(\text{CH}_3)_2$ )	-402	7					C	81R072
2.4.14	( <b>2q</b> , $\text{R}^5 = \text{SO}_2$ -( <i>N</i> -morpholino))	-406	7					C	81R072
2.4.15	( <b>2q</b> , $\text{R}^5 = \text{SO}_2\text{NHCH}_2$ -( <i>N</i> -morpholino))	-394	7	MV <sup>2+</sup>	-447	2-PrOH	→0	C	80R183
2.4.16	( <b>2q</b> , $\text{R}^5 = \text{OC}_6\text{H}_5$ )	-560	7					C	84R150
2.4.17	( <b>2q</b> , $\text{R}^5 = O$ -( <i>p</i> -hydroxyphenyl))	-565	7					C	84R150
2.4.18	1-Methyl-5-phenylsulfonyl-4-nitroimidazole ( <b>2q</b> , $\text{R}^5 = \text{SO}_2\text{C}_6\text{H}_5$ )	-376	7					C	81R072
2.4.19	1-Methyl-5-phenoxy sulfonyl-4-nitroimidazole ( <b>2q</b> , $\text{R}^5 = \text{SO}_2\text{OC}_6\text{H}_5$ )	-342	7	MV <sup>2+</sup>	-447	2-PrOH	→0	C	80R183
2.4.20	1-Methyl-5-(4-chlorophenoxy)sulfonyl-4-nitroimidazole ( <b>2q</b> , $\text{R}^5 = \text{SO}_2\text{O}$ -( <i>4</i> -chlorophenyl))	-345	7	MV <sup>2+</sup>	-447	2-PrOH	→0	C	80R183
2.4.21	1-Methyl-5-(4-nitrophenoxy)sulfonyl-4-nitroimidazole ( <b>2q</b> , $\text{R}^5 = \text{SO}_2\text{O}$ -( <i>4</i> -nitrophenyl))	-302	7					C	81R072
2.4.22	1-Methyl-5-phenylaminosulfonyl-4-nitroimidazole ( <b>2q</b> , $\text{R}^5 = \text{SO}_2\text{NHC}_6\text{H}_5$ )	-398	7	MV <sup>2+</sup>	-447	2-PrOH	→0	C	80R183
2.4.23	1-Methyl-5-(2-chlorophenyl)aminosulfonyl-4-nitroimidazole ( <b>2q</b> , $\text{R}^5 = \text{SO}_2\text{NH}$ -( <i>2</i> -chlorophenyl))	-444	7					C	81R072
2.4.24	1-Methyl-5-(2-methylphenyl)aminosulfonyl-4-nitroimidazole ( <b>2q</b> , $\text{R}^5 = \text{SO}_2\text{NH}$ -( <i>2</i> -tolyl))	-426	7					C	81R072
2.4.25	( <b>2q</b> , $\text{R}^5 = \text{SO}_2\text{O}$ -( <i>2</i> -methoxyphenyl))	-365	7					C	81R072
2.4.26	( <b>2q</b> , $\text{R}^5 = \text{SO}_2\text{O}$ -( <i>4</i> -methoxyphenyl))	-335	7					C	81R072
2.4.27	( <b>2q</b> , $\text{R}^5 = \text{SO}_2\text{NH}$ -( <i>2</i> -methoxyphenyl))	-408	7					C	81R072
2.4.28	( <b>2q</b> , $\text{R}^5 = 3$ -1'-(3-aminopurine))	-490	7	MV <sup>2+</sup>	-447	2-PrOH	→0	C	80R183
2.4.29	( <b>2q</b> , $\text{R}^5 = 3$ -1'-(3-amino-6-(2-methylpropyl)purine))	-503	7	TQ <sup>2+</sup>	-548	2-PrOH	→0	C	80R183
2.4.30	( <b>2q</b> , $\text{R}^5 = \text{SO}_2\text{O}$ -( <i>1</i> -naphthyl))	-340	7					C	81R072
2.4.31	( <b>2q</b> , $\text{R}^5 = \text{SO}_2\text{NH}$ -( <i>1</i> -naphthyl))	-453	7					C	81R072

TABLE 2. Reduction potentials of nitroaryl compounds ( $\text{RNO}_2/\text{RNO}_2^-$ )—Continued

No.	Compound or couple	E/mV	pH	Ref. compound	Ref. E /mV	Co-solute	I	Method/ comments	Ref.
<b>2.4. 4-Nitroimidazoles—Continued</b>									
2.4.32	(2r, $\text{R}^1 = \text{CH}_3$ , $\text{R}^2 = \text{Br}$ )	-515	7					C	84R150
2.4.33	2-Iodo-1-methyl-4-nitroimidazole (2r, $\text{R}^1 = \text{CH}_3$ , $\text{R}^2 = \text{I}$ )	-521	7	$\text{MV}^{2+}$	-447	2-PrOH	$\rightarrow 0$	C	82A033
2.4.34	(2r, $\text{R}^1 = \text{CH}_3$ , $\text{R}^2 = \text{NO}_2$ )	-243	7					C	84R150
2.4.35	(2r, $\text{R}^1 = \text{CH}_3$ , $\text{R}^2 = \text{SO}_2\text{CH}_3$ )	-446	7					C	84R150
2.4.36	(2r, $\text{R}^1 = \text{CH}_2\text{CH}(\text{OH})\text{CH}_2\text{OH}$ , $\text{R}^5 = \text{I}$ )	-512	7						84R150
2.4.37	(2r, $\text{R}^1 = \text{CH}_2\text{CO}_2\text{C}_2\text{H}_5$ , $\text{R}^5 = \text{I}$ )	-436	7	$\text{AQS}^-$	-480			C (K)	85A303
2.4.38	(2r, $\text{R}^1 = \text{CH}_2\text{CH}(\text{OH})\text{CH}_2\text{OCH}_3$ , $\text{R}^5 = \text{I}$ )	-497	7	$\text{AQS}^-$	-480			C	85A303
2.4.39	(2r, $\text{R}^1 = \text{CH}_2\text{CH}(\text{OH})\text{CH}_2\text{OCH}_3$ , $\text{R}^2 = \text{CH}_3$ )	-564	7	$\text{MV}^{2+}$	-447		$\rightarrow 0$	C	79R017
		-583	7	$\text{TQ}^{2+}$	-548		$\rightarrow 0$	C	80C008
2.4.40	(2r, $\text{R}^1 = \text{CH}_2\text{CH}_2$ - ( <i>N</i> -morpholino))	-554	7	$\text{MV}^{2+}$	-554		$\rightarrow 0$	C	79R017
2.4.41	(2r, $\text{R}^1 = \text{CH}_2\text{CONHCH}_2$ - (3-pyridyl- <i>N</i> -oxide), $\text{R}^5 = \text{I}$ )	-465	7	$\text{AQS}^-$	-380			C	85A303
2.4.42	(2s)	-439	7	$\text{AQS}^-$	-375		$\rightarrow 0$	C	771044
2.4.43	(2t)	-335	7					C	84R150
2.4.44	(2q, $\text{R}^5 = \text{SC}_6\text{H}_5$ )	-501	7						84R150
<b>2.5. 5-Nitroimidazoles</b>									
2.5.1	4-Bromo-1-methyl-5-nitroimidazole (2u, $\text{R}^1 = \text{Br}$ )	-460	7	$\text{MV}^{2+}$	-447	2-PrOH	$\rightarrow 0$	C	82A033
2.5.2	4-Iodo-1-methyl-5-nitroimidazole (2u, $\text{R}^1 = \text{I}$ )	-461	7	$\text{MV}^{2+}$	-447	2-PrOH	$\rightarrow 0$	C(K)	82A033
		-464	7	$\text{AQS}^-$	-380			C	85A303
2.5.3	(2u, $\text{R}^1 = \text{SO}_2$ - ( <i>N</i> -morpholino))	-334	7					C	83R015
2.5.4	(2u, $\text{R}^1 = \text{SO}_2\text{NH}_2$ )	-336	7					C	83R015
2.5.5	(2u, $\text{R}^1 = \text{SO}_2\text{C}_6\text{H}_5$ )	-324	7					C	83R015
2.5.6	(2u, $\text{R}^1 = \text{SO}_2\text{OC}_6\text{H}_5$ )	-259	7					C	83R015








TABLE 2. Reduction potentials of nitroaryl compounds ( $\text{RNO}_2/\text{R}\dot{\text{N}}\text{O}_2^-$ )—Continued

No.	Compound or couple	$E/\text{mV}$	pH	Ref. compound	Ref. $E/\text{mV}$	Co-solute	$I$	Method/comments	Ref.
<b>2.5. 5-Nitroimidazoles—Continued</b>									
2.5.7	2-Iodo-1-methyl-5-nitroimidazole ( <b>2u</b> , $\text{R}^2 = \text{I}$ )	-454	7	$\text{MV}^{2+}$	-447	2-PrOH	$\rightarrow 0$	C	82A033
2.5.8	( <b>2u</b> , $\text{R}^2 = \text{NO}_2$ )	-178	7					C	84R150
2.5.9	1-Methyl-5-nitroimidazole-2-carboxaldehyde ( <b>2u</b> , $\text{R}^2 = \text{CHO}$ )	-360	7	$\text{AQS}^-$	-375	2-PrOH	$\rightarrow 0$	C	82R117
2.5.10	1,2-Dimethyl-5-nitroimidazole ( <b>2u</b> , $\text{R}^2 = \text{CH}_3$ )	-360	7	$\text{BV}^{2+}$	-354	2-PrOH	$\rightarrow 0$	C	82R117
		-475	7	$\text{AQS}^-$	-375	2-PrOH	$\rightarrow 0$	C	761070
2.5.11	(2u, $\text{R}^2 = \text{SOCH}_3$ )	-480	7	$\text{AQS}^-$	-375	$\text{HCO}_2^-$	$\rightarrow 0$	C, calc. data	761070
		-361	7					C	84R150
2.5.12	(2u, $\text{R}^2 = \text{SO}_2\text{CH}_3$ )	-351	7					C	84R150
2.5.13	(2u, $\text{R}^2 = \text{S}(\text{CH}_2)_2\text{O}$ - (4-carboxyphenyl))	-481	7	$\text{MV}^{2+}$	-447	2-PrOH	$\rightarrow 0$	C	85R035
2.5.14	(2v, $\text{R}^1 = \text{CH}_2\text{CH}_2\text{OPO}_3^{2-}$ , $\text{R}^2 = \text{CH}_3$ , $\text{Na}_2\text{salt}$ (?))	-509	7	$\text{AQS}^-$	-375	<i>t</i> -BuOH	$\rightarrow 0$	C	771044
2.5.15	(2v, $\text{R}^1 = \text{CH}_2\text{CH}_2\text{OH}$ , $\text{R}^2 = \text{CH}_3$ )	-486	* 7					Rec.	
		-485	7	$\text{AQS}^-$	-375	2-PrOH	$\rightarrow 0$	C, calc. data	761070
		-488	7	$\text{AQS}^-$	-375	<i>t</i> -BuOH	$\rightarrow 0$	C (K), calc. data	761070
		-486	7	$\text{AQS}^-$	-375	<i>t</i> -BuOH	$\rightarrow 0$	C	771044
		-451	7	3.8.10	-410	<i>t</i> -BuOH		C	85A090
2.5.16	(2v, $\text{R}^1 = \text{CH}_2\text{CH}(\text{OH})\text{CH}_2\text{Cl}$ , $\text{R}^2 = \text{CH}_3$ )	-476	7	$\text{AQS}^-$	-380	<i>t</i> -BuOH		C	85A090
		-467	* 7	$\text{AQS}^-$	-375	2-PrOH	$\rightarrow 0$	Rec.; C	761070
		-474	7	$\text{AQS}^-$	-375	$\text{HCO}_2^-$	$\rightarrow 0$	C, calc. data	761070
2.5.17	(2v, $\text{R}^1 = \text{CH}_2\text{CO}_2\text{C}_2\text{H}_5$ , $\text{R}^2 = \text{I}$ )	-475	7	$\text{AQS}^-$	-375			C	85A303
2.5.18	(2v, $\text{R}^1 = \text{CH}_2\text{CH}(\text{OH})\text{CH}_2\text{OCH}_3$ , $\text{R}^2 = \text{I}$ )	-441	7	$\text{AQS}^-$	-375			C	85A303
2.5.19	(2v, $\text{R}^1 = \text{CH}_2\text{CH}_2\text{NHC}(=\text{S})\text{OCH}_3$ , $\text{R}^2 = \text{CH}_3$ )	-498	7	$\text{MV}^{2+}$	-447		$\rightarrow 0$	C	79R017
2.5.20	(2v, $\text{R}^1 = \text{CH}_2\text{CH}(\text{OH})\text{CH}_2\text{OCH}_3$ , $\text{R}^2 = \text{CH}_3$ )	-479	* 7	$\text{AQS}^-$	-375	2-PrOH	$\rightarrow 0$	Rec.; C	761070
		-475	7	$\text{AQS}^-$	-375	$\text{HCO}_2^-$	$\rightarrow 0$	C	761070
2.5.21	1-(2-Ethylsulfonyl)-ethyl-2-methyl-5-nitroimidazole ( <b>2v</b> , $\text{R}^1 = \text{CH}_2\text{CH}_2\text{SO}_2\text{C}_2\text{H}_5$ , $\text{R}^2 = \text{CH}_3$ )	-464	7	$\text{AQS}^-$	-375	<i>t</i> -BuOH	$\rightarrow 0$	C	761070



(2v)

TABLE 2. Reduction potentials of nitroaryl compounds ( $RNO_2/R\dot{N}O_2^-$ )—Continued

No.	Compound or couple	$E/mV$	pH	Ref. compound	Ref. $E/mV$	Co-solute	$I$	Method/comments	Ref.
<b>2.5. 5-Nitroimidazoles—Continued</b>									
		-464	7	AQS <sup>-</sup>	-375	<i>t</i> -BuOH	→0	C	771044
2.5.22	1-(2- <i>N</i> -Morpholinoethyl)-5-nitroimidazole ( <b>2v</b> , R <sup>1</sup> = CH <sub>2</sub> CH <sub>2</sub> -( <i>N</i> -morpholino))	-457	7	AQS <sup>-</sup>	-375	<i>t</i> -BuOH	→0	C	761070
2.5.23	( <b>2v</b> , R <sup>1</sup> = CH <sub>2</sub> CONH <sub>2</sub> CH <sub>2</sub> -(3-pyridyl), R <sup>1</sup> = I)	-448	7	AQS <sup>-</sup>	-380			C(K)	85A303
2.5.24	( <b>2w</b> , X = S)	-467	7					C	84R150
2.5.25	( <b>2w</b> , X = SO <sub>2</sub> )	-342	7					C	84R150
<b>2.6. Nitroazaindoles</b>									
2.6.1	1-Methyl-3-nitro-7-azaindole ( <b>2x</b> , R <sup>1</sup> = CH <sub>3</sub> )	-566	7	3.5.1	-700	HCO <sub>2</sub> <sup>-</sup>	→0		86C027
2.6.2	1-(2-Bromoethyl)-3-nitro-7-azaindole ( <b>2x</b> , R <sup>1</sup> = CH <sub>2</sub> CH <sub>2</sub> Br)	-605	7			HCO <sub>2</sub> <sup>-</sup>	→0		86C027
2.6.3	( <b>2x</b> , R <sup>1</sup> = CH <sub>2</sub> CH(OH)CH <sub>2</sub> OH)	-607	7			HCO <sub>2</sub> <sup>-</sup>	→0		86C027
2.6.4	( <b>2x</b> , R <sup>1</sup> = CH <sub>2</sub> CONHCH <sub>2</sub> CH <sub>2</sub> OH)	-546	7			HCO <sub>2</sub> <sup>-</sup>	→0		86C027
2.6.5	( <b>2x</b> , R <sup>1</sup> = CH <sub>2</sub> CONH(CH <sub>2</sub> ) <sub>3</sub> - <i>N</i> -morpholino)	-532	7			HCO <sub>2</sub> <sup>-</sup>	→0		86C027
2.6.6	( <b>2y</b> , R <sup>7</sup> = CH <sub>2</sub> CO <sub>2</sub> C <sub>2</sub> H <sub>5</sub> )	-616	7			HCO <sub>2</sub> <sup>-</sup>	→0		86C027
2.6.7	( <b>2y</b> , R <sup>7</sup> = CH <sub>2</sub> CONH(CH <sub>2</sub> ) <sub>3</sub> - <i>N</i> -morpholino)	-632	7			HCO <sub>2</sub> <sup>-</sup>	→0		86C027
2.6.8	( <b>2z</b> )	-626	7			HCO <sub>2</sub> <sup>-</sup>	→0		86C027
<b>2.7. Nitroacridines</b>									
2.7.1	Nitroakridin 3582 ( <b>2aa</b> )	-260	7	BV <sup>2+</sup>	-354	2-PrOH	→0	C	84R148
2.7.2	Nitracrine ( <b>2bb</b> , R <sup>4</sup> = H)	-275	7	BV <sup>2+</sup>	-354	2-PrOH	→0	C	87R070
		-303	7	BV <sup>2+</sup>	-380	2-PrOH	→0	C; further values, pH 3-11	89R018











TABLE 2. Reduction potentials of nitroaryl compounds ( $\text{RNO}_2/\text{R}\dot{\text{N}}\text{O}_2^-$ )—Continued


No.	Compound or couple	$E/\text{mV}$	pH	Ref. compound	Ref. $E/\text{mV}$	Co-solute	$I$	Method/comments	Ref.
<b>2.7. Nitroacridines—Continued</b>									
2.7.3	(2bb, $\text{R}^4 = \text{Cl}$ )	-325	7	$\text{BV}^{2+}$	-380	2-PrOH	$\rightarrow 0$	C	89R018
2.7.4	(2bb, $\text{R}^4 = \text{F}$ )	-354	7	$\text{BV}^{2+}$	-380	2-PrOH	$\rightarrow 0$	C	89R018
2.7.5	(2bb, $\text{R}^4 = \text{CH}_3$ )	-321	7	$\text{BV}^{2+}$	-380	2-PrOH	$\rightarrow 0$	C	89R018
2.7.6	(2bb, $\text{R}^4 = \text{OCH}_3$ )	-361	7	$\text{BV}^{2+}$	-380	2-PrOH	$\rightarrow 0$	C	89R018
2.7.7	(2bb, $\text{R}^4 = \text{CO}_2\text{CH}_3$ )	-244	7	$\text{BV}^{2+}$	-380	2-PrOH	$\rightarrow 0$	C	89R018
2.7.8	(2bb, $\text{R}^4 = \text{N}(\text{CH}_3)_2$ )	-334	7	$\text{BV}^{2+}$	-380	2-PrOH	$\rightarrow 0$	C	89R018
2.7.9	(2bb, $\text{R}^4 = \text{N}(\text{CH}_2\text{CH}_2\text{OCOCH}_3)_2$ )	-314	7	$\text{BV}^{2+}$	-380	2-PrOH	$\rightarrow 0$	C	89R018
<b>2.8. Miscellaneous nitroaryl compounds</b>									
2.8.1	2-Nitrobenzimidazole (2cc)	-300	7	$\text{AQS}^-$	-375	2-PrOH	$\rightarrow 0$	C	80R187
2.8.2	8-Nitrotheophylline (2dd)	-494	7	$\text{MV}^{2+}$	-447		$\rightarrow 0$	C	80R187
2.8.3	8-Nitrocaffeine (2ee)	-205	7	DQ	-244	2-PrOH	$\rightarrow 0$	C	80R187
2.8.4	2-Nitrobenzofuran (2ff)	-292	7	DQ	-244	2-PrOH	$\sim 0.020$	C	82R087
2.8.5	7-Hydroxy-2-nitrobenzofuran (2ff, $\text{R}^7 = \text{OH}$ )	-288 -305	7	DQ $\text{AQS}^-$	-244 -375	2-PrOH	$\sim 0.020$	C	82R087
2.8.6	7-Methoxy-2-nitrobenzofuran (2ff, $\text{R}^7 = \text{OCH}_3$ )	-296	7	DQ	-244	2-PrOH	$\sim 0.020$	C	82R087
2.8.7	5-Hydroxy-2-nitrobenzofuran (2ff, $\text{R}^5 = \text{OH}$ )	-285 -309	7	DQ $\text{AQS}^-$	-244 -375	2-PrOH	$\sim 0.020$	C	82R087
2.8.8	5-Methoxy-2-nitrobenzofuran (2ff, $\text{R}^5 = \text{OCH}_3$ )	-292	7	DQ	-244	2-PrOH	$\sim 0.020$	C	82R087
2.8.9	4-Nitropyridine (2gg)	-191	7	DQ	-235	2-PrOH	$\sim 0.010$	C (K)	751117
2.8.10	2-Nitrothiophene (2hh)	-395	7	$\text{AQS}^-$	-380	2-PrOH	$\sim 0.010$	C	751117
		-390	7	DQ	-235	2-PrOH	$\sim 0.010$	C	751117
2.8.11	5-Nitouracil (2ii)	-527	7	$\text{AQS}^-$	-380	2-PrOH	$\sim 0.010$	C	751117
2.8.12	6-Hydroxy-5-nitrothymine (2jj)	-405	7	$\text{AQS}^-$	-375				80A210
2.8.13	1-Ethyl-2,3-dihydro-6-nitroimidazo[1,2- $\alpha$ ]pyridinium (2kk, $\text{R} = \text{C}_2\text{H}_5$ )	-356	7	$\text{BV}^{2+}$	-354	2-PrOH	$\rightarrow 0$	C	78R212




(2cc)



(2dd)




(2ee)




(2ff)




(2gg)




(2hh)



(2ii)



(2jj)



(2kk)

PETER WARDMAN

TABLE 2. Reduction potentials of nitroaryl compounds ( $RNO_2/R\dot{N}O_2^-$ )—Continued

Compound or couple	$E/mV$	pH	Ref. compound	Ref. $E/mV$	Co-solute	$I$	Method/comments	Ref.
<b>2.8. Miscellaneous nitroaryl compounds—Continued</b>								
2.8.14 1-Phenyl-2,3-dihydro-6-nitroimidazo[1,2-c]pyridinium (2kk, R = $C_6H_5$ )	-335	7	BV <sup>2+</sup>	-354	2-PrOH	→0	C	78R212

\* Recommended value.

TABLE 3. Reduction potentials of bipyridinium and related compounds ( $BP^{2+}/BP^{\cdot+}$ )

No.	Compound or couple	$E/mV$	pH	Ref. compound	Ref. $E/mV$	Co-solute	$I$	Method/comments	Ref.
<b>3.1. Unbridged 2,2'-bipyridinium compounds</b>									
3.1.1	2,2'-Bipyridinium ( <b>3a</b> , $R^1 = R^{1'} = H$ )	-500	(<0)	$Co(bpy)_3^{3+}$	-890	$HCO_2^-$		Kin.; $E^{\circ}$ .	83C017
3.1.2	1,1'-Dimethyl-2,2'-bipyridinium ( <b>3a</b> , $R^1 = R^{1'} = CH_3$ )	-776	5.9-8.0					Pol., $I^-$ salt.	67C004
		-658						Pol.	68C004, 73C001
		-720	7					Cyc. v.	80A247
3.1.3	( <b>3a</b> , $R^1 = R^{1'} = (CH_2)_3SO_3^-$ )	-680						No details.	85F007
		-620	9.2					Cyc. v.	85N094
3.1.4	4,4'-Dimethyl-2,2'-bipyridinium ( <b>3a</b> , $R^4 = R^{4'} = CH_3$ )	-540	(<0)	$Co(bpy)_3^{3+}$	-890	$HCO_2^-$		Kin.; $E^{\circ}$ .	83C017
<b>3.2. Bridged 2,2'-bipyridinium compounds: derivatives of dipyrido[1,2-<math>\alpha</math>:2',1'-<math>c</math>]pyrazinedium</b>									
3.2.1	Dipyrido[1,2- $\alpha$ :2',1'- $c$ ]pyrazinedium ( <b>3b</b> )	-270	3.4-8.6					Pol., $Br^-$ salt.	68C002, 69C004
		-290						Pol.	68C004
3.2.2	6-Methyldipyrido[1,2- $\alpha$ :2',1'- $c$ ]pyrazinedium ( <b>3b</b> , $R^6 = CH_3$ )	-300						Pol., $Br^-$ salt.	71C001
3.2.3	6-Phenyldipyrido[1,2- $\alpha$ :2',1'- $c$ ]pyrazinedium ( <b>3b</b> , $R^6 = C_6H_5$ )	-270						Pol., $Br^-$ salt.	71C001
<b>3.3. Bridged 2,2'-bipyridinium compounds: derivatives of 6,7-dihydrodipyrido[1,2-<math>\alpha</math>:2',1'-<math>c</math>]pyrazinedium ('diquat')</b>									
3.3.1	6,7-Dihydrodipyrido[1,2- $\alpha$ :2',1'- $c$ ]pyrazinedium ( <b>3c</b> )	-358 *						Rec.	
		-349	10					Pot., $Br^-$ salt.	60C001
		-354	7.8	$NAD^+/NADH$	-345			Enzyme-catalysed equilibrium.	65F032
		-396	2.2-11.0					Pol.	66C002
		-342						Pol.	66C001
		-360						Pol., $Br^-$ salt.	67C003
		-349						Pol., $Br^-$ salt.	68C004, 73C001
		-366	8.3					Pol., $I^-$ salt.	68C001
		-366	1.6-9.2					Pol., $I^-$ salt.	69C001
		-381						Cyc. v., $Br^-$ and $Cl^-$ salts.	749062
		-366						Pol., $Br^-$ salt.	77Z190
		-370	7					Cyc. v.	80A247







TABLE 3. Reduction potentials of bipyridinium and related compounds (BP<sup>2+</sup>/BP<sup>•+</sup>)—Continued

No.	Compound or couple	<i>E</i> /mV	pH	Ref. compound	Ref. <i>E</i> /mV	Co-solute	<i>I</i>	Method/ comments	Ref.
<b>3.3. Bridged 2,2'-bipyridinium compounds: derivatives of 6,7-dihydrodipyrido[1,2-<i>a</i>:2',1'-<i>c</i>]pyrazinedium ('diquat')—Continued</b>									
3.3.2	4-Bromo-6,7-dihydrodipyrido[1,2- <i>a</i> :2',1'- <i>c</i> ]pyrazinedium ( <b>8c</b> , R <sup>4</sup> = Br)	-10	1.9-4.5					Pol., Br <sup>-</sup> salt, unstable pH 7.	74C003
3.3.3	6,7-Dihydro-6-hydroxydipyrido[1,2- <i>a</i> :2',1'- <i>c</i> ]pyrazinedium ( <b>8c</b> , R <sup>6</sup> = OH)	-290	1.8-4.0					Pol., Br <sup>-</sup> salt.	69C004
3.3.4	3-Cyano-6,7-dihydrodipyrido[1,2- <i>a</i> :2',1'- <i>c</i> ]pyrazinedium ( <b>8c</b> , R <sup>3</sup> = CN)	0	2-6					Pol., Br <sup>-</sup> salt.	76C002
3.3.5	6,7-Dihydro-4-methyldipyrido[1,2- <i>a</i> :2',1'- <i>c</i> ]pyrazinedium ( <b>8c</b> , R <sup>4</sup> = CH <sub>3</sub> )	-410	4.0-9.0					Pol., Br <sup>-</sup> salt.	77C006
3.3.6	6,7-Dihydro-6-methyldipyrido[1,2- <i>a</i> :2',1'- <i>c</i> ]pyrazinedium ( <b>8c</b> , R <sup>6</sup> = CH <sub>3</sub> )	-350						Pol., Br <sup>-</sup> salt.	71C001
3.3.7	6,7-Dihydro-3-methoxydipyrido[1,2- <i>a</i> :2',1'- <i>c</i> ]pyrazinedium ( <b>8c</b> , R <sup>3</sup> = OCH <sub>3</sub> )	-450	4.5-10.4					Pol.	76C002
3.3.8	3-Methoxycarbonyl-6,7-dihydrodipyrido[1,2- <i>a</i> :2',1'- <i>c</i> ]pyrazinedium ( <b>8c</b> , R <sup>3</sup> = CO <sub>2</sub> CH <sub>3</sub> )	-140	3-7					Pol.	76C002
3.3.9	4-Ethyl-6,7-dihydrodipyrido[1,2- <i>a</i> :2',1'- <i>c</i> ]pyrazinedium ( <b>8c</b> , R <sup>4</sup> = C <sub>2</sub> H <sub>5</sub> )	-420	4.0-9.0					Pol., Br <sup>-</sup> salt.	77C006
3.3.10	3-Ethoxy-6,7-dihydrodipyrido[1,2- <i>a</i> :2',1'- <i>c</i> ]pyrazinedium ( <b>8c</b> , R <sup>3</sup> = OC <sub>2</sub> H <sub>5</sub> )	-440	4.5-10.4					Pol.	76C002
3.3.11	6,7-Dihydro-1,12-dimethyldipyrido[1,2- <i>a</i> :2',1'- <i>c</i> ]pyrazinedium ( <b>8c</b> , R <sup>1</sup> = R <sup>12</sup> = CH <sub>3</sub> )	-580						Pot.	60C001
3.3.12	6,7-Dihydro-2,11-dimethyldipyrido[1,2- <i>a</i> :2',1'- <i>c</i> ]pyrazinedium ( <b>8c</b> , R <sup>2</sup> = R <sup>11</sup> = CH <sub>3</sub> )	-590	7					Cyc. v.	80A247
		-487						Pot.	60C001
		-490	7					Cyc. v.	80A247
3.3.13	6,7-Dihydro-3,10-dimethyldipyrido[1,2- <i>a</i> :2',1'- <i>c</i> ]pyrazinedium ( <b>8c</b> , R <sup>3</sup> = R <sup>10</sup> = CH <sub>3</sub> )	-491		2.4.39	-583	2-PrOH	→0	C; Br <sup>-</sup> salt.	84A292
		-479						Pot.	60C001
		-480	7					Cyc. v.	80A247
3.3.14	6,7-Dihydro-4,9-dimethyldipyrido[1,2- <i>a</i> :2',1'- <i>c</i> ]pyrazinedium ( <b>8c</b> , R <sup>4</sup> = R <sup>9</sup> = CH <sub>3</sub> )	-480							82C019



TABLE 3. Reduction potentials of bipyridinium and related compounds (BP<sup>2+</sup>/BP<sup>•+</sup>)—Continued


No.	Compound or couple	E/mV	pH	Ref. compound	Ref. E /mV	Co-solute	I	Method/ comments	Ref.
<b>3.3. Bridged 2,2'-bipyridinium compounds: derivatives of 6,7-dihydrodipyrido[1,2-a:2',1'-c]pyrazinedium ('diquat')—Continued</b>									
3.3.15	6,7-Dihydro-6,6-dimethyldipyrido[1,2-a:2',1'-c]pyrazinedium (8c, R <sup>6</sup> = R <sup>6'</sup> = CH <sub>3</sub> )	-350						Pol., Br <sup>-</sup> salt.	71C001
3.3.16	6,7-Dihydro-3-propoxydipyrido[1,2-a:2',1'-c]pyrazinedium (8c, R <sup>3</sup> = OC <sub>3</sub> H <sub>7</sub> )	-440	4.5-10.4					Pol.	76C002
3.3.17	6,7-Dihydro-2,3,10,11-tetramethyldipyrido[1,2-a:2',1'-c]pyrazinedium (8c, R <sup>2</sup> = R <sup>3</sup> = R <sup>10</sup> = R <sup>11</sup> = CH <sub>3</sub> )	-613	7	3.4.1	-548	2-PrOH	-0		84A292
3.3.18	6,7-Dihydro-4(2-pyridyl)dipyrido[1,2-a:2',1'-c]pyrazinedium (8c, R <sup>4</sup> = 2-pyridyl)	-320	1.5-8.2					Pol., Br <sup>-</sup> salt	69C002
3.3.19	6,7-Dihydro-6-phenyldipyrido[1,2-a:2',1'-c]pyrazinedium (8c, R <sup>6</sup> = C <sub>6</sub> H <sub>5</sub> )	-290						Pol., Br <sup>-</sup> salt.	71C001
<b>3.4. Bridged 2,2'-bipyridinium compounds: derivatives of 7,8-dihydro-6H-dipyrido[1,2-a:2',1'-c][1,4]diazepinedium ('triquat')</b>									
3.4.1	7,8-Dihydrodipyrido[1,2-a:2',1'-c][1,4]diazepinedium (8d)	-549 *						Rec.	
		-548	10					Pot., Br <sup>-</sup> salt.	60C001
		-521	7.8					Pol.	66C001
		-550	8.3					Pol., I <sup>-</sup> salt.	08C001
		-539	4.9-9.2						69C001
		-608						Pol.	73C001
		-556	7					Cyc. v., Br <sup>-</sup> salt.	749062
		-550	7					Cyc. v.	80A247
		-549	7					Diff. pulse volt.; Br <sup>-</sup> salt.	80C045
		-547	7					Pol.; Br <sup>-</sup> salt.	80C045
		-490						Pol.; Br <sup>-</sup> salt.	81S024
3.4.2	7,8-Dihydro-4-methyldipyrido[1,2-a:2',1'-c]diazepinedium (8d, R <sup>4</sup> = CH <sub>3</sub> )	-590	7.0-9.0					Pol., Br <sup>-</sup> salt.	77C006
3.4.3	7,8-Dihydro-3-methoxydipyrido[1,2-a:2',1'-c]diazepinedium (8d, R <sup>3</sup> = OCH <sub>3</sub> )	-630	4.5-10.4					Pol., Br <sup>-</sup> salt.	76C002



(3d)

TABLE 3. Reduction potentials of bipyridinium and related compounds (BP<sup>2+</sup>/BP<sup>•+</sup>)—Continued

No.	Compound or couple	<i>E</i> /mV	pH	Ref. compound	Ref. <i>E</i> /mV	Co-solute	<i>I</i>	Method/ comments	Ref.
<b>3.4. Bridged 2,2'-bipyridinium compounds: derivatives of 7,8-dihydro-6<i>H</i>-dipyrido[1,2-<i>a</i>:2',1'-<i>c</i>][1,4]diazepinedium ('triquat')—Continued</b>									
3.4.4	7,8-Dihydro-2,12-dimethyldipyrido[1,2- <i>a</i> :2',1'- <i>c</i> ][1,4]diazepinedium (3d, R <sup>2</sup> = R <sup>12</sup> = CH <sub>3</sub> )	-691 *						Rec.	
		-739						Pol., Br <sup>-</sup> salt, meas. by T.E. Tomlinson	65C002
		-560 †	7.8					Pol., Br <sup>-</sup> salt.	66C001
		-690	7					Pol.	66C001
		-690	7					Diff. pulse volt.; Br <sup>-</sup> salt.	80C045
		-686	7					Pol.; Br <sup>-</sup> salt.	80C045
		-630						Pol.; Br <sup>-</sup> salt.	81S024
		-700							82C019
		-695	7	2.4.39	-583	2-PrOH	→0	C; Br <sup>-</sup> salt.	84A292
		-686	7	3.3.17	-613	2-PrOH	→0	C; Br <sup>-</sup> salt.	84A292
3.4.5	7,8-Dihydro-3,11-dimethyldipyrido[1,2- <i>a</i> :2',1'- <i>c</i> ][1,4]diazepinedium (3d, R <sup>3</sup> = R <sup>11</sup> = CH <sub>3</sub> )	-671						Pol., Br <sup>-</sup> salt.	65C002
		-636							66C001
		-671						Pol.	66C001
		-664	7					Diff. pulse volt.; Br <sup>-</sup> salt.	80C045
		-662	7					Pol.; Br <sup>-</sup> salt.	80C045
3.4.6	7,8-Dihydro-2,3,11,12-tetramethyldipyrido[1,2- <i>a</i> :2',1'- <i>c</i> ][1,4]diazepinedium (3d, R <sup>2</sup> = R <sup>3</sup> = R <sup>11</sup> = R <sup>12</sup> = CH <sub>3</sub> )	-770						Approx. (Value from cyc. v. in CH <sub>3</sub> CN taken, less 30 mV.) ClO <sub>4</sub> <sup>-</sup> salt.	82S257
		-775	7	2.4.39	-583		→0	C; Br <sup>-</sup> salt.	84A292
		-778	7	3.3.17	-613		→0	C; Br <sup>-</sup> salt.	84A292
<b>3.5. Bridged 2,2'-bipyridinium compounds: derivatives of 6,7,8,9-tetrahydrodipyrido[1,2-<i>a</i>:2',1'-<i>c</i>][1,4]diazocinedium ('tetraquat')</b>									
3.5.1	6,7,8,9-Tetrahydrodipyrido[1,2- <i>a</i> :2',1'- <i>c</i> ][1,4]diazocinedium (3e)	~700	10					Pot., Br <sup>-</sup> salt, cryst. with 1/2 mol HBr.	60C001
		-636	8.3					Pol., I <sup>-</sup> salt.	68C001
		-641	6.7-9.1					Pol., I <sup>-</sup> salt.	69C001
		-650	7					Cyc. v.	80A247



(3e)

TABLE 3. Reduction potentials of bipyridinium and related compounds (BP<sup>2+</sup>/BP<sup>•+</sup>)—Continued

No.	Compound or couple	<i>E</i> /mV	pH	Ref. compound	Ref. <i>E</i> /mV	Co-solute	<i>I</i>	Method/ comments	Ref.
<b>3.5. Bridged 2,2'-bipyridinium compounds: derivatives of 6,7,8,9-tetrahydrodipyrido[1,2-<i>a</i>:2',1'-<i>c</i>][1,4]diazocinedium ('tetraquat')—Continued</b>									
3.5.2	6,7,8,9-Tetrahydro-2,12-dimethyl-dipyrido[1,2- <i>a</i> :2',1'- <i>c</i> ][1,4]diazocinedium (3e, R <sup>2</sup> = R <sup>13</sup> = CH <sub>3</sub> )	-780							80A247
		-735	7	2.4.39	-583	2-PrOH	-0	C; Br <sup>-</sup> salt.	84A292
		-745	7	3.3.17	-613	2-PrOH	-0	C; Br <sup>-</sup> salt.	84A292
3.5.3	6,7,8,9-Tetrahydro-2,3,12,13-tetramethyl-dipyrido[1,2- <i>a</i> :2',1'- <i>c</i> ][1,4]diazocinedium (3e, R <sup>2</sup> = R <sup>3</sup> = R <sup>12</sup> = R <sup>13</sup> = CH <sub>3</sub> )	-832	7		-613	<i>t</i> -BuOH	-0	C; Br <sup>-</sup> salt.	84A292
<b>3.6. Miscellaneous 2,2'-bipyridinium compounds</b>									
3.6.1	1,10-Phenanthrolium (3f, R = R' = H)	-540						Approx., from kin. of quenching react. and comp. with bipyridyls (E).	83C017
3.6.2	1,10-Dimethyl-1,10-phenanthrolium (3f, R = R' = CH <sub>3</sub> )	-510						Cyc. v.	83N211
3.6.3	Phenanthroliino[4,5- <i>α</i> :6,7- <i>c</i> ]pyrazinedium (3g)	-280	7					Pol., Br <sup>-</sup> salt.	68C003
		-234						Pol., Br <sup>-</sup> salt.	68C004
		-250						Cyc. v.	83N211
3.6.4	Phenanthroliino[4,5- <i>α</i> :6,7- <i>c</i> ]diazepinedium (3h, R = R' = H)	-270	7					Pol., Br <sup>-</sup> salt.	68C003
		-114						Pol., Br <sup>-</sup> salt.	68C004
		-130						Cyc. v.	83N211
		-180						Pol.; Br <sup>-</sup> salt.	81S024
3.6.5	1-Chlorophenanthroliino-[4,5- <i>α</i> :6,7- <i>c</i> ]diazepinedium (3h, R = H, R' = Cl)	-110						Pol.; Br <sup>-</sup> salt.	81S024
3.6.6	1-Methylphenanthroliino-[4,5- <i>α</i> :6,7- <i>c</i> ]diazepinedium (3h, R = H, R' = CH <sub>3</sub> )	-220						Pol.; Br <sup>-</sup> salt.	81S024
3.6.7	1,11-Dimethylphenanthroliino-[4,5- <i>α</i> :6,7- <i>c</i> ]diazepinedium (3h, R = R' = CH <sub>3</sub> )	-400						Pol.; Br <sup>-</sup> salt.	81S024








TABLE 3. Reduction potentials of bipyridinium and related compounds (BP<sup>2+</sup>/BP<sup>•+</sup>)—Continued


No.	Compound or couple	<i>E</i> /mV	pH	Ref. compound	Ref. <i>E</i> /mV	Co-solute	<i>I</i>	Method/ comments	Ref.
<b>3.6. Miscellaneous 2,2'-bipyridinium compounds—Continued</b>									
3.6.8	1,11-Diphenylphenanthroline-[4,5- $\alpha$ 6,7- <i>c</i> ]diazepinedium ( <b>3h</b> , R = R' = C <sub>6</sub> H <sub>5</sub> )	-310						Pol.; Br <sup>-</sup> salt.	81S024
3.6.9	Phenanthroline[4,5- $\alpha$ 6,7- <i>c</i> ]diazocinedium ( <b>3i</b> )	-450						Cyc. v.	83N211
3.6.10	1,1'-Dimethyl-2,2'-biquinolium ( <b>3j</b> )	-250	2.2-9.9					Pol., CH <sub>3</sub> SO <sub>4</sub> <sup>-</sup> salt.	69C002
<b>3.7. 2,4'-Bipyridinium compounds</b>									
3.7.1	1,1'-Dimethyl-2,4'-bipyridinium ( <b>3k</b> )	-640						Pot., I <sup>-</sup> salt.	60C002
<b>3.8. Symmetrical 1,1'-disubstituted 4,4'-bipyridinium compounds (viologens, R<sup>1</sup> = R<sup>1'</sup>) without additional ring substituents</b>									
3.8.1	4,4'-Bipyridine ( <b>3l</b> , R = H)	-485	1.5					Pol., Cl <sup>-</sup> salt.	81Z316
3.8.2	Methyl viologen (1,1'-Dimethyl-4,4'-bipyridinium) ( <b>3l</b> , R = CH <sub>3</sub> )	-448 *						Rec.	
		-440	9-13					Pot., Cl <sup>-</sup> salt.	33C001
		-434	1.2-13					Pol., Cl <sup>-</sup> salt.	57C001
		-446						Pot., I <sup>-</sup> salt.	60C002
		-426	7.8					Pol., Cl <sup>-</sup> salt.	66C001
		-445						Pol., I <sup>-</sup> salt.	67C002
		-418						Pol., I <sup>-</sup> salt.	68C004, 73C001
			8.3					Pol.	68C001
		-444	9, 11					Pot.	69C003
		-454						Cyc. v.	69C005
		-443	6.8				0.11	Pol., Cl <sup>-</sup> salt.	70C001, 81Z316
		-449						Cyc. v., Cl <sup>-</sup> salt.	749062
		-441						Pol. or Pot., Cl <sup>-</sup> salt.	75C001
		-464	7.45		-242			Cyc. v., At 0.1 mmol dm <sup>-3</sup> viologen; value increased to -447 mV at 2 mmol dm <sup>-3</sup> viologen.	76C001
		-445	11.0					Pot.	76C001
		-460	7.45					Reduct. by H <sub>2</sub> /hydrogenase, extinction values assumed.	76C001




(3i)



(3j)



(3k)



(3l)

TABLE 3. Reduction potentials of bipyridinium and related compounds ( $BP^{2+}/BP^{\cdot+}$ )—Continued

No.	Compound or couple	$E/mV$	pH	Ref. compound	Ref. $E/mV$	Co-solute	$I$	Method/comments	Ref.
<b>3.8. Symmetrical 1,1'-disubstituted 4,4'-bipyridinium compounds (viologens, <math>R^1 = R^{1'}</math>) without additional ring substituents—Continued</b>									
		-450	7					Pol.	77Z190
		-462						Pol., bis( <i>O,O</i> -dimethyl phosphate) salt.	78C017
		-446						Reduct. by $H_2$ /hydrogenase, extinction values assumed.	78C016
		-440	7					Cyc. v.	80A247
		-465	7	AQS <sup>-</sup>	-373		-0	C; via $BV^{2+}$	80A349
		-456	1,7					Cyc. v.; 0.05 mol $dm^{-3}$ $H_2SO_4$ or 0.5 mol $dm^{-3}$ $Na_2SO_4$ .	80C004
		-456						Cyc. v.	80C044
		-453						Pot.; no details.	80R192
		-430	3.12		-247			Pol.; 25 mV lower using glassy carbon electrode.	81C038
		-448	7.4					Pot.	83R178
		-430						Cyc. v.	84N047
		-479						Cyc. v.	85A301
		-450						Cyc. v.	85E687
		-458	7.0					Cyc. v.	85M420
		-446						Cyc. v.	85N197
		-441						Pot. (also data on $MV^{2+}$ covalently linked to polymers)	86A072
3.8.3	1,1'-Dimethoxy-4,4'-bipyridinium ( <b>31</b> , $R = OCH_3$ )	-651	6.8					Pol., $I^-$ salt.	81Z316
3.8.4	1,1'-Bis(cyanomethyl)-4,4'-bipyridinium ( <b>31</b> , $R = CH_2CN$ )	-150	6.8					Pol., $I^-$ salt.	70C001, 81Z316
3.8.5	1,1'-Bis(carboxymethyl)-4,4'-bipyridinium ( <b>31</b> , $R = CH_2CO_2H$ )	-444						Pot.	33C001
		-410	5.0					Pol., $Cl^-$ salt.	81Z316
3.8.6	1,1'-Bis(2-sulfonatoethyl)-4,4'-bipyridinium ( <b>31</b> , $R = CH_2CH_2SO_3^-$ )	-360						No details	86N260
3.8.7	1,1'-Bis(2-chloroethyl)-4,4'-bipyridinium ( <b>31</b> , $R = CH_2CH_2Cl$ )	-335	76.8					Pol. 30° C, $Cl^-$ salt.	70C001, 81Z316
3.8.8	1,1'-Bis(carbamylmethyl)-4,4'-bipyridinium ( <b>31</b> , $R = CH_2CONH_2$ )	-296	6.8					Pol. 30° C, $Cl^-$ salt.	70C001, 81Z316

TABLE 3. Reduction potentials of bipyridinium and related compounds (BP<sup>2+</sup>/BP<sup>•+</sup>)—Continued

No.	Compound or couple	<i>E</i> /mV	pH	Ref. compound	Ref. <i>E</i> /mV	Co-solute	<i>I</i>	Method/comments	Ref.
<b>3.8. Symmetrical 1,1'-disubstituted 4,4'-bipyridinium compounds (viologens, R<sup>1</sup> = R<sup>1'</sup>) without additional ring substituents—Continued</b>									
3.8.9	1,1'-Bis(2-hydroxyiminoethyl)-4,4'-bipyridinium ( <b>31</b> , R = CH <sub>2</sub> CH=NOH)	-325	6.8					Pol., Cl <sup>-</sup> salt.	70C001, 81Z316
3.8.10	1,1'-Diethyl-4,4'-bipyridinium ( <b>31</b> , R = C <sub>2</sub> H <sub>5</sub> )	-455 *						Rec.	
		-449	11.0					Pot., Cl <sup>-</sup> salt.	33C001
		-480						Pol., See 76C001	61C001
		-466						Pol.	61M014
		-451	7					Pol.	81Z316
		-480						Pot.; no details.	80R192
3.8.11	1,1'-Bis(2-hydroxyethyl)-4,4'-bipyridinium ( <b>31</b> , R = CH <sub>2</sub> CH <sub>2</sub> OH)	-403 *						Rec.	
		-408						Pot., Br <sup>-</sup> salt.	60C002
		-401	1.5-9.2					Pol., Br <sup>-</sup> salt.	69C001
		-399	6.8					Pol., Cl <sup>-</sup> salt.	70C001, 81Z316
		-408						Cyc. v.	77C007
		-400	7					Cyc. v.	80A247
3.8.12	1,1'-Bis(2-aminoethyl)-4,4'-bipyridinium ( <b>31</b> , R = CH <sub>2</sub> CH <sub>2</sub> NH <sub>2</sub> )	-280						Pol.	81Z316
3.8.13	1,1'-Bis(2-propynyl)-4,4'-bipyridinium ( <b>31</b> , R = CH <sub>2</sub> C≡CH)	-435						Pol.	81Z316
3.8.14	1,1'-Bis(1,2-dichloroethyl)-4,4'-bipyridinium ( <b>31</b> , R = CH <sub>2</sub> (Cl)=CHCl)	-266	6.8					Pol., Cl <sup>-</sup> salt.	81Z316
3.8.15	1,1'-Diallyl-4,4'-bipyridinium ( <b>31</b> , R = CH <sub>2</sub> CH=CH <sub>2</sub> )	-408						Pol.	81Z316
3.8.16	1,1'-Bis(2-oxopropyl)-4,4'-bipyridinium ( <b>31</b> , R = CH <sub>2</sub> COCH <sub>3</sub> )	-305	1.5					Pol., Br <sup>-</sup> salt.	81Z316
3.8.17	1,1'-Bis(2-carboxyethyl)-4,4'-bipyridinium ( <b>31</b> , R = CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> H)	-431						Pot., Cl <sup>-</sup> salt.	60C002
3.8.18	1,1'-Bis(3-sulfonatopropyl)-4,4'-bipyridinium ( <b>31</b> , R = (CH <sub>2</sub> ) <sub>3</sub> SO <sub>3</sub> <sup>-</sup> )	-380 *						Rec.	
		-345						Pulse rad. and cyc. v.; 85F007 gives -370 mV (no details).	84A392
		-386						Cyc. v.	84N047
		-390	9.2					Cyc. v.	85N094

TABLE 3. Reduction potentials of bipyridinium and related compounds (BP<sup>2+</sup>/BP<sup>•+</sup>)—Continued

No.	Compound or couple	<i>E</i> /mV	pH	Ref. compound	Ref. <i>E</i> /mV	Co-solute	<i>I</i>	Method/ comments	Ref.
<b>3.8. Symmetrical 1,1'-disubstituted 4,4'-bipyridinium compounds (vtologens, R<sup>1</sup> = R<sup>1'</sup>) without additional ring substituents—Continued</b>									
3.8.19	1,1'-Dipropyl-4,4'-bipyridinium ( <b>31</b> , R = <i>n</i> -C <sub>3</sub> H <sub>7</sub> )	-438						Pot., I <sup>-</sup> salt.	60C002
		-446	3.3					Pol., Br <sup>-</sup> salt.	75C002
3.8.20	1,1'-Bis(1-methylethyl)-4,4'-bipyridinium ( <b>31</b> , R = CH(CH <sub>3</sub> ) <sub>2</sub> )	-450							82C019
3.8.21	1,1'-Bis(ethylthiomethyl)-4,4'-bipyridinium ( <b>31</b> , R = CH <sub>2</sub> SEt)	-308	6.8					Pol., Cl <sup>-</sup> salt.	81Z316
3.8.22	1,1'-Bis(3-cyanopropyl)-4,4'-bipyridinium ( <b>31</b> , R = (CH <sub>2</sub> ) <sub>3</sub> CN)	-362	6.8					Pol., Cl <sup>-</sup> salt.	81Z316
3.8.23	1,1'-Bis(ethoxycarbonylmethyl)-4,4'-bipyridinium ( <b>31</b> , R = CH <sub>2</sub> CO <sub>2</sub> Et)	-422						Pot., Cl <sup>-</sup> salt.	60C002
		-207 *	6.8					Rec.; Pol., Br <sup>-</sup> salt.	70C001, 81Z316
3.8.24	1,1'-Bis(dimethylamino-carbonylmethyl)-4,4'-bipyridinium ( <b>31</b> , R = CH <sub>2</sub> CON(CH <sub>3</sub> ) <sub>2</sub> )	-301	1.5-9.2					Pol.	69C001
		-302	6.8					Pol., Cl <sup>-</sup> salt.	81Z316
3.8.25	1,1'-Bis(2-ethoxyethyl)-4,4'-bipyridinium ( <b>31</b> , R = CH <sub>2</sub> CH <sub>2</sub> OEt)	-386						Pot., I <sup>-</sup> salt.	60C002
		-386	6.8					Pol., I <sup>-</sup> salt.	81Z316
3.8.26	1,1'-Bis[2-(ethoxycarbonyl)ethyl]-4,4'-bipyridinium ( <b>31</b> , R = (CH <sub>2</sub> ) <sub>2</sub> CO <sub>2</sub> Et)	-376	6.8					Pol., Br <sup>-</sup> salt.	81Z316
3.8.27	1,1'-Bis[2-(dimethylaminocarbonyl)ethyl]-4,4'-bipyridinium ( <b>31</b> , R = (CH <sub>2</sub> ) <sub>2</sub> CON(CH <sub>3</sub> ) <sub>2</sub> )	-385	6.8					Pol., Cl <sup>-</sup> salt.	81Z316
3.8.28	1,1'-Bis[3-(ethoxycarbonyl)propyl]-4,4'-bipyridinium ( <b>31</b> , R = (CH <sub>2</sub> ) <sub>3</sub> CO <sub>2</sub> Et)	-433	6.8					Pol., Br <sup>-</sup> salt.	81Z316
3.8.29	1,1'-Bis[2-(trimethylammonio)ethyl]-4,4'-bipyridinium ( <b>31</b> , R = (CH <sub>2</sub> ) <sub>2</sub> N <sup>+</sup> (CH <sub>3</sub> ) <sub>3</sub> )	-280	6.8					Pol., Br <sup>-</sup> salt.	81Z316
3.8.30	1,1'-Bis(4-nitrophenyl)-4,4'-bipyridinium ( <b>31</b> , R = <i>p</i> -NO <sub>2</sub> C <sub>6</sub> H <sub>4</sub> )	-150	6.8					Pol., I <sup>-</sup> salt.	81Z316
3.8.31	1,1'-Diphenyl-4,4'-bipyridinium ( <b>31</b> , R = C <sub>6</sub> H <sub>5</sub> )	-288	6.8					Pol., Cl <sup>-</sup> salt.	81Z316

Compound	<i>E</i> /mV	pH	Ref. compound	Ref. <i>E</i> /mV	Co-solute	<i>I</i>	Method/comments	Ref.
<b>3.8. Symmetrical 1,1'-disubstituted 4,4'-bipyridinium compounds (viologens, R<sup>1</sup> = R<sup>1'</sup>) without additional ring substituents—Continued</b>								
3.8.32	1,1'-Bis(2-pyridylmethyl)-4,4'-bipyridinium ( <b>31</b> , R = CH <sub>2</sub> (2-pyridyl))	-325	6.8				Pol., Cl <sup>-</sup> salt.	70C001, 81Z316
3.8.33	1,1'-Bis(diethylaminocarbonylmethyl)-4,4'-bipyridinium ( <b>31</b> , R = CH <sub>2</sub> CON(C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> )	-318						65C002
3.8.34	1,1'-Bis[3-(dimethylaminocarbonyl)propyl]-4,4'-bipyridinium ( <b>31</b> , R = (CH <sub>2</sub> ) <sub>3</sub> CON(CH <sub>3</sub> ) <sub>2</sub> )	-399	6.8				Pol., Cl <sup>-</sup> salt.	70C001, 81Z316
3.8.35	1,1'-Dihexyl-4,4'-bipyridinium ( <b>31</b> , R = <i>n</i> -C <sub>6</sub> H <sub>13</sub> )	-439					Pot., Br <sup>-</sup> salt.	60C002
		-466	3.3				Pol., Br <sup>-</sup> salt.	75C002
3.8.36	1,1'-Bis(2,2-diethoxyethyl)-4,4'-bipyridinium ( <b>31</b> , R = CH <sub>2</sub> CH(OEt) <sub>2</sub> )	-373	6.8				Pol., Cl <sup>-</sup> salt.	81Z316
3.8.37	1,1'-Bis[3-(trimethylammonio)propyl]-4,4'-bipyridinium ( <b>31</b> , R = (CH <sub>2</sub> ) <sub>3</sub> N <sup>+</sup> (CH <sub>3</sub> ) <sub>3</sub> )	-331	6.8				Pol., Br <sup>-</sup> salt.	81Z316
		-330					No details	86N260
3.8.38	1,1'-Bis(α-cyanobenzyl)-4,4'-bipyridinium ( <b>31</b> , R = CH(C <sub>6</sub> H <sub>5</sub> )CN)	-73	1.5, 7.0				Pol., Br <sup>-</sup> salt.	81Z316
3.8.39	1,1'-Dibenzyl-4,4'-bipyridinium ( <b>31</b> , R = CH <sub>2</sub> C <sub>6</sub> H <sub>5</sub> )	-370 *					See introduction (Sec. 6.3)	
		-359	8.0				Pot., Cl <sup>-</sup> salt.	33C001
		-348	1.2-13				Pol., Cl <sup>-</sup> salt.	57C001
		-350					Pot., Cl <sup>-</sup> salt.	60C002
		-341	8.3				Pol.	68C001
		-335					Pol.	73C001
		-358	7.0				Cyc. v.	749062
		-329	3.3				Pol., Cl <sup>-</sup> salt.	75C002
		-326	3.3				Pol., Br <sup>-</sup> salt.	75C002
		-324	3.3				Pol., I <sup>-</sup> salt.	75C002
		-330	7				Cyc. v.	80A247
		-350					Pot.; no details.	80R192
		-350	7				Pol.	81C038
		-340	6.8				Pol., Br <sup>-</sup> salt.	81Z316
		-351	7.4				Pot.; extrap. to zero radical concn. (more positive at higher radical concn.).	83R178
3.8.40	1,1'-Diheptyl-4,4'-bipyridinium ( <b>31</b> , R = <i>n</i> -C <sub>7</sub> H <sub>15</sub> )	-356					Pol., Br <sup>-</sup> salt.	75C002



TABLE 3. Reduction potentials of bipyridinium and related compounds (BP<sup>2+</sup>/BP<sup>•+</sup>)—Continued

No.	Compound or couple	E/mV	pH	Ref. compound	Ref. E /mV	Co-solute	I	Method/ comments	Ref.
<b>3.8. Symmetrical 1,1'-disubstituted 4,4'-bipyridinium compounds (viologens, R<sup>1</sup> = R<sup>1'</sup>) without additional ring substituents—Continued</b>									
		-410							82C019
3.8.41	1,1'-Bis[4-(trimethylammonio)butyl]-4,4'-bipyridinium ( <b>3l</b> , R = (CH <sub>2</sub> ) <sub>4</sub> N <sup>+</sup> (CH <sub>3</sub> ) <sub>3</sub> )	-367	8.0-10.0					Pot., Br <sup>-</sup> salt.	81Z316
3.8.42	1,1'-Bis(α-cyanobenzyl)-4,4'-bipyridinium ( <b>3l</b> , R = CH(C <sub>6</sub> H <sub>5</sub> )CN)	-73	1.5, 7.0					Pol., Br <sup>-</sup> salt.	70C001, 81Z316
3.8.43	1,1'-Bis[2-(3,5-dimethyl-4-morpholinyl)-2-oxoethyl]-4,4'-bipyridinium ( <b>3l</b> , R = <b>3m</b> )	-291	1.6-9.2					Pol., Cl <sup>-</sup> salt.	69C001
		-305	7					Pol.	81Z316
3.8.44	1,1'-Dioctyl-4,4'-bipyridinium ( <b>3l</b> , R = n-C <sub>8</sub> H <sub>17</sub> )	-461	3.3					Pol., Br <sup>-</sup> salt.	75C002
		-470						Cyc. v.	83N190
3.8.45	1,1'-Dioctadecyl-4,4'-bipyridinium ( <b>3l</b> , R = n-C <sub>18</sub> H <sub>37</sub> )	-280						No details	86N260
3.8.46	1,1'-Bis[ethoxycarbonyl(phenyl)methyl]-4,4'-bipyridinium ( <b>3l</b> , R = CH(C <sub>6</sub> H <sub>5</sub> )CO <sub>2</sub> Et)	-188	6.8					Pol., Br <sup>-</sup> salt.	81Z316
3.8.47	( <b>3n</b> )	0	7					Cyc. v.	83N149
		-139						Cyc. v.	85A301
3.8.48	( <b>3o</b> , n = 2)	-280	7.3	3.3.1	-350	HCO <sub>2</sub> <sup>-</sup>	0.1	C	86A266
3.8.49	( <b>3o</b> , n = 3)	-330						Calcn.	86A266
3.8.50	( <b>3o</b> , n = 4)	-390						Calcn.	86A266

**3.9. Symmetrical 1,1'-disubstituted 4,4'-bipyridinium compounds (viologens, R<sup>1</sup> = R<sup>1'</sup>) with additional ring substituents**

3.9.1	1,1',2-Trimethyl-4,4'-bipyridinium ( <b>3p</b> , R <sup>1</sup> = R <sup>1'</sup> = CH <sub>3</sub> , R <sup>2</sup> = CH <sub>3</sub> )	-500	3.0-9.0					Pol., Br <sup>-</sup> salt.	77C006
-------	--	------	---------	--	--	--	--	-----------------------------	--------







TABLE 3. Reduction potentials of bipyridinium and related compounds ( $BP^{2+}/BP^{\bullet+}$ )—Continued

No.	Compound or couple	$E/mV$	pH	Ref. compound	Ref. $E/mV$	Co-solute	$I$	Method/comments	Ref.
<b>3.9. Symmetrical 1,1'-disubstituted 4,4'-bipyridinium compounds (viologens, <math>R^1 = R^{1'}</math>) with additional ring substituents—Continued</b>									
3.9.2	1,1'-Diethyl-2-methyl-4,4'-bipyridinium ( <b>3p</b> , $R^1 = R^{1'} = C_2H_5$ , $R^2 = CH_3$ )	-510	3.0-9.0					Pol., $Br^-$ salt. 77C006	
3.9.3	2-Methyl-1,1'-dipropyl-4,4'-bipyridinium ( <b>3p</b> , $R^1 = R^{1'} = C_3H_7$ , $R^2 = CH_3$ )	-500	3.0-9.0					Pol., $Br^-$ salt. 77C006	
3.9.4	2,2'-Dicyano-1,1'-dimethyl-4,4'-bipyridinium ( <b>3p</b> , $R^1 = R^{1'} = CH_3$ , $R^2 = R^{2'} = CN$ )	90	1.9-7.0					Pol., $CH_3SO_4^-$ salt. 74C002	
3.9.5	1,1',2,2'-Tetramethyl-4,4'-bipyridinium ( <b>3p</b> , $R^1 = R^{1'} = CH_3$ , $R^2 = R^{2'} = CH_3$ )	552	7					Pol. 70C001	
		510						Approx. (Value from cyc. v. in $CH_3CN$ taken, less 30 mV.) $Cl^-$ salt. 82S257	
3.9.6	1,1',3,3'-Tetramethyl-4,4'-bipyridinium ( <b>3p</b> , $R^1 = R^{1'} = CH_3$ , $R^3 = R^{3'} = CH_3$ )	-930						Approx. (Value from cyc. v. in $CH_3CN$ taken, less 30 mV.) $ClO_4^-$ salt. 82S257	
3.9.7	1,1',2,2',6,6'-Hexamethyl-4,4'-bipyridinium ( <b>3p</b> , $R^1 = R^{1'} = CH_3$ , $R^2 = R^{2'} = CH_3$ , $R^6 = R^{6'} = CH_3$ )	-640						Approx. (Value from cyc. v. in $CH_3CN$ taken, less 30 mV.) $Cl^-$ salt. 82S257	
3.9.8	1,1'-Dimethyl-2,2'-diphenyl-4,4'-bipyridinium ( <b>3p</b> , $R^1 = R^{1'} = CH_3$ , $R^2 = R^{2'} = C_6H_5$ )	-390						Pol. 67C002	
3.9.9	1,1'-Dimethyl-2,2'-bis(4-methylphenyl)-4,4'-bipyridinium ( <b>3p</b> , $R^1 = R^{1'} = CH_3$ , $R^2 = R^{2'} = C_6H_4CH_3$ )	-439						Pol. 67C002	
3.9.10	1,1'-Bis(cyanomethyl)-2,2'-dimethyl-4,4'-bipyridinium ( <b>3p</b> , $R^1 = R^{1'} = CH_2CN$ , $R^2 = R^{2'} = CH_3$ )	-140	7					Pol. 70C001	
3.9.11	1,1'-Bis(2-chloroethyl)-2,2'-dimethyl-4,4'-bipyridinium ( <b>3p</b> , $R^1 = R^{1'} = CH_2CH_2Cl$ , $R^2 = R^{2'} = CH_3$ )	-422	7					Pol. 70C001	
3.9.12	1,1'-Bis(2-hydroxyethyl)-2,2'-dimethyl-4,4'-bipyridinium ( <b>3p</b> , $R^1 = R^{1'} = CH_2CH_2OH$ , $R^2 = R^{2'} = CH_3$ )	-481	7					Pol. 70C001	

TABLE 3. Reduction potentials of bipyridinium and related compounds (BP<sup>2+</sup>/BP<sup>•+</sup>)—Continued

No.	Compound or couple	E/mV	pH	Ref. compound	Ref. E /mV	Co-solute	I	Method/ comments	Ref.
<b>3.9. Symmetrical 1,1'-disubstituted 4,4'-bipyridinium compounds (viologens, R<sup>1</sup> = R<sup>1'</sup>) with additional ring substituents—Continued</b>									
3.9.13	1,1'-Bis(2-oxopropyl)-2,2'-dimethyl-4,4'-bipyridinium ( <b>3p</b> , R <sup>1</sup> = R <sup>1'</sup> = CH <sub>2</sub> COCH <sub>3</sub> , R <sup>2</sup> = R <sup>2'</sup> = CH <sub>3</sub> )	-356	7					Pol.	70C001
3.9.14	1,1'-Bis(ethoxycarbonylmethyl)-2,2'-dimethyl-4,4'-bipyridinium ( <b>3p</b> , R <sup>1</sup> = R <sup>1'</sup> = CH <sub>2</sub> CO <sub>2</sub> Et, R <sup>2</sup> = R <sup>2'</sup> = CH <sub>3</sub> )	-323	7					Pol.	70C001
3.9.15	( <b>3p</b> , R <sup>1</sup> = R <sup>1'</sup> = (CH <sub>2</sub> ) <sub>3</sub> SO <sub>3</sub> <sup>-</sup> , R <sup>3</sup> = R <sup>3'</sup> = CH <sub>3</sub> )	-790	9.2					Cyc. v.	85N094
3.9.16	( <b>3p</b> , R <sup>1</sup> = R <sup>1'</sup> = (CH <sub>2</sub> ) <sub>3</sub> SO <sub>3</sub> <sup>-</sup> , R <sup>2</sup> = R <sup>2'</sup> = CH <sub>3</sub> )	-460	9.2					Cyc. v.	85N094
3.9.17	( <b>3p</b> , R <sup>1</sup> = R <sup>1'</sup> = (CH <sub>2</sub> ) <sub>3</sub> SO <sub>3</sub> <sup>-</sup> , R <sup>2</sup> = R <sup>2'</sup> = R <sup>6</sup> = R <sup>6'</sup> = CH <sub>3</sub> )	-540	9.2					Cyc. v.	85N094
<b>3.10. Asymmetrical 1,1'-disubstituted 4,4'-bipyridinium compounds (viologens, R<sup>1</sup> = CH<sub>3</sub>, R<sup>1'</sup> = variable)</b>									
3.10.1	1-Methyl-4,4'-bipyridinium-1'-oxide ( <b>3q</b> , R' = -O <sup>-</sup> )	-490	6.8					Pol., CH <sub>3</sub> SO <sub>4</sub> <sup>-</sup> salt.	81Z316
3.10.2	1-Methyl-1'-cyanomethyl-4,4'-bipyridinium ( <b>3q</b> , R' = CH <sub>2</sub> CN)	-287	6.8					Pol., Cl <sup>-</sup> salt.	70C001, 81Z316
3.10.3	1-Methyl-1'-carbamylmethyl-4,4'-bipyridinium ( <b>3q</b> , R' = CH <sub>2</sub> CONH <sub>2</sub> )	-371	6.8					Pol., I <sup>-</sup> salt.	70C001, 81Z316
3.10.4	1-Methyl-1'-(2-hydroxyethyl)-4,4'-bipyridinium ( <b>3q</b> , R' = CH <sub>2</sub> CH <sub>2</sub> OH)	-422	6.8					Pol., Cl <sup>-</sup> salt.	70C001, 81Z316
3.10.5	1-Methyl-1'-allyl-4,4'-bipyridinium ( <b>3q</b> , R' = CH <sub>2</sub> CH=CH <sub>2</sub> )	-426	6.8					Pol., I <sup>-</sup> salt.	81Z316
3.10.6	1-Methyl-1'-(2-oxopropyl)-4,4'-bipyridinium ( <b>3q</b> , R' = CH <sub>2</sub> COCH <sub>3</sub> )	-380	6.8					Pol., I <sup>-</sup> salt.	70C001, 81Z316
3.10.7	1-Methyl-1'-(3-cyano-2-propenyl)-4,4'-bipyridinium ( <b>3q</b> , R' = CH <sub>2</sub> CH=CHCN)	-369	6.8					Pol., I <sup>-</sup> salt.	81Z316
3.10.8	1-Methyl-1'-(2-bis(methylthio)ethenyl)-4,4'-bipyridinium ( <b>3q</b> , R' = CH=C(SCH <sub>3</sub> ) <sub>2</sub> )	-330	6.8					Pol., I <sup>-</sup> salt.	81Z316




TABLE 3. Reduction potentials of bipyridinium and related compounds (BP<sup>2+</sup>/BP<sup>•+</sup>)—Continued

No.	Compound or couple	<i>E</i> /mV	pH	Ref. compound	Ref. <i>E</i> /mV	Co-solute	<i>I</i>	Method/comments	Ref.
<b>3.10. Asymmetrical 1,1'-disubstituted 4,4'-bipyridinium compounds (viologens, R<sup>1</sup> = CH<sub>3</sub>, R<sup>1'</sup> = variable)—Continued</b>									
3.10.9	1-Methyl-1'-ethoxycarbonylmethyl-4,4'-bipyridinium ( <b>3q</b> , R' = CH <sub>2</sub> CO <sub>2</sub> Et)	-362	6.8					Pol., I <sup>-</sup> salt.	70C001, 81Z316
3.10.10	1-Methyl-1'-(cyano(ethoxycarbonyl)methyl)-4,4'-bipyridinium ( <b>3q</b> , R' = CH(CN)CO <sub>2</sub> C <sub>2</sub> H <sub>5</sub> )	-287	1.5					Pol., I <sup>-</sup> salt.	81Z316
3.10.11	1-Methyl-1'-[3-(methoxycarbonyl)-2-propenyl]-4,4'-bipyridinium ( <b>3q</b> , R' = CH <sub>2</sub> CH=CHCO <sub>2</sub> CH <sub>3</sub> )	-381	6.8					Pol., I <sup>-</sup> salt.	81Z316
3.10.12	1-Methyl-1'-[(1-pyrazolyl)thiocarbonylmethyl]-4,4'-bipyridinium ( <b>3q</b> , R' = CH <sub>2</sub> CSNO)	-371	6.8					Pol., I <sup>-</sup> salt.	81Z316
3.10.13	1-Methyl-1'-benzyl-4,4'-bipyridinium	-408	6.8					Pol., Br <sup>-</sup> salt.	81Z316
3.10.14	1-Methyl-1'-[anilino(thiocarbonylmethyl)-4,4'-bipyridinium ( <b>3q</b> , R' = CH <sub>2</sub> CSNHCH <sub>6</sub> H <sub>5</sub> )	-357	6.8					Pol., I <sup>-</sup> salt.	81Z316
3.10.15	1-Methyl-1'-[2-(3,5-dimethyl-4-morpholinyl)-2-oxoethyl]-4,4'-bipyridinium	-374	6.8					Pol., Cl <sup>-</sup> salt.	81Z316
<b>3.11. Asymmetrical 1,1'-disubstituted 4,4'-bipyridinium compounds (viologens, R<sup>1</sup> ≠ R<sup>1'</sup> ≠ CH<sub>3</sub>)</b>									
3.11.1	1-Ethyl-1'-(2-ethylthioethyl)-4,4'-bipyridinium ( <b>3r</b> , R = C <sub>2</sub> H <sub>5</sub> , R' = (CH <sub>2</sub> ) <sub>2</sub> SEt)	-428						Pol.	81Z316
3.11.2	1-(2-Methoxycarbonylethyl)-1'-propyl-4,4'-bipyridinium ( <b>3r</b> , R = C <sub>3</sub> H <sub>7</sub> , R' = (CH <sub>2</sub> ) <sub>2</sub> CO <sub>2</sub> CH <sub>3</sub> )	-408						Pol.	81Z316
3.11.3	1-(2-Hydroxyethyl)-1'-pentyl-4,4'-bipyridinium ( <b>3r</b> , R = C <sub>5</sub> H <sub>11</sub> , R' = CH <sub>2</sub> CH <sub>2</sub> OH)	-438						Pol.	81Z316
3.11.4	1-Allyl-1'-carboxymethyl-4,4'-bipyridinium ( <b>3r</b> , R = CH <sub>2</sub> CH=CH <sub>2</sub> , R' = CH <sub>2</sub> CO <sub>2</sub> H)	-390						Pol.	81Z316




TABLE 3. Reduction potentials of bipyridinium and related compounds (BP<sup>2+</sup>/BP<sup>•+</sup>)—Continued

No.	Compound or couple	E/mV	pH	Ref. compound	Ref. E /mV	Co-solute	I	Method/ comments	Ref.
<b>3.11. Asymmetrical 1,1'-disubstituted 4,4'-bipyridinium compounds (viologens, R<sup>1</sup> ≠ R<sup>1'</sup> ≠ CH<sub>3</sub>)—Continued</b>									
3.11.5	1-Allyl-1'-ethyl-4,4'-bipyridinium ( <b>3r</b> , R = CH <sub>2</sub> CH=CH <sub>2</sub> , R' = C <sub>2</sub> H <sub>5</sub> )	-428						Pol.	81Z316
3.11.6	1-Allyl-1'-(3-cyanopropyl)-4,4'-bipyridinium ( <b>3r</b> , R = CH <sub>2</sub> CH=CH <sub>2</sub> , R' = (CH <sub>2</sub> ) <sub>3</sub> CN)	-383						Pol.	81Z316
3.11.7	1-Allyl-1'-[2-(diethylaminocarbonyl)ethyl]-4,4'-bipyridinium ( <b>3r</b> , R = CH <sub>2</sub> CH=CH <sub>2</sub> , R' = (CH <sub>2</sub> ) <sub>2</sub> CONEt <sub>2</sub> )	-383						Pol.	81Z316
3.11.8	1-(3-Butenyl)-1'-(3-cyanopropyl)-4,4'-bipyridinium ( <b>3r</b> , R = (CH <sub>2</sub> ) <sub>3</sub> CH=CH <sub>2</sub> , R' = (CH <sub>2</sub> ) <sub>3</sub> CN)	-394						Pol.	81Z316
3.11.9	1-(2-Butenyl)-1'-(3-fluoropropyl)-4,4'-bipyridinium ( <b>3r</b> , R = CH <sub>2</sub> CH=CH(CH <sub>3</sub> ), R' = (CH <sub>2</sub> ) <sub>3</sub> F)	-418						Pol.	81Z316
3.11.10	1-(Carbamylmethyl)-1'-(2-methyl-2-propenyl)-4,4'-bipyridinium ( <b>3r</b> , R = CH <sub>2</sub> C(CH <sub>3</sub> )=CH <sub>2</sub> , R' = CH <sub>2</sub> CONH <sub>2</sub> )	-336						Pol.	81Z316
3.11.11	1-(2-Ethyl-2-propenyl)-1'-(2-methoxyethyl)-4,4'-bipyridinium ( <b>3r</b> , R = CH <sub>2</sub> CH <sub>2</sub> OCH <sub>3</sub> , R' = CH <sub>2</sub> C(Et)=CH <sub>2</sub> )	-396						Pol.	81Z316
3.11.12	1-(3-Chloro-2-butenyl)-1'-(2-methoxyethyl)-4,4'-bipyridinium ( <b>3r</b> , R = CH <sub>2</sub> CH <sub>2</sub> OCH <sub>3</sub> , R' = CH <sub>2</sub> CH=C(Cl)CH <sub>3</sub> )	-393						Pol.	81Z316
<b>3.12. Quaternary derivatives of phenanthrolines, diasapyrenes and diazapentaphenes (see also 3.6.)</b>									
3.12.1	1,10-Phenanthroline (see 3.6.1)	-470						Calcn.	83C017
3.12.2	1,9-Dimethyl-1,9-phenanthroline ( <b>3s</b> )	-426						Pol.; BF <sub>4</sub> <sup>-</sup> salt.	73C002
3.12.3	2,8-Dimethyl-2,8-phenanthroline ( <b>3t</b> )	-440						Pol.; BF <sub>4</sub> <sup>-</sup> salt.	73C002







TABLE 3. Reduction potentials of bipyridinium and related compounds (BP<sup>2+</sup>/BP<sup>•+</sup>)—Continued


No.	Compound or couple	<i>E</i> /mV	pH	Ref. compound	Ref. <i>E</i> /mV	Co-solute	<i>I</i>	Method/comments	Ref.
<b>3.12. Quaternary derivatives of phenanthrolines, diazapyrenes and diazapentaphenes (see also 3.6.)—Continued</b>									
3.12.4	2,7-Dimethyl-2,7-phenanthroline (3u)	-302						Pol.; BF <sub>4</sub> <sup>-</sup> salt.	73C002
3.12.5	3,8-Dimethyl-3,8-phenanthroline (3v)	-374						Pol.; BF <sub>4</sub> <sup>-</sup> salt.	73C002
3.12.6	3,7-Dimethyl-3,7-phenanthroline (3w)	-406						Pol.; BF <sub>4</sub> <sup>-</sup> salt.	73C002
3.12.7	4,7-Dimethyl-4,7-phenanthroline (3x)	-268						Pol.; BF <sub>4</sub> <sup>-</sup> salt.	73C002
3.12.8	(3y)	-272						Pol.; BF <sub>4</sub> <sup>-</sup> salt.	73C002
3.12.9	(3z)	-300						Pol.; BF <sub>4</sub> <sup>-</sup> salt.	73C002
3.12.10	(3aa)	-228						Pol.; BF <sub>4</sub> <sup>-</sup> salt.	73C002




(3u)




(3v)




(3w)




(3x)



(3y)



(3z)



(3aa)

\* Recommended value.

† Questionable or superseded value.

TABLE 4. Reduction potentials of miscellaneous organic compounds (A/A<sup>-</sup>)






No.	Compound or couple	<i>E</i> /mV	pH	Ref. compound	Ref. <i>E</i> /mV	Co-solute	<i>I</i>	Method/ comments	Ref.
<b>4.1. Aldehydes and ketones</b>									
4.1.1	CH <sub>2</sub> O/·CH <sub>2</sub> O <sup>-</sup>	~-2500	≥12					Pol.	761170
		~-1600						Calc.	80A123
		-1810		Tl <sup>+</sup>	-1940		-0	C (+ K)	89C001
4.1.2	CH <sub>2</sub> O, H <sup>+</sup> /·CH <sub>2</sub> OH	-920						Calc.	75Z006
		~-970						Pol.	761170
		~-900						Calc.	80A123
		-1180		Tl <sup>+</sup>	-1940		-0	C (+ K)	89C001
4.1.3	CH <sub>3</sub> CHO/CH <sub>3</sub> ·CHO <sup>-</sup>	~-2500	≥12.5					Pol.	761170
		~-1800						Calc.	80A123
		-1930		Tl <sup>+</sup>	-1940		-0	C (+ K)	89C001
4.1.4	CH <sub>3</sub> ·CHO, H <sup>+</sup> / CH <sub>3</sub> ·CHOH	~-1100						Pol.	761170
		~-1100						Calc.	80A123
		-1250		Tl <sup>+</sup>	-1940		-0	C (+ K)	89C001
4.1.5	(CH <sub>3</sub> ) <sub>2</sub> CO/(CH <sub>3</sub> ) <sub>2</sub> ·C·O <sup>-</sup>	~-2500	≥13					Pol.	761170
		~-2100						Calc.	80A123
		-2100		Tl <sup>+</sup>	-1940		-0	C (+ K)	89C001
4.1.6	(CH <sub>3</sub> ) <sub>2</sub> CO, H <sup>+</sup> / (CH <sub>3</sub> ) <sub>2</sub> COH	~-1800						Pol.	761170
		~-1500						Calc.	80A123
		-1390		Tl <sup>+</sup>	-1940		-0	C (+ K)	89C001
<b>4.2. Disulfides (RSSR)</b>									
4.2.1	Cystine and similar [-SCH <sub>2</sub> CH(NH <sub>2</sub> )CO <sub>2</sub> H] <sub>2</sub>	~-1700						Calc.	84A044
4.2.2	β-Mercaptoethanol (oxidized) [-SCH <sub>2</sub> CH <sub>2</sub> OH] <sub>2</sub>	-1570						Calc.	87C020
4.2.3	Lipoamide (oxidized)	-1600						Calc.	87C020
<b>4.3. Amides</b>									
4.3.1	Hydroxyurea (HONHCONH <sub>2</sub> )	-552 †	7	MV <sup>2+</sup>	-465	2-PrOH t-BuOH	-0	C (high value, query).	80A349
4.3.2	4(5)-Aminoimidazole- 5(4)-carboxamide (4a)	-584 †	7	MV <sup>2+</sup>	-465	2-PrOH t-BuOH	-0	C (high value, query).	80A349
4.3.3	5-(3,3-Dimethyl-1- triazeno)imidazole-4- carboxamide (4b)	-571 †	7	MV <sup>2+</sup>	-465	2-PrOH t-BuOH	-0	C (high value, query).	80A349
<b>4.4. Pyridinium and related compounds</b>									
4.4.1	1-Methylnicotinamide (4c, R <sup>1</sup> = CH <sub>3</sub> , R <sup>3</sup> = CONH <sub>2</sub> , R <sup>4</sup> = H)	-936	7					Cyc. v.	74C004
		<-845	7					Pol.	76C003
									
	(4a)								
									
	(4b)								
									
	(4c)								

TABLE 3 Reduction potentials of miscellaneous organic compounds (A/A<sup>•-</sup>)—Continued

No.	Compound or couple	<i>E</i> /mV	pH	Ref. compound	Ref. <i>E</i> /mV	Co-solute	<i>I</i>	Method/comments	Ref.
<b>4.4. Pyridinium and related compounds—Continued</b>									
		-918	7	3.5.2	-735	2-PrOH	→0	C	80C008
		-1010	7	3.5.3	-832	<i>t</i> -BuOH	→0	C	84A292
4.4.2	1-Methyl-isonicotinamide (4c, R <sup>1</sup> = CH <sub>3</sub> , R <sup>3</sup> = H, R <sup>4</sup> = CONH <sub>2</sub> )	-770	7	3.5.1	-640	HCO <sub>2</sub> <sup>-</sup>	→0	C	80C007
4.4.3	4-Acetyl-1-methylpyridinium (4c, R <sup>1</sup> = CH <sub>3</sub> , R <sup>3</sup> = H, R <sup>4</sup> = COCH <sub>3</sub> )	-510	5					Cyc. v.	85E687
4.4.4	4-(Methoxycarbonyl)-1-methylpyridinium (4c, R <sup>1</sup> = CH <sub>3</sub> , R <sup>3</sup> = H, R <sup>4</sup> = CO <sub>2</sub> CH <sub>3</sub> )	-720	5					Cyc. v.	85E687
4.4.5	4-Cyano-1-ethylpyridinium (4c, R <sup>1</sup> = C <sub>2</sub> H <sub>5</sub> , R <sup>3</sup> = H, R <sup>4</sup> = CN)	-626						Pol.	61M014
4.4.6	Nicotinamide adenine dinucleotide	-930 *						Rec.	
		<-730	7					Pol.	76C003
		-660 to -880	7					Pol.	761206
		-940	7	4.4.2	-770	HCO <sub>2</sub> <sup>-</sup>	→0	C	80C007
		-922	7	3.5.2	-735	2-PrOH	→0	C	80C008
		-879						Calc.	89M376
		-911	9.1					Cyc. v.	84C009
4.4.7	2,2'-Bipyridine (bpyH <sup>+</sup> /bpyH <sup>•</sup> )	-970		Co(bpy) <sub>3</sub> <sup>2+</sup>	-890			K	83C017
4.4.8	4,4'-Dimethyl-2,2'-bipyridine (Me <sub>2</sub> bpyH <sup>+</sup> /Me <sub>2</sub> bpyH <sup>•</sup> )	-1050		Co(bpy) <sub>3</sub> <sup>2+</sup>	-890			K	83C017
4.4.9	1,10-Phenanthroline (phenH <sup>+</sup> /phenH <sup>•</sup> )	-850						Calc.	83C017
<b>4.5. Phenothiazinium derivatives</b>									
4.5.1	Thionine (4d, R = H)	192-200	~1.7					Kinetics + <i>E</i> (Q/QH <sub>2</sub> ); not <i>E</i> <sup>0</sup> ; <i>E</i> (QH <sup>•</sup> /QH <sub>2</sub> ) = 566-575 mV at pH ~1.7.	78A103
4.5.2	Methylene Blue (4d, R = CH <sub>3</sub> )	187-197	~1.7					Kinetics + <i>E</i> (Q/QH <sub>2</sub> ); not <i>E</i> <sup>0</sup> ; <i>E</i> (QH <sup>•</sup> /QH <sub>2</sub> ) = 507-516 mV at pH ~1.7.	81A127
<b>4.6. Flavins (isalloxazines) and lumichrome derivatives (alloxazines)</b>									



(4d)



(4e)



TABLE 4. Reduction potentials of miscellaneous organic compounds (A/A<sup>-</sup>)—Continued

No.	Compound or couple	E/mV	pH	Ref. compound	Ref. E /mV	Co-solute	I	Method/ comments	Ref.
<b>4.6. Flavins (isalloxazines) and lumichrome derivatives (alloxazines)—Continued</b>									
4.6.1	Riboflavin (4e, R <sup>10</sup> = CH <sub>2</sub> [CH(OH)] <sub>5</sub> CH <sub>2</sub> OH)	-292	7	DQ	-235	HCO <sub>2</sub> <sup>-</sup>	0.1	C + K; other values, pH 6-12.	761150
		-318	7	DQ	-247	2-PrOH	→0	C	83C002
		-317	7	AQS <sup>-</sup>	-374	2-PrOH	→0	C	83C002
4.6.2	Flavine mononucleotide (riboflavin phosphate)	-313	7	DQ	-247	2-PrOH	→0	C; other values, pH 5-12.	83C002
		-308	7	AQS <sup>-</sup>	-374	2-PrOH	→0		83C002
4.6.3	Flavine adenine dinucleotide (4e, R <sup>10</sup> = 5'-adenosine diphosphate)	-241	7	BV <sup>2+</sup>	-354	HCO <sub>2</sub> <sup>-</sup>	→0	C + K; incorrect ionic strength correction, value revised to -296 mV in 83C002.	761169
		-231	7	3.3.1	-356	HCO <sub>2</sub> <sup>-</sup>	→0	C + K; see above.	761169
		-308	7	DQ	-247	2-PrOH	→0	C	83C002
		-317	7	AQS <sup>-</sup>	-374	2-PrOH	→0	C	83C002
4.6.4	8α-N-Imidazolylriboflavin (4f, R <sup>10</sup> = CH <sub>2</sub> [CH(OH)] <sub>5</sub> CH <sub>2</sub> OH, R' = H)	-173	7.01					Pot.; other values pH 2.6-11.5	85C018
4.6.5	8α-(N-Methyl-N-imidazolium)tetra-O-acetylriboflavin (4f, R <sup>10</sup> = CH <sub>2</sub> [CHOAc] <sub>5</sub> CH <sub>2</sub> OAc, R' = CH <sub>3</sub> )	-118	7.29					Pot.; other values pH 2.6-10.0	85C018
4.6.6	Lumichrome (4g, R <sup>1</sup> = R <sup>3</sup> = H)	-502	7	AQS <sup>-</sup> 4.4.2	-380 -770	HCO <sub>2</sub> <sup>-</sup> 2-PrOH	→0	C; interpolated from data at pH 2.7-4.0 (10.2-10.8).	85C005
4.6.7	1-Methyllumichrome (4g, R <sup>1</sup> = CH <sub>3</sub> , R <sup>3</sup> = H)	-509	7	AQS <sup>-</sup> 4.4.2	-380 -770	HCO <sub>2</sub> <sup>-</sup> 2-PrOH	→0	C; interpolated from data at pH 2.0-3.1 (8.6-10.9).	85C005
4.6.8	3-Methyllumichrome (4g, R <sup>1</sup> = H, R <sup>3</sup> = CH <sub>3</sub> )	-535	7	AQS <sup>-</sup> 4.4.2	-380 -770		→0	C; interpolated from data at pH 2.5-3.7 (9.5-10.9).	85C005
4.6.9	1,3-Dimethyl-lumichrome (4g, R <sup>1</sup> = R <sup>3</sup> = CH <sub>3</sub> )	-530	7	AQS <sup>-</sup> 4.4.2	-380 -770		→0	C; interpolated from data at pH 2.8-3.5 (9.8-10.5).	85C005
<b>4.7. Dioxathiadiazaheteropentalenes</b>									
4.7.1	(4h, X = S)	-376						C	84A449
4.7.2	(4h, X = SO)	-277						C	84A449
4.7.3	(4h, X = SO <sub>2</sub> )	-227						C	84A449








TABLE 4. Reduction potentials of miscellaneous organic compounds (A/A<sup>•-</sup>)—Continued


No.	Compound or couple	<i>E</i> /mV	pH	Ref. compound	Ref. <i>E</i> /mV	Co-solute	<i>I</i>	Method/comments	Ref.
<b>4.7. Dioxathiadiazaheteropentalenes—Continued</b>									
4.7.4	(4h, X = CH <sub>2</sub> )	-416						C	84A449
<b>4.8. Miscellaneous organic compounds</b>									
4.8.1	9-(2-Methoxy-4-methylsulfonylaminoanilino)-acridinium (4i)	-803	7	3.4.6	-775	2-PrOH	→0	C + K.	84C001
4.8.2	2,1,3-Benzothiadiazole-4,7-dicarbonitrile (4j)	-490	7	MV <sup>2+</sup>	-447	2-PrOH			86A098
4.8.3	5,6-Di(2-furyl)-[1,2,5]thiadiazolo[3,4- <i>b</i> ]pyrazine (4k, R <sup>5</sup> = R <sup>6</sup> = 2-furyl)	-506 -374	7	BV <sup>2+</sup>	-354	2-PrOH		Cyc. v. C	86A098 87C023
4.8.4	5,6-Di(2-pyridinyl)-[1,2,5]thiadiazolo[3,4- <i>b</i> ]pyrazine (4k, R <sup>5</sup> = R <sup>6</sup> = 2-pyridinyl)	-286	7	BV <sup>2+</sup>	-354	2-PrOH		C	87C023
4.8.5	5,6-Di(2-pyridinyl)-[1,2,5]thiadiazolo[3,4- <i>b</i> ]pyrazine <i>N</i> -oxide (4k, R <sup>5</sup> = 2-pyridinyl, R <sup>6</sup> = 2-pyridinyl- <i>N</i> -oxide)	-253	7	BV <sup>2+</sup>	-354	2-PrOH		C	87C023



(4i)



(4j)




(4k)

\* Recommended value.

† Questionable or superseded value.

TABLE 5. Reduction potentials of phenoxy radicals (ArO<sup>•</sup>/ArO<sup>-</sup>)


No.	Compound or couple	<i>E</i> /mV	pH	Ref. compound	Ref. <i>E</i> /mV	Co-solute	<i>I</i>	Method/comments	Ref.	
<b>5.1. Phenols</b>										
5.1.1	Phenol (PhOH) ( <b>5a</b> )  <i>E</i> <sup>•</sup> (PhO <sup>•</sup> , H <sup>+</sup> /PhOH)	>500 †	13.5	5.3.1	300	glycol	0.5	C, ref. pot. later revised	79A100	
		>600	13.5	5.3.1	385	glycol	0.5	C	82A253	
		>800	7						calc.	
		700	11.1	SO <sub>3</sub> <sup>-</sup>	630				C + K 900 mV calc. for pH 7.	84A327
		860	7						Cyc. v., not <i>E</i> <sup>•</sup> .	87C019
		800	13	ClO <sub>2</sub>	936					88A024
		1352	(6.0)	7.5.1	830			→0	C	87C020
		1340							Calc.	87C020
	1340						Calc. from data in 84A327	87C020		
5.1.2	4-Aminophenol ( <b>5a</b> , R <sup>4</sup> = NH <sub>2</sub> )	217 410	13.5 7	DMAP	174	glycol	0.5	C + K calc.	82A253	
5.1.3	4-Hydroxybenzoic acid ( <b>5a</b> , R <sup>4</sup> = CO <sub>2</sub> H)	>500	13.5	5.3.1	300	glycol	0.5	C	79A100	
5.1.4	<i>p</i> -Cresol ( <b>5a</b> , R <sup>4</sup> = CH <sub>3</sub> )	770	7					Cyc. v.	87C019	
5.1.5	4-Methoxyphenol ( <b>5a</b> , R <sup>4</sup> = OCH <sub>3</sub> )	320 †	13.5			glycol	0.5	From 2 indicators as below	79A100	
		~312 †		TMPD	82				C + K, calc. data, ref. pot. later revised to +266	79A100
		~335 †		6.1.4	183				C + K, calc. data, ref. pot. later revised to ~+330	79A100
		402 * 000	13.5 7	6.2.10	208	glycol	0.5	Rec., C + K calc.	82A253	
		945	2					0.2	Cyc. v.	87C019
		655	7					0.2	Cyc. v.	87C019
5.1.6	4-(Methylamino)phenol ( <b>5a</b> , R <sup>4</sup> = NHCH <sub>3</sub> )	146	13.5	CAT	43	glycol	0.5	C + K	82A253	
		156		HQ	23					
		146		TMPD	266					
5.1.7	4-Acetamidophenol ( <b>5a</b> , R <sup>4</sup> = NHCOCH <sub>3</sub> )	460							88A464	
5.1.8	4-(Dimethylamino)phenol ( <b>5a</b> , R <sup>4</sup> = N(CH <sub>3</sub> ) <sub>2</sub> )	174	13.5	HQ	23	glycol	0.5	C + K	82A253 (81C030)	
		174		CAT	43					
5.1.9	Tyrosine ( <b>5a</b> , R <sup>4</sup> = CH <sub>2</sub> CH(NH <sub>2</sub> )CO <sub>2</sub> H)	640	13.0	6.2.9	560			Few details C + K	86A110	
		1220	2					Cyc. v.	87C019	
		930	7					Cyc. v.	87C019	
		720	13					Cyc. v.	87C019	




(5a)

TABLE 5. Reduction potentials of phenoxyl radicals (ArO<sup>•</sup>/ArO<sup>-</sup>)—Continued

No.	Compound or couple	<i>E</i> /mV	pH	Ref. compound	Ref. <i>E</i> /mV	Co-solute	<i>I</i>	Method/comments	Ref.
<b>5.1. Phenols—Continued</b>									
5.1.10	DL-Tyrosine, methyl ester (5a, R <sup>1</sup> = CH <sub>2</sub> CH(NH <sub>2</sub> )CO <sub>2</sub> CH <sub>3</sub> )	870	7.0	6.4.4	910			Few details C + K	86A110
		660	13.0	6.2.9	560			Few details C + K	86A110
5.1.11	N-Acetyl-L-tyrosinamide (5a, R <sup>1</sup> = CH <sub>2</sub> CH(NHCOCH <sub>3</sub> )CO <sub>2</sub> H)	650	12.0	6.2.9	560			Few details C + K	86A110
5.1.12	L-Alanyl-L-tyrosine (5a, R <sup>1</sup> = CH <sub>2</sub> CH(CO <sub>2</sub> H)-NHCOCH(NH <sub>2</sub> )CH <sub>3</sub> )	850	7.0	6.4.4	910			Few details C + K	86A110
<b>5.2. 1,2-Dihydroxybenzenes</b>									
5.2.1	1,2-Dihydroxybenzene (5b)	43 139 98 530	13.5 11.0 11.0 7	HQ HQ	23 57	glycol	0.5	C + K Calc. Calc.	79A100
5.2.2	2,3-Dihydroxybenzoic acid (5b, R <sup>3</sup> = CO <sub>2</sub> H)	118 * 126 †	13.5	HQ 5.3.1	23 300	glycol	0.5	Rec., C + K K, ref. pot. later revised	79A100
5.2.3	3,4-Dihydroxybenzoic acid (5b, R <sup>4</sup> = CO <sub>2</sub> H)	119	13.5	HQ	23	glycol	0.5	C + K	79A100
5.2.4	3,4-Dihydroxyphenylacetic acid (5b, R <sup>4</sup> = CH <sub>2</sub> CO <sub>2</sub> H)	21	13.5	DMAP	174	glycol	0.5	C	82A253 (81C030)
5.2.5	3-Hydroxytyramine (5b, R <sup>4</sup> = CH <sub>2</sub> CH <sub>2</sub> NH <sub>2</sub> )	18	13.5	DMAP	176	glycol	0.5	C + K	82A253 (81C030)
5.2.6	Norepinephrine (5b, R <sup>4</sup> = CH(OH)CH <sub>2</sub> NH <sub>2</sub> )	44	13.5	DMAP	174	glycol	0.5	C + K	82A253 (81C030)
5.2.7	trans-3,4-Dihydroxycinnamic acid (5b, R <sup>4</sup> = CH=CHCO <sub>2</sub> H)	84	13.5	DMAP	174	glycol	0.5	C + K	82A253
5.2.8	Adrenalone (5b, R <sup>4</sup> = COCH <sub>2</sub> NHCH <sub>3</sub> )	~180	13.5	DMAP	175	glycol	0.5	C	81C030
5.2.9	(5b, R <sup>4</sup> = CH <sub>2</sub> CH(NH <sub>2</sub> )CO <sub>2</sub> H)	14 * 22	13.5	DMAP HQ	174 23	glycol	0.5	Rec., C C	81C030
<b>5.3. 1,3-Dihydroxybenzenes</b>									
5.3.1	1,3-Dihydroxybenzene (5c)	385 * 392 379 810	13.5 13.5 13.5 7					Rec. C + K C + K Calc.	82A253




(5b)



(5c)

TABLE 5. Reduction potentials of phenoxy radicals (ArO•/ArO<sup>-</sup>)—Continued

No.	Compound or couple	<i>E</i> /mV	pH	Ref. compound	Ref. <i>E</i> /mV	Co-solute	<i>I</i>	Method/ comments	Ref.
<b>5.3. 1,3-Dihydroxybenzenes—Continued</b>									
		292 †	13.5	5.2.2	118	glycol	0.5	K	79A100
		303 †		5.2.3	119			K	
		299 †			82			K, ref. potl. later revised	
5.3.2	2,5-Dihydroxybenzoic acid (5e, R <sup>1</sup> = CO <sub>2</sub> H)	33	13.5	CAT	43	glycol	0.5	C + K	79A100
5.3.3	3,5-Dihydroxybenzoic acid (5e, R <sup>1</sup> = CO <sub>2</sub> H)	280	13.5	5.2.3	119	glycol	0.5	C + K	79A100
<b>5.4. 1,4-Dihydroxybenzenes (1,4-Hydroquinones)</b>									
5.4.1	1,4-Dihydroxybenzene (5d)	1041 459	0 7					Calcn.	761063
		57 23	11 13.5					Calcn., see 751090	79A100
5.4.2	1,4-Dihydroxybenzene-2,5-disulfonate	116	12.9	HQ	23			C	85A255
5.4.3	Methylhydroquinone (5d, R <sup>2</sup> = CH <sub>3</sub> )	460	7					Calcn.	761063
5.4.4	Methoxyhydroquinone (5d, R <sup>2</sup> = OCH <sub>3</sub> )	-85	13.5	CAT	43	glycol	0.5	C + K	79A100
5.4.5	2',5'-Dihydroxyacetophenone (5d, R <sup>2</sup> = COCH <sub>3</sub> )	118	13.5	CAT	43	glycol	0.5	C + K	79A100
5.4.6	Homogentisic acid (5d, R <sup>2</sup> = CH <sub>2</sub> CO <sub>2</sub> H)	-50	13.5	CAT	33	glycol	0.5	C + K	82A253
5.4.7	(5d, R <sup>2</sup> = R <sup>3</sup> = CH <sub>3</sub> )	430	7					Calcn.	761063
5.4.8	(5d, R <sup>2</sup> = R <sup>5</sup> = CH <sub>3</sub> )	980 420	0 7					Calcn.	761063
5.4.9	Trimethylhydroquinone (5d, R <sup>2</sup> = R <sup>3</sup> = R <sup>5</sup> = CH <sub>3</sub> )	385	7					Calcn.	761063
5.4.10	Tetramethylhydroquinone (5d, R <sup>2</sup> = R <sup>3</sup> = R <sup>5</sup> = R <sup>6</sup> = CH <sub>3</sub> )	350	7					Calcn.	74C001
		895 360	0 7					Calcn.	761063
		-54	13.5					Calcn., see 751090	79A100
		-54	13.5	5.2.3	119	glycol	0.5	C + K	82A253
<b>5.5. Trihydroxybenzenes</b>									
5.5.1	1,2,3-Trihydroxybenzene (5b, R <sup>3</sup> = OH)	-9	13.5	HQ	23	glycol	0.5	C	79A100
5.5.2	5-Hydroxydopamine (5b, R <sup>3</sup> = OH, R <sup>5</sup> = CH <sub>2</sub> CH <sub>2</sub> NH <sub>2</sub> )	42	13.5	DMAP	174	glycol	0.5	C + K	82A253



(5d)

Table 2. Dissolution potentials of phenoxyl radicals (ArO<sup>•</sup>/ArO<sup>-</sup>)—Continued


Ref.	Structure of radical	$E/mV$	pH	Ref. compound	Ref. $E$ /mV	Co-solute	$I$	Method/ comments	Ref.
<b>5.5. Trihydroxybenzenes—Continued</b>									
4.5.3	Ethyl gallate ( <b>5b</b> , R <sup>3</sup> = OH, R <sup>6</sup> = CO <sub>2</sub> C <sub>2</sub> H <sub>5</sub> )	-54	13.5	HQ	23	glycol	0.5	C + K	82A253
5.5.4	1,2,4-Trihydroxy- benzene ( <b>5b</b> , R <sup>4</sup> = OH)	-110	13.5	CAT	43	glycol	0.5	C	79A100

\* Recommended value.

† Questionable or superseded value.

TABLE 6. Reduction potentials of amine, indole, pyrimidine and purine radicals (A<sup>•</sup>/A<sup>-</sup>)


No.	Compound or couple	E/mV	pH	Ref. compound	Ref. E /mV	Co-solute	I	Method/ comments	Ref.
<b>6.1. Aminobenzenes and phenylenediamines</b>									
6.1.1	Aniline	1030	6.9	ClO <sub>2</sub> <sup>•</sup>	936	ClO <sub>2</sub> <sup>-</sup>		C	86A059
6.1.2	<i>N,N</i> -Dimethylaniline	~770	10	SO <sub>3</sub> <sup>•-</sup>	630	SO <sub>3</sub> <sup>2-</sup>		C	85A103
		800	9.0	ClO <sub>2</sub> <sup>•</sup>	936	ClO <sub>2</sub> <sup>-</sup>		K	86A059
6.1.3	<i>o</i> -Phenylenediamine (6a)	>270	11.5	HQ	57	glycol		K	79A100
		346 362	13.5	TMPD 6.1.4	266 309	glycol	0.5	C + K C	82A253
6.1.4	<i>p</i> -Phenylenediamine (6b)	183	13.5	HQ	23	glycol	0.5	C + K	79A100
		~200	11.0	HQ	57				
		309 *	13.5	DMAP	174	glycol	0.5	Rec., C + K	82A253
		366	13.5	TMPD	266			Au. rec.	
		340 730	13.5 7					Au. calc.	
6.1.5	<i>N,N,N',N'</i> -Tetramethyl- <i>p</i> -phenylenediamine (6c)	<600 *	5.2	SO <sub>3</sub> <sup>•-</sup>	740	HSO <sub>3</sub> <sup>-</sup>		Rec., C	85A103
		~265	8-9					Pol. other values pH 4-8	58C002
		82 †	13.5	6.1.4	183	glycol	0.5	C + K, ref. potl. later revised	79A100
		240	7-12					Pol.	81C038
		266 * 265	13.5	DMAP 6.2.10	174 208	glycol	0.5	Rec., C + K C + K, E same at pH 7	82A253
<b>6.2. Indoles (IndH)</b>									
6.2.1	Indole (6d, R <sup>1</sup> = R <sup>2</sup> = R <sup>3</sup> = R <sup>5</sup> = H)	<i>E</i> (IndH <sup>•+</sup> /IndH)	1240	ClO <sub>2</sub>	936	Br <sup>-</sup>	→0	K	87A247
		<i>E</i> (Ind <sup>•</sup> /Ind <sup>-</sup> )	530					Calc. from IndH <sup>•+</sup> /IndH and p <i>K</i> <sub>a</sub> 's	87A247
6.2.2	5-Hydroxyindole (6d, R <sup>1</sup> = R <sup>2</sup> = R <sup>3</sup> = H, R <sup>5</sup> = OH)	970	7				0.2	Cyc. v.	87C019
		216 197	13.5	DMAP TMPD	174 266	glycol	0.5	C + K C + K	82A253 (81C030)
6.2.3	1-Methylindole (6d, R <sup>1</sup> = CH <sub>3</sub> , R <sup>2</sup> = R <sup>3</sup> = R <sup>5</sup> = H)	<i>E</i> (IndH <sup>•+</sup> /IndH)	1230	ClO <sub>2</sub>	936	Br <sup>-</sup>	→0	K	88A024
6.2.4	2-Methylindole (6d, R <sup>1</sup> = R <sup>3</sup> = R <sup>5</sup> = H, R <sup>2</sup> = CH <sub>3</sub> )	<i>E</i> (IndH <sup>•+</sup> /IndH)	1100	ClO <sub>2</sub>	936	Br <sup>-</sup>		K	88A024




(6a)



(6b)




(6c)



(6d)

TABLE 6. Reduction potentials of amine, indole, pyrimidine and purine radicals (A<sup>•</sup>/A<sup>-</sup>)—Continued

No.	Compound or couple	<i>E</i> /mV	pH	Ref. compound	Ref. <i>E</i> /mV	Co-solute	<i>I</i>	Method/ comments	Ref.
<b>6.2. Indoles (IndH)—Continued</b>									
6.2.5	3-Methylindole ( <b>6d</b> , R <sup>1</sup> = R <sup>2</sup> = R <sup>5</sup> = H, R <sup>3</sup> = CH <sub>3</sub> )	1010						Calc. (rate data + Marcus theory)	87A247
	<i>E</i> (IndH <sup>•+</sup> /IndH)	1070		ClO <sub>2</sub>	936	Br <sup>-</sup>		K	88A024
6.2.6	Indole-3-acetic acid ( <b>6d</b> , R <sup>1</sup> = R <sup>2</sup> = R <sup>5</sup> = H, R <sup>3</sup> = CH <sub>2</sub> CO <sub>2</sub> H)	840	7					Cyc. v.	87C019
6.2.7	2,3-Dimethylindole ( <b>6d</b> , R <sup>1</sup> = H, R <sup>2</sup> = R <sup>3</sup> = CH <sub>3</sub> , R <sup>5</sup> = H)	780						Calc. (rate data + Marcus theory)	87A247
	<i>E</i> (IndH <sup>•+</sup> /IndH)	930		ClO <sub>2</sub>	936	Br <sup>-</sup>		K	88A024
6.2.8	Tryptamine ( <b>6d</b> , R <sup>1</sup> = R <sup>2</sup> = R <sup>5</sup> = H, R <sup>3</sup> = CH <sub>2</sub> CH <sub>2</sub> NH <sub>2</sub> )	970	3.0	HSO <sub>3</sub> <sup>-</sup>	840			Few details K	86A110
		640	7.5	5.1.5	600			Few details C + K	86A110
		560	13.0	5.1.5	400			Few details C + K	86A110
6.2.9	Tryptophan (TrpH) ( <b>6e</b> , R <sup>1</sup> = R <sup>2</sup> = R <sup>5</sup> = H, R <sup>3</sup> = CH <sub>2</sub> CH(NH <sub>2</sub> )CO <sub>2</sub> H)	1140		9.56	1250	SCN <sup>-</sup>	~1	Calc. from data in 761151, ± 200 mV	82A183
	<i>E</i> (TrpH <sup>•+</sup> /TrpH)	940	† 3	HSO <sub>3</sub> <sup>-</sup>	840			Few details K see 86A215, 87C007	86A110
		640	† 7.5	5.1.5	600			Few details C + K see 86A215, 87C007	86A110
		560	† 13.0	5.1.5	400			Few details C + K see 86A215, 87C007	86A110
		1150	2				0.2	Cyc. v.	87C019
		1015	7				0.2	Cyc. v.	87C019
		650	13				0.2	Cyc. v.	87C019
		1080	7					Calc. from <i>E</i> and p <i>K</i> <sub>n</sub>	88A024
		830	7	(Fe(III))	660	N <sub>3</sub> <sup>-</sup>	0.15	C + K Fe(III) = ferrocinium-1,1'-dicarboxylic acid	88A126



(6e)




TABLE 6. Reduction potentials of amine, indole, pyrimidine and purine radicals ( $A^{\cdot}/A^{-}$ )—Continued


No.	Compound or couple	$E/mV$	pH	Ref. compound	Ref. $E/mV$	Co-solute	$I$	Method/comments	Ref.
<b>6.2. Indoles (IndH)—Continued</b>									
	$E(\text{TrpH}^{\cdot+}/\text{TrpH})$	1240		$\text{ClO}_2$	936	$\text{Br}^-$		K	88A024
6.2.10	5-Hydroxytryptophan ( <b>6e</b> , $R^3 = \text{CH}_2\text{CH}(\text{NH}_2)\text{CO}_2\text{H}$ , $R^5 = \text{OH}$ )	208	13.5	DMAP	174	glycol	0.5	C + K	82A253 (81C030)
6.2.11	DL-Tryptophanamide ( <b>6e</b> , $R^3 = \text{CH}_2\text{CH}(\text{NH}_2)\text{CONH}_2$ )	940	3.0	$\text{HSO}_3^-$	840			Few details K	86A110
		680	7.5	5.1.5	600			Few details C + K	86A110
		620	12.0	5.1.11	650			Few details C + K	86A110
6.2.12	N-Acetyl-L-tryptophan ( <b>6e</b> , $R^3 = \text{CH}_2\text{CH}(\text{NHCOCH}_3)\text{CO}_2\text{H}$ )	<870	3.0	$\text{HSO}_3^-$	840			Few details	86A110
		690	6.5	5.1.5	600			Few details C + K	86A110
6.2.13	L-Tryptophyl-L-alanine ( <b>6e</b> , $R^3 = \text{CH}_2\text{CH}(\text{NH}_2)\text{CONHCH}(\text{CH}_3)\text{CO}_2\text{H}$ )	670	7.5	5.1.5	600			Few details C + K	86A110
<b>6.3. Pyrimidines<sup>a</sup></b>									
6.3.1	Uracil ( <b>6f</b> , $R^1 = R^5 = \text{H}$ )	870	13.0	6.4.5	740	$\text{Br}^-$	0.2	K	86C005
		850	13.0	6.4.1	750	$\text{Br}^-$	0.2	K	86C005
		880	13.0	6.3.4	780	$\text{Br}^-$	0.2	C + K	86C005
6.3.2	1-Methyluracil ( <b>6f</b> , $R^1 = \text{CH}_3$ , $R^5 = \text{H}$ )	~1600	13.0	9.9	1700	$\text{Br}^-$	0.2	C	86C005
6.3.3	Thymine ( <b>6f</b> , $R^1 = \text{H}$ , $R^5 = \text{CH}_3$ )	780	13.0	6.4.5	740	$\text{Br}^-$	0.2	C + K	86C005
		800	13.0	6.4.3	630	$\text{Br}^-$	0.2	C + K	86C005
6.3.4	Barbituric acid ( <b>6g</b> )	790	13.0	6.4.3	630	$\text{Br}^-$	0.2	C + K	86C005
		780	13.0	6.4.5	740	$\text{Br}^-$	0.2	C + K	86C005
6.3.5	Isobarbituric acid ( <b>6h</b> )	132	13.5	TMPD	266	glycol	0.5	C	82A253
6.3.6	Cytosine ( <b>6i</b> , $R^1 = \text{H}$ )	830	13.0	6.4.5	740	$\text{Br}^-$	0.2	C + K	86C005
		790	13.0	6.4.1	750	$\text{Br}^-$	0.2	C + K	86C005
6.3.7	1-Methylcytosine ( <b>6i</b> , $R^1 = \text{CH}_3$ )	~1630	13.0	9.9	1700	$\text{Br}^-$	0.2	C	86C005




(6f)



(6g)




(6h)




(6i)

TABLE B Reduction potentials of amine, indole, pyrimidine and purine radicals ( $A^{\cdot}/A^{-}$ )—Continued


No.	Compound or couple	$E/mV$	pH	Ref. compound	Ref. $E/mV$	Co-solute	$I$	Method/comments	Ref.
<b>6.4. Purines<sup>a</sup></b>									
6.4.1	Adenine (6j), $R^9 = H$	750	13.0	6.4.3	630	$Br^-$	0.2	C + K	86C005
6.4.2	Adenosine (6j), $R^9 = \beta$ -D-ribofuranosyl, 6k)	810	13.0	6.3.1	880	$Br^-$	0.2	C + K	86C005
6.4.3	Guanine (6l), $R^9 = H$	620	13.0	6.4.6	590	$Br^-$	0.2	K	86C005
		650	13.0	6.2.9	570	$Br^-$	0.2	C + K	86C005
6.4.4	Guanosine (6l), $R^9 = \beta$ -D-ribofuranosyl, 6k)	710	13.0	6.2.9	570	$Br^-$	0.2	C + K	86C005
		740	13.0	6.2.9	570	$Br^-$	0.2	C + K	86C005
6.4.5	Hypoxanthine (6m)	780	13.0	6.4.3	630	$Br^-$	0.2	K	86C005
		590	13.0	5.1.5	400	$Br^-$	0.2	K	86C005
6.4.6	Xanthine (6n)	260	13.0	8.4.1	190	$Br^-$	0.2	C + K	86C005




(6j)




(6k)




(6l)



(6m)



(6n)



(6o)


\* Recommended value.

† Questionable or superseded value.

<sup>a</sup> Some of these data need corroboration, in view of the direct or indirect coupling to tryptophan (6.2.9) as a reference, and the comments expressed in 86A215, 87C007.

TABLE 7. Reduction potentials of phenothiazine radicals ( $Pz^{\cdot+}/Pz$ )


No.	Compound or couple	$E/mV$	pH	Ref. compound	Ref. $E/mV$	Co-solute	$I$	Method/ comments	Ref.
<b>7.1. 10H-Phenothiazine</b>									
7.1.1	Phenothiazine ( <b>7a</b> )	701	~2					Pot. ( $Br_2$ ); 90% v/v AcOH.	419001
		696	~2					Pot. ( $Br_2$ ); 80% v/v AcOH.	609013
<b>7.2. 10H-Phenothiazines with one ring carbon substituent</b>									
7.2.1	3-Bromophenothiazine ( <b>7a</b> , $R^3 = Br$ )	766	~2					Pot. ( $Br_2$ ); 80% v/v AcOH.	609013
7.2.2	3-Chlorophenothiazine ( <b>7a</b> , $R^3 = Cl$ )	763	~2					Pot. ( $Br_2$ ); 80% v/v AcOH.	609013
		776	~2					Pot. ( $Br_2$ ); 80% v/v AcOH.	609014
7.2.3	3-Fluorophenothiazine ( <b>7a</b> , $R^3 = F$ )	722	~2					Pot. ( $Br_2$ ); 80% v/v AcOH.	609013
7.2.4	3-Iodophenothiazine ( <b>7a</b> , $R^3 = I$ )	758	~2					Pot. ( $Br_2$ ); 80% v/v AcOH.	609013
7.2.5	3-Nitrophenothiazine ( <b>7a</b> , $R^3 = NO_2$ )	~900	~2					Pot. ( $Br_2$ ); 80% v/v AcOH.	609013
7.2.6	3-Methylphenothiazine ( <b>7a</b> , $R^3 = CH_3$ )	651	~2					Pot. ( $Br_2$ ); 80% v/v AcOH.	609013
7.2.7	1-Methoxyphenothiazine ( <b>7a</b> , $R^1 = OCH_3$ )	698	~2					Pot. ( $Br_2$ ); 80% v/v AcOH.	609014
7.2.8	3-Methoxyphenothiazine ( <b>7a</b> , $R^3 = OCH_3$ )	590	~2					Pot. ( $Br_2$ ); 80% v/v AcOH; 2nd oxidn. at 736 mV.	609013 609014
7.2.9	1-Ethoxyphenothiazine ( <b>7a</b> , $R^1 = OC_2H_5$ )	692	~2					Pot. ( $Br_2$ ); 80% v/v AcOH.	609014
7.2.10	3-Ethoxyphenothiazine ( <b>7a</b> , $R^3 = OC_2H_5$ )	580	~2					Pot. ( $Br_2$ ); 80% v/v AcOH; 2nd oxidn. at 729 mV.	609014
7.2.11	3-Phenylphenothiazine ( <b>7a</b> , $R^3 = C_6H_5$ )	679	~2					Pot. ( $Br_2$ ); 80% v/v AcOH.	609013
<b>7.3. 10H-Phenothiazines with two ring carbon substituents</b>									
7.3.1	2-Chloro-7-methoxyphenothiazine ( <b>7a</b> , $R^2 = Cl$ , $R^7 = OCH_3$ )	662	~2					Pot. ( $Br_2$ ); 80% v/v AcOH	609014
7.3.2	4-Chloro-7-methoxyphenothiazine ( <b>7a</b> , $R^4 = Cl$ , $R^7 = OCH_3$ )	668	~2					Pot. ( $Br_2$ ); 80% v/v AcOH	609014
7.3.3	3,7-Dimethylphenothiazine ( <b>7a</b> , $R^3 = R^7 = CH_3$ )	626	~2					Pot. ( $Br_2$ ); 90% v/v AcOH	419001
		590	~2					Pot. ( $Br_2$ ); 80% v/v AcOH	609013 609014



(7a)

TABLE 7. Reduction potentials of phenothiazine radicals ( $Pz^{\cdot+}/Pz$ )—Continued

No.	Compound or couple	$E/mV$	pH	Ref. compound	Ref. $E/mV$	Co-solute	$I$	Method/comments	Ref.
<b>7.8. 10H-Phenothiazines with two ring carbon substituents—Continued</b>									
7.3.4	3,7-Dimethoxyphenothiazine ( <b>7a</b> , $R^3 = R^7 = OCH_3$ )	475	~2					Pot. ( $Br_2$ ); 80% v/v AcOH.	609013
		474	~2					Pot. ( $Br_2$ ); 80% v/v AcOH	609014
<b>7.4. N-Substituted phenothiazines without ring carbon substitution</b>									
7.4.1	10-Phenothiazine-carboxaldehyde ( <b>7b</b> , $R^{10} = CHO$ )	~980	~2					Pot. ( $Br_2$ ); 80% v/v AcOH.	609013
7.4.2	10-Methylphenothiazine ( <b>7b</b> , $R^{10} = CH_3$ )	829	~2					Pot.; 80% v/v AcOH.	419001
		882	~2					Pot.; 90% v/v AcOH.	419001
		846	~2					Pot. ( $Br_2$ ); 80% v/v AcOH.	609013
		~716	~1-2	Fe(III)	738		~0.02-0.2	K; stopped-flow spect. (calc. au.)	83N008
		884					$CH_3CN/H_2O$ 80/20% v/v	Cyc. v.	86A139
7.4.3	10-Acetylphenothiazine ( <b>7b</b> , $R^{10} = COCH_3$ )	~960	~2					Pot. ( $Br_2$ ); 80% v/v AcOH.	609013
7.4.4	( <b>7b</b> , $R^{10} = (CH_2)_3SO_3^-$ )	834				$CH_3CN/H_2O$ 80/20% v/v		Cyc. v.	86A139
7.4.5	Promazine ( <b>7b</b> , $R^{10} = (CH_2)_3N(CH_3)_2$ )	715						Recommended value.	
		753	~1	(NCE)				Pol.	599011
		844	<0					Pol.; 6 mol $dm^{-3}$ $H_2SO_4$ .	649028
		715	0	Fe(III)	738		1.0	C(+K); stopped-flow spect.	79A456
7.4.6	Promethazine ( <b>7b</b> , $CH_2CH(CH_3)N(CH_3)_2$ )	865						Recommended value.	
		899	~1	(NCE)				Pol.	599011
		944	<0					Pol.; 7 mol $dm^{-3}$ $H_2SO_4$ .	649028
		837	<0	(Ag/AgCl, KCl(s))				Chronopot.; 3 mol $dm^{-3}$ $H_2SO_4$ .	70M264
		865	0	Fe(III)	738		1.0	C(+K); stopped-flow spect.	79A456



(7b)

TABLE 7. Reduction potentials of phenothiazine radicals ( $Pz^{\cdot+}/Pz$ )—Continued







No.	Compound or couple	$E/mV$	pH	Ref. compound	Ref. $E/mV$	Co-solute	$I$	Method/ comments	Ref.
<b>7.4. N-Substituted phenothiazines without ring carbon substitution—Continued</b>									
7.4.7	10-(1-Methyl-2-dimethyl-aminoethyl)phenothiazine ( <b>7b</b> , $R^{10} = CH(CH_3)CH_2N(CH_3)_2$ )	890	0	Fe(III)	738		1.0	C(+K); stopped-flow spect.	79A456
7.4.8	10-(2-Pyrrolidinyloethyl)-phenothiazine ( <b>7b</b> , $R^{10} = 7c$ )	847	~1	(NCE)				Pol.	599011
7.4.9	( <b>7b</b> , $R^{10} = (CH_2)_6SO_3^-$ )	834				$CH_3CN/H_2O$ 80/20% v/v		Cyc. v.	86A139
7.4.10	Diethazine ( <b>7b</b> , $R^{10} = (CH_2)_2N(C_2H_5)_2$ )	807	<0	(Ag/AgCl, KCl(s)).				Chronopot.; 3 mol $dm^{-3}$ $H_2SO_4$ .	70M264
		820	0	Fe(III)	738		1.0	C(+K); stopped-flow spect.	79A456
7.4.11	Multergan ( <b>7b</b> , $R^{10} = CH_2CH(CH_3)^+N(CH_3)_3$ )	861	<0	(Ag/AgCl, KCl(s))				Chronopot.; 3 mol $dm^{-3}$ $H_2SO_4$ ; $CH_3SO_4^-$ salt.	70M264
7.4.12	10-Benzoylphenothiazine ( <b>7b</b> , $R^{10} = COC_6H_5$ )	≈ 920						Pot. ( $Br_2$ ); 80% v/v AcOH.	609013
7.4.13	10-(N-Methyl-3-piperidinyl)-methylphenothiazine ( <b>7b</b> , $R^{10} = 7d$ )	783	~1	(NCE)				Pol.	599011
7.4.14	10-(2-Methyl-2-diethylaminoethyl)-phenothiazine ( <b>7b</b> , $R^{10} = CH_2CH(CH_3)N(C_2H_5)_2$ )	900	~1	(NCE)				Pol.	599011
7.4.15	( <b>7b</b> , $R^{10} = (CH_2)_3N(C_2H_5)_3$ )	954				$CH_3CN/H_2O$ 80/20% v/v		Cyc. v.	86A139
7.4.16	( <b>7b</b> , $R^{10} = (CH_2)_6N(C_2H_5)_3$ )	864 †				$CH_3CN/H_2O$ 80/20% v/v		Cyc. v.	86A139
7.4.17	10-[3-(4-Methyl-1-piperazinyl)-propyl]phenothiazine ( <b>7b</b> , $R^{10} = 7e$ )	720	0	Fe(III)	738		1.0	C(+K); stopped-flow spect.	79A456
7.4.18	10-[3-(4-(2-Hydroxyethyl)-1-piperazinyl)propyl]-phenothiazine ( <b>7b</b> , $R^{10} = 7f$ )	762	~1	(NCE)				Pol.	599011
<b>7.5. N-Substituted phenothiazines with one ring carbon substituent</b>									
7.5.1	Chlorpromazine ( <b>7b</b> , $R^{10} = (CH_2)_3N(CH_3)_2$ , $R^2 = Cl$ )	780						Recommended value.	
		821	~1	(NCE)				Pol.	599011
									
	( <b>7c</b> )								
									
	( <b>7d</b> )								
									
	( <b>7e</b> )								
									
	( <b>7f</b> )								

TABLE 7. Reduction potentials of phenothiazine radicals ( $Pz^{\cdot+}/Pz$ )—Continued


No.	Compound or couple	$E/mV$	pH	Ref. compound	Ref. $E/mV$	Co-solute	$I$	Method/comments	Ref.
		844						Pol.; 6 mol $dm^{-3}$ $H_2SO_4$ .	649028
		766	<0	( $\Lambda_g/\Lambda_gCl$ , $KCl(s)$ )				Chronopot.; 3 mol $dm^{-3}$ $H_2SO_4$ .	70M264
		780	0	Fe(III)	738		1.0	C(+K); stopped-flow spect.	79A456
7.5.2	Triflupromazine ( <b>7b</b> , $R^{10} = (CH_2)_3N(CH_3)_2$ , $R^2 = CF_3$ )	894	<0					Pol.; 6 mol $dm^{-3}$ $H_2SO_4$ .	649028
7.5.3	2-Hydroxy-10-(3-dimethylaminopropyl)phenothiazine ( <b>7b</b> , $R^{10} = (CH_2)_3N(CH_3)_2$ , $R^2 = OH$ )	625	0	Fe(III)	738		1.0	C(+K); stopped-flow spect.	79A456
7.5.4	2-Methoxy-10-(3-dimethylaminopropyl)phenothiazine ( <b>7b</b> , $R^{10} = (CH_2)_3N(CH_3)_2$ , $R^2 = OCH_3$ )	710	0		738		1.0	C(+K); stopped-flow spect.	79A456
7.5.5	2-Acetyl-10-(3-dimethylaminopropyl)phenothiazine ( <b>7b</b> , $R^{10} = (CH_2)_3N(CH_3)_2$ , $R^2 = COCH_3$ )	863		(NCE)				Pol.	599011
7.5.6	Thioridazine ( <b>7b</b> , $R^{10} = 7g$ )	794	<0					Pol.; 6 mol $dm^{-3}$ $H_2SO_4 = 30\%$ v/v EtOH.	649028
7.5.7	Prochlorperazine ( <b>7b</b> , $R^{10} = 7e$ )	827	-1	(NCE)				Pol.	599011
		844	<0					Pol.; 6 mol $dm^{-3}$ $H_2SO_4$ .	649028
7.5.8	Trifluoperazine ( <b>7b</b> , $R^{10} = 7e$ )	944	<0					Pol.; 6 mol $dm^{-3}$ $H_2SO_4$ .	649028
7.5.9	Thiopropazine ( <b>7b</b> , $R^{10} = 7e$ )	877	<0	( $Ag/AgCl$ , $KCl(s)$ )				Chronopot.; 3 mol $dm^{-3}$ $H_2SO_4$ .	70M264
7.5.10	2-Chloro-10-[3-(4-(2-hydroxyethyl)-1-piperazinyl)propyl]-phenothiazine ( <b>7b</b> , $R^{10} = 7f$ )	830	-1	(NCE)				Pol.	599011
<b>7.6. Benzophenothiazines</b>									
7.6.1	12 <i>H</i> -Benzo[ <i>d</i> ]phenothiazine ( <b>7h</b> )	633	-2					Pot. ( $Br_2$ ); 80% v/v AcOH.	609013
7.6.2	7 <i>H</i> -Benzo[ <i>c</i> ]phenothiazine ( <b>7i</b> )	628	-2					Pot. ( $Br_2$ ); 80% v/v AcOH.	609013



(7g)




(7h)




(7i)

TABLE 7. Reduction potentials of phenothiazine radicals ( $Pz^{\bullet+}/Pz$ )—Continued


No.	Compound or couple	$E/mV$	pH	Ref. compound	Ref. $E/mV$	Co-solute	$I$	Method/ comments	Ref.
<b>7.6. Benzophenothiazines—Continued</b>									
7.6.3	13 <i>H</i> -Dibenzo[ <i>a,j</i> ]phenothiazine ( <b>7j</b> )	544	~ 2					Pot. ( $Br_2$ ); 80% v/v AcOH.	609013
7.6.4	7 <i>H</i> -Dibenzo[ <i>c,h</i> ]phenothiazine ( <b>7k</b> )	548						Pot. ( $Br_2$ ); 80% v/v AcOH.	609013
<b>7.7. Phenothiazines with oxidized sulfur</b>									
7.7.1	10 <i>H</i> -Phenothiazine sulfoxide ( <b>7l</b> )	800	~ 2					Pot. ( $Br_2$ ); 80% v/v AcOH.	609013
7.7.2	10 <i>H</i> -Phenothiazine sulfone ( <b>7m</b> , $R^{10} = H$ )	≈ 900	~ 2					Pot. ( $Br_2$ ); 80% v/v AcOH.	609013
7.7.3	10- Carbethoxyphenothiazine sulfone ( <b>7m</b> , $R^{10} = CO_2C_2H_5$ )	≈ 900	~ 2					Pot. ( $Br_2$ ); 80% v/v AcOH.	609013




(7j)



(7k)



(7l)




(7m)


† Questionable or superseded value.

TABLE 8. Reduction potentials of radicals from miscellaneous organic compounds ( $A^{\cdot}/A^{-}$ )


No.	Compound or couple	$E/mV$	pH	Ref. compound	Ref. $E/mV$	Co-solute	$I$	Method/comments	Ref.		
<b>8.1. Hydroxy compounds</b>											
8.1.1	Ascorbic acid (8a)	~15	13.5	CAT	43	glycol	0.5	C C + K	79A100		
		85	11.1	CAT	139						
		300	7							Calc.	82A253
		282	7							Calc. not $E^{\cdot}$ .	82A232
		19								Calc.	82A232
		720								Calc.	82A232
		330	7							Calc. see Introduction (Sec. 5.3)	85R025
8.1.2	7-Hydroxycoumarin (8b)	315	13.5	DMAP	174	glycol	0.5	C + K	82A253		
8.1.3	1,4-Dihydroxy-2-methylnaphthalene (8c)	190						Calc.	761063		
8.1.4	Vitamin K <sub>1</sub> (8d)	22	7					Calc.	761063		
8.1.5	1,2,5,8-Tetrahydroxy-9,10-anthraquinone (8e)	73	13.5	HQ	23	glycol	0.5	C + K	82A253		
8.1.6	3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethylbenzopyran-2-carboxylic acid (8f)	192 *	13.5	DMAP	174	glycol	0.5	Rec., C C + K calc.	82A253 (81C030)		
		185	13.5	CAT	43						
		480	7								
8.1.7	Catechin (8g)	79	13.5	DMAP	174	glycol	0.5	C + K	82A253		
8.1.8	L-Epicatechin (8h)	48	13.5	DMAP	174	glycol	0.5	C + K	82A253		
8.1.9	Quercetin (8i)	-37	13.5	HQ	23	glycol	0.5	C + K	82A253		




(8a)




(8b)




(8c)




(8d)




(8e)




(8f)




(8g)



(8h)



(8i)






(8j)



TABLE 8. Reduction potentials of radicals from miscellaneous organic compounds ( $A^{\cdot}/A^{-}$ )—Continued

No.	Compound or couple	$E/mV$	pH	Ref. compound	Ref. $E/mV$	Co-solute	$i$	Method/comments	Ref.
<b>8.1. Hydroxy compounds—Continued</b>									
8.1.10	Ellagic acid (8j)	187	13.5	HQ	23	glycol	0.5	C + K	82A253
<b>8.2. Dihyronicotinamides</b>									
8.2.1	Nicotinamide adenine dinucleotide, reduced $NAD^{\cdot}$ , $H^+$ /NADH	282	7					Calcn. not $E^{\circ}$ .	80C008
		930						Kinetics + assumptions.	83M234, 84A319
<b>8.3. Thiols (RSH)</b>									
<b>8.3.1 <math>RS^{\cdot}/RS^{-}</math></b>									
8.3.1.1	Cysteine ( $HSCH_2CH(NH_2)CO_2H$ )	1100						Calcn.	84A044
		920						Calcn.	86C016
		730	9.15	GlyTyr	600			C + calc. (ref. pot. at pH 13.5, corr. for pH)	86C031
8.3.1.2	$\beta$ -Mercaptoethanol ( $HSCH_2CH_2OH$ )	750						Calcn.	87C020
<b>8.3.2 <math>RS^{\cdot}</math>, <math>H^+</math>/RSH</b>									
8.3.2.1	$\beta$ -Mercaptoethanol ( $HSCH_2CH_2OH$ )	1328	6.0	7.5.1	830		$\rightarrow 0$	C	87C020
		1342						Calcn.	87C020
8.3.2.2	Mercaptoacetic acid ( $HSCH_2CO_2H$ )	1347		8.3.4.4	1727		$\rightarrow 0$	C(+K)	87C020
8.3.2.3	Penicillamine ( $HSC(CH_3)_2CH(NH_2)CO_2H$ )	1345		8.3.4.4	1727		$\rightarrow 0$	C	87C020
8.3.2.4	3-Mercaptopropionic acid ( $HSCH_2CH_2CO_2H$ )	1359		8.3.4.4	1727		$\rightarrow 0$	C(+K)	87C020
<b>8.3.3 <math>RSSR^{\cdot-}/2RS^{-}</math></b>									
8.3.3.1	Cysteine	650						Calcn.	86C016
<b>8.3.4 <math>RSSR^{\cdot-}</math>, <math>2H^+</math>/2RSH</b>									
8.3.4.1	$\beta$ -Mercaptoethanol	1726	9	5.1.1	1352		$\rightarrow 0$	C	87C020
		1718	10	5.1.1	1352		$\rightarrow 0$	C	87C020
8.3.4.2	Dithiothreitol ( $HSCH_2[CH(OH)]_2CH_2SH$ )	1752	7-10	5.1.1	1352		$\rightarrow 0$	C(+K)	87C020
		1702	7	8.3.2 (several)			$\rightarrow 0$	C(+K)	87C020
8.3.4.3	Dihydrolipoamide $HS(CH_2)_2CH(SH)(CH_2)_4CONH_2$	1700	9	5.1.1	1352		$\rightarrow 0$	C	87C020
		1709	7	8.3.2.1	1335		$\rightarrow 0$	C	87C020
8.3.4.4	Dithioerythritol	1724		8.3.2.1	1359		$\rightarrow 0$	C(+K)	87C020
<b>8.3.5 <math>RSSR^{\cdot+}/RSSR</math></b>									
8.3.5.1	Dimethyl disulfide ( $RSSR = CH_3SSCH_3$ )	1391	$\sim 4$	9.56	1331		$\rightarrow 0$	C + K	86A403

TABLE 8. Reduction potentials of radicals from miscellaneous organic compounds (A<sup>•</sup>/A<sup>-</sup>)—Continued

No.	Compound or couple	<i>E</i> /mV	pH	Ref. compound	Ref. <i>E</i> /mV	Co-solute	<i>I</i>	Method/ comments	Ref.
<b>8.3.5 RSSR<sup>•+</sup>/RSSR—Continued</b>									
8.3.5.2	Lipoic acid (RSSR = <b>8k</b> )	1130	3.6	9.29	1030			K	86A403
		1100	9	9.29	1030			K	86A403
		1140	3.6	9.56	1331			K	86A403
<b>8.4. Pyrazollones</b>									
8.4.1	3-Methyl-2-pyrazolin-5-one ( <b>8l</b> , R <sup>3</sup> = CH <sub>3</sub> , R <sup>4</sup> = H)	390	12.2	TMPD	270	Br <sup>-</sup>	0.1	C + K	85A390
8.4.2	4-Methyl-2-pyrazolin-5-one ( <b>8l</b> , R <sup>3</sup> = H, R <sup>4</sup> = CH <sub>3</sub> )	320	12.2	5.1.4	400	Br <sup>-</sup>	0.1		85A390
8.4.3	3,4-Dimethyl-2-pyrazolin-5-one ( <b>8l</b> , R <sup>3</sup> = R <sup>4</sup> = CH <sub>3</sub> )	330	12.2	5.1.4	400	Br <sup>-</sup>	0.1	C + K	85A390
8.4.4	2,3-Dimethyl-1-phenyl-3-pyrazolin-5-one (antipyrine) ( <b>8m</b> )	1200-1500	7					K, not-equilibrium	85A390
<b>8.5. Peroxy radicals</b>									
8.5.1	CH <sub>3</sub> O <sub>2</sub> <sup>•</sup>	600-700	7-13					Prediction from rate data	86A291
8.5.2	Cl <sub>3</sub> CO <sub>2</sub> <sup>•</sup>	>1000	7-13					Prediction from rate data	86A291
									
	<b>(8k)</b>								
									
	<b>(8l)</b>								
									
	<b>(8m)</b>								

\* Recommended value.

TABLE 9. Reduction potentials of inorganic couples

No.	Compound or couple	$E/mV$	pH	Ref. compound	Ref. $E/mV$	Co-solute	$I$	Method/comments	Ref.
9.1.	aq/ $\epsilon_{aq}^-$	-2700						Calcn.	649025
		-2900						Calcn.	730274
		-2870 *						Rec., Calcn.	81Z010
9.2.	Br $\cdot$ /Br $^-$	2000						Calcn.; $\pm 100$ mV.	70C002
		2200						Calcn.	727506
		1970						Calcn.	72M258
		2080						Calcn.; $\pm 50$ mV.	737316
		2060						Calcn.	73M369
		1760						Calcn.	761181
		~2000						Calcn.	79C029
		1904						Calcn.	82A154
		1930	9.39	1890				Calcn.; $\pm 30-40$ mV.	84C015
		2070						Calcn.	86C016
9.3.	HBrO, H $^+$ /H $_2$ O, Br $\cdot$	-180					Calcn.	86C012	
9.4.	HBrO/Br $^-$ , OH $\cdot$	-360					Calcn.	85C012	
9.5.	BrOH $\cdot$ /Br $^-$ , OH $^-$	1740		9.39	1890		Calcn.; $\pm 30-40$ mV.	84C015	
9.6.	BrO $_2\cdot$ /BrO $_2^-$	1330						72M258	
9.7.	BrO $_2\cdot$ , H $^+$ /HBrO $_2$	1330					Calcn.	85M419	
9.8.	BrO $_3^-$ , 2H $^+$ /BrO $_2\cdot$ , H $_2$ O	1150					Calcn.	85M419	
9.9.	Br $_2\cdot^-$ /2 Br $^-$	1660 *						Rec.	
		1900						Calcn.	727506
		1620	~1	Mn $^{3+}$	1550		4	Kinetics + assumptions.	737317
		1770						Calcn.; $\pm 50$ mV.	737316
		1670						Calcn.	73M369
		1450						Calcn.	761181
		1660						Calcn.; another value: $\leq 1590$ mV.	79C029
		1700						Calcn.	80C019
		1630	9.39	1890				Calcn.; $\pm 30-40$ mV.	84C015
		1690						Calcn.	86C016
9.10.	Br $_2$ /Br $_2\cdot^-$	300						Calcn.	727506
		410						Calcn.; $\pm 50$ mV.	737316
		510						Calcn.	73M369
		680						Calcn.	761181
		430						Calcn.	80C019
		520						Calcn.	86C016
9.11.	CN $\cdot$ /CN $^-$	1900						Calcn.; $\pm 300$ mV.	70C002
		~2800						Calcn.	75Z006
9.12.	Cyanate radical ( $^-O_2CNHNCO^-$ )/2NCO $^-$ (?)	600-700						Prediction from rate data	87A220
9.13.	CO $_2$ /CO $_2\cdot^-$	~2000						Pol.	761170
		~2000							80A123
		-1900 *						Rec., Calcn.	85A034
		-1930						Calcn. $\pm \geq 220$ mV	87C013
		-1900		Tl $^+$	-1940		-0	C (+ K)	89C001

TABLE 9. Reduction potentials of inorganic couples—Continued

No.	Compound or couple	<i>E</i> /mV	pH	Ref. compound	Ref. <i>E</i> /mV	Co-solute	<i>I</i>	Method/ comments	Ref.
9.14.	CO <sub>2</sub> <sup>•-</sup> , H <sup>+</sup> /HCO <sub>2</sub> <sup>-</sup>	1070	7					Calcn. ± ≥220 mV	87C013
9.15.	Cl <sup>•</sup> /Cl <sup>-</sup>	2550						Calcn.; ± 100 mV.	70C002
		2600						Calcn.	727506
		2600							
		2590						Calcn.; ± 50 mV.	737316
		2200						Calcn.	82A154
		2410		9.39	1890			Calcn.; ± 30-40 mV.	84C015
		2600						Calcn.	85C012
9.16.	HClO, H <sup>+</sup> /H <sub>2</sub> O, Cl <sup>•</sup>	-460						Calcn.	85C012
9.17.	HClO/Cl <sup>-</sup> , •OH	-40						Calcn.	85C012
9.18.	ClOH <sup>•</sup> /Cl <sup>-</sup> , OH <sup>-</sup>	1900		9.39	1890			Calcn.; ± 30-40 mV.	84C015
9.19.	ClO <sub>2</sub> <sup>•</sup> /ClO <sub>2</sub> <sup>-</sup>	934	4-6					Pot.	58C001
		936	4-6					Pot.	59C001
		954						Pot.	62C001
		919							65C003
		954							78Z277
		934 *						Rec., Pot.; other values 11-29°C; ± 2 mV.	85A039
9.20.	ClO <sub>2</sub> <sup>•</sup> , H <sup>+</sup> /HClO <sub>2</sub>	1277	0						78Z277
		1275						Calcn.	85M419
9.21.	ClO <sub>3</sub> <sup>-</sup> , 2H <sup>+</sup> /ClO <sub>2</sub> <sup>•</sup> , H <sub>2</sub> O	1150						Calcn.	85M419
9.22.	Cl <sub>2</sub> <sup>•-</sup> /2 Cl <sup>-</sup>	2300						Calcn.	727506
		2290						Calcn.; ± 50 mV.	737316
		2200	~1	Co <sup>3+</sup>	1850		~0.2	Kinetics + assumptions; ± 60 mV.	737316
		2300						Calcn.	80C019
		2090		9.39	1890			Calcn.; ± 30-40 mV.	84C015
9.23.	Cl <sub>2</sub> /Cl <sub>2</sub> <sup>•-</sup>	600						Calcn.	727506
		430						Calcn.; ± 50 mV.	737316
		420						Calcn.	80C019
9.24.	F <sup>•</sup> /F	3600						Calcn.; ± 100 mV.	70C002
9.25.	I <sup>•</sup> /I <sup>-</sup>	1270						Calcn.; no details.	63F022
		1400						Calcn.; ± 50 mV.	70C002
		1400						Calcn.	727506
		1310						Calcn.; ± 50 mV.	737316
		1420						Calcn.	73M369
		1380	~1.3	O <sub>2</sub> (bpy) <sub>3</sub> <sup>3+</sup>	840		1	Kinetics.	78A485
		1330						Kinetics + assumptions.	80A447
		1280	~3.5	7.4.6	865		~0.1	C + K	83A273
		1410						Calcn.	86C016
		1330		9.41	-330			HO <sub>2</sub> <sup>•</sup> /I <sub>2</sub> reaction; C + K + calcn.	86A070

TABLE 9. Reduction potentials of inorganic couples—Continued

No.	Compound or couple	E/mV	pH	Ref. compound	Ref. E /mV	Co-solute	I	Method/ comments	Ref.
9.26.	$\text{ICl}_2^- / \text{I}_2, 2 \text{Cl}^-$	1056							78Z277
9.27.	$\text{HIO}, \text{H}^+ / \text{H}_2\text{O}, \text{I}^\cdot$	-160						Calcn.	85C012
9.28.	$\text{HIO} / \text{I}^-, \cdot\text{OH}$	-1040						Calcn.	85C012
9.29.	$\text{I}_2^- / 2 \text{I}^-$	1040						Calcn.; no details.	63F022
		1100						Calcn.	727506
		1000						Calcn.; $\pm 50$ mV.	737316
		1130						Calcn.	73M369
		1080	~1.3	$\text{Os}(\text{bpy})_3^{3+}$	840		1	Kinetics + calcn.	78A485
		1000						Calcn.	80C019
		1040		9.25	1330			Calcn.	80A447
		1063	~3	$\text{Os}(\text{bpy})_3^{3+}$	857		0.1	Kinetics; $\pm 11$ mV.	82A115
		981	~3.5	7.4.6	865		~0.1	C + K	83A273
		1130						Calcn.	86C016
		1030		9.41	-330			$\text{HO}_2^- / \text{I}_2$ reaction; C + K + calcn.	86A070
9.30.	$\text{I}_2 / \text{I}_2^-$	300						Calcn.	727506
		60						Calcn.; $\pm 50$ mV.	737316
		110						Calcn.	73M369
		160						Calcn.	78A485
		200						Calcn.	83C019
		110						Calcn.	86C016
		210		9.41	-330			$\text{HO}_2^- / \text{I}_2$ reaction; C + K	86A070
9.31.	$\text{IO}_2^\cdot, \text{H}^+ / \text{HIO}_2$	1000						Calcn.	76M471
9.32.	$\text{IO}_3^-, 2\text{H}^+ / \text{IO}_2^\cdot, \text{H}_2\text{O}$	800						Calcn.	76M471
9.33.	$\text{N}_3^\cdot / \text{N}_3^-$	1330 *						Rec.	
		~1900						Calcn.	75Z006
		1370						Calcn.; $\pm 220$ mV.	83C030
		1330	6.5	$\text{IrCl}_6^{2-}$	930		1.0	K	85C023 (86A223)
		1350		9.9	1630	$\text{Br}^-$	2-3		87C002
		1320						Cyc. v.; $\pm 30$ mV	87C002
		$\leq 1365$		9.10	510			Calcn.	87M124
9.34.	$\text{N}_6^\cdot / 2\text{N}_3^-$	1930		9.33	1900			C	84A013
9.35.	$\text{N}_2\text{H}_4^+ / \text{N}_2\text{H}_4$	$\leq 730$		$\text{Fe}(\text{CN})_6^{3-}$				Kinetics + assumptions.	84A237
9.36.	$\cdot\text{NO}_2 / \text{NO}_2^-$	1000						Calcn.; $\pm 100$ mV.	70C002
		870							
		910						Calcn.	82C006
		1030						Calcn.; $\pm 40$ mV.	83C030
		1040		$\text{Fe}(\text{TMP})_3^{2+}$			0.3	TMP = 3,4,7,8-tetramethylphenanthroline	85A480
		870						Calcn.	85C012
9.37.	$\text{NO}_3^\cdot / \text{NO}_3^-$	2300						Calcn.; $\pm 100$ mV.	70C002
		~1900						Calcn.	75Z006
		2300-2600						Prediction based on rate data	86A278
9.38.	$\cdot\text{OH}, \text{H}^+ / \text{H}_2\text{O}$	2730 *						Rec.	

TABLE 9. Reduction potentials of inorganic couples—Continued

No.	Compound or couple	$E/mV$	pH	Ref. compound	Ref. $E/mV$	Co-solute	$I$	Method/comments	Ref.
		1800	7					Calcn.; not $E^{\circ}$ .	769245
		2850	0					Calcn.	78Z277
		2180	7					Calcn.; not $E^{\circ}$ .	82C006
		2590	0					Calcn.	84C002
		2720	0	Tl <sup>2+</sup>	2220			Tl <sup>+</sup> / $\cdot$ OH reaction (kinetics); $\pm 20$ mV.	84C015
		2740	0	9.19	934			ClO <sub>2</sub> <sup>-</sup> /O <sub>3</sub> reaction (kinetics), + calcn.	85A039
9.39.	$\cdot$ OH/OH <sup>-</sup>	1900 *						Rec.	
		1900						Calcn.; $\pm 100$ mV.	70C002
		2020							78Z277
		1770						Calcn.	84C002
		1890		Tl <sup>2+</sup>	2220			Tl <sup>+</sup> / $\cdot$ OH reaction (kinetics) $\pm 20$ mV.	84C015
		1910		9.19	934			ClO <sub>2</sub> <sup>-</sup> /O <sub>3</sub> reaction (kinetics), + calcn.; $\pm 10$ mV.	85A039
9.40.	O $\cdot^-$ , H <sub>2</sub> O/2 OH <sup>-</sup>	1870						Calcn.	80C019
		1760		Tl <sup>2+</sup>	2220			Tl <sup>+</sup> / $\cdot$ OH reaction (kinetics), + calcn.; $\pm 20$ mV.	84C015
		1780		9.19	934			ClO <sub>2</sub> <sup>-</sup> /O <sub>3</sub> reaction (kinetics), + calcn.	85A039
9.41.	O <sub>2</sub> /O <sub>2</sub> <sup>-</sup>	-330 *						Rec.	
		-330						Calcn.	72C001
		-288						Pol.; -532 mV vs SCE	72C002
		-330		DQ	-250			Calcn.	74C001
		-330	7.2	1.1.4	-67	HCO <sub>2</sub> <sup>-</sup>	0.1	C(+K).	741141
		-310		DQ				Calc. from data in	741141
								730125.	
		-325	7	DQ	-235	HCO <sub>2</sub> <sup>-</sup>		C; -155 mV for 1 mol dm <sup>-3</sup> O <sub>2</sub> .	751090
		-330	7	1.1.1	100			Kin. reaction QH <sub>2</sub> + H <sub>2</sub> O <sub>2</sub> cat. peroxidase.	75C004
9.42.	O <sub>2</sub> , H <sup>+</sup> /HO <sub>2</sub> $\cdot$	-37	0					Calcn.	761063
		-50							
		-50						Calcn.	85C012
9.43.	O <sub>2</sub> ( <sup>1</sup> $\Delta_g$ )/O <sub>2</sub> $\cdot^-$	650	7						769245
9.44.	O <sub>2</sub> $\cdot^-$ , H <sup>+</sup> /HO <sub>2</sub> <sup>-</sup>	1000						Calcn.	761063
9.45.	O <sub>2</sub> $\cdot^-$ , 2 H <sup>+</sup> /H <sub>2</sub> O <sub>2</sub>	1710	0					Calcn.	761063
		1760							
		1760						Calcn.	85C012
9.46.	O <sub>2</sub> $\cdot^-$ , 2 H <sup>+</sup> /H <sub>2</sub> O <sub>2</sub>	940	7					Calcn.; + 20 mV, not $E^{\circ}$ .	74C001
		865	7					Calcn.; not $E^{\circ}$ .	751090
		940	7					Calcn.; not $E^{\circ}$ .	769245

TABLE 9. Reduction potentials of inorganic couples—Continued

No.	Compound or couple	$E/mV$	pH	Ref. compound	Ref. $E/mV$	Co-solute	$I$	Method/comments	Ref.
9.47.	$HO_2^{\cdot}, H^+/H_2O_2$	1420	0					Calcn.; not $E^{\circ}$ .	761063
		1480							
		1495	0					Calcn.	782277
		1480						Calcn.	85C012
9.48.	$HO_2^{\cdot}/HO_2^{-}$	790					Calcn.	85C012	
9.49.	$H_2O_2, H^+/H_2O, \cdot OH$	800	7					Calcn.; not $E^{\circ}$ .	769245
		870							
		460	7					Calcn.; not $E^{\circ}$ .	82C006
		460-520	7					Calcn.; not $E^{\circ}$ .	84C002
		870					Calcn.	85C012	
9.50.	$O_3/O_3^{\cdot-}$	1600	$\geq 11$					Calcn.; $\pm 100$ mV.	82C006
		1040							
		1190	$\geq 11$					Calcn.	84C002
		1010	* 11-12	9.19	934			Rec., $ClO_2^{-}/O_3$ reaction (kinetics).	85A039
		1040					Calcn.	85C012	
9.51.	$O_3, H^+/HO_3^{\cdot}$	1800	7				Calcn.; not $E^{\circ}$ .	82C006	
9.52.	$S, H^+/HS^{\cdot}$	~1300	0				Calcn.	87A082	
9.53.	$HS^{\cdot}/HS^{-}$	1150					Calcn.	86C016	
9.54.	$HSSH^{\cdot}/2HS^{-}$	900					Calcn.	86C016	
9.55.	$SCN^{\cdot}/SCN^{-}$	1620	~1.3	$Fe(bpy)_3^{3+}$	1065		1	Kinetics (one rate const. assumed).	78A485
		1680	~1.3	$Os(bpy)_3^{3+}$	837		1	Kinetics + calcn. (some assumptions).	78A485
		1650		9.25	1380			Calcn.	78A485
		1660		9.25	1330			Calcn.	80A447
		1601						Calcn.	82A154
		1620						Calcn.	86A070
		1660		6.2.9	1240			Calcn.	88A024
				1330	*				Rec.
9.56.	$(SCN)_2^{\cdot-}/2 SCN^{-}$	1310	~1.3	$Fe(bpy)_3^{3+}$	1065		1	Kinetics + calcn. (rate const. assumed).	78A485
		1370	~1.3	$Os(bpy)_3^{3+}$	837		1	Kinetics + calcn. (some assumptions).	78A485
		1290		9.55	1660			Calcn.	80A447
		1250		9.29	1000			Calcn.; $\pm 220$ mV.	82A183
		1331	~3	$Os(bpy)_3^{3+}$	857		0.1	Kinetics; $\pm 8$ mV.	82A115
		1310						Calcn.	86A070
		1350		6.2.9	1240			Calcn.	88A024
				540					Calcn.
9.57.	$(SCN)_2/(SCN)_2^{\cdot-}$	540						78A485	
9.58.	$SO_2/SO_2^{\cdot-}$	-262						Calcn.	84A454
		-280							
		-280						Calcn.	85C012
		-288	1					Cyc. v.	87A083
9.59.	$SO_2^{\cdot-}, H_2O/HSO_3^{\cdot-}, H^+$	-660	7					$S_2O_4^{2-}/MV^{2+}$ reaction + calcn.; not $E^{\circ}$ .	78C016

TABLE 9. Reduction potentials of inorganic couples—Continued

No.	Compound or couple	$E/mV$	pH	Ref. compound	Ref. $E/mV$	Co-solute	$I$	Method/comments	Ref.
9.60.	$\dot{S}O_3^-/SO_3^{2-}$	630	$\approx 8$					Calc. from value at pH 3.6	84A327
		760	11	9.19	936		-0		88A024
9.61.	$\dot{S}O_3^-/HSO_3^-$	840	3.6	7.5.1	780		-0.1	C	84A327
9.62.	$SO_4^{2-}, H_2O/\dot{S}O_3^-, 2OH^-$	-2470						Calcn.	84A327
9.63.	$SO_4^-/SO_4^{2-}$	~2430						Calcn. (see ref.)	89Z064
9.64.	$SO_5^-/HSO_5^-$	~1100	6.7	9.29	1130			Equilibrium not attained.	84A327
9.65.	$S_2O_5^-/S_2O_5^{2-}$	1340						Calcn.	82A154
		1350						Calcn.	83C030
		1600							
		1600						Calcn.	85C012
9.66.	$SeO_3^-/SeO_3^{2-}$	1680						K + calcn.	86A335
9.67.	$SeO_3^-, H^+/HSeO_3^-$	2180						K + calcn.; further calcns. of related couples	86A335
9.68.	$(SeCN)_2^-/2 SeCN^-$	900-1000						Calcn. + assumptions.	79A035

\* Recommended value.



## 13. References to Tables

- 33C001 The viologen indicators. Michaelis, L.; Hill, E.S., J. Gen. Physiol. **16**: 859-73 (1933)
- 419001 Another type of free radical in the group of thiazines and some other related heterocyclic rings. Michaelis, L.; Granick, S.; Schubert, M.P., J. Am. Chem. Soc. **63**: 351-5 (1941)
- 57C001 Polarographic behavior of the viologen indicators. Elofson, R.M.; Edsberg, R.L., Can. J. Chem. **35**: 646-50 (1957)
- 58C001 The oxidation potentials of solutions of chlorite and chlorine dioxide. Flis, I.E., Zh. Fiz. Khim. **32**: 573-9 (1958)
- 58C002 A polarographic study of some Wurster salts. Friend, J.A.; Roberts, N.K., Aust. J. Chem. **11**: 104-19 (1958)
- 599011 Polarographic oxidation of phenothiazine tranquilizers. Kabasakalian, P.; McGlotten, J., Anal. Chem. **31**: 431-3 (1959)
- 59C001 The equilibrium  $\text{ClO}_2 + e \rightleftharpoons \text{ClO}_2^-$  in aqueous solution at different temperatures. Troitskaya, N.V.; Mishchenko, K.P.; Flis, I.E., Russ. J. Phys. Chem. **33**: 77-9 (1959) Translated from: Zh. Fiz. Khim. **33**: 1614-7 (1959)
- 59C002 Oxidation-reduction potentials, ionization constants and semiquinone formation of indigo sulfonates and their reduction products. Preisler, P.W.; Hill, E.S.; Loeffel, R.G.; Shaffer, P.A., J. Am. Chem. Soc. **81**: 1991-5 (1959)
- 600012 Chemical constitution and anthelmintic activity. IV. Substituted phenothiazines. Craig, J.C.; Tate, M.E.; Warwick, G.P.; Rogers, W.P., J. Med. Pharm. Chem. **2**: 659-68 (1960)
- 609014 Chemical constitution and anthelmintic activity. V. Alkoxy- and chlorophenothiazines. Craig, J.C.; Tate, M.E.; Donovan, F.W.; Rogers, W.P., J. Med. Pharm. Chem. **2**: 669-80 (1960)
- 60C001 The stereochemistry of the bridged quaternary salts of 2,2'-bipyridyl. Homer, R.F.; Tomlinson, T.E., J. Chem. Soc. **2498-503** (1960)
- 60C002 Mode of action of dipyriddy quaternary salts as herbicides. Homer, R.F.; Mees, G.C.; Tomlinson, T.E., J. Sci. Food Agric. **11**: 309-15 (1960)
- 61C001 Investigation of stable free radicals formed by electroreduction of N-alkylpyridinium salts. Schwarz, W.M., Jr., Ph.D., Thesis, Univ. Wisconsin, Madison, WI, 1961, 151p.
- 61M014 Formation of stable free radicals on electroreduction of N-alkylpyridinium salts. Schwarz, W.M.; Kosower, E.M.; Shain, I., J. Am. Chem. Soc. **83**: 3164-5 (1961)
- 62C001 The oxidation by chlorine dioxide and sodium chlorite. I. Measurement of normal oxidation-reduction potential of chlorine dioxide. Naito, T., J. Chem. Soc. Jpn., Indust. Chem. Sect. (Kogyo Kagaku Zasshi) **65**: 749-52 (1962)
- 63F022 The reactions of iodopentamminecobalt(III) with various "one-electron" oxidation-reduction reagents. Haim, A.; Taube, H., J. Am. Chem. Soc. **85**: 495-500 (1963)
- 649025 Addendum: Redox potential and hydration energy of the hydrated electron. Baxendale, J.H., Radiat. Res. Suppl. **4**: 139-40 (1964)
- 649028 Controlled-potential coulometric analysis of N-substituted phenothiazine derivatives. Merkle, F.H.; Discher, C.A., Anal. Chem. **36**: 1639-43 (1964)
- 65C002 The reducing power generated in photoact I of photosynthesis. Kok, B.; Rurainki, H.J.; Owens, O.V.H., Biochim. Biophys. Acta **109**: 347-56 (1965)
- 65C003 The thermodynamic characteristics of certain equilibria in solutions of chlorine dioxide and chlorite at different temperatures. Zolotukhin, V.M.; Flis, I.E.; Mishchenko, K.P., J. Appl. Chem. USSR **38**: 363-7 (1965) Translated from: Zh. Prikl. Khim. (Leningrad) **38**: 369-74 (1965)
- 65F032 Diquat (1,1'-ethylene-2,2'-dipyridylum dibromide) in photoreactions of isolated chloroplasts. Zweig, G.; Shavit, N.; Avron, M., Biochim. Biophys. Acta **109**: 332-46 (1965)
- 66C001 Chloroplast reactions with dipyriddy salts. Black, C.C., Jr., Biochim. Biophys. Acta **120**: 332-40 (1966)
- 66C002 Bipyridylum herbicides. Polarography of 1,1'-ethylene-2,2'-bipyridylum dibromide. Engelhardt, J.; McKinley, W.P., J. Agric. Food Chem. **14**: 377-80 (1966)
- 66C003 One-electron-transfer reactions in biochemical systems. I. Kinetic analysis of the oxidation-reduction equilibrium between quinol-quinone and ferro-ferricytochrome c. Yamazaki, I.; Ohnishi, T., Biochim. Biophys. Acta **112**: 469-81 (1966)
- 67C002 Aryl-substituted derivatives of 4,4'-bipyridylum salts: their spectroscopic properties and stereochemistry. Downes, J.E., J. Chem. Soc. C **1491-3** (1967)
- 67C003 Effect of introducing a sulphur bridge on the herbicidal activity of diquat. Summers, L.A., Nature **214**: 381-2 (1967)
- 67C004 Radical cation from 2,2'-bipyridyl dimethiodide. Summers, L.A., Naturwissenschaften **54**: 491-2 (1967)
- 68C001 The relationship between herbicidal activity and electrochemical properties of quaternary bipyridylum salts. Volke, J., Collect. Czech. Chem. Commun. **33**: 3044-8 (1968)
- 68C002 Herbicidal activity of an aromatic analogue of diquat. Summers, L.A.; Black, A.L., Nature **218**: 1067-8 (1968)
- 68C003 Chemical constitution and activity of bipyridylum herbicides. II. Diquaternary salts of 1,10-phenanthroline. Summers, L.A., Tetrahedron **24**: 5433-7 (1968)
- 68C004 Reversible Redoxsysteme vom Weitz-Typ. Eine polarographische Studie. Huenig, S.; Gross, J., Tetrahedron Lett. **21**: 2599-604 (1968)
- 69C001 Reduction of some recent bipyridylum herbicides at the dropping mercury electrode. Volke, J.; Volkova, V., Collect. Czech. Chem. Commun. **34**: 2037-47 (1969)
- 69C002 Electron transfer properties and phytotoxicity of a diquaternary salt from 2,2':6',2"-terpyridine. Dickeson, J.E.; Summers, L.A., Experientia **25**: 1247-8 (1969)
- 69C003 Conversion of light to chemical free energy. I. Porphyrin-sensitized photoreduction of ferredoxin by glutathione. Eisenstein, K.K.; Wang, J.H., J. Biol. Chem. **244**: 1720-8 (1969)
- 69C004 One-electron transfer properties of dipyriddy[1,2-a:2',1'-c]pyrazinium dibromide. Black, A.L.; Summers, L.A., J. Chem. Soc. C **610-1** (1969)
- 69C005 Non-aqueous electrochemistry using optically transparent electrodes. Osa, T.; Kuwana, T., J. Electroanal. Chem. Interfacial Electrochem. **22**: 389-406 (1969)
- 70C001 Phytotoxicity control exerted by redox potential values of the bipyridylum quaternaries. White, B.G., Proc. 10th British Weed Control Conf., 1970, p.997-1007
- 70C002 Oxidation-reduction potentials of certain inorganic radicals in aqueous solutions. Berdnikov, V.M.; Bazhin, N.M., Russ. J. Phys. Chem. **44**: 395-8 (1970) Translated from: Zh. Fiz. Khim. **44**: 712 (1970)
- 70M264 Chronopotentiometry and coulometric titration of N-substituted phenothiazines. Patriarche, G.J.; Lingane, J.J., Anal. Chim. Acta **49**: 25-34 (1970)
- 71C001 Chemical constitution and activity of bipyridylum herbicides. Part VII. 6-Substituted derivatives of 6,7-dihydrodipyriddy[1,2-a:2',1'-c]pyrazinedium dibromide (diquat) and dipyriddy[1,2-a:2',1'-c]pyrazinedium dibromide. Black, A.L.; Summers, L.A., J. Heterocycl. Chem. **8**: 29-31 (1971)
- 727506 The photochemical behavior of cobalt complexes containing macrocyclic ( $\text{N}_4$ ) ligands. Oxidation-reduction chemistry of dihalogen radical anions. Malone, S.D.; Endicott, J.F., J. Phys. Chem. **76**: 2223-9 (1972)

- 72C001 Thermodynamic characteristics of the hydroperoxy radical in aqueous solution. Berdnikov, V.M.; Zhuravleva, O.S., Russ. J. Phys. Chem. **46**: 1521-3 (1972) Translated from: Zh. Fiz. Khim. **46**: 2658-60 (1972)
- 72C002 Electrogeneration and some properties of the superoxide ion in aqueous solutions. Chevalet, J.; Rouelle, F.; Gierst, L.; Lambert, J.P., J. Electroanal. Chem. Interfacial Electrochem. **39**: 201-16 (1972)
- 72M258 Oscillations in chemical systems. II. Thorough analysis of temporal oscillation in the bromate-cerium-malonic acid system. Field, R.J.; Koros, E.; Noyes, R.M., J. Am. Chem. Soc. **94**: 8649-64 (1972)
- 730274 Radiation Chemistry. An Introduction. Swallow, A.J., John Wiley and Sons, New York, 1973, 275p.
- 737316 Kinetics of oxidation of transition-metal ions by halogen radical anions. Part II. The oxidation of cobalt(II) by dichloride ions generated by flash photolysis. Thornton, A.T.; Laurence, G.S., J. Chem. Soc., Dalton Trans. : 1632-6 (1973)
- 737317 Kinetics of oxidation of transition-metal ions by halogen radical anions. Part III. The oxidation of manganese(II) by dibromide and dichloride ions generated by flash photolysis. Laurence, G.S.; Thornton, A.T., J. Chem. Soc., Dalton Trans. : 1637-44 (1973)
- 73C001 Two-step redox systems. XI. Diquaternary salts of bipyridyls and dipyrindylethylenes: Syntheses and polarography. Huenig, S.; Gross, J.; Schenk, W., Justus Liebig's Ann. Chem. : 324-38 (1973)
- 73C002 Two-step redox systems. XII. Synthesis and polarography of quaternary salts derived from phenanthrolines, 2,7-diazapyrene and from diazoniapentaphenes. Huenig, S.; Gross, J.; Lier, E.F.; Quast, H., Justus Liebig's Ann. Chem. **339**-58 (1973)
- 73M369 Thermochemical parameters of aqueous halogen radicals. Woodruff, W.H.; Margerum, D.W., Inorg. Chem. **12**: 962-4 (1973)
- 741141 The redox potential of the  $O_2-O_2^-$  system in aqueous media. Ilan, Y.A.; Meisel, D.; Czapski, G., Isr. J. Chem. **12**: 891-5 (1974)
- 749062 Spectroelectrochemical study of mediators. I. Bipyridylum salts and their electron transfer rates to cytochrome c. Steckhan, E.; Kuwana, T., Ber. Bunsenges. Phys. Chem. **78**: 253-9 (1974)
- 74C001 The redox potential of the system oxygen-superoxide. Wood, P.M., FEBS Lett. **44**: 22-4 (1974)
- 74C002 The 2,2'-dicyano-1,1'-dimethyl-4,4'-bipyridylum dication: A viologen indicator with a high redox potential. Fielden, R.; Summers, L.A., Experientia **30**: 843-4 (1974)
- 74C003 Chemical constitution and activity of bipyridylum herbicides. Part VIII. 4-Bromo-6,7-dihydrodipyrido[1,2-a:2',1'-c]-pyrazinedium dibromide and related compounds. Pojer, P.M.; Summers, L.A., J. Heterocycl. Chem. **11**: 303-5 (1974)
- 74C004 Electrochemical redox patterns for pyridinium species: 1-Methylnicotinamide and nicotinamide mononucleotide. Schmakel, C.O.; Santhanam, K.S.V.; Elving, P.J., J. Electrochem. Soc. **121**: 1033-45 (1974)
- 751090 One-electron transfer equilibria and redox potentials of radicals studied by pulse radiolysis. Meisel, D.; Czapski, G., J. Phys. Chem. **79**: 1503-9 (1975)
- 751117 One-electron redox potentials of nitro compounds and radiosensitizers. Correlation with spin densities of their radical anions. Meisel, D.; Neta, P., J. Am. Chem. Soc. **97**: 5198-203 (1975)
- 751150 One-electron reduction potential of riboflavine studied by pulse radiolysis. Meisel, D.; Neta, P., J. Phys. Chem. **79**: 2459-61 (1975)
- 75C001 The thermochemical characterization of sodium dithionite, flavin mononucleotide, flavin-adenine dinucleotide and methyl and benzyl viologens as low-potential reductants for biological systems. Watt, G.D.; Burns, A., Biochem. J. **152**: 33-7 (1975)
- 75C002 Characteristics of viologen derivatives for electrochromic display. Kawata, T.; Yamamoto, M.; Yamana, M.; Tajima, M.; Nakano, T., Jpn. J. Appl. Phys. **14**: 725-6 (1975)
- 75C004 Relation between redox potentials and rate constants in reactions coupled with the system oxygen-superoxide. Sawada, Y.; Iyanagi, T.; Yamazaki, I., Biochemistry **14**: 3761-4 (1975)
- 75Z006 Charge-transfer photochemistry. Endicott, J.F., Concepts of Inorganic Photochemistry, A.W. Adamson and P.D. Fleischauer (eds.), Wiley, New York, NY, 1975, p.81-142
- 761037 Oxygen inhibition of nitroreductase: Electron transfer from nitro radical-anions to oxygen. Wardman, P.; Clarke, E.D., Biochem. Biophys. Res. Commun. **69**: 942-9 (1976)
- 761063 The one-electron transfer redox potentials of free radicals. I. The oxygen/superoxide system. Ilan, Y.A.; Czapski, G.; Meisel, D., Biochim. Biophys. Acta **430**: 209-24 (1976)
- 761070 One-electron reduction potentials of substituted nitroimidazoles measured by pulse radiolysis. Wardman, P.; Clarke, E.D., J. Chem. Soc., Faraday Trans. **1** **72**: 1377-90 (1976)
- 761111 Pulse radiolysis and electron spin resonance studies of nitroaromatic radical anions. Optical absorption spectra, kinetics, and one-electron redox potentials. Neta, P.; Simic, M.G.; Hoffman, M.Z., J. Phys. Chem. **80**: 2018-23 (1976)
- 761169 Electron transfer and equilibria between pyridinyl radicals and FAD. Anderson, R.F., Ber. Bunsenges. Phys. Chem. **80**: 969-72 (1976)
- 761170 Mechanism of the reduction of lead ions in aqueous solution (a pulse radiolysis study). Breitenkamp, M.; Henglein, A.; Lillie, J., Ber. Bunsenges. Phys. Chem. **80**: 973-9 (1976)
- 761181 Kinetics of the heterogeneous electron transfer reaction of triplet pyrene in micelles to  $Br_2^-$  radicals in aqueous solution. Frank, A.J.; Graetzel, M.; Henglein, A.; Janata, E., Int. J. Chem. Kinet. **8**: 817-24 (1976)
- 761206 Nicotinamide-NAD sequence: redox process and related behavior, behavior and properties of intermediate and final products. Elving, P.J.; Schmakel, C.O.; Santhanam, K.S.V., Crit. Rev. Anal. Chem. **6**: 1-67 (1976)
- 765319 Electron exchange and electron transfer of semiquinones in aqueous solutions. Meisel, D.; Fessenden, R.W., J. Am. Chem. Soc. **98**: 7505-10 (1976)
- 769245 Reactions involving singlet oxygen and the superoxide anion. Koppenol, W.H., Nature (London) **262**: 420-1 (1976)
- 76C001 Oxidation-reduction properties of several low potential iron-sulfur proteins and of methylviologen. Stombaugh, N.A.; Sundquist, J.E.; Burris, R.H.; Orme-Johnson, W.H., Biochemistry **15**: 2633-41 (1976)
- 76C002 Chemical constitution and activity of bipyridylum herbicides. X. 3-Substituted-6,7-dihydrodipyrido[1,2-a:2',1'-c]-pyrazinedium dibromides and related compounds. Pirzada, N.H.; Pojer, P.M.; Summers, L.A., Z. Naturforsch., Teil B **31B**: 115-21 (1976)
- 76C003 Nicotinamide-dependent one-electron and two-electron (flavin) oxidoreduction: Thermodynamics, kinetics, and mechanism. Blankenhorn, G., Eur. J. Biochem. **67**: 67-80 (1976)
- 76M471 Oscillations in chemical systems. 13. A detailed molecular mechanism for the Bray-Liebhafsky reaction of iodate and hydrogen peroxide. Sharma, K.R.; Noyes, R.M., J. Am. Chem. Soc. **98**: 4345-61 (1976)

- 771044 One electron reduction potentials of some substituted 4(5)-nitroimidazoles in aqueous solution studied by pulse radiolysis. Sjoeborg, L.; Eriksen, T.E.; Mustea, I.; Revesz, L., *Radiochem. Radioanal. Lett.* **29**: 19-26 (1977)
- 773087 The use of nitroaromatic compounds as hypoxic cell radiosensitizers. Wardman, P., *Curr. Top. Radiat. Res. Q.* **11**: 347-98 (1977)
- 77C006 Chemical constitution and activity of bipyridylum herbicides. XII. Diquaternary salts of 6-methyl-2,2'-bipyridyl and 2-methyl-4,4'-bipyridyl. Schmalzl, K.J.; Summers, L.A., *Aust. J. Chem.* **30**: 657-62 (1977)
- 77C007 Evaluation of mediator-titrants for the indirect coulometric titration of biocomponents. Szentirmay, R.; Yeh, P.; Kuwana, T., *Electrochemical Studies of Biological Systems*, D.T. Sawyer (ed.), ACS Symposium 38, American Chem. Soc., Washington, D.C., 1977, p.143-69
- 77Z190 Electron transfer reactions of paraquat. Ledwith, A., *Biochemical Mechanisms of Paraquat Toxicity*, A.P. Autor (ed.), Academic Press, New York, NY, 1977, p.21-37
- 78A103 Indirect measurement of the thionine-leucothionine synproportionation rate constant by a photochemical perturbation technique. Wildes, P.D.; Lichtin, N.N., *J. Phys. Chem.* **82**: 981-4 (1978)
- 78A485 Outer-sphere oxidation of iodide and thiocyanate by tris(2,2'-bipyridyl)- and tris(1,10-phenanthroline)osmium(III) in aqueous solutions. Nord, G.; Pedersen, B.; Farver, O., *Inorg. Chem.* **17**: 2233-8 (1978)
- 78C016 The redox potential of dithionite and  $\text{SO}_2^-$  from equilibrium reactions with flavodoxins, methyl viologen and hydrogen plus hydrogenase. Mayhew, S.G., *Eur. J. Biochem.* **85**: 535-47 (1978)
- 78C017 Examination of the electrochemical properties of N,N-dimethyl-4,4'-bipyridinium bis(O,O-dimethylphosphate) by classical and ac polarography. Grachev, V.N.; Zhdanov, S.I.; Supin, G.S., *Sov. Electrochem.* **14**: 1180-6 (1978) Translated from: *Elektrokhimiya* **14**: 1353-62 (1978)
- 78R212 Radiosensitization of *Serratia marcescens* by nitropyridinium compounds. Anderson, R.F.; Patel, K.B.; Smithen, C.E., *Br. J. Cancer, Suppl.* **37**: 103-6 (1978)
- 78Z277 Tables of standard electrode potentials. Milazzo, G.; Caroli, S., Wiley, Chichester, 1978, 421p.
- 79A035 Pulse radiolysis of  $\text{SeCN}^-$  and reactions of  $(\text{SeCN})_2^-$  radicals with biochemical compounds. Badiello, R.; Tamba, M., *Radiochem. Radioanal. Lett.* **37**: 165-71 (1979)
- 79A100 Electron transfer rates and equilibria between substituted phenoxide ions and phenoxyl radicals. Steenken, S.; Neta, P., *J. Phys. Chem.* **83**: 1134-7 (1979)
- 79A456 Cation radicals of phenothiazines. Electron transfer with aquoiron(II) and -(III) and hexacyanoferrate(II) and -(III). Pelizzetti, E.; Mentasti, E., *Inorg. Chem.* **18**: 583-8 (1979)
- 79C021 Redox potentials of radical anions of nitrofurans derivatives. Khudiyakov, I.V.; Kuzhkov, V.B.; Kuz'min, V.A., *Dokl. Phys. Chem.* **246**: 424-6 (1979) Translated from: *Dokl. Akad. Nauk SSSR* **246**: 397-400 (1979)
- 79C029 Horseradish peroxidase. XXXIV. Oxidation of compound II to I by periodate and inorganic anion radicals. Nadezhdin, A.; Dunford, H.B., *Can. J. Biochem.* **57**: 1080-3 (1979)
- 79R017 Structure-activity relationships in the development of hypoxic cell radiosensitizers. I. Sensitization efficiency. Adams, G.E.; Clarke, E.D.; Flockhart, I.R.; Jacobs, R.S.; Sehmi, D.S.; Stratford, I.J.; Wardman, P.; Watts, M.E.; Parrick, J.; Wallace, R.G.; Smithen, C.E., *Int. J. Radiat. Biol. Relat. Stud. Phys., Chem. Med.* **35**(2): 133-50 (1979)
- 79R037 Radiosensitization of hypoxic mammalian cells by dinitroimidazoles. Agrawal, K.C.; Millar, B.C.; Neta, P., *Radiat. Res.* **78**: 532-41 (1979)
- 80A123 Elementary reactions of the reduction of  $\text{Tl}^+$  in aqueous solution. Butler, J.; Henglein, A., *Radiat. Phys. Chem.* **15**: 603-12 (1980)
- 80A136 Are ortho-substituted 4-nitroimidazoles a new generation of radiation-induced arylating agents? Clarke, E.D.; Wardman, P., *Int. J. Radiat. Biol. Relat. Stud. Phys., Chem. Med.* **37**: 463-8 (1980)
- 80A210 A pulse-radiolysis study of the reduction of 6-hydroxy-5-nitrothymine in acid aqueous solutions. Eriksen, T.E.; Sjoeborg, L.; Mustea, I.; Revesz, L., *Radiat. Phys. Chem.* **16**: 213-7 (1980)
- 80A247 Excited-state electron-transfer quenching by a series of water photoreduction mediators. Amouyal, E.; Zidler, B.; Keller, P.; Moradpour, A., *Chem. Phys. Lett.* **74**: 314-7 (1980)
- 80A349 The electron affinity of some radiotherapeutic agents used in cancer therapy. Wold, E.; Kaalhus, O.; Johansen, E.S.; Ekse, A.T., *Int. J. Radiat. Biol. Relat. Stud. Phys., Chem. Med.* **38**: 599-611 (1980)
- 80A447 Oxidation of thiocyanate and iodide by iridium(IV). Stanbury, D.M.; Wilmarth, W.K.; Khalaf, S.; Po, H.N.; Byrd, J.E., *Inorg. Chem.* **19**: 2715-22 (1980)
- 80C004 Applications of light-induced electron-transfer reactions: Generation and reaction of  $\text{Ag}^0$  in solution via visible light photolysis of  $\text{Ru}(\text{bpy})_3^{2+}$ . Foreman, T.K.; Giannotti, C.; Whitten, D.G., *J. Am. Chem. Soc.* **102**: 1170-1 (1980)
- 80C007 The one-electron reduction potentials of NAD. Farrington, J.A.; Land, E.J.; Swallow, A.J., *Biochim. Biophys. Acta* **590**: 273-6 (1980)
- 80C008 Energetics of the one-electron steps in the  $\text{NAD}^+/\text{NADH}$  redox couple. Anderson, R.F., *Biochim. Biophys. Acta* **590**: 277-81 (1980)
- 80C019 Energetics of reactions of  $\text{O}_{\text{aq}}^-$  and of O<sup>-</sup>-transfer reactions between radicals. Henglein, A., *Radiat. Phys. Chem.* **15**: 151-8 (1980)
- 80C024 Nitrobenzenes: a comparison of pulse radiolytically determined one-electron reduction potentials and calculated electron affinities. Sjoeborg, L.; Eriksen, T.E., *J. Chem. Soc., Faraday Trans.* **1** **76**: 1402-8 (1980)
- 80C044 The half-wave potential and homogeneous electron-transfer rate constant in sodium dodecyl sulphate micellar solution. Ohsawa, Y.; Shimazaki, Y.; Aoyagi, S., *J. Electroanal. Chem. Interfacial Electrochem.* **114**: 235-46 (1980)
- 80C045 The electrochemical properties of three dipyrindinium salts as mediators. Salmon, R.T.; Hawkrige, F.M., *J. Electroanal. Chem. Interfacial Electrochem.* **112**: 253-64 (1980)
- 80R182 Anaerobic reduction of nitroimidazoles by reduced flavin mononucleotide and by xanthine oxidase. Clarke, E.D.; Wardman, P.; Goulding, K.H., *Biochem. Pharmacol.* **29**: 2684-7 (1980)
- 80R183 The development of some nitroimidazoles as hypoxic cell sensitizers. Adams, G.E.; Ahmed, I.; Fielden, E.M.; O'Neill, P.; Stratford, I.J., *Cancer Clin. Trials* **3**: 37-42 (1980)
- 80R184 Structure-activity relationships in the development of hypoxic cell radiosensitizers. III. Effects of basic substituents in nitroimidazole sidechains. Adams, G.E.; Ahmed, I.; Clarke, E.D.; O'Neill, P.; Parrick, J.; Stratford, I.J.; Wallace, R.G.; Wardman, P.; Watts, M.E., *Int. J. Radiat. Biol.* **38**: 613-26 (1980)
- 80R185 Toxicity of nitro compounds toward hypoxic mammalian cells in vitro: Dependence on reduction potential. Adams, G.E.; Stratford, I.J.; Wallace, R.G.; Wardman, P.; Watts, M.E., *J. Nat. Cancer Inst.* **64**: 555-60 (1980)

- 80R186 Novel (nitro-1-imidazolyl)alkanolamines as potential radiosensitizers with improved therapeutic properties. Smithen, C.E.; Clarke, E.D.; Dale, J.A.; Jacobs, R.S.; Wardman, P.; Watts, M.E.; Woodcock, M., *Radiation Sensitizers: Their Use in the Clinical Management of Cancer*, L.W. Brady (ed.), Masson, New York, NY, 1980, p.22-32
- 80R187 Development of hypoxic cell radiosensitizers. The second and third generations. Wardman, P.; Clarke, E.D.; Jacobs, R.S.; Minchinton, A.; Stratford, M.R.L.; Watts, M.E.; Woodcock, M.; Moazzam, M.; Parrick, J.; Wallace, R.G.; Smithen, C.E., *Radiation Sensitizers: Their Use in the Clinical Management of Cancer*, L.W. Brady (ed.), Masson, New York, NY, 1980, p.83-90
- 80R192 Redox and spectroscopic properties of oxidized MoFe protein from *Azotobacter vinelandii*. Watt, G.D.; Burns, A.; Lough, S.; Tennent, D.L., *Biochemistry* **19**: 4926-32 (1980)
- 80R193 Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Brown, J.M.; Workman, P., *Radiat. Res.* **82**: 171-90 (1980)
- 81A127 Disproportionation of semimethylene blue and oxidation of leucomethylene blue by methylene blue and by Fe(III). Kinetics, equilibria, and medium effects. Hay, D.W.; Martin, S.A.; Ray, S.; Lichtin, N.N., *J. Phys. Chem.* **85**: 1474-9 (1981)
- 81A405 Intermediate products of the photoreduction of diphenoquinones. Lantratova, O.B.; Kuz'min, V.A.; Prokof'ev, A.I.; Khudyakov, I.V.; Pokrovskaya, I.E., *Bull. Acad. Sci. USSR, Div. Chem. Sci.* **30**: 1459-65 (1981) Translated from: *Izv. Akad. Nauk SSSR, Ser. Khim.* : 1789-96 (1981)
- 81C030 Phenoxyl radicals: Formation, detection, and redox properties in aqueous solutions. Neta, P.; Steenken, S., *Oxygen and Oxy-Radicals in Chemistry and Biology*, M.A.J. Rodgers and E.L. Powers (eds.), Academic Press, New York, NY, 1981, p.83-8
- 81C031 Pulse radiolysis studies of antitumor quinones: Radical lifetimes, reactivity with oxygen, and one-electron reduction potentials. Svungen, B.A.; Powis, G., *Arch. Biochem. Biophys.* **209**: 119-26 (1981)
- 81C038 The thermodynamic properties of some commonly used oxidation-reduction mediators, inhibitors and dyes, as determined by polarography. Prince, R.C.; Linkletter, S.J.G.; Dutton, P.L., *Biochim. Biophys. Acta.* **635**: 132-48 (1981)
- 81R072 Radiosensitization of hypoxic mammalian cells in vitro by some 5-substituted-4-nitroimidazoles. Adams, G.E.; Fielden, E.M.; Hardy, C.; Millar, B.C.; Stratford, I.J.; Williamson, C., *Int. J. Radiat. Biol. Relat. Stud. Phys., Chem. Med.* **40**: 153-61 (1981)
- 81S024 Model systems for photocatalytic water reduction: Role of pH and metal colloid catalysts. Miller, D.; McLendon, G., *Inorg. Chem.* **20**: 950-3 (1981)
- 81Z010 Free radicals generated by radiolysis of aqueous solutions. Schwarz, H.A., *J. Chem. Educ.* **58**: 101-5 (1981)
- 81Z316 Electrochemistry of the viologens. Bird, C.L.; Kuhn, A.T., *Chem. Soc. Rev.* **10**: 49-82 (1981)
- 82A033 Formation of halide-ions on one-electron reduction of halogenated nitroimidazoles in aqueous solution. A radiolytic study. Ma, H.; Hardy, C.R.; O'Neill, P., *Int. J. Radiat. Biol. Relat. Stud. Phys., Chem. Med.* **41**: 151-60 (1982)
- 82A115 Outer-sphere oxidation. 2. Pulse-radiolysis study of the rates of reaction of the  $I_2^{\cdot-}$  and  $(SCN)_2^{\cdot-}$  radical anions with the tris(2,2'-bipyridyl) complexes of Os(II) and Os(III). Nord, G.; Pedersen, B.; Floryan-Lovborg, E.; Pagsberg, P., *Inorg. Chem.* **21**: 2327-30 (1982)
- 82A154 Electron-transfer reactions of the 2-nitrothiophen triplet state studied by laser flash photolysis. Martins, L.J.A., *J. Chem. Soc., Faraday Trans. 1* **78**: 533-43 (1982)
- 82A183 Charge transfer between tryptophan and tyrosine in proteins. Butler, J.; Land, E.J.; Pruetz, W.A.; Swallow, A.J., *Biochim. Biophys. Acta* **705**: 150-62 (1982)
- 82A232 Outer-sphere electron-transfer reactions of ascorbate anions. Williams, N.H.; Yandell, J.K., *Aust. J. Chem.* **35**: 1133-44 (1982)
- 82A253 One-electron redox potentials of phenols. Hydroxy- and aminophenols and related compounds of biological interest. Steenken, S.; Neta, P., *J. Phys. Chem.* **86**: 3661-7 (1982)
- 82A329 Radiation sensitization and chemical studies on isoindole-4,7-diones. Infante, G.A.; Gonzalez, P.; Cruz, D.; Correa, J.; Myers, J.A.; Ahmad, M.F.; Whitter, W.L.; Santos, A.; Neta, P., *Radiat. Res.* **92**: 296-306 (1982)
- 82C006 The reduction potential of the couple  $O_3/O_3^{\cdot-}$ . Consequences for mechanisms of ozone toxicity. Koppenol, W.H., *FEBS Lett.* **140**: 169-72 (1982)
- 82C019 On the effect of electron relay redox potential on electron transfer reactions in a water photoreduction model system. Amouyal, E.; Zidler, B., *Isr. J. Chem.* **22**: 117-24 (1982)
- 82M376 Theoretical analysis of electrochemical reactions involving two successive one-electron transfers with dimerization of intermediate-application to  $NAD^+/NADH$  redox couple. Samec, Z.; Bresnahan, W.T.; Elving, P.J., *J. Electroanal. Chem. Interfacial Electrochem.* **133**: 1-23 (1982)
- 82R087 Pulse radiolysis and cellular studies of a new class of radiosensitizers: 2-nitrobenzofurans. Averbek, D.; Bensuson, R.V.; Buisson, J.P.; Land, E.J.; Rene, L.; Royer, R.; Santus, R., *Int. J. Radiat. Biol. Relat. Stud. Phys., Chem. Med.* **42**: 457-68 (1982)
- 82R117 Nitroimidazoles as anaerobic electron acceptors for xanthine oxidase. Clarke, E.D.; Goulding, K.H.; Wardman, P., *Biochem. Pharmacol.* **31**: 3237-42 (1982)
- 82R118 Radiosensitization by non-nitro compounds. Wardman, P.; Anderson, R.F.; Hodgkiss, R.J.; Parrick, J.; Smithen, C.E.; Wallace, R.G.; Watts, M.E., *Int. J. Radiat. Oncol. Biol. Phys.* **8**: 399-401 (1982)
- 82S257 Solar reduction of water. III. Improved electron-transfer agents for the system water-tris(2,2'-bipyridine)ruthenium dication-ethylenediaminetetraacetic acid-platinum. Launikonis, A.; Loder, J.W.; Mau, A.W.-H.; Sasse, W.H.F.; Summers, L.A.; Wells, D., *Aust. J. Chem.* **35**: 1341-55 (1982)
- 82Z198 Molecular structure and biological activity of hypoxic cell radiosensitizers and hypoxic-specific cytotoxins. Wardman, P., *Advanced Topics on Radiosensitizers of Hypoxic Cells*, A. Breccia, C. Rimondi and G.E. Adams (eds.), Plenum Press, New York, NY, 1982, p.40-75
- 83A039 Reduction of the naphthazarin molecule as studied by pulse radiolysis. Part 1. Addition of a single electron. Land, E.J.; Mukherjee, T.; Swallow, A.J.; Bruce, J.M., *J. Chem. Soc., Faraday Trans. 1* **79**: 391-404 (1983)
- 83A273 Phenothiazine radical-cations: Electron transfer equilibria with iodide ions and the determination of one-electron redox potentials by pulse radiolysis. Bahnmann, D.; Asmus, K.-D.; Willson, R.L., *J. Chem. Soc., Perkin Trans. 2* : 1669-73 (1983)
- 83C002 Energetics of the one-electron reduction steps of riboflavin, FMN and FAD to their fully reduced forms. Anderson, R.F., *Biochim. Biophys. Acta* **722**: 158-62 (1983)
- 83C017 Reduction potentials for 2,2'-bipyridine and 1,10-phenanthroline couples in aqueous solutions. Krishnan, C.V.; Creutz, C.; Schwarz, H.A.; Sutin, N., *J. Am. Chem. Soc.* **105**: 5617-23 (1983)
- 83C018 One-electron reduction of adriamycin: Properties of the semiquinone. Land, E.J.; Mukherjee, T.; Swallow, A.J.; Bruce, J.M., *Arch. Biochem. Biophys.* **225**: 116-21 (1983)

- 83C019 Review of the heat of formation of the hydroperoxyl radical. Shum, L.G.S.; Benson, S.W., *J. Phys. Chem.* **87**: 3479-82 (1983)
- 83C030 Electron-transfer reactions involving simple free radicals. Wilmarth, W.K.; Stanbury, D.M.; Byrd, J.E.; Po, H.N.; Chua, C.-P., *Coord. Chem. Rev.* **51**: 155-79 (1983)
- 83M234 Oxidation of NADH by ferrocenium salts. Rate-limiting one-electron transfer. Carlson, B.W.; Miller, L.L., *J. Am. Chem. Soc.* **105**: 7453-4 (1983)
- 83N008 One-electron transfer equilibria and kinetics of N-methylphenothiazine in micellar systems. Minero, C.; Pramauro, E.; Pelizzetti, E.; Meisel, D., *J. Phys. Chem.* **87**: 399-407 (1983)
- 83N149 Light-induced electron transfer in colloidal semiconductor dispersions: Single vs. dielectronic reduction of acceptors by conduction-band electrons. Moser, J.; Graetzel, M., *J. Am. Chem. Soc.* **105**: 6547-55 (1983)
- 83N190 Photochemical and chemical reduction of vicinal dibromides via phase transfer of 4,4'-bipyridinium radical: The role of radical disproportionation. Goren, Z.; Willner, I., *J. Am. Chem. Soc.* **105**: 7764-5 (1983)
- 83N211 Electron-transfer quenching and hydrogen generation from water by a series of 1,10-phenanthroline salt relays. Amouyal, E.; Zidler, B.; Keller, P., *Nouv. J. Chim.* **7**: 725-8 (1983)
- 83R015 Abnormal radiosensitizing and cytotoxic properties of ortho-substituted nitroimidazoles. Stratford, I.J.; Hoe, S.; Adams, G.E.; Hardy, C.; Williamson, C., *Int. J. Radiat. Biol. Relat. Stud. Phys., Chem. Med.* **43**: 31-43 (1983)
- 83R178 Reduction potential and thermodynamic parameters of adrenodoxin by the use of an anaerobic thin-layer electrode. Huang, Y.-Y.; Kimura, T., *Anal. Biochem.* **133**: 385-93 (1983)
- 84A013 The azide radical and its reaction with tryptophan and tyrosine. Butler, J.; Land, E.J.; Swallow, A.J.; Pruetz, W.A., *Radiat. Phys. Chem.* **23**: 265-70 (1984)
- 84A044 The effect of pH and complexation on redox reactions between RS<sup>•</sup> radicals and flavins. Ahmad, R.; Armstrong, D.A., *Can. J. Chem.* **62**: 171-7 (1984)
- 84A208 The mechanism of the free-radical-induced chain isomerisation of 2-(furyl)-3-(5-nitro-2-furyl)acrylamide. Clarke, E.D.; Wardman, P.; Wilson, I.; Tatsumi, K., *J. Chem. Soc., Perkin Trans. 2* : 1155-61 (1984)
- 84A237 Reactions involving the hydrazinium free radical: Oxidation of hydrazine by hexachloroiridate. Stanbury, D.M., *Inorg. Chem.* **23**: 2870-82 (1984)
- 84A263 The triplet state of N-(n-butyl)-5-nitro-2-furamide by laser flash photolysis. Spectrum, lifetime, energy and electron-transfer reactions. Martins, L.J.A.; Kemp, T.J., *J. Chem. Soc., Faraday Trans. 1* **80**: 2509-24 (1984)
- 84A292 Radical cations of some low-potential viologen compounds. Reduction potentials and electron-transfer reactions. Anderson, R.F.; Patel, K.B., *J. Chem. Soc., Faraday Trans. 1* **80**: 2693-702 (1984)
- 84A327 Chemical behavior of SO<sub>3</sub><sup>•-</sup> and SO<sub>6</sub><sup>•-</sup> radicals in aqueous solutions. Huie, R.E.; Neta, P., *J. Phys. Chem.* **88**: 5665-9 (1984)
- 84A392 Pulse radiolysis studies of electron transfer between polymer and zwitterionic viologen radicals. Sakamoto, T.; Ohsako, T.; Matsuo, T.; Mulac, W.A.; Meisel, D., *Chem. Lett.* : 1893-6 (1984)
- 84A449 Dioxathiadiazaheteropentalenes. New photosystem-I electron acceptors. Camilleri, P.; Bowyer, J.R.; Clark, M.T.; O'Neill, P., *Biochim. Biophys. Acta* **765**: 236-8 (1984)
- 84A454 Outer-sphere electron-transfer reactions involving the chlorite/chlorine dioxide couple. Activation barriers for bent triatomic species. Stanbury, D.M.; Lednický, L.A., *J. Am. Chem. Soc.* **106**: 2847-53 (1984)
- 84C001 One-electron reduction potential of m-AMSA<sup>+</sup> [9-(2-methoxy-4-methylsulphonylaminoanilino)acridinium] as measured by pulse radiolysis. Anderson, R.F.; Packer, J.E.; Denny, W.A., *J. Chem. Soc., Perkin Trans. 2* : 49-52 (1984)
- 84C002 The oxidizing nature of the hydroxyl radical. A comparison with the ferryl ion [FeO<sup>2+</sup>]. Koppenol, W.H.; Liebman, J.F., *J. Phys. Chem.* **88**: 99-101 (1984)
- 84C009 Nicotinamide adenine dinucleotide (NAD<sup>+</sup>). Formal potential of the NAD<sup>+</sup>/NAD<sup>•</sup> couple and NAD<sup>•</sup> dimerization rate. Jensen, M.A.; Elving, P.J., *Biochim. Biophys. Acta* **764**: 310-5 (1984)
- 84C015 Equilibrium between hydroxyl radicals and thallium(II) and the oxidation potential of OH(aq). Schwarz, H.A.; Dodson, R.W., *J. Phys. Chem.* **88**: 3643-7 (1984)
- 84C026 The equilibrium reaction of the luminol radical with oxygen and the one-electron-reduction potential of 5-aminophthalazine-1,4-dione. Merenyi, G.; Lind, J.; Eriksen, T.E., *J. Phys. Chem.* **88**: 2320-3 (1984)
- 84N047 Amphiphilic copolymers as media for light-induced electron transfer. I. Electrostatic effect on the forward reaction as studied by fluorescence quenching. Itoh, Y.; Morishima, Y.; Nozakura, S., *Photochem. Photobiol.* **39**: 451-7 (1984)
- 84R027 Radiosensitization by derivatives of isoindole-4,7-dione. Infante, G.A.; Guzman, P.; Alvarez, R.; Figueroa, A.; Correa, J.N.; Myers, J.A.; Lanier, L.J.; Williams, T.M.; Burgos, S.; Vera, J.; Neta, P., *Radiat. Res.* **98**: 234-41 (1984)
- 84R148 Nitroaryl compounds as potential fluorescent probes for hypoxia. I. Chemical criteria and constraints. Wardman, P.; Clarke, E.D.; Hodgkiss, R.J.; Middleton, R.W.; Parrick, J.; Stratford, M.R.L., *Int. J. Radiat. Oncol. Biol. Phys.* **10**: 1347-51 (1984)
- 84R149 Radiation sensitization and chemopotentialization: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo. Adams, G.E.; Ahmed, I.; Sheldon, P.W.; Stratford, I.J., *Br. J. Cancer* **49**: 571-7 (1984)
- 84R150 Thiol reactive nitroimidazoles: radiosensitization studies in vitro and in vivo. Stratford, I.J.; Adams, G.E.; Hardy, C.; Hoe, S.; O'Neill, P.; Sheldon, P.W., *Int. J. Radiat. Biol. Relat. Stud. Phys., Chem. Med.* **46**: 731-45 (1984)
- 85A001 Pulse-radiolysis study of daunorubicin redox cycles. Reduction by e<sub>aq</sub><sup>-</sup> and COO<sup>-</sup> free radicals. Houee-Levin, C.; Gardes-Albert, M.; Ferradini, C.; Faraggi, M.; Klapper, M., *FEBS Lett.* **179**: 46-50 (1985)
- 85A034 Cobalt(II) polypyridine complexes. Redox and substitutional kinetics and thermodynamics in the aqueous 2,2'-bipyridine and 4,4'-dimethyl-2,2'-bipyridine series studied by the pulse-radiolysis technique. Schwarz, H.A.; Creutz, C.; Sutin, N., *Inorg. Chem.* **24**: 433-9 (1985)
- 85A039 Standard Gibbs energy of formation of the hydroxyl radical in aqueous solution. Rate constants for the reaction ClO<sub>2</sub><sup>-</sup> + O<sub>3</sub> ⇌ O<sub>3</sub><sup>-</sup> + ClO<sub>2</sub>. Klanning, U.K.; Sehested, K.; Holcman, J., *J. Phys. Chem.* **89**: 760-3 (1985)
- 85A090 The radiation chemistry of some platinum-containing radiosensitizers and related compounds. Butler, J.; Hoey, B.M.; Swallow, A.J., *Radiat. Res.* **102**: 1-13 (1985)
- 85A103 One-electron redox reactions involving sulfite ions and aromatic amines. Neta, P.; Huie, R.E., *J. Phys. Chem.* **89**: 1783-7 (1985)
- 85A255 One-electron redox reactions in aqueous solutions of sulfite with hydroquinone and other hydroxyphenols. Huie, R.E.; Neta, P., *J. Phys. Chem.* **89**: 3918-21 (1985)
- 85A301 Intramolecular association of covalently linked viologen radicals. Neta, P.; Richoux, M.-C.; Harriman, A., *J. Chem. Soc., Faraday Trans. 2* **81**: 1427-43 (1985)
- 85A303 Potential radiosensitizing agents. 7. 4(5)-Iodo-5(4)-nitroimidazole derivatives. Gupta, R.P.; Larroquette, C.A.; Agrawal, K.C.; Grodkowski, J.; Neta, P., *J. Med. Chem.* **28**: 987-91 (1985)

- 85A390 One-electron redox reactions of pyrazolin-5-ones. A pulse radiolysis study of antipyrine and analogues. Jovanovic, S.V.; Neta, P.; Simic, M.G., *Mol. Pharmacol.* **28**: 377-80 (1985)
- 85A480 Kinetics and equilibria for reactions of the hexachloroiridate redox couple in nitrous acid. Ram, M.S.; Stanbury, D.M., *Inorg. Chem.* **24**: 2954-62 (1985)
- 85C005 Pulse-radiolysis study of the effect of pH on the one-electron reduction potentials of lumichrome derivatives. Heelis, P.F.; Parsons, B.J.; Phillips, G.O.; Land, E.J.; Swallow, A.J., *J. Chem. Soc., Faraday Trans. 1* **81**: 1225-35 (1985)
- 85C012 Energetics of interconversion reactions of oxyradicals. Koppenol, W.H.; Butler, J., *Adv. Free Radical Biol. Med.* **1**: 91-131 (1985)
- 85C018 Effect of pH on oxidation-reduction potentials of 8 $\alpha$ -N-imidazole-substituted flavins. Williamson, G.; Edmondson, D.E., *Biochemistry* **24**: 7790-7 (1985)
- 85C023 Reduction potential of the trinitrogen radical as determined by chemical kinetics: Novel application of spin trapping. Ram, M.S.; Stanbury, D.M., *Inorg. Chem.* **24**: 4233-4 (1985)
- 85E687 Pyridinium quenchers of Ru(bpy)<sub>3</sub><sup>2+</sup>. Charge effects of the yield of electron transfer. Jones, G., II; Malba, V., *J. Org. Chem.* **50**: 5776-82 (1985)
- 85F007 Photochemical generation of long-living redox pairs by the use of polypyridineruthenium(II) complex, zwitterionic electron mediator, and viologen polymer as an electron pool. Ohsako, T.; Sakamoto, T.; Matsuo, T., *J. Phys. Chem.* **89**: 222-5 (1985)
- 85M419 A mechanism for dynamical behavior in the oscillatory chlorite-iodide reaction. Epstein, I.R.; Kustin, K., *J. Phys. Chem.* **89**: 2275-82 (1985)
- 85M420 Inclusion, solubilization, and stabilization of two-electron reduced species of methyl viologen by cyclodextrins. Matsue, T.; Kato, T.; Akiba, U.; Osa, T., *Chem. Lett.* **1825-8** (1985)
- 85N094 Interfacial charge separation in the photoreduction of water: Effects of colloidal silica. Furlong, D.N.; Johansen, O.; Launikonis, A.; Loder, J.W.; Mau, A.W.-H.; Sasse, W.H.F., *Aust. J. Chem.* **38**: 363-7 (1985)
- 85N197 Micellar effects on the reductive electrochemistry of methylviologen. Kaifer, A.E.; Bard, A.J., *J. Phys. Chem.* **89**: 4876-80 (1985)
- 85R016 Reactions of the semiquinone free radicals of antitumour agents with oxygen and iron complexes. Butler, J.; Hoey, B.M.; Swallow, A.J., *FEBS Lett.* **182**: 95-8 (1985)
- 85R025 One-electron oxidation-reduction properties of ascorbic acid. Iyanagi, T.; Yamazaki, I.; Anan, K.F., *Biochim. Biophys. Acta* **806**: 255-61 (1985)
- 85R035 Reduction of nitroimidazole derivatives by hydrogenosomal extracts of *Trichomonas vaginalis*. Yarlett, N.; Gorrell, T.E.; Marczak, R.; Mueller, M., *Mol. Biochem. Parasitol.* **14**: 29-40 (1985)
- 86A059 Kinetics of one-electron transfer reactions involving ClO<sub>2</sub> and NO<sub>2</sub>. Huie, R.E.; Neta, P., *J. Phys. Chem.* **90**: 1193-8 (1986)
- 86A070 Reactions of HO<sub>2</sub> and O<sub>2</sub><sup>-</sup> with iodine and bromine and the I<sub>2</sub><sup>-</sup> and I atom reduction potentials. Schwarz, H.A.; Bielski, B.H.J., *J. Phys. Chem.* **90**: 1445-8 (1986)
- 86A072 Effect of ionic polymer environment on the photoinduced electron transfer from zinc porphyrin to viologen. Nosaka, Y.; Kuwabara, A.; Miyama, H., *J. Phys. Chem.* **90**: 1465-70 (1986)
- 86A098 One-electron reduction of 2,1,3-benzothiadiazole-4,7-dicarbonitrile in aqueous solutions. Camilleri, P.; Dearing, A.; Cole-Hamilton, D.J.; O'Neill, P., *J. Chem. Soc., Perkin Trans. 2* **2**: 569-72 (1986)
- 86A110 Electron-transfer reactions of tryptophan and tyrosine derivatives. Jovanovic, S.V.; Harriman, A.; Simic, M.G., *J. Phys. Chem.* **90**: 1935-9 (1986)
- 86A139 Coulombic effect on photoinduced electron-transfer reactions between phenothiazines and viologens. Kawanishi, Y.; Kitamura, N.; Tazuke, S., *J. Phys. Chem.* **90**: 2469-75 (1986)
- 86A266 Reactions of three bis(viologen) tetraquaternary salts and their reduced radicals. Atherton, S.J.; Tsukahara, K.; Wilkins, R.G., *J. Am. Chem. Soc.* **108**: 3380-5 (1986)
- 86A278 Rate constants for reactions of NO<sub>3</sub> radicals in aqueous solutions. Neta, P.; Huie, R.E., *J. Phys. Chem.* **90**: 4644-8 (1986)
- 86A291 Rate constants for one-electron oxidation by methylperoxy radicals in aqueous solutions. Huie, R.E.; Neta, P., *Int. J. Chem. Kinet.* **18**: 1185-91 (1986)
- 86A335 Selenium(V). A pulse radiolysis study. Klaning, U.K.; Sehested, K., *J. Phys. Chem.* **90**: 5460-4 (1986)
- 86A403 One-electron redox potentials of RSSR<sup>+</sup>-RSSR couples from dimethyl disulphide and lipoic acid. Bonifacic, M.; Asmus, K.-D., *J. Chem. Soc., Perkin Trans. 2* **2**: 1805-9 (1986)
- 86A520 The methoxatin semiquinone: A pulse radiolysis study. Faraggi, M.; Chandrasekar, R.; McWhirter, R.B.; Klapper, M.H., *Biochem. Biophys. Res. Commun.* **139**: 955-60 (1986)
- 86B096 One-electron reduction of 2- and 6-methyl-1,4-naphthoquinone bioreductive alkylating agents. Wilson, I.; Wardman, P.; Lin, T.S.; Sartorelli, A.C., *J. Med. Chem.* **29**: 1381-4 (1986)
- 86C005 One-electron redox potentials of purines and pyrimidines. Jovanovic, S.V.; Simic, M.G., *J. Phys. Chem.* **90**: 974-8 (1986)
- 86C016 Redox potentials of some sulfur-containing radicals. Surdhar, P.S.; Armstrong, D.A., *J. Phys. Chem.* **90**: 5915-7 (1986)
- 86C027 Determination of one-electron reduction potential of 3-nitro-7-azaindole compounds. Jin, Y.; Handman, J., *J. Radiat. Res. Radiat. Process. (Fushe Yanjiu Yu Fushe Gongyi Xuebao)* **4**: 43-7 (1986)
- 86C031 Unpaired electron migration between aromatic and sulfur peptide units. Pruetz, W.A.; Butler, J.; Land, E.J.; Swallow, A.J., *Free Radical Res. Commun.* **2**: 69-75 (1986)
- 86N260 Electron transfer through a lipid-bilayer-membrane-aqueous-solution interface and kinetics of the oxidation of viologen radicals in homogeneous and vesicular systems. Shafirovich, V.Ya.; Levin, P.P.; Khannanov, N.K.; Kuz'min, V.A., *Bull. Acad. Sci. USSR, Div. Chem. Sci.* **35**: 728-33 (1986) Translated from: *Izv. Akad. Nauk SSSR, Ser. Khim.* **35**: 801-6 (1986)
- 86R230 The apparent inhibition of superoxide dismutase activity by quinones. Butler, J.; Hoey, B.M., *J. Free Radicals Biol. Med.* **2**: 77-81 (1986)
- 87A082 Thermal and photochemical reactions of sulfhydryl radicals. Implications for colloid photocorrosion. Mills, G.; Schmidt, K.H.; Matheson, M.S.; Meisel, D., *J. Phys. Chem.* **91**: 1590-6 (1987)
- 87A083 One-electron-transfer reactions of the couple SO<sub>2</sub>/SO<sub>2</sub><sup>-</sup> in aqueous solutions. Pulse radiolytic and cyclic voltammetric studies. Neta, P.; Huie, R.E.; Harriman, A., *J. Phys. Chem.* **91**: 1606-11 (1987)
- 87A220 Kinetics of one-electron oxidation by the cyanate radical. Alfassi, Z.B.; Huie, R.E.; Mosseri, S.; Neta, P., *J. Phys. Chem.* **91**: 3888-91 (1987)
- 87A234 One-electron reduction of juglone (5-hydroxy-1,4-naphthoquinone): A pulse radiolysis study. Mukherjee, T., *Radiat. Phys. Chem.* **29**: 455-62 (1987)
- 87A247 One-electron oxidation of indoles and acid-base properties of the indolyl radicals. Shen, X.; Lind, J.; Merenyi, G., *J. Phys. Chem.* **91**: 4403-6 (1987)

- 87A269 The reduction of anti-tumour diaziridinyl benzoquinones. Butler, J.; Hoey, B.M.; Lea, J.S., *Biochim. Biophys. Acta* **925**: 144-9 (1987)
- 87C002 The redox potential of the azide/azidyl couple. Alfassi, Z.B.; Harriman, A.; Huie, R.E.; Mosseri, S.; Neta, P., *J. Phys. Chem.* **91**: 2120-2 (1987)
- 87C013 Reduction potential of the  $\text{CO}_2/\text{CO}_2^-$  couple. A comparison with other C<sub>1</sub> radicals. Koppenol, W.H.; Rush, J.D., *J. Phys. Chem.* **91**: 4429-30 (1987)
- 87C019 Further comments on the redox potentials of tryptophan and tyrosine. Harriman, A., *J. Phys. Chem.* **91**: 6102-4 (1987)
- 87C020 Reduction potentials and exchange reactions of thiyl radicals and disulfide anion radicals. Surdhar, P.S.; Armstrong, D.A., *J. Phys. Chem.* **91**: 6532-7 (1987)
- 87C023 Electrochemical properties of pyrazinethiadiazoles. Camilleri, P.; Odell, B.; O'Neill, P., *J. Chem. Soc., Perkin Trans. 2* : 1671-4 (1987)
- 87M124 Comment: On the mechanism of the azide-bromine reaction in aqueous medium. Alfassi, Z.B., *Int. J. Chem. Kinet.* **19**: 777-80 (1987)
- 87R070 Hypoxia-selective radiosensitization of mammalian cells by nitracrine, an electron-affinic DNA intercalator. Roberts, P.B.; Anderson, R.F.; Wilson, W.R., *Int. J. Radiat. Biol. Relat. Stud. Phys., Chem. Med.* **51**: 641-54 (1987)
- 87R083 Radiosensitization by the 2,4-dinitro-5-aziridinyl benzamide CB 1954: a structure/activity study. Walling, J.M.; Stratford, I.J.; Adams, G.E., *Int. J. Radiat. Biol. Relat. Stud. Phys., Chem. Med.* **52**: 31-41 (1987)
- 87R243 The effect of the anthrapyrazole antitumour agent CI941 on rat liver microsome and cytochrome P-450 reductase mediated free radical processes. Inhibition of doxorubicin activation in vitro. Graham, M.A.; Newell, D.R.; Butler, J.; Hoey, B.; Patterson, L.H., *Biochem. Pharmacol.* **36**: 3345-51 (1987)
- 87R257 Are reduced quinones necessarily involved in the anti-tumour activity of quinone drugs? Butler, J.; Hoey, B.M., *Br. J. Cancer, Suppl.* **55**: 53-9 (1987)
- 88A024 Electron transfer from indoles, phenol, and sulfite ( $\text{SO}_3^{2-}$ ) to chlorine dioxide ( $\text{ClO}_2^{\cdot}$ ). Merenyi, G.; Lind, J.; Shen, X., *J. Phys. Chem.* **92**: 134-7 (1988)
- 88A125 One-electron redox chemistry of amsacrine, mAMSA [9-(2-methoxy-4-methylsulphonylaminoanilino)acridinium], its quinone di-imine, and an analogue. A radiolytic study. Anderson, R.F.; Packer, J.E.; Denny, W.A., *J. Chem. Soc., Perkin Trans. 2* : 489-96 (1988)
- 88A126 One-electron oxidations of ferrocenes: A pulse radiolysis study. Faraggi, M.; Weinraub, D.; Broitman, F.; DeFelippis, M.R.; Klapper, M.H., *Radiat. Phys. Chem.* **32**: 293-7 (1988)
- 88A464 Properties of the radicals formed by one-electron oxidation of acetaminophen. A pulse radiolysis study. Bisby, R.H.; Tabassum, N., *Biochem. Pharmacol.* **37**: 2731-8 (1988)
- 88A901 Successive addition of electrons to sodium quinizarin 2- and 5-sulphonate in aqueous solution; a pulse and gamma-radiolysis study. Mukherjee, T.; Land, E.J.; Swallow, A.J.; Guyan, P.M.; Bruce, J.M., *J. Chem. Soc., Faraday Trans. 1* **84**: 2855-73 (1988)
- 89C001 Reduction potentials of  $\text{CO}_2^-$  and the alcohol radicals. Schwarz, H.A.; Dodson, R.W., *J. Phys. Chem.* **93**: 409-14 (1989)
- 89R018 Hypoxia-selective antitumor agents. 1. Relationships between structure, redox properties and hypoxia-selective cytotoxicity for 4-substituted derivatives of nitracrine. Wilson, W.R.; Anderson, R.F.; Denny, W.A., *J. Med. Chem.* **32**: 23-30 (1989)
- 89Z064 Reduction potentials involving inorganic free radicals in aqueous solution. Stanbury, D.M., *Adv. Inorg. Chem.* **33**: 69-138 (1989)

## 14. Compound Name Index

- 0582 2.3.35  
 AF-2 (cis) 2.2.9  
 AF-2 (trans) 2.2.10  
 AM-1 2.4.39  
 Acetaldehyde 4.1.3, 4.1.4  
 4-Acetamidophenol 5.1.7  
 Acetaminophen 5.1.7  
 Acetic acid, 2,5-dihydroxyphenyl- 5.4.6  
 Acetic acid, 3,4-dihydroxyphenyl- 5.2.4  
 Acetone 4.1.5, 4.1.6  
 Acetone ketyl radical 4.1.5  
 Acetophenone, 3',4'-dihydroxy-2-(methylamino)- 5.2.8  
 Acetophenone, 2-(dimethylamino)methyl-4'-nitro- 2.1.19  
 Acetophenone, 3-nitro- 2.1.9  
 Acetophenone, 4'-nitro- 2.1.10  
 5-Acetylaminosulfonyl-1-methyl-4-nitroimidazole 2.4.12  
 2-Acetyl-10-(3-dimethylaminopropyl)phenothiazine 7.5.5  
 4-Acetyl-1-methylpyridinium 4.4.3  
 2-[(Acetyloxy)methyl]-1,4-naphthoquinone 1.2.9  
 6-[(Acetyloxy)methyl]-1,4-naphthoquinone 1.2.13  
 10-Acetylphenothiazine 7.4.3  
*N*-Acetyl-L-tryptophan 6.2.12  
*N*-Acetyl-L-tyrosinamide 5.1.11  
 Acridine, 9-[3-(*N,N*-dimethylamino)propyl]amino-1-nitro- 2.7.2  
 Acridine, 9-[3-(*N,N*-dimethylamino)propyl]amino-4-chloro-1-nitro- 2.7.3  
 Acridine, 9-[3-(*N,N*-dimethylamino)propyl]amino-4-fluoro-1-nitro- 2.7.4  
 Acridine, 9-[3-(*N,N*-dimethylamino)propyl]amino-4-methyl-1-nitro- 2.7.5  
 Acridine, 9-[3-(*N,N*-dimethylamino)propyl]amino-4-methoxy-1-nitro- 2.7.6  
 Acridine, 9-[3-(*N,N*-dimethylamino)propyl]amino-4-methoxycarbonyl-1-nitro- 2.7.7  
 Acridine, 9-[3-(*N,N*-dimethylamino)propyl]amino-4-dimethylamino-1-nitro- 2.7.8  
 Acridine, 9-[3-(*N,N*-dimethylamino)propyl]amino-4-[di(2-acetoxyethyl)amino]-1-nitro- 2.7.9  
*N*<sup>1</sup>-(Acridinyl)-*N*<sup>4</sup>-methylsulfonyl-2-dimethylaminocyclohexa-2,5-diene-1',4'-diimine 1.5.13  
*N*<sup>1</sup>-(Acridinyl)-*N*<sup>4</sup>-methylsulfonyl-2-methoxycyclohexa-2,5-diene-1',4'-diimine 1.5.12  
 Acrylamide, 2-(2-furyl)-3-(5-nitro-2-furyl)- (*E*)- 2.2.10  
 Acrylamide, 2-(2-furyl)-3-(5-nitro-2-furyl)- (*Z*)- 2.2.9  
 Adenine 6.4.1  
 Adenosine 6.4.2  
 Adrenalone 5.2.8  
 Adrenochrome 1.5.1  
 Adriamycin 1.5.4  
*L*-Alanyl-*L*-tyrosine 5.1.12  
 1-Allyl-1'-carboxymethyl-4,4'-bipyridinium 3.11.4  
 1-Allyl-1'-(3-cyanopropyl)-4,4'-bipyridinium 3.11.6  
 1-Allyl-1'-[2-(diethylaminocarbonyl)ethyl]-4,4'-bipyridinium 3.11.7  
 1-Allyl-1'-ethyl-4,4'-bipyridinium 3.11.5  
 1-Allyl-1'-methyl-4,4'-bipyridinium 3.10.5  
 α-(Allyloxymethyl)-2-nitroimidazole-1-ethanol 2.3.38  
 2-Amino-5-aziridinyl-4-nitrobenzamide 2.1.26  
 4-Amino-5-aziridinyl-2-nitrobenzamide 2.1.27  
 3-Aminocarbonyl-1-methylpyridinium ion 4.4.1  
 4-Aminocarbonyl-1-methylpyridinium 4.4.2  
 5-Amino-2,4-dinitrobenzamide 2.1.24  
 3-(2-Aminoethyl)indole 6.2.8  
 2-Amino-6-hydroxypurine 6.4.3  
 4(5)-Aminoimidazole-5(4)-carboxamide 4.3.2  
 α-(Aminomethyl)-3,4-dihydroxybenzyl alcohol 5.2.6  
 5-[3-Amino-6-(2-methylpropyl)purinyl]-1-methyl-4-nitroimidazole 2.4.29  
 4-Amino-1-methyl-2-pyrimidinone 6.3.7  
 4-Aminophenol 5.1.2  
 5-Aminophthalazine-1,4-dione 1.5.2  
 6-Aminopurine 6.4.1  
 5-(3-Aminopurinyl)-1-methyl-4-nitroimidazole 2.4.28  
 4-Amino-2-pyrimidinone 6.3.6  
 4-Aminosulfonyl-1-methyl-5-nitroimidazole 2.5.4  
 5-Aminosulfonyl-1-methyl-4-nitroimidazole 2.4.8  
 Amsacrine, conjugate acid 4.8.1  
 Aniline 6.1.1  
 Aniline, *N,N*-dimethyl- 6.1.2  
 1-(2-Anilinoethyl)-2-nitroimidazole 2.3.61  
 1-[Anilino(thiocarbonylmethyl)]-1'-methyl-4,4'-bipyridinium 3.10.14  
 Anthra[1,9-*cd*]pyrazol-6-one, 7-hydroxy-2-[2-(2-hydroxyethyl)aminoethyl]-5-[[2-(2-hydroxyethyl)aminoethyl]amino]- 1.5.11  
 9,10-Anthraquinone, 1,4-bis[(2-hydroxyethylamino)ethyl]amino-, diacetate 1.3.5  
 9,10-Anthraquinone, 1,4-dihydroxy-5,8-bis[(2-hydroxyethylamino)ethyl]amino-, 1.3.4  
 9,10-Anthraquinone, 1,2,5,8-tetrahydroxy- 8.1.5  
 9,10-Anthraquinone-2-sulfonate ion 1.3.1  
 Antipyrine 8.4.4  
 Ascorbic acid 8.1.1  
 Azaquinone 1.5.2  
 Azide dimer radical anion 9.34.  
 Azide ion 9.33., 9.34.  
 Azide radical 9.33.



- 1-[2-(1-Aziridinoethyl)amino-2-hydroxypropyl]-2-nitroimidazole 2.3.63
- 5-Aziridinyl-*N*-[(2,2-dimethoxy)ethyl]-2,4-dinitrobenzamide 2.1.23
- 5-Aziridinyl-*N,N*-dimethyl-2,4-dinitrobenzamide 2.1.22
- 5-Aziridinyl-2,4-dinitrobenzamide 2.1.20
- 5-Aziridinyl-*N*-methyl-2,4-dinitrobenzamide 2.1.21
- Azirino[2',3':3,4]pyrrolo[1,2-*a*]indole-4,7-dione, 6-amino-8-[[aminocarbonyloxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5 1.5.7
- Azomycin 2.3.1
- Barbituric acid 6.3.4
- Basic Blue 9 4.5.2
- Benzaldehyde, 2-nitro- 2.1.12
- Benzaldehyde, 4-nitro- 2.1.13
- Benzamide, 2-amino-5-aziridinyl-4-nitro- 2.1.26
- Benzamide, 4-amino-5-aziridinyl-2-nitro- 2.1.27
- Benzamide, 5-amino-2,4-dinitro- 2.1.24
- Benzamide, 5-aziridinyl-*N,N*-dimethyl-2,4-dinitro- 2.1.22
- Benzamide, 5-aziridinyl-*N*-[(2,2-dimethoxy)ethyl]-2,4-dinitro- 2.1.23
- Benzamide, 5-aziridinyl-2,4-dinitro- 2.1.20
- Benzamide, 5-aziridinyl-*N*-methyl-2,4-dinitro- 2.1.21
- Benzamide, 5-(dimethylamino)-2,4-dinitro- 2.1.25
- Benzenamine, *N,N*-dimethyl- 6.1.2
- Benzene, 1-cyano-2-nitro- 2.1.17
- Benzene, 1,2-dihydroxy- 5.2.1
- Benzene, 1,3-dihydroxy- 5.3.1
- Benzene, 1,4-dihydroxy- 5.4.1
- Benzene, 1,4-dihydroxy-2-methyl- 5.4.3
- Benzene, 1,4-dihydroxytetramethyl- 5.4.10
- Benzene, 1,2-dinitro- 2.1.1
- Benzene, 1,3-dinitro- 2.1.2
- Benzene, 1,4-dinitro- 2.1.3
- Benzene, nitro- 2.1.11
- Benzene, 1,2,4-trihydroxy- 5.5.4
- 1,4-Benzenediamine, *N,N,N',N'*-tetramethyl- 6.1.5
- 1,2-Benzenediamine 6.1.3
- 1,4-Benzenediamine 6.1.4
- 1,4-Benzenediol, 2,3-dimethyl- 5.4.7
- 1,4-Benzenediol, 2,5-dimethyl- 5.4.8
- 1,2,3-Benzenetriol 5.5.1
- 1,2,4-Benzenetriol 5.5.4
- Benzimidazole, 2-nitro- 2.8.1
- Benzimidazole 2.3.42
- Benzo[1,2-*b*:3,4-*b'*]diquinolizium 3.12.8
- Benzo[1,2-*b*:3,4-*g'*]diquinolizium 3.12.10
- Benzo[1,2-*b*:5,6-*b'*]diquinolizium 3.12.9
- Benzofuran, 5-hydroxy-2-nitro- 2.8.7
- Benzofuran, 7-hydroxy-2-nitro- 2.8.5
- Benzofuran, 5-methoxy-2-nitro- 2.8.8
- Benzofuran, 7-methoxy-2-nitro- 2.8.6
- Benzofuran, 2-nitro- 2.8.4
- Benzoic acid, 2,3-dihydroxy- 5.2.2
- Benzoic acid, 2,5-dihydroxy- 5.3.2
- Benzoic acid, 3,4-dihydroxy- 5.2.3
- Benzoic acid, 3,5-dihydroxy- 5.3.3
- Benzoic acid, 2,4-dinitro- 2.1.4
- Benzoic acid, 2,5-dinitro- 2.1.5
- Benzoic acid, 3,4-dinitro- 2.1.6
- Benzoic acid, 3,5-dinitro- 2.1.7
- Benzoic acid, 4-hydroxy- 5.1.3
- Benzoic acid, 2-nitro- 2.1.14
- Benzoic acid, 3-nitro- 2.1.15
- Benzoic acid, 4-nitro- 2.1.16
- Benzoic acid, 3,4,5-trihydroxy-, ethyl ester 5.5.3
- Benzonitrile, 2-nitro- 2.1.17
- 12*H*-Benzo[*a*]phenothiazine 7.6.1
- 7*H*-Benzo[*c*]phenothiazine 7.6.2
- Benzo[*g*]pteridine-2,4-dione, 7,8-dimethyl- 4.6.6
- Benzo[*g*]pteridine-2,4-dione, 1,3,7,8-tetramethyl- 4.6.9
- Benzo[*g*]pteridine-2,4-dione, 1,7,8-trimethyl- 4.6.7
- Benzo[*g*]pteridine-2,4-dione, 3,7,8-trimethyl- 4.6.8
- 2*H*-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl- 8.1.6
- [5,4,3-*cde*][1]Benzopyran-5,7-dione, 2,3,7,8-tetrahydroxy[1]benzopyrano- 8.1.10
- 1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy- 8.1.9
- 1-Benzopyran-3,5,7-triol, 2-(3,4-dihydroxyphenyl)-3,4-dihydro- (*E*)- 8.1.7
- 1-Benzopyran-3,5,7-triol, 2-(3,4-dihydroxyphenyl)-3,4-dihydro- (*Z*)- 8.1.8
- 1,4-Benzoquinone, 2,5-bis(1-aziridinyl)-3,6-bis(2-hydroxyethylamino)- 1.1.8
- 1,4-Benzoquinone, 2,5-diaziridinyl-3,6-bis(carbethoxyamino)- 1.1.9
- 1,4-Benzoquinone, 2,3-dimethyl- 1.1.3
- 1,4-Benzoquinone, 2,5-dimethyl- 1.1.4
- 1,4-Benzoquinone, 2,6-dimethyl- 1.1.5
- 1,4-Benzoquinone, methyl- 1.1.2
- 1,4-Benzoquinone, tetramethyl- 1.1.7
- 1,4-Benzoquinone, 2,3,5-trimethyl- 1.1.6
- 1,4-Benzoquinone 1.1.1
- 2,1,3-Benzothiadiazole-4,7-dicarbonitrile 4.8.2
- 10-Benzoylphenothiazine 7.4.12
- Benzyl alcohol,  $\alpha$ -(aminomethyl)-3,4-dihydroxy- 5.2.6
- Benzyl alcohol, 4-nitro- 2.1.18
- 1-[3-(Benzylamino)-2-hydroxypropyl]-2-nitroimidazole 2.3.68
- 1-(Benzylcarbonylmethyl)-2-nitroimidazole 2.3.42
- 1-Benzyl-1'-methyl-4,4'-bipyridinium 3.10.13
- N*-Benzyl-2-nitroimidazole-1-acetamide 2.3.42

- Benzyl viologen 3.8.39  
 2,2'-Bipyridine, conjugate diacid 3.1.1  
 2,2'-Bipyridine, 4,4'-dimethyl- 4.4.8  
 2,2'-Bipyridine 4.4.7  
 4,4'-Bipyridine 3.8.1  
 4,4'-Bipyridinium, 1-allyl-1'-carboxymethyl- 3.11.4  
 4,4'-Bipyridinium, 1-allyl-1'-(3-cyanopropyl)- 3.11.6  
 4,4'-Bipyridinium, 1-allyl-1'-[2-(diethylaminocarbonyl)ethyl]- 3.11.7  
 4,4'-Bipyridinium, 1-allyl-1'-ethyl- 3.11.5  
 4,4'-Bipyridinium, 1-benzyl-1'-methyl- 3.10.13  
 4,4'-Bipyridinium, 1,1'-bis(2-aminoethyl)- 3.8.12  
 4,4'-Bipyridinium, 1,1'-bis(carbamylmethyl)- 3.8.8  
 4,4'-Bipyridinium, 1,1'-bis(2-carboxyethyl)- 3.8.17  
 4,4'-Bipyridinium, 1,1'-bis(carboxymethyl)- 3.8.5  
 4,4'-Bipyridinium, 1,1'-bis(2-chloroethyl)- 3.8.7  
 4,4'-Bipyridinium, 1,1'-bis(2-chloroethyl)-2,2'-dimethyl- 3.9.11  
 4,4'-Bipyridinium, 1,1'-bis( $\alpha$ -cyanobenzyl)- 3.8.38, 3.8.42  
 4,4'-Bipyridinium, 1,1'-bis(cyanomethyl)- 3.8.4  
 4,4'-Bipyridinium, 1,1'-bis(cyanomethyl)-2,2'-dimethyl- 3.9.10  
 4,4'-Bipyridinium, 1,1'-bis(3-cyanopropyl)- 3.8.22  
 4,4'-Bipyridinium, 1,1'-bis(1,2-dichloroethyl)- 3.8.14  
 4,4'-Bipyridinium, 1,1'-bis(2,2-diethoxyethyl)- 3.8.36  
 4,4'-Bipyridinium, 1,1'-bis(diethylaminocarbonylmethyl)- 3.8.33  
 4,4'-Bipyridinium, 1,1'-bis(dimethylaminocarbonylmethyl)- 3.8.24  
 4,4'-Bipyridinium, 1,1'-bis[2-(dimethylaminocarbonyl)ethyl]- 3.8.27  
 4,4'-Bipyridinium, 1,1'-bis[3-(dimethylaminocarbonyl)propyl]- 3.8.34  
 4,4'-Bipyridinium, 1,1'-bis[2-(3,5-dimethyl-4-morpholinyl)-2-oxoethyl]- 3.8.43  
 4,4'-Bipyridinium, 1,1'-bis(ethoxycarbonylmethyl)- 3.8.23  
 4,4'-Bipyridinium, 1,1'-bis(ethoxycarbonylmethyl)-2,2'-dimethyl- 3.9.14  
 4,4'-Bipyridinium, 1,1'-bis[2-(ethoxycarbonyl)ethyl]- 3.8.26  
 4,4'-Bipyridinium, 1,1'-bis[3-(ethoxycarbonyl)propyl]- 3.8.28  
 4,4'-Bipyridinium, 1,1'-bis[ethoxycarbonyl(phenyl)methyl]- 3.8.46  
 4,4'-Bipyridinium, 1,1'-bis(2-ethoxyethyl)- 3.8.25  
 4,4'-Bipyridinium, 1,1'-bis(ethylthiomethyl)- 3.8.21  
 4,4'-Bipyridinium, 1,1'-bis(2-hydroxyethyl)- 3.8.11  
 4,4'-Bipyridinium, 1,1'-bis(2-hydroxyethyl)-2,2'-dimethyl- 3.9.12  
 4,4'-Bipyridinium, 1,1'-bis(2-hydroxyiminoethyl)- 3.8.9  
 4,4'-Bipyridinium, 1,1'-bis(1-methylethyl)- 3.8.20  
 4,4'-Bipyridinium, 1,1'-bis(4-nitrophenyl)- 3.8.30  
 4,4'-Bipyridinium, 1,1'-bis(2-oxopropyl)- 3.8.16  
 4,4'-Bipyridinium, 1,1'-bis(2-oxopropyl)-2,2'-dimethyl- 3.9.13  
 4,4'-Bipyridinium, 1,1'-bis(2-propynyl)- 3.8.13  
 4,4'-Bipyridinium, 1,1'-bis(2-pyridylmethyl)- 3.8.32  
 2,2'-Bipyridinium, 1,1'-bis(3-sulfonatopropyl)-, dihydroxide bis(inner salt) 3.1.3  
 4,4'-Bipyridinium, 1,1'-bis(2-sulfonatoethyl)- 3.8.6  
 4,4'-Bipyridinium, 1,1'-bis(3-sulfonatopropyl)-2,2'-dimethyl- 3.9.16  
 4,4'-Bipyridinium, 1,1'-bis(3-sulfonatopropyl)-2,2',6,6'-tetramethyl- 3.9.17  
 4,4'-Bipyridinium, 1,1'-bis(3-sulfonatopropyl)-3,3'-dimethyl- 3.9.15  
 4,4'-Bipyridinium, 1,1'-bis(4-sulfonatopropyl)-, dihydroxide bis(inner salt) 3.8.18  
 4,4'-Bipyridinium, 1,1'-bis[2-(trimethylammonio)ethyl]- 3.8.29  
 4,4'-Bipyridinium, 1,1'-bis[3-(trimethylammonio)propyl]- 3.8.37  
 4,4'-Bipyridinium, 1,1'-bis[4-(trimethylammonio)butyl]- 3.8.41  
 4,4'-Bipyridinium, 1,4-butanediylbis(1'-methyl)- 3.8.50  
 4,4'-Bipyridinium, 1-(3-butenyl)-1'-(3-cyanopropyl)- 3.11.8  
 4,4'-Bipyridinium, 1-(2-butenyl)-1'-(3-fluoropropyl)- 3.11.9  
 4,4'-Bipyridinium, 1-(carbamylmethyl)-1'-(2-methyl-2-propenyl)- 3.11.10  
 4,4'-Bipyridinium, 1-(3-chloro-2-butenyl)-1'-(2-methoxyethyl)- 3.11.12  
 4,4'-Bipyridinium, 1,1'-diallyl- 3.8.15  
 4,4'-Bipyridinium, 1,1'-dibenzyl- 3.8.39  
 4,4'-Bipyridinium, 2,2'-dicyano-1,1'-dimethyl- 3.9.4  
 4,4'-Bipyridinium, 1,1'-diethyl- 3.8.10  
 4,4'-Bipyridinium, 1,1'-diethyl-2-methyl- 3.9.2  
 4,4'-Bipyridinium, 1,1'-diheptyl- 3.8.40  
 4,4'-Bipyridinium, 1,1'-dihexyl- 3.8.35  
 4,4'-Bipyridinium, 1,1'-dimethoxy- 3.8.3  
 2,2'-Bipyridinium, 1,1'-dimethyl- 3.1.2  
 2,2'-Bipyridinium, 4,4'-dimethyl- 3.1.4  
 2,4'-Bipyridinium, 1,1'-dimethyl- 3.7.1  
 4,4'-Bipyridinium, 1,1'-dimethyl- 3.8.2  
 4,4'-Bipyridinium, 1,1'-dimethyl-2,2'-bis(4-methylphenyl)- 3.9.9  
 4,4'-Bipyridinium, 1,1'-dimethyl-2,2'-diphenyl- 3.9.8  
 2,2'-Bipyridinium, 1,1'-[(1,1-dimethylethylene)- 3.3.15  
 2,2'-Bipyridinium, 4,4'-dimethyl-1,1'-tetramethylene- 3.5.2  
 2,2'-Bipyridinium, 4,4'-dimethyl-1,1'-trimethylene- 3.4.4

- 4,4'-Bipyridinium, 1,1'-dioctadecyl- 3.8.45  
 4,4'-Bipyridinium, 1,1'-dioctyl- 3.8.44  
 4,4'-Bipyridinium, 1,1'-diphenyl- 3.8.31  
 4,4'-Bipyridinium, 1,1'-dipropyl- 3.8.19  
 4,4'-Bipyridinium, 1,2-ethanediylbis(1'-methyl)- 3.8.48  
 2,2'-Bipyridinium, 1,1'-ethylene- 3.3.1  
 2,2'-Bipyridinium, 1,1'-ethylene-4,4'-dimethyl- 3.3.12  
 4,4'-Bipyridinium, 1-ethyl-1'-(2-ethylthioethyl)- 3.11.1  
 4,4'-Bipyridinium, 1-(2-ethyl-2-propenyl)-1'-(2-methoxyethyl)- 3.11.11  
 4,4'-Bipyridinium, 1,1',2,2',6,6'-hexamethyl 3.9.7  
 2,2'-Bipyridinium, 1,1'-hydroxyethylene- 3.3.3  
 4,4'-Bipyridinium, 1-(2-hydroxyethyl)-1'-pentyl- 3.11.3  
 4,4'-Bipyridinium, 1-(2-methoxycarbonylethyl)-1'-propyl- 3.11.2  
 4,4'-Bipyridinium, 1-methyl-1'-allyl- 3.10.5  
 4,4'-Bipyridinium, 1-methyl-1'-[anilino(thiocarbonylmethyl)]- 3.10.14  
 4,4'-Bipyridinium, 1-methyl-1'-[2-bis(methylthio)ethenyl]- 3.10.8  
 4,4'-Bipyridinium, 1-methyl-1'-carbamylnmethyl- 3.10.3  
 4,4'-Bipyridinium, 1'methyl-1'-[cyano(ethoxycarbonyl)methyl]- 3.10.10  
 4,4'-Bipyridinium, 1-methyl-1'-cyanomethyl- 3.10.2  
 4,4'-Bipyridinium, 1-methyl-1'-(3-cyano-2-propenyl)- 3.10.7  
 4,4'-Bipyridinium, 1-methyl-1'-[2-(3,5-dimethyl-4-morpholinyl)-2-oxoethyl]- 3.10.15  
 4,4'-Bipyridinium, 2-methyl-1',1'-dipropyl- 3.9.3  
 4,4'-Bipyridinium, 1-methyl-1'-ethoxycarbonylmethyl- 3.10.9  
 4,4'-Bipyridinium, 1-methyl-1'-(2-hydroxyethyl)- 3.10.4  
 4,4'-Bipyridinium, 1-methyl-1'-[3-(methoxycarbonyl)-2-propenyl]- 3.10.11  
 4,4'-Bipyridinium, 1-methyl-1'-oxide 3.10.1  
 4,4'-Bipyridinium, 1-methyl-1'-(2-oxopropyl)- 3.10.6  
 4,4'-Bipyridinium, 1-methyl-1'-[(1-pyrazoloyl)thiocarbonylmethyl]- 3.10.12  
 2,2'-Bipyridinium, 1,1'-(1-phenylethylene)- 3.3.19  
 4,4'-Bipyridinium, 1,3-propanediylbis(1'-methyl)- 3.8.49  
 2,2'-Bipyridinium, 1,1'-(1,2-propylene) 3.3.6  
 4,4'-Bipyridinium, 1,1',2,2'-tetramethyl- 3.9.5  
 4,4'-Bipyridinium, 1,1',3,3'-tetramethyl- 3.9.6  
 2,2'-Bipyridinium, 1,1'-tetramethylene- 3.5.1  
 4,4'-Bipyridinium, 1,1',2-trimethyl- 3.9.1  
 2,2'-Bipyridinium, 1,1'-trimethylene- 3.4.1  
 2,2'-Bipyridinium, 1,1'-trimethylene-5-methoxy- 3.4.3  
 4,4'-Bipyridinium, 1,1'-*o*-xylylenebis- 3.8.47  
 2,2'-Bipyridinium 3.1.1  
 2,2'-Biquinolium, 1,1'-dimethyl- 3.6.10  
 1,1'-Bis(2-aminoethyl)-4,4'-bipyridinium 3.8.12  
 1,1'-Bis(carbamylmethyl)-4,4'-bipyridinium 3.8.8  
 1,1'-Bis( $\alpha$ -carboxybenzyl)-4,4'-bipyridinium, diethyl ester 3.8.46  
 1,1'-Bis(2-carboxyethyl)-4,4'-bipyridinium 3.8.17  
 1,1'-Bis(2-carboxyethyl)-4,4'-bipyridinium, diethyl ester 3.8.26  
 1,1'-Bis(carboxymethyl)-4,4'-bipyridinium 3.8.5  
 1,1'-Bis(3-carboxypropyl)-4,4'-bipyridinium, diethyl ester 3.8.28  
 1,1'-Bis(2-chloroethyl)-4,4'-bipyridinium 3.8.7  
 1,1'-Bis(2-chloroethyl)-2,2'-dimethyl-4,4'-bipyridinium 3.9.11  
 1,1'-Bis( $\alpha$ -cyanobenzyl)-4,4'-bipyridinium 3.8.38, 3.8.42  
 1,1'-Bis(cyanomethyl)-4,4'-bipyridinium 3.8.4  
 1,1'-Bis(cyanomethyl)-2,2'-dimethyl-4,4'-bipyridinium 3.9.10  
 1,1'-Bis(3-cyanopropyl)-4,4'-bipyridinium 3.8.22  
 1,1'-Bis(1,2-dichloroethyl)-4,4'-bipyridinium 3.8.14  
 1,1'-Bis(2,2-diethoxyethyl)-4,4'-bipyridinium 3.8.36  
 1,1'-Bis(diethylaminocarbonylmethyl)-4,4'-bipyridinium 3.8.33  
 1,4-Bis(*N,N*-dimethylamino)benzene 6.1.5  
 1,1'-Bis[2-(dimethylaminocarbonyl)ethyl]-4,4'-bipyridinium 3.8.27  
 1,1'-Bis(dimethylaminocarbonylmethyl)-4,4'-bipyridinium 3.8.24  
 1,1'-Bis[3-(dimethylaminocarbonyl)propyl]-4,4'-bipyridinium 3.8.34  
 3,7-Bis(dimethylamino)phenothiazin-5-ium chloride 4.5.2  
 1,1'-Bis[2-(3,5-dimethyl-4-morpholinyl)-2-oxoethyl]-4,4'-bipyridinium 3.8.43  
 1,1'-Bis[2-(ethoxycarbonyl)ethyl]-4,4'-bipyridinium 3.8.26  
 1,1'-Bis(ethoxycarbonylmethyl)-4,4'-bipyridinium 3.8.23  
 1,1'-Bis(ethoxycarbonylmethyl)-2,2'-dimethyl-4,4'-bipyridinium 3.9.14  
 1,1'-Bis[ethoxycarbonyl(phenyl)methyl]-4,4'-bipyridinium 3.8.46  
 1,1'-Bis[3-(ethoxycarbonyl)propyl]-4,4'-bipyridinium 3.8.28  
 1,1'-Bis(2-ethoxyethyl)-4,4'-bipyridinium 3.8.25  
 1,1'-Bis(ethylthiomethyl)-4,4'-bipyridinium 3.8.27  
 1-[Bis(2-hydroxyethyl)]aminocarbonylmethyl-2-nitroimidazole 2.3.39  
 1,4-Bis[(2-hydroxyethylamino)ethyl]amino-9,10-anthraquinone diacetate 1.3.5  
 1-[3-Bis(2-hydroxyethylamino)-2-hydroxypropyl]-2-nitroimidazole 2.3.66  
 1,1'-Bis(2-hydroxyethyl)-4,4'-bipyridinium 3.8.11

- 1,1'-Bis(2-hydroxyethyl)-2,2'-dimethyl-4,4'-bipyridinium 3.9.12
- 1,1'-Bis(2-hydroxyiminoethyl)-4,4'-bipyridinium 3.8.9
- 1-[2,2-Bis(isopropyl)aminoethyl]-2-nitroimidazole 2.3.62
- 5-[Bis(methylcarbonyloxy)methyl]-1-methyl-2-nitroimidazole 2.3.16
- 1,1'-Bis(1-methylethyl)-4,4'-bipyridinium 3.8.20
- 1-[2-Bis(methylthio)ethenyl]-1'-methyl-4,4'-bipyridinium 3.10.8
- 1,1'-Bis(4-nitrophenyl)-4,4'-bipyridinium 3.8.30
- 1,1'-Bis(2-oxopropyl)-4,4'-bipyridinium 3.8.16
- 1,1'-Bis(2-oxopropyl)-2,2'-dimethyl-4,4'-bipyridinium 3.9.13
- 1,1'-Bis(2-propynyl)-4,4'-bipyridinium 3.8.13
- 1,1'-Bis(2-pyridylmethyl)-4,4'-bipyridinium 3.8.32
- 1,1'-Bis(2-sulfonatoethyl)-4,4'-bipyridinium 3.8.6
- 1,1'-Bis(3-sulfonato-1-propyl)-2,2'-bipyridinium 3.1.3
- 1,1'-Bis(3-sulfonatopropyl)-4,4'-bipyridinium 3.8.18
- 1,1'-Bis(3-sulfonatopropyl)-2,2'-dimethyl-4,4'-bipyridinium 3.9.16
- 1,1'-Bis(3-sulfonatopropyl)-3,3'-dimethyl-4,4'-bipyridinium 3.9.15
- 1,1'-Bis(3-sulfonatopropyl)-2,2',6,6'-tetramethyl-4,4'-bipyridinium 3.9.17
- 1,1'-Bis[4-(trimethylammonio)butyl]-4,4'-bipyridinium 3.8.41
- 1,1'-Bis[2-(trimethylammonio)ethyl]-4,4'-bipyridinium 3.8.29
- 1,1'-Bis[3-(trimethylammonio)propyl]-4,4'-bipyridinium 3.8.37
- Bisulfide ion 9.53., 9.54.
- Bromate ion 9.8.
- Bromide ion 9.2., 9.4., 9.5., 9.9.
- Bromine 9.10.
- Bromine atom 9.2., 9.3.
- Bromine dioxide 9.6., 9.7., 9.8.
- Bromite ion 9.6.
- 4-Bromo-6,7-dihydrodipyrido[1,2-*a*:2',1'-*c*]pyrazinediium 3.3.2
- 6-Bromo-1,1'-ethylene-2,2'-bipyridinium 3.3.2
- 1-(2-Bromoethyl)-3-nitro-7-azaindole 2.6.2
- 6-(Bromomethyl)-1,4-naphthoquinone 1.2.11
- 2-Bromo-1-methyl-4-nitroimidazole 2.4.32
- 4-Bromo-1-methyl-5-nitroimidazole 2.5.1
- 5-Bromo-1-methyl-4-nitroimidazole 2.4.4
- 3-Bromophenothiazine 7.2.1
- Bromosyl hydride 9.5.
- Bromous acid 9.7.
- 2,3-Butanediol, 1,4-dimercapto- 8.3.4.4
- 1,4-Butanediylbis(1'-methyl-4,4'-bipyridinium) 3.8.50
- 1-(3-Butenyl)-1'-(3-cyanopropyl)-4,4'-bipyridinium 3.11.8
- 1-(2-Butenyl)-1'-(3-fluoropropyl)-4,4'-bipyridinium 3.11.9
- 1-[3-(*tert*-Butylamino)-2-hydroxypropyl]-2-nitroimidazole 2.3.67
- 1,1'-Butylene-2,2'-bipyridinium 3.5.1
- N*-Butyl-5-nitro-2-furamide 2.2.11
- CB 10-020 2.1.21
- CB 10-092 2.1.25
- CB 10-107 2.1.22
- CB 10-212 2.1.23
- CB 10-236 2.1.27
- CB 10-441 2.1.24
- CB 1954 2.1.20
- CB 7080 2.1.26
- C.I. 52015 4.5.2
- CI941 1.5.11
- Caffeic acid 5.2.7
- Carbamothioic acid, [2-(2-methyl-5-nitroimidazol-1-yl)ethyl]-, *O*-methyl ester 2.5.19
- 1-Carbamylmethyl-1'-methyl-4,4'-bipyridinium 3.10.3
- 1-(Carbamylmethyl)-1'-(2-methyl-2-propenyl)-4,4'-bipyridinium 3.11.10
- 10-Carbethoxyphenothiazine, 5,5'-dioxide 7.7.3
- 10-Carbethoxyphenothiazine sulfone 7.7.3
- 1-Carboethoxymethyl-5-iodo-4-nitroimidazole 2.4.37
- Carbon dioxide 9.13.
- Carbon dioxide radical anion 9.13., 9.14.
- 1-(2-Carboxyethyl)-1'-propyl-4,4'-bipyridinium, methyl ester 3.11.2
- Carboxyl radical anion 9.13., 9.14.
- 1-(2-Carboxymethyl)-2-nitroimidazole 2.3.20
- 5-Carboxymethylthio-1-methyl-4-nitroimidazole 2.4.10
- 2-[[4-Carboxyphenoxy]ethyl]thio-1-methyl-5-nitroimidazole 2.5.13
- Catechin 8.1.7
- Catechol 5.2.1
- Chlorate ion 9.21.
- Chloride ion 9.15., 9.17., 9.18., 9.22., 9.26.
- Chlorine 9.23.
- Chlorine atom 9.15., 9.16.
- Chlorine dioxide 9.19., 9.20., 9.21.
- Chlorite ion 9.19.
- 1-(3-Chloro-2-butenyl)-1'-(2-methoxyethyl)-4,4'-bipyridinium 3.11.12
- 2-Chloro-10-dimethylaminopropylphenothiazine 7.5.1
- 2-Chloro-*N,N*-dimethyl-10*H*-phenothiazine-10-propanamine 7.5.1
- 2-[[[(2-Chloroethyl)amino]carbonyl]oxy]methyl-1,4-naphthoquinone 1.2.10
- 2-Chloro-10-[3-(4-(2-hydroxyethyl)-1-piperazinyl)propyl]phenothiazine 7.5.10
- 1-(3-Chloro-2-hydroxypropyl)-2-nitroimidazole 2.3.26

- 2-Chloro-7-methoxyphenothiazine 7.3.1  
 4-Chloro-7-methoxyphenothiazine 7.3.2  
 1-[3-[(1-Chloromethyl-2-isopropoxy)ethoxy]-2-hydroxypropyl]-2-nitroimidazole 2.3.44  
 $\alpha$ -(Chloromethyl)-2-methyl-5-nitroimidazole-1-ethanol 2.5.16  
 6-(Chloromethyl)-1,4-naphthoquinone 1.2.12  
 5-Chloro-1-methyl-4-nitroimidazole 2.4.5  
 2-Chloro-10-[3-(4-methyl-1-piperazinyl)propyl]phenothiazine 7.5.7  
 1-Chlorophenanthroline[4,5-*a*:6,7-*c*]diazepinediium 3.6.5  
 3-Chlorophenothiazine 7.2.2  
 Chlorosyl hydride 9.18.  
 Chlorous acid 9.20.  
 Chlorpromazine 7.5.1  
 6-Chromanol, 2-carboxy-2,5,7,8-tetramethyl- 8.1.6  
 (*E*)-Cinnamic acid, 3,4-dihydroxy- 5.2.7  
 Cleland's Reagent, 8.3.4.2  
*p*-Cresol 5.1.4  
 Cyanate radical anion 9.12.  
 Cyanide ion 9.11.  
 Cyanide radical 9.11.  
 3-Cyano-6,7-dihydrodipyrido[1,2-*a*:2',1'-*c*]pyrazinediium 3.3.4  
 1-[Cyano(ethoxycarbonyl)methyl]-1'-methyl-4,4'-bipyridinium 3.10.10  
 5-Cyano-1,1'-ethylene-2,2'-bipyridinium 3.3.4  
 4-Cyano-1-ethylpyridinium 4.4.5  
 1-Cyanomethyl-1'-methyl-4,4'-bipyridinium 3.10.2  
 5-Cyano-1-methyl-2-nitroimidazole 2.3.3  
 1-(3-Cyano-2-propenyl)-1'-methyl-4,4'-bipyridinium 3.10.7  
 Cysteine 8.3.1.1, 8.3.3.1  
 Cystine 4.2.1  
 Cytosine 6.3.6  
 DL-DOPA 5.2.9  
 DTE 8.3.4.4  
 Daunomycin 1.5.5  
 Daunorubicin 1.5.5  
 1,1'-Diallyl-4,4'-bipyridinium 3.8.15  
 1,2-Diaminobenzene 6.1.3  
 1,4-Diaminobenzene 6.1.4  
 3,7-Diamino-5-phenothiazinium chloride 4.5.1  
 4,5-Diazaphenanthrene 3.12.1, 4.4.9  
 5*H*-[1,4]-Diazepino[1,2,3,4-*lmn*][1,10]phenanthroline-diium, 6,7-dihydro- 3.6.4  
 [1,4]Diazepino[1,2,3,4-*lmn*][1,10]phenanthroline-diium, 6,7-dihydro-1,11-dimethyl- 3.6.7  
 [1,4]Diazepino[1,2,3,4-*lmn*][1,10]phenanthroline-diium, 1-chloro-6,7-dihydro- 3.6.5  
 [1,4]Diazepino[1,2,3,4-*lmn*][1,10]phenanthroline-diium, 6,7-dihydro-1-methyl- 3.6.6  
 [1,4]Diazepino[1,2,3,4-*lmn*][1,10]phenanthroline-diium, 6,7-dihydro-1-phenyl- 3.6.8  
 2,5-Diaziridinyl-3,6-bis(carbethoxyamino)-1,4-benzoquinone 1.1.9  
 2,5-Diaziridinyl-3,6-bis(2-hydroxyethylamino)-1,4-benzoquinone 1.1.8  
 [1,4]Diazocino[1,2,3,4-*lmn*][1,10]phenanthroline-diium, 5,6,7,8-tetrahydro- 3.6.9  
 13*H*-Dibenzo[*a*,*j*]phenothiazine 7.6.3  
 7*H*-Dibenzo[*c*,*h*]phenothiazine 7.6.4  
 1,1'-Dibenzyl-4,4'-bipyridinium 3.8.39  
 Dibromine radical ion 9.9., 9.10.  
 Dichlorine radical ion 9.22., 9.23.  
 2,2'-Dicyano-1,1'-dimethyl-4,4'-bipyridinium 3.9.4  
 Dicyanodisulfide radical ion 9.56., 9.57.  
 5-(2,2-Dicyanoethenyl)-1-methyl-2-nitroimidazole 2.3.15  
 Diethazine 7.4.10  
 10-[6-(Diethylamino)hexyl]phenothiazine 7.4.16  
 1-(3-Diethylamino-2-hydroxypropyl)-2-nitroimidazole 2.3.65  
 9-(Diethylamino-2-hydroxypropyl)amino-2,3-dimethoxy-6-nitroacridine 2.7.1  
 10-[3-(Diethylamino)propyl]phenothiazine 7.4.15  
 1,1'-Diethyl-4,4'-bipyridinium 3.8.10  
 1,1'-Diethyl-2-methyl-4,4'-bipyridinium 3.9.2  
 5,6-Di(2-furyl)-[1,2,5]thiadiazolo[3,4-*b*]pyrazine 4.8.3  
 1,1'-Diheptyl-4,4'-bipyridinium 3.8.40  
 1,1'-Dihexyl-4,4'-bipyridinium 3.8.35  
 7,8-Dihydro-2,12-dimethyldipyrido[1,2-*a*:2',1'-*c*][1,4]diazepinediium 3.4.4  
 7,8-Dihydro-3,11-dimethyldipyrido[1,2-*a*:2',1'-*c*]diazepinediium 3.4.5  
 6,7-Dihydro-1,12-dimethyldipyrido[1,2-*a*:2',1'-*c*]pyrazinediium 3.3.11  
 6,7-Dihydro-2,11-dimethyldipyrido[1,2-*a*:2',1'-*c*]pyrazinediium 3.3.12  
 6,7-Dihydro-3,10-dimethyldipyrido[1,2-*a*:2',1'-*c*]pyrazinediium 3.3.13  
 6,7-Dihydro-4,9-dimethyldipyrido[1,2-*a*:2',1'-*c*]pyrazinediium 3.3.14  
 6,7-Dihydro-6,6-dimethyldipyrido[1,2-*a*:2',1'-*c*]pyrazinediium 3.3.15  
 3,7-Dihydro-1,3-dimethyl-8-nitropurine-2,6-dione 2.8.2  
 4,5-Dihydro-4,5-dioxopyrrolo[2,3-*f*]quinoline-2,7,9-tricarboxylic acid 1.5.10  
 7,8-Dihydrodipyrido[1,2-*a*:2',1'-*c*][1,4]diazepinediium 3.4.1  
 6,7-Dihydrodipyrido[1,2-*a*:2',1'-*c*]pyrazinediium 3.3.1  
 6,7-Dihydro-6-hydroxydipyrido[1,2-*a*:2',1'-*c*]pyrazinediium 3.3.3

- 7,8-Dihydro-3-methoxydipyrido[1,2-*a*:2',1'-*c*]diazepinediium 3.4.3
- 6,7-Dihydro-3-methoxydipyrido[1,2-*a*:2',1'-*c*]pyrazinediium 3.3.7
- 7,8-Dihydro-4-methyldipyrido[1,2-*a*:2',1'-*c*]diazepinediium 3.4.2
- 6,7-Dihydro-4-methyldipyrido[1,2-*a*:2',1'-*c*]pyrazinediium 3.3.5
- 6,7-Dihydro-6-methyldipyrido[1,2-*a*:2',1'-*c*]pyrazinediium 3.3.6
- Dihydronicotinamide adenine dinucleotide 8.2.1
- 7,8-Dihydro-6*H*[1,2,5]oxathiazolo[4,3-*b*][2,1,3]benzoxathiazole-3-*S*<sup>IV</sup> 4.7.4
- 6,7-Dihydro-6-phenyldipyrido[1,2-*a*:2',1'-*c*]pyrazinediium 3.3.19
- 6,7-Dihydro-3-propoxydipyrido[1,2-*a*:2',1'-*c*]pyrazinediium 3.3.16
- 3,7-Dihydropurine-2,6-dione 6.4.6
- 6,7-Dihydro-2-pyridyldipyrido[1,2-*a*:2',1'-*c*]pyrazinediium 3.3.18
- 6,7-Dihydro-2,3,10,11-tetramethyldipyrido[1,2-*a*:2',1'-*c*]pyrazinediium 3.3.17
- 7,8-Dihydro-2,3,11,12-tetramethyldipyrido[1,2-*a*:2',1'-*c*][1,4]diazepinediium 3.4.6
- 2,5-Dihydroxyacetophenone 5.4.5
- 1,4-Dihydroxy-9,10-anthraquinone-2-sulfonate ion 1.3.2
- 1,4-Dihydroxy-9,10-anthraquinone-6-sulfonate ion 1.3.3
- 1,2-Dihydroxybenzene 5.2.1
- 1,3-Dihydroxybenzene 5.3.1
- 1,4-Dihydroxybenzene 5.4.1
- 1,4-Dihydroxybenzene-2,5-disulfonate ion 5.4.2
- 2,3-Dihydroxybenzoic acid 5.2.2
- 2,5-Dihydroxybenzoic acid 5.3.2
- 3,4-Dihydroxybenzoic acid 5.2.3
- 3,5-Dihydroxybenzoic acid 5.3.3
- 1,4-Dihydroxy-5,8-bis[(2-hydroxyethylamino)ethyl]amino-9,10-anthraquinone 1.3.4
- 2,3-Dihydroxy-1,4-butanedithiol (*R*<sup>\*</sup>,*R*<sup>\*</sup>)(±) 8.3.4.2
- (*E*)-3,4-Dihydroxycinnamic acid 5.2.7
- 1,4-Dihydroxy-2,3-dimethylbenzene 5.4.7
- 1,4-Dihydroxy-2,5-dimethylbenzene 5.4.8
- 2,3-Dihydroxy-1,4-dithiol (*R*<sup>\*</sup>,*S*<sup>\*</sup>) 8.3.4.4
- 5-(1,2-Dihydroxyethyl)-1-methyl-2-nitroimidazole 2.3.11
- 3,4-Dihydroxy- $\alpha$ -(methylamino)acetophenone 5.2.8
- 1,4-Dihydroxy(methyl)benzene 5.4.3
- 5-(Dihydroxymethyl)-1-methyl-2-nitroimidazole diacetate 2.3.16
- 1,4-Dihydroxy-2-methylnaphthalene 8.1.3
- 2,4-Dihydroxy-5-methylpyrimidine 6.3.3
- 5,8-Dihydroxy-1,4-naphthoquinone 1.2.4
- 3,4-Dihydroxyphenethylamine 5.2.5
- 2,5-Dihydroxyphenylacetic acid 5.4.6
- 3,4-Dihydroxyphenylacetic acid 5.2.4
- 3-(3,4-Dihydroxyphenyl)-DL-alanine 5.2.9
- (*E*)-2-(3,4-Dihydroxyphenyl)-3,4-dihydro-1-benzopyran-3,5,7-triol 8.1.7
- (*Z*)-2-(3,4-Dihydroxyphenyl)-3,4-dihydro-1-benzopyran-3,5,7-triol 8.1.8
- 1-(2,3-Dihydroxypropyl)aminocarbonylmethyl-2-nitroimidazole 2.3.37
- 1-(2,3-Dihydroxypropyl)-5-iodo-4-nitroimidazole 2.4.36
- 1-(2,3-Dihydroxypropyl)-3-nitro-7-azaindole 2.6.3
- 1-(2,3-Dihydroxypropyl)-2-nitroimidazole 2.3.29
- 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-1-benzopyran-4-one 8.1.9
- Diiodine radical ion 9.29, 9.30.
- erythro*-1,4-Dimercapto-2,3-butanediol 8.3.4.4
- threo*-1,4-Dimercapto-2,3-butanediol 8.3.4.2
- 1,1'-Dimethoxy-4,4'-bipyridinium 3.8.3
- 3,7-Dimethoxyphenothiazine 7.3.4
- 7,8-Dimethylalloxazine 4.6.6
- 5-(Dimethylamino)-2,4-dinitrobenzamide 2.1.25
- 1-(3-Dimethylamino-2-hydroxypropyl)-2-nitroimidazole 2.3.64
- 5-(Dimethylaminoiminomethyl)-1-methyl-2-nitroimidazole 2.3.14
- 5-[(Dimethylaminomethyl)aminosulfonyl]-1-methyl-4-nitroimidazole 2.4.13
- 3-Dimethylamino-1-(4-nitrophenyl)-1-propanone 2.1.19
- 4-(*N,N*-Dimethylamino)phenol 5.1.8
- 9-[3-(*N,N*-Dimethylamino)propyl]amino-4-chloro-1-nitroacridine 2.7.3
- 9-[3-(*N,N*-Dimethylamino)propyl]amino-4-dimethylamino-1-nitroacridine 2.7.8
- 9-[3-(*N,N*-Dimethylamino)propyl]amino-[4-[di(2-acetoxyethyl)amino]-1-nitroacridine 2.7.9
- 9-[3-(*N,N*-Dimethylamino)propyl]amino-4-fluoro-1-nitroacridine 2.7.4
- 9-[3-(*N,N*-Dimethylamino)propyl]amino-4-methoxy-1-nitroacridine 2.7.6
- 9-[3-(*N,N*-Dimethylamino)propyl]amino-4-methoxycarbonyl-1-nitroacridine 2.7.7
- 9-[3-(*N,N*-Dimethylamino)propyl]amino-4-methyl-1-nitroacridine 2.7.5
- 10-(3-Dimethylaminopropyl)phenothiazine 7.4.5
- 10-(3-Dimethylaminopropyl)-2-trifluoromethylphenothiazine 7.5.2
- 2-Dimethylaminosulfonamido-10-[3-(4-methyl-1-piperazinyl)propyl]phenothiazine 7.5.9
- 5-(Dimethylaminosulfonyl)-1-methyl-4-nitroimidazole 2.4.11
- N,N*-Dimethylaniline 6.1.2

- 2,3-Dimethyl-1,4-benzoquinone 1.1.3  
 2,5-Dimethyl-1,4-benzoquinone 1.1.4  
 2,6-Dimethyl-1,4-benzoquinone 1.1.5  
 4,4'-Dimethyl-2,2'-bipyridine, conjugate diacid 3.1.4  
 4,4'-Dimethyl-2,2'-bipyridine 4.4.8  
 1,1'-Dimethyl-2,2'-bipyridinium 3.1.2  
 1,1'-Dimethyl-2,4'-bipyridinium 3.7.1  
 1,1'-Dimethyl-4,4'-bipyridinium 3.8.2  
 4,4'-Dimethyl-2,2'-bipyridinium 3.1.4  
 1,1'-Dimethyl-2,2'-biquinolinium 3.6.10  
 1,1'-Dimethyl-2,2'-bis(4-methylphenyl)-4,4'-bipyridinium 3.9.9  
 4,5-Dimethyl-1,2-dihydro-3-pyrazolone 8.4.3  
 1,1'-Dimethyl-2,2'-diphenyl-4,4'-bipyridinium 3.9.8  
 Dimethyl disulfide 8.3.5.1  
 1,1'-(1,1-Dimethylethylene)-2,2'-bipyridinium 3.3.15  
 4,4'-Dimethyl-1,1'-ethylene-2,2'-bipyridinium 3.3.12  
 5,5'-Dimethyl-1,1'-ethylene-2,2'-bipyridinium 3.3.13  
 2,3-Dimethylindole 6.2.7  
 1,3-Dimethylalumichrome 4.6.9  
 2,3-Dimethyl-1,4-naphthoquinone 1.2.15  
 1,2-Dimethyl-5-nitroimidazole 2.5.10  
 1,10-Dimethyl-1,10-phenanthroline 3.6.2  
 1,9-Dimethyl-1,9-phenanthroline 3.12.2  
 2,7-Dimethyl-2,7-phenanthroline 3.12.4  
 2,8-Dimethyl-2,8-phenanthroline 3.12.3  
*N,N'*-Dimethyl-2,7-phenanthroline 3.12.4  
 3,7-Dimethyl-3,7-phenanthroline 3.12.6  
 3,8-Dimethyl-3,8-phenanthroline 3.12.5  
 4,7-Dimethyl-4,7-phenanthroline 3.12.7  
 1,11-Dimethylphenanthroline[4,5-a:6,7-c]diazepinedium 3.6.7  
 3,7-Dimethylphenothiazine 7.3.3  
*N,N*-Dimethylphenothiazine-10-propanamine 7.4.5  
 1,2-Dimethyl-3-phenylisoindole-4,7-dione 1.4.1  
 2,3-Dimethyl-1-phenyl-3-pyrazolin-5-one 8.4.4  
 5,6-Dimethyl-3-phenyl-1,2-trimethyleneisoindole-4,7-dione 1.4.7  
 3,4-Dimethyl-2-pyrazolin-5-one 8.4.3  
 4,4'-Dimethyl-1,1'-tetramethylene-2,2'-bipyridinium 3.5.2  
 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide 4.3.3  
 4,4'-Dimethyl-1,1'-trimethylene-2,2'-bipyridinium 3.4.4  
 5,5'-Dimethyl-1,1'-trimethylene-2,2'-bipyridinium 3.4.5  
 1,2-Dinitrobenzene 2.1.1  
 1,3-Dinitrobenzene 2.1.2  
 1,4-Dinitrobenzene 2.1.3  
*m*-Dinitrobenzene 2.1.2  
*o*-Dinitrobenzene 2.1.7  
*p*-Dinitrobenzene 2.1.3  
 2,4-Dinitrobenzoic acid 2.1.4  
 2,5-Dinitrobenzoic acid 2.1.5  
 3,4-Dinitrobenzoic acid 2.1.6  
 3,5-Dinitrobenzoic acid 2.1.7  
 2,4-Dinitroimidazole 2.3.2  
 2,4-Dinitrophenol 2.1.8  
 1,1'-Dioctadecyl-4,4'-bipyridinium 3.8.45  
 1,1'-Dioctyl-4,4'-bipyridinium 3.8.44  
 5*H*,7*H*-2,3-Dioxa-2a,6-dithia(2a-S<sup>IV</sup>)-1,4-diazacyclopent[c,d -indene 4.7.1  
 5*H*,7*H*-2,3-Dioxa-2a,6-dithia(2a-S<sup>IV</sup>)-1,4-diazacyclopent[c,d -indene 6-oxide 4.7.2  
 5*H*,7*H*-2,3-Dioxa-2a,6-dithia(2a-S<sup>IV</sup>)-1,4-diazacyclopent[c,d -indene 6,6-dioxide 4.7.3  
 Dioxygen anion 9.41., 9.43., 9.44., 9.45., 9.46.  
 Diphenoquinone, 3,3',5,5'-tetrabromo- 1.5.8  
 Diphenoquinone, 3,3',5,5'-tetrachloro- 1.5.9  
 1,1'-Diphenyl-4,4'-bipyridinium 3.8.31  
 1,11-Diphenylphenanthroline[4,5-a:6,7-c]diazepinedium 3.6.8  
 1,1'-Dipropyl-4,4'-bipyridinium 3.8.19  
 5,6-Di(2-pyridinyl)-[1,2,5]thiadiazolo[3,4-*b*]pyrazine 4.8.4  
 5,6-Di(2-pyridinyl)-[1,2,5]thiadiazolo[3,4-*b*]pyrazine *N*-oxide 4.8.5  
 Dipyrido[1,2-*a*:2',1'-*c*][1,4]diazepinedium, 7,8-dihydro-2,12-dimethyl- 3.4.4  
 Dipyrido[1,2-*a*:2',1'-*c*][1,4]diazepinedium, 7,8-dihydro-3.4.1  
 Dipyrido[1,2-*a*:2',1'-*c*][1,4]diazepinedium, 7,8-dihydro-2,3,11,12-tetramethyl- 3.4.6  
 Dipyrido[1,2-*a*:2',1'-*c*]diazepinedium, 7,8-dihydro-4-methyl- 3.4.2  
 Dipyrido[1,2-*a*:2',1'-*c*]diazepinedium, 7,8-dihydro-3,11-dimethyl- 3.4.5  
 Dipyrido[1,2-*a*:2',1'-*c*]diazepinedium, 7,8-dihydro-3-methoxy- 3.4.3  
 Dipyrido[1,2-*a*:2',1'-*c*][1,4]diazocinedium, 6,7,8,9-tetrahydro-2,13-dimethyl- 3.5.2  
 Dipyrido[1,2-*a*:2',1'-*c*][1,4]diazocinedium, 6,7,8,9-tetrahydro- 3.5.1  
 Dipyrido[1,2-*a*:2',1'-*c*][1,4]diazocinedium, 6,7,8,9-tetrahydro-2,3,12,13-tetramethyl- 3.5.3  
 Dipyrido[1,2-*a*:2',1'-*c*]pyrazinedium, 4-bromo-6,7-dihydro- 3.3.2  
 Dipyrido[1,2-*a*:2',1'-*c*]pyrazinedium, 3-cyano-6,7-dihydro- 3.3.4  
 Dipyrido[1,2-*a*:2',1'-*c*][1,4]pyrazinedium, 6,7-dihydro-3.3.1  
 Dipyrido[1,2-*a*:2',1'-*c*]pyrazinedium, 6,7-dihydro-1,12-dimethyl- 3.3.11  
 Dipyrido[1,2-*a*:2',1'-*c*]pyrazinedium, 6,7-dihydro-2,11-dimethyl- 3.3.12

- Dipyrido[1,2-*a*:2',1'-*c*]pyrazinediium, 6,7-dihydro-4,9-dimethyl- 3.3.14
- Dipyrido[1,2-*a*:2',1'-*c*]pyrazinediium, 6,7-dihydro-2,3,10,11-tetramethyl- 3.3.17
- Dipyrido[1,2-*a*:2',1'-*c*]pyrazinediium, 6,7-dihydro-6-hydroxy- 3.3.3
- Dipyrido[1,2-*a*:2',1'-*c*]pyrazinediium, 6,7-dihydro-6-methyl- 3.3.6
- Dipyrido[1,2-*a*:2',1'-*c*]pyrazinediium, 6,7-dihydro-3,10-dimethyl- 3.3.13
- Dipyrido[1,2-*a*:2',1'-*c*]pyrazinediium, 6,7-dihydro-6,6-dimethyl- 3.3.15
- Dipyrido[1,2-*a*:2',1'-*c*]pyrazinediium, 6,7-dihydro-3-propoxy- 3.3.16
- Dipyrido[1,2-*a*:2',1'-*c*]pyrazinediium, 6,7-dihydro-2-pyridyl- 3.3.16
- Dipyrido[1,2-*a*:2',1'-*c*]pyrazinediium, 6,7-dihydro-6-phenyl- 3.3.19
- Dipyrido[1,2-*a*:2',1'-*c*]pyrazinediium, 4-ethoxy-6,7-dihydro- 3.3.10
- Dipyrido[1,2-*a*:2',1'-*c*]pyrazinediium, 4-ethyl-6,7-dihydro- 3.3.9
- Dipyrido[1,2-*a*:2',1'-*c*]pyrazinediium, 3-methoxycarbonyl-6,7-dihydro- 3.3.8
- Dipyrido[1,2-*a*:2',1'-*c*]pyrazinediium, 6-methyl- 3.2.2
- Dipyrido[1,2-*a*:2',1'-*c*]pyrazinediium, 6-phenyl- 3.2.3
- Dipyrido[1,2-*a*:2',1'-*c*]pyrazinediium 3.2.1
- 2,2'-Dipyridyl 4.4.7
- 4,4'-Dipyridyl 3.8.1
- Diquat 3.3.1
- Di(thiocyanate) radical ion 9.56., 9.57.
- 2,2'-Dithiodiethanol 4.2.2
- Dithioerythritol 8.3.4.4
- 1,2-Dithiolane-3-pentanamide 4.2.3, 8.3.4.3
- 1,2-Dithiolane-3-pentanoic acid 8.3.5.2
- Dithiothreitol 8.3.4.2
- Dopamine 5.2.5
- Doxorubicin 1.5.4
- Durohydroquinone 5.4.10
- Duroquinone 1.1.7
- Ellagic acid 8.1.10
- l*-Epicatechin 8.1.8
- Etanidazole 2.3.32
- 1,2-Ethandiol, 1-(1-methyl-2-nitroimidazol-5-yl)- 2.3.11
- 1,2-Ethanediylobis(1'-methyl-4,4'-bipyridinium) 3.8.48
- 1,2-[Ethanediylysulfonyl]-5-nitroimidazole 2.5.25
- 3,4-[Ethanediylysulfonyl]-5-nitroimidazole 2.4.43
- 1,2-[Ethanediylothio]-5-nitroimidazole 2.5.24
- Ethanone, 1-(3,4-dihydroxyphenyl)-2-(methylamino)- 5.2.8
- 5-Ethenyl-1-methyl-2-nitroimidazole 2.3.8
- Ethopropazine 7.4.14
- 1-Ethoxycarbonyl-2,5-dimethyl-3-phenylisoindole-4,7-dione 1.4.10
- 1-Ethoxycarbonyl-6-methoxy-5-methyl-2,3-trimethyleneisoindole-4,7-dione 1.4.11
- 1-(Ethoxycarbonylmethyl)-4-iodo-5-nitroimidazole 2.5.17
- 1-Ethoxycarbonylmethyl-1'-methyl-4,4'-bipyridinium 3.10.9
- 7-(Ethoxycarbonylmethyl)-3-nitro-7-azaindole 2.6.6
- 1-Ethoxycarbonyl-5-methyl-2,3-trimethyleneisoindole-4,7-dione 1.4.9
- 3-Ethoxy-6,7-dihydrodipyrido[1,2-*a*:2',1'-*c*]pyrazinediium 3.3.10
- 5-Ethoxy-1,1'-ethylene-2,2'-bipyridinium 3.3.10
- 1-(2-Ethoxyethyl)-2-nitroimidazole 2.3.34
- 1-Ethoxyphenothiazine 7.2.9
- 3-Ethoxyphenothiazine 7.2.10
- Ethylamine, 3,4-dihydroxyphenyl- 5.2.5
- 4-Ethyl-6,7-dihydrodipyrido[1,2-*a*:2',1'-*c*]pyrazinediium 3.3.9
- 1-Ethyl-2,3-dihydro-6-nitroimidazo[1,2-*a*]pyridinium 2.8.13
- 1,1'-Ethylene-2,2'-bipyridinium 3.3.1
- 1,1'-Ethylene-3,3'-dimethyl-2,2'-bipyridinium 3.3.11
- 1,1'-Ethylene-4,4'-dimethyl-2,2'-bipyridinium 3.3.12
- 1,1'-Ethylene-6,6'-dimethyl-2,2'-bipyridinium 3.3.14
- 1,10-Ethylene-1,10-phenanthroline 3.6.3
- 6-Ethyl-1,1'-ethylene-2,2'-bipyridinium 3.3.9
- Ethyl 5-ethyl-2-nitroimidazole-1-acetate 2.3.33
- 1-Ethyl-1'-(2-ethylthioethyl)-4,4'-bipyridinium 3.11.1
- Ethyl gallate 5.5.3
- Ethyl 5-iodo-4-nitroimidazole-1-acetate 2.4.37
- 1-(2-Ethyl-2-propenyl)-1'-(2-methoxyethyl)-4,4'-bipyridinium 3.11.11
- 1-(2-Ethylsulfonyl)ethyl-2-methyl-5-nitroimidazole 2.5.21
- 1-[(2-Ethylsulfonyl)ethyl]-2-nitroimidazole 2.3.36
- Flagyl 2.5.15
- Flavine adenine dinucleotide 4.6.3
- Flavine mononucleotide 4.6.2
- Fluoride ion 9.24.
- Fluorine atom 9.24.
- 1-(3-Fluoro-2-hydroxypropyl)-2-nitroimidazole 2.3.27
- 3-Fluorophenothiazine 7.2.3
- Formaldehyde 4.1.1, 4.1.2
- Formate ion 9.14.
- Furadantin 2.2.5
- 2-Furaldehyde, 5-nitro-, semicarbazone 2.2.4
- 2-Furamide, *N*-butyl-5-nitro- 2.2.11
- Furan, 2-methoxymethyl-5-nitro- 2.2.3
- 2-Furanacetamide,  $\alpha$ -[(5-nitro-2-furanyl)methylene]- (*Z*) 2.2.9



- 2-Furanacetamide,  $\alpha$ -[(5-nitro-2-furyl)methylene]-  
(*E*) 2.2.10
- Furaspor 2.2.3
- 2-Furoic acid, 5-nitro- 2.2.1
- (*E*)-2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide 2.2.10
- (*Z*)-2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide 2.2.9
- cis*-2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide 2.2.9
- trans*-2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide 2.2.10
- Gentisic acid 5.3.2
- Glutamine, *N*-[1-[[[carboxymethyl]amino]carbonyl]-2-  
[[1,4-dihydro-2-methyl-1,4-  
dioxo-3-naphthyl]thio]ethyl]- 1.2.16
- 3-(*S*-Glutathionyl)-2-methyl-1,4-naphthoquinone 1.2.16
- Guanine 6.4.3
- Guanosine 6.4.4
- 4,4',5,5',6,6'-Hexahydroxydiphenic acid, 1,6,1',6'-  
dilactone 8.1.10
- 1,1',2,2',6,6'-Hexamethyl-4,4'-bipyridinium 3.9.7
- Homogentisic acid 5.4.6
- Hydrated electron 9.1.
- Hydrazine 9.35.
- Hydrazine radical cation 9.35.
- Hydrodioxy 9.42., 9.47., 9.48.
- Hydrogen 9.1.
- Hydrogen hypiodite 9.27., 9.28.
- Hydrogen peroxide 9.45., 9.46., 9.47., 9.49.
- Hydrogen peroxomonosulfate ion 9.64.
- Hydrogen selenite(IV) ion 9.67.
- Hydrogen sulfite ion 9.59., 9.61.
- Hydroperoxide ion 9.44., 9.48.
- Hydroperoxyl 9.42., 9.47., 9.48.
- Hydroquinone 5.4.1
- Hydroquinone-2,5-disulfonate ion 5.4.2
- Hydroxide ion 9.39., 9.40.
- p*-Hydroxyacetanilide 5.1.7
- 4-Hydroxybenzoic acid 5.1.3
- 7-Hydroxycoumarin 8.1.2
- 2-Hydroxy-10-(3-dimethylaminopropyl)phenothiazine  
7.5.3
- 5-Hydroxydopamine 5.5.2
- 1-Hydroxyethyl 4.1.4
- 1-(2-Hydroxyethyl)aminocarbonylmethyl-2-  
nitroimidazole 2.3.32
- 1-[(2-Hydroxyethyl)aminocarbonylmethyl]-3-nitro-7-  
azaindole 2.6.4
- 1-(2-Hydroxyethyl)-2,4-dinitroimidazole 2.3.22
- 2-Hydroxyethyl disulfide 4.2.2
- 1,1'-Hydroxyethylene-2,2'-bipyridinium 3.3.3
- 1-Hydroxyethyl(1-) ion 4.1.3
- 1-(2-Hydroxyethyl)-1'-methyl-4,4'-bipyridinium 3.10.4
- 1-(2-Hydroxyethyl)-2-methyl-5-nitroimidazole 2.5.15
- 1-(2-Hydroxyethyl)-5-methyl-2-nitroimidazole 2.3.23
- 1-(2-Hydroxyethyl)-2-nitroimidazole 2.3.21
- 1-(2-Hydroxyethyl)-2-nitroimidazole acetate 2.3.31
- 1-(2-Hydroxyethyl)-1'-pentyl-4,4'-bipyridinium 3.11.3
- 10-[3-(4-(2-Hydroxyethyl)-1-  
piperazinyl)propyl]phenothiazine 7.4.18
- Hydroxyhydroquinone 5.5.4
- 7-Hydroxy-2-[2-(2-hydroxyethyl)aminoethyl]-5-[[2-(2-  
hydroxyethyl)aminoethyl]amino]-anthra[1,9-*cd*]pyrazol  
1.5.11
- 5-Hydroxyindole 6.2.2
- Hydroxyl 9.4., 9.17., 9.28., 9.38., 9.39., 9.49.
- 1-(2-Hydroxy-3-methoxypropyl)-5-iodo-4-  
nitroimidazole 2.4.38, 2.5.18
- 1-(2-Hydroxy-3-methoxypropyl)-2-methyl-4-  
nitroimidazole 2.4.39
- 1-(2-Hydroxy-3-methoxypropyl)-2-methyl-5-  
nitroimidazole 2.5.20
- 1-(2-Hydroxy-3-methoxypropyl)-2-nitroimidazole  
2.3.35
- Hydroxymethyl 4.1.2
- Hydroxymethyl, conjugate base 4.1.1
- 1-Hydroxy-1-methylethyl, conjugate base 4.1.5
- 1-Hydroxy-1-methylethyl 4.1.6
- 5-(1-Hydroxy-1-methylethyl)-1-methyl-2-  
nitroimidazole 2.3.13
- 5-Hydroxymethyl-1-methyl-2-nitroimidazole 2.3.7
- 2-Hydroxymethyl-1,4-naphthoquinone 1.2.7
- 5-Hydroxy-1,4-naphthoquinone 1.2.3
- 5-Hydroxy-2-nitrobenzofuran 2.8.7
- 7-Hydroxy-2-nitrobenzofuran 2.8.5
- 6-Hydroxy-5-nitrothymine 2.8.12
- 1-[3-*N*-(3-Hydroxypiperidino)-2-hydroxypropyl]-2-  
nitroimidazole 2.3.75
- 6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic  
acid 8.1.6
- 5-Hydroxytryptophan 6.2.10
- 3-Hydroxytyramine 5.2.5
- Hydroxyurea 4.3.1
- Hypobromous acid 9.3., 9.4.
- Hypochlorous acid 9.16., 9.17.
- Hypiodous acid 9.27., 9.28.
- Hypoxanthine 6.4.5
- Imidazole, 1-[2-(1-aziridinoethyl)amino-2-  
hydroxypropyl]-2-nitro- 2.3.63
- Imidazole, 1-[2,2-bis(isopropyl)aminoethyl]-2-nitro-  
2.3.62
- Imidazole, 2-bromo-1-methyl-4-nitro- 2.4.32
- Imidazole, 4-bromo-1-methyl-5-nitro- 2.5.1
- Imidazole, 5-bromo-1-methyl-4-nitro- 2.4.4
- Imidazole, 2-[(4-carboxyphenoxy)ethyl]thio-1-methyl-5-  
nitro- 2.5.13
- Imidazole, 5-chloro-1-methyl-4-nitro- 2.4.5

- Imidazole, 5-(1,2-dihydroxyethyl)-1-methyl-2-nitro- 2.3.11
- Imidazole, 5-(dihydroxymethyl)-1-methyl-2-nitro-, diacetate 2.3.16
- Imidazole, 1-(2,3-dihydroxypropyl)-2-nitro- 2.3.29
- Imidazole, 1-(2,3-dihydroxypropyl)-5-iodo-4-nitro- 2.4.36
- Imidazole, 1,2-dimethyl-5-nitro- 2.5.10
- Imidazole, 2,4-dinitro- 2.3.2
- Imidazole, 5-ethenyl-1-methyl-2-nitro- 2.3.8
- Imidazole, 1-(2-ethoxyethyl)-2-nitro- 2.3.34
- Imidazole, 1-(2-ethylsulfonyl)ethyl-2-methyl-5-nitro- 2.5.21
- Imidazole, 1-[(2-ethylsulfonyl)ethyl]-2-nitro- 2.3.36
- Imidazole, 1-[3-*N*-(3-hydroxypiperidino)-2-hydroxypropyl]-2-nitro- 2.3.75
- Imidazole, 2-iodo-1-methyl-4-nitro- 2.4.33
- Imidazole, 2-iodo-1-methyl-5-nitro- 2.5.7
- Imidazole, 4-iodo-1-methyl-5-nitro- 2.5.2
- Imidazole, 5-iodo-1-methyl-4-nitro- 2.4.6
- Imidazole, 4-iodo-5-nitro- 2.4.2
- Imidazole, 1-(2-methoxyethyl)-2-nitro- 2.3.28
- Imidazole, 1-[2-(methoxythiocarbonylamino)ethyl]-2-methyl-5-nitro- 2.5.19
- Imidazole, 1-methyl-2,4-dinitro- 2.4.34
- Imidazole, 1-methyl-2,5-dinitro- 2.5.8
- Imidazole, 1-methyl-5-(1-methylethyl)-2-nitro- 2.3.12
- Imidazole, 1-methyl-5-[methyl(oxyamino)methylene]-2-nitro- 2.3.10
- Imidazole, 1-methyl-2-(methylsulfonyl)-4-nitroimidazole 2.4.35
- Imidazole, 1-methyl-2-(methylsulfonyl)-5-nitro- 2.5.12
- Imidazole, 1-methyl-2-(methylsulfonyl)-5-nitro- 2.5.11
- Imidazole, 1-methyl-5-(methylsulfonyl)-4-nitro- 2.4.9
- Imidazole, 1-methyl-4-(*N*-morpholinosulfonyl)-5-nitro- 2.5.3
- Imidazole, 1-methyl-5-(*N*-morpholinoiminomethyl)-2-nitro- 2.3.17
- Imidazole, 1-methyl-5-(*N*-morpholinosulfonyl)-4-nitro- 2.4.14
- Imidazole, 2-methyl-4-nitro- 2.4.3
- Imidazole, 1-methyl-4-nitro-5-(*p*-hydroxyphenoxy)- 2.4.17
- Imidazole, 1-methyl-4-nitro-5-(phenylthio)- 2.4.44
- Imidazole, 1-methyl-4-nitro-5-phenoxy- 2.4.16
- Imidazole, 1-methyl-5-phenylsulfonyl-4-nitro- 2.4.18
- Imidazole, 1-[3-*N*-(4-methylpiperazino)-2-hydroxypropyl]-2-nitro- 2.3.77
- Imidazole, 1-[2-(methylsulfonyl)ethyl]-2-nitro- 2.3.30
- Imidazole, 1-(3-*N*-morphinolopropyl)-2-nitro- 2.3.47
- Imidazole, 1-(4-*N*-morpholinobutyl)-2-nitro- 2.3.48
- Imidazole, 1-(4-*N*-morpholinobutyl)-2-nitro-, methiodide 2.3.49
- Imidazole, 1-(2-*N*-morpholinoethyl)-2-nitro- 2.3.45
- Imidazole, 1-(2-*N*-morpholinoethyl)-2-nitro-, methiodide 2.3.46
- Imidazole, 1-(2-*N*-morpholinoethyl)-4-nitro- 2.4.40
- Imidazole, 1-(5-*N*-morpholinohexyl)-2-nitro- 2.3.51
- Imidazole, 1-(8-*N*-morpholinooctyl)-2-nitro- 2.3.52
- Imidazole, 1-(5-*N*-morpholinopentyl)-2-nitro- 2.3.50
- Imidazole, 1-(11-*N*-morpholinoundecyl)-2-nitro- 2.3.53
- Imidazole, 2-nitro- 2.3.1
- Imidazole, 4-nitro- 2.4.1
- Imidazole, 2-nitro-1-(2-oxopropyl)- 2.3.24
- Imidazole, 2-nitro-1-(2-phenoxyethyl)- 2.3.40
- Imidazole, 2-nitro-1-(3-phenoxypropyl)- 2.3.43
- Imidazole, 2-nitro-1-(2-phenylsulfonyl)ethyl- 2.3.41
- Imidazole, 2-nitro-1-[2-(2-pyridylethyl)]- 2.3.60
- Imidazole, 2-nitro-1-[2-(1-pyrrolidiny)ethyl]- 2.3.54
- Imidazole, 2-nitro-1-[4-(1-pyrrolidiny)butyl]- 2.3.55
- Imidazole, 5-(*N*-piperazinoiminomethyl)-1-methyl-2-nitro- 2.3.18
- Imidazole, 1-(3-*N*-piperidino-2-hydroxypropyl)-2-nitro- 2.3.74
- Imidazole, 5-(*N*-piperidinoiminomethyl)-1-methyl-2-nitro- 2.3.19
- Imidazole, 1-(4-*N*-piperidinylbutyl)-2-nitro- 2.3.58
- Imidazole, 1-(2-piperidinylethyl)-2-nitro- 2.3.56
- Imidazole, 1-(5-*N*-piperidinylhexyl)-2-nitro- 2.3.59
- Imidazole, 1-(3-*N*-piperidinylpropyl)-2-nitro- 2.3.57
- Imidazole, 1-[3-[4-(2,2,5,5-tetramethyl-1-oxypiperidinyl)amino]-2-hydroxypropyl]-2-nitro- 2.3.71
- Imidazole, 1-[3-[4-(2,2,5,5-tetramethylpiperidinyl)amino]-2-hydroxypropyl]-2-nitro- 2.3.72
- Imidazole-1-acetamide, *N*-benzyl-2-nitro- 2.3.42
- Imidazole-1-acetamide, *N,N*-bis(2-hydroxyethyl)-2-nitro- 2.3.39
- Imidazole-1-acetamide, *N*-(2,3-dihydroxypropyl)-2-nitro- 2.3.37
- Imidazole-1-acetamide, *N*-(2-hydroxyethyl)-2-nitro- 2.3.32
- Imidazole-1-acetamide, 4-iodo-*N'*-(3-pyridylmethyl)-5-nitro- 2.5.23
- Imidazole-1-acetic acid, 5-ethyl-2-nitro-, ethyl ester 2.3.33
- Imidazole-1-acetic acid, 4-iodo-5-nitro-, ethyl ester 2.5.17
- Imidazole-1-acetic acid, 5-iodo-4-nitro-, ethyl ester 2.4.37
- Imidazole-1-acetic acid, 2-nitro- 2.3.20
- Imidazole-1-acetic acid, 2-nitro-, methyl ester 2.3.25
- Imidazole-5-carbonitrile, 1-methyl-2-nitro- 2.3.3
- Imidazole-2-carboxaldehyde, 1-methyl-5-nitro- 2.5.9

- Imidazole-5-carboxaldehyde, 1-methyl-2-nitro, dimethylhydrazone 2.3.14
- Imidazole-5-carboxaldehyde, 1-methyl-2-nitro- 2.3.4
- Imidazole-5-carboxamide, 1-methyl-2-nitro- 2.3.6
- Imidazole-5-carboxylate ion, 1-methyl-2-nitro- 2.3.5
- Imidazole-5-carboxylic acid, 1-methyl-2-nitro-, methyl ester 2.3.9
- Imidazole-1-ethanamine, *N,N*-bis(1-methylethyl)-2-nitro- 2.3.62
- Imidazole-1-ethanamine, 2-nitro-*N*-phenyl- 2.3.61
- Imidazole-1-ethanol,  $\alpha$ -[(benzylamino)methyl]-2-nitro- 2.3.68
- Imidazole-1-ethanol,  $\alpha$ -[bis(2-hydroxyethyl)aminomethyl]-2-nitro- 2.3.66
- Imidazole-1-ethanol,  $\alpha$ -(chloromethyl)-2-methyl-5-nitro- 2.5.16
- Imidazole-1-ethanol,  $\alpha$ -(chloromethyl)-2-nitro- 2.3.26
- Imidazole-1-ethanol,  $\alpha$ -(diethylamino)methyl-2-nitro- 2.3.65
- Imidazole-1-ethanol,  $\alpha$ -[(1,1-dimethylethyl)amino]methyl]-2-nitro- 2.3.67
- Imidazole-1-ethanol,  $\alpha$ -[(dimethylamino)methyl]-2-nitro- 2.3.64
- Imidazole-1-ethanol, 2,4-dinitro- 2.3.22
- Imidazole-1-ethanol,  $\alpha$ -(fluoromethyl)-2-nitro- 2.3.27
- Imidazole-1-ethanol, 5-iodo- $\alpha$ -(methoxymethyl)-4-nitro- 2.4.38, 2.5.18
- Imidazole-1-ethanol,  $\alpha$ -[(4-methoxybenzylamino)methyl]-2-nitro- 2.3.70
- Imidazole-1-ethanol,  $\alpha$ -(methoxymethyl)-2-methyl-4-nitro- 2.4.39
- Imidazole-1-ethanol,  $\alpha$ -(methoxymethyl)-2-methyl-5-nitro- 2.5.20
- Imidazole-1-ethanol,  $\alpha$ -(methoxymethyl)-2-nitro- 2.3.35
- Imidazole-1-ethanol,  $\alpha$ -[(4-methoxyphenylamino)methyl]-2-nitro- 2.3.69
- Imidazole-1-ethanol,  $\alpha$ -[[2-(1-methylethyl)oxy-1-(chloromethyl)ethoxy]methyl]- 2.3.44
- Imidazole-1-ethanol, 2-methyl-4-nitro-, dihydrogen phosphate ester 2.5.14
- Imidazole-1-ethanol, 2-methyl-5-nitro- 2.5.15
- Imidazole-1-ethanol, 5-methyl-2-nitro- 2.3.23
- Imidazole-1-ethanol,  $\alpha$ -(4-morpholinomethyl)-2-nitro- 2.3.76
- Imidazole-1-ethanol, 2-nitro, acetate 2.3.31
- Imidazole-1-ethanol, 2-nitro- 2.3.21
- Imidazole-1-ethanol, 2-nitro- $\alpha$ -[(3-propenyloxy)methyl]- 2.3.38
- Imidazole-1-ethanol, 2-nitro- $\alpha$ -(pyrrolidinylmethyl)- 2.3.73
- Imidazole-5-methanol, 1-methyl-2-nitro- 2.3.7
- Imidazole-5-methanol,  $\alpha,\alpha,1$ -trimethyl-2-nitro- 2.3.13
- Imidazole-5-sulfonamide, *N'*-acetyl-1-methyl-4-nitro- 2.4.12
- Imidazole-5-sulfonamide, *N'*-(2-chlorophenyl)-1-methyl-4-nitro- 2.4.23
- Imidazole-4-sulfonamide, 1-methyl-5-nitro- 2.5.4
- Imidazole-5-sulfonamide, 1-methyl-4-nitro 2.4.8
- Imidazole-5-sulfonamide, 1-methyl-4-nitro-*N'*-phenyl- 2.4.22
- Imidazole-5-sulfonamide, 1-methyl-*N'*-(1-naphthyl)-4-nitro- 2.4.31
- Imidazole-5-sulfonamide, 1-methyl-*N'*-(2-methylphenyl)-4-nitro- 2.4.24
- Imidazole-5-sulfonamide, 1-methyl-*N'*-(dimethylamino)methyl-4-nitro- 2.4.13
- Imidazole-5-sulfonamide, 1-methyl-*N*-(4-morpholinomethyl)-4-nitro- 2.4.15
- Imidazole-5-sulfonamide, *N'*-(2-methoxyphenyl)-1-methyl-4-nitro- 2.4.27
- Imidazole-5-sulfonamide, *N',N'*,1-trimethyl-4-nitro- 2.4.11
- Imidazole-4-sulfonic acid, 1-methyl-5-nitro-, phenyl ester 2.5.6
- Imidazole-4-sulfonic acid, 1-methyl-5-nitro-, phenyl ester 2.5.5
- Imidazole-5-sulfonic acid, 1-methyl-4-nitro-, 1-naphthyl ester 2.4.30
- Imidazole-5-sulfonic acid, 1-methyl-4-nitro-, 2-methoxyphenyl ester 2.4.25
- Imidazole-5-sulfonic acid, 1-methyl-4-nitro-, 4-chlorophenyl ester 2.4.20
- Imidazole-5-sulfonic acid, 1-methyl-4-nitro-, 4-methoxyphenyl ester 2.4.26
- Imidazole-5-sulfonic acid, 1-methyl-4-nitro-, 4-nitrophenyl ester 2.4.21
- Imidazole-5-sulfonic acid, 1-methyl-4-nitro-, phenyl ester 2.4.19
- Imidazole-5-thioacetic acid, 1-methyl-4-nitro- 2.4.10
- Imidazole-5-thiol, 1-methyl-4-nitro- 2.4.7
- 2,4-Imidazolidinedione, 1-[(5-nitro-2-furanyl)methylene]amino]- 2.2.5
- Imidazo[5-one], 1-methyl-4-nitro- 2.4.42
- 8 $\alpha$ -*N*-Imidazolylriboflavin 4.6.4
- Imidazo[1,2-*a*]pyridinium, 1-ethyl-2,3-dihydro-6-nitro- 2.8.13
- Imidazo[1,2-*a*]pyridinium, 1-phenyl-2,3-dihydro-6-nitro- 2.8.14
- Imidazo[2,1-*b*]thiazole, 2,3-dihydro-5-nitro-, 2.5.24
- Imidazo[2,1-*b*]thiazole, 2,3-dihydro-5-nitro-, 1,1-dioxide 2.5.25
- Imidazo[5,1-*b*]thiazole, 2,3-dihydro-7-nitro-, 1,1-dioxide 2.4.43
- Indigodisulfonate ion 1.5.6
- Indole 6.2.1
- Indole, 1-methyl- 6.2.3

- Indole, 2-methyl- 6.2.4  
 Indole, 3-methyl- 6.2.5  
 Indole-3-acetic acid 6.2.6  
 5,6-Indolinedione, 3-hydroxy-1-methyl 1.5.1  
 5-Indolol 6.2.2  
 Iodate ion 9.32.  
 Iodide ion 9.25., 9.28., 9.29.  
 Iodine 9.26., 9.30.  
 Iodine atom 9.25., 9.27.  
 Iodine dichloride dianion 9.26.  
 Iodine dioxide 9.31., 9.32.  
 2-Iodo-1-methyl-4-nitroimidazole 2.4.33  
 2-Iodo-1-methyl-5-nitroimidazole 2.5.7  
 4-Iodo-1-methyl-5-nitroimidazole 2.5.2  
 5-Iodo-1-methyl-4-nitroimidazole 2.4.6  
 4-Iodo-5-nitroimidazole 2.4.2  
 5-Iodo-4-nitroimidazole 2.4.2  
 4-Iodo-5-nitro-1-(3-pyridylmethylaminocarbonylmethyl)imidazole 2.5.23  
 3-Iodophenothiazine 7.2.4  
 Iodous acid 9.31.  
 Isobarbituric acid 6.3.5  
 Isocyanate ion 9.12.  
 Isoindole-4,7-dione, 1,2-dimethyl-3-phenyl- 1.4.1  
 Isoindole-4,7-dione, 5,6-dimethyl-3-phenyl-1,2-trimethylene- 1.4.7  
 Isoindole-4,7-dione, 1-ethoxycarbonyl-2,5-dimethyl-3-phenyl- 1.4.10  
 Isoindole-4,7-dione, 1-ethoxycarbonyl-5-methyl-2,3-trimethylene- 1.4.9  
 Isoindole-4,7-dione, 1-ethoxycarbonyl-6-methoxy-5-methyl-2,3-trimethylene- 1.4.11  
 Isoindole-4,7-dione, 2-methyl-3-phenyl- 1.4.5  
 Isoindole-4,7-dione, 1-methyl-2,3-trimethylene- 1.4.6  
 Isoindole-4,7-dione, 5-methyl-1,2-trimethylene- 1.4.2  
 Isoindole-4,7-dione, 1-phenyl-2,3-trimethylene- 1.4.4  
 Isoindole-4,7-dione, 1,2,5,6-tetramethyl-3-phenyl- 1.4.8  
 Isoindole-4,7-dione, 1,2,5-trimethyl-3-phenyl- 1.4.3  
 Isopromethazine 7.4.7  
 5-Isopropyl-1-methyl-2-nitroimidazole 2.3.12  
 Juglone 1.2.3  
 L-10333 2.3.9  
 L-10522 2.3.18  
 L-10926 2.3.16  
 L-11174 2.3.19  
 L-11175 2.3.17  
 L-12134 2.3.13  
 L-6347 2.3.12  
 L-6678 2.3.23  
 L-8580 2.3.8  
 L-8711 2.3.4  
 L-8713 2.3.11  
 L-8938 2.3.7  
 L-8939 2.3.14  
 L-9451 2.3.10  
 Lipoamide 4.2.3, 8.3.4.3  
 Lipoic acid 8.3.5.2  
 Lumichrome 4.6.6  
 Me 108 2.5.19  
 Menadiol 8.1.3  
 Menadione 1.2.6  
 Menaquinone 1.2.6  
 Mepazine 7.4.13  
 Mercapto 9.52., 9.53.  
 Mercaptoacetic acid 8.3.2.2  
 2-Mercaptoethanol 8.3.1.2, 8.3.2.1, 8.3.4.1  
 $\beta$ -Mercaptoethanol (oxidized) 4.2.2  
 5-Mercapto-1-methyl-4-nitroimidazole 2.4.7  
 3-Mercaptopropionic acid 8.3.2.4  
 Methanamine, *N*-[(1-methyl-2-nitroimidazol-5-yl)methylene], *N*-oxide 2.3.10  
 Methanediol, (1-methyl-2-nitroimidazol-5-yl)-, diacetate 2.3.16  
 Methanesulfonamide, *N*-[4-(9-acridinylamino)-3-methoxyphenyl]-, conjugate acid 4.8.1  
 Methoxatine 1.5.10  
 1-[3-(4-Methoxybenzylamino)-2-hydroxypropyl]-2-nitroimidazole 2.3.70  
 3-Methoxycarbonyl-6,7-dihydrodipyrido[1,2-*a*:2',1'-*c*]pyrazinediium 3.3.8  
 5-Methoxycarbonyl-1,1'-ethylene-2,2'-bipyridinium 3.3.8  
 1-(2-Methoxycarbonylethyl)-1'-propyl-4,4'-bipyridinium 3.11.2  
 1-(Methoxycarbonylmethyl)-2-nitroimidazole 2.3.25  
 4-(Methoxycarbonyl)-1-methylpyridinium 4.4.4  
 1-[3-(Methoxycarbonyl)-2-propenyl]-1'-methyl-4,4'-bipyridinium 3.10.11  
 2-Methoxy-10-(3-dimethylaminopropyl)phenothiazine 7.5.4  
 1-(2-Methoxyethyl)-2-nitroimidazole 2.3.28  
 Methoxyhydroquinone 5.4.4  
 $\alpha$ -(Methoxymethyl)-2-methyl-4-nitroimidazole-1-ethanol 2.4.39  
 $\alpha$ -(Methoxymethyl)-2-methyl-5-nitroimidazole-1-ethanol 2.5.20  
 2-(Methoxymethyl)-1,4-naphthoquinone 1.2.8  
 2-Methoxymethyl-5-nitrofuran 2.2.3  
 9-(2-Methoxy-4-methylsulfonylaminoanilino)acridinium 4.8.1  
 5-Methoxy-2-nitrobenzofuran 2.8.8  
 7-Methoxy-2-nitrobenzofuran 2.8.6  
 4-Methoxyphenol 5.1.5  
 1-Methoxyphenothiazine 7.2.7

- 3-Methoxyphenothiazine 7.2.8  
 1-[3-(4-Methoxyphenylamino)-2-hydroxypropyl]-2-nitroimidazole 2.3.69  
 Methoxypromazine 7.5.4  
 1-[2-(Methoxythiocarbonylamino)ethyl]-2-methyl-5-nitroimidazole 2.5.19  
 1-Methyl-1'-(acetyl)-4,4'-bipyridinium 3.10.6  
*N*-Methyl-4-acetylpyridinium 4.4.3  
 1-Methyl-1'-allyl-4,4'-bipyridinium 3.10.5  
 6-[[[(Methylamino)carbonyl]oxy]methyl-1,4-naphthoquinone 1.2.14  
 4-(Methylamino)phenol 5.1.6  
*p*-Methylaminophenol 5.1.6  
 1-Methyl-1'-[anilino(thiocarbonylmethyl)]-4,4'-bipyridinium 3.10.14  
 Methyl-1,4-benzoquinone 1.1.2  
 1-Methyl-1'-benzyl-4,4'-bipyridinium 3.10.13  
 1-Methyl-4,4'-bipyridinium-1'-oxide 3.10.1  
 1-Methyl-1'-[2-bis(methylthio)ethenyl]-4,4'-bipyridinium 3.10.8  
 1-Methyl-1'-carbamylmethyl-4,4'-bipyridinium 3.10.3  
 1-(2-Methylcarbonyloxyethyl)-2-nitroimidazole 2.3.31  
 1-Methyl-5-(4-chlorophenoxy)sulfonyl-4-nitroimidazole 2.4.20  
 1-Methyl-5-(2-chlorophenyl)aminosulfonyl-4-nitroimidazole 2.4.23  
 1-Methyl-1'-[cyano(ethoxycarbonyl)methyl]-4,4'-bipyridinium 3.10.10  
 1-Methyl-1'-cyanomethyl-4,4'-bipyridinium 3.10.2  
 1-Methyl-1'-(3-cyano-2-propenyl)-4,4'-bipyridinium 3.10.7  
 1-Methylcytosine 6.3.7  
*N*<sub>1</sub>-Methylcytosine 6.3.7  
 10-(2-Methyl-2-diethylaminoethyl)phenothiazine 7.4.14  
 10-(1-Methyl-2-dimethylaminoethyl)phenothiazine 7.4.7  
 10-(2-Methyl-2-dimethylaminoethyl)phenothiazine 7.4.6  
 1-Methyl-1'-[2-(3,5-dimethyl-4-morpholinyl)-2-oxoethyl]-4,4'-bipyridinium 3.10.15  
 1-Methyl-2,4-dinitroimidazole 2.4.34  
 1-Methyl-2,5-dinitroimidazole 2.5.8  
 Methylendioxy 8.5.1  
 2-Methyl-1,1'-dipropyl-4,4'-bipyridinium 3.9.3  
 6-Methyldipyrido[1,2-*a*:2',1'-*c*]pyrazinediium 3.2.2  
 Methyl disulfide 8.3.5.1  
 Methylene Blue 4.5.2  
 1-Methyl-1'-ethoxycarbonylmethyl-4,4'-bipyridinium 3.10.9  
 Methylhydroquinone 5.4.3  
 1-Methyl-1'-(2-hydroxyethyl)-4,4'-bipyridinium 3.10.4  
 8 $\alpha$ -(*N*-Methyl-*N*-imidazolium)tetra-*O*-acetylriboflavin 4.6.5  
 1-Methylindole 6.2.3  
 2-Methylindole 6.2.4  
 3-Methylindole 6.2.5  
 1-Methylisonicotinamide 4.4.2  
 1-Methylumichrome 4.6.7  
 3-Methylumichrome 4.6.8  
 1-Methyl-1'-[3-(methoxycarbonyl)-2-propenyl]-4,4'-bipyridinium 3.10.11  
*N*-Methyl-4-(methoxycarbonyl)pyridinium 4.4.4  
 1-Methyl-5-(2-methoxyphenoxy)sulfonyl-4-nitroimidazole 2.4.25  
 1-Methyl-5-(4-methoxyphenoxy)sulfonyl-4-nitroimidazole 2.4.26  
 1-Methyl-2-methoxyphenylaminosulfonyl-4-nitroimidazole 2.4.27  
 1-Methyl-5-(1-methylethyl)-2-nitroimidazole 2.3.12  
 Methyl 1-methyl-2-nitroimidazole-5-carboxylate 2.3.9  
 1-Methyl-5-[methyl(oxyamino)methylene]-2-nitroimidazole 2.3.10  
 1-Methyl-5-(2-methylphenyl)aminosulfonyl-4-nitroimidazole 2.4.24  
 1-Methyl-2-(methylsulfinyl)-5-nitroimidazole 2.5.11  
 1-Methyl-2-(methylsulfonyl)-4-nitroimidazole 2.4.35  
 1-Methyl-2-(methylsulfonyl)-5-nitroimidazole 2.5.12  
 1-Methyl-5-(methylsulfonyl)-4-nitroimidazole 2.4.9  
 1-Methyl-5-(*N*-morpholinoiminomethyl)-2-nitroimidazole 2.3.17  
 1-Methyl-5-[(*N*-morpholinomethylamino)sulfonyl]-4-nitroimidazole 2.4.15  
 1-Methyl-4-(*N*-morphinosulfonyl)-5-nitroimidazole 2.5.3  
 1-Methyl-5-(*N*-morphinosulfonyl)-4-nitroimidazole 2.4.14  
 2-Methyl-1,4-naphthoquinol 8.1.3  
 2-Methyl-1,4-naphthoquinone 1.2.6  
 1-Methyl-5-(1-naphthylamino)sulfonyl-4-nitroimidazole 2.4.31  
 1-Methyl-5-(1-naphthylthio)sulfonyl-4-nitroimidazole 2.4.30  
 1-Methylnicotinamide 4.4.1  
 1-Methyl-3-nitro-7-azaindole 2.6.1  
 1-Methyl-4-nitro-5-(*p*-hydroxyphenoxy)imidazole 2.4.17  
 2-Methyl-4-nitroimidazole 2.4.3  
 2-Methyl-5-nitroimidazole 2.4.3  
 Methyl 2-nitroimidazole-1-acetate 2.3.25  
 1-Methyl-2-nitroimidazole-5-carboxaldehyde 2.3.4  
 1-Methyl-2-nitroimidazole-5-carboxamide 2.3.6  
 1-Methyl-2-nitroimidazole-5-carboxylate ion 2.3.5  
 1-Methyl-5-nitroimidazole-2-carboxaldehyde 2.5.9  
 1-Methyl-4-nitroimidazole-5-sulfonamide 2.4.8  
 1-Methyl-4-nitroimidazol-5-one 2.4.42  
 1-(1-Methyl-2-nitroimidazol-5-yl)-1,2-ethanediol 2.3.11

- [(1-Methyl-2-nitroimidazol-5-yl)methylene]propanedinitrile 2.3.15  
 (1-Methyl-4-nitroimidazol-5-yl)thioacetic acid 2.4.10  
 1-Methyl-4-nitro-5-phenoxyimidazole 2.4.16  
 1-Methyl-5-(4-nitrophenoxy)sulfonyl-4-nitroimidazole 2.4.21  
 1-Methyl-5-nitro-4-phenylsulfonylimidazole 2.5.5  
 1-Methyl-5-nitro-4-phenylsulfonyloxyimidazole 2.5.6  
 1-Methyl-4-nitro-5-(phenylthio)imidazole 2.4.44  
 1-Methyl-2-nitro-5-vinylimidazole 2.3.6  
 1-Methyl-5-oxo-4-nitroimidazole 2.4.42  
 1-Methyl-1'-(2-oxopropyl)-4,4'-bipyridinium 3.10.6  
 Methylperoxyl 8.5.1  
 1-Methylphenanthrolino[4,5-*a*:6,7-*c*]diazepinedium 3.6.6  
 4-Methylphenol 5.1.4  
 10-Methylphenothiazine 7.4.2  
 8-Methylphenothiazine 7.2.6  
*N*-Methylphenothiazine 7.4.2  
 1-Methyl-5-phenoxy sulfonyl-4-nitroimidazole 2.4.19  
 1-Methyl-5-phenylaminosulfonyl-4-nitroimidazole 2.4.22  
 2-Methyl-3-phenylisindole-4,7-dione 1.4.5  
 1-Methyl-5-phenylsulfonyl-4-nitroimidazole 2.4.18  
 2-Methyl-1-(2-phosphatoethyl)-4-nitroimidazole 2.5.14  
 2-Methyl-3-phytyl-1,4-naphthoquinone 1.2.17, 8.1.4  
 1-[3-*N*-(4-Methylpiperazino)-2-hydroxypropyl]-2-nitroimidazole 2.3.77  
 10-[3-(4-Methyl-1-piperaziny)propyl]phenothiazine 7.4.17  
 10-[3-(4-Methyl-1-piperaziny)propyl]-2-trifluoromethylphenothiazine 7.5.8  
 10-(*N*-Methyl-3-piperidinyl)methylphenothiazine 7.4.13  
 3-Methyl-2-pyrazolin-5-one 8.4.1  
 4-Methyl-2-pyrazolin-5-one 8.4.2  
 1-Methyl-1'-[(1-pyrazolyl)thiocarbonylmethyl]-4,4'-bipyridinium 3.10.12  
 1-[2-(Methylsulfonyl)ethyl]-2-nitroimidazole 2.3.30  
 2-Methylthio-10-[2-(*N*-methyl-2-piperidinyl)ethyl]phenothiazine 7.5.6  
 10-(2-Methyl-2-trimethylammonioethyl)phenothiazine 7.4.11  
 6-Methyl-1,1'-trimethylene-2,2'-bipyridinium 3.4.2  
 1-Methyl-2,3-trimethyleneisindole-4,7-dione 1.4.6  
 5-Methyl-1,2-trimethyleneisindole-4,7-dione 1.4.2  
 1-Methyluracil 6.3.2  
 5-Methyluracil 6.3.3  
*N*<sub>1</sub>-Methyluracil 6.3.2  
 Methyl viologen 3.8.2  
 Metronidazole 2.5.15  
 Misonidazole 2.3.35  
 Mitomycin C 1.5.7  
 Mitozantrone 1.3.4  
 Morfamquat 3.8.43  
 1-(3-*N*-Morpholinopropyl)-2-nitroimidazole 2.3.47  
 4-Morpholinamine, *N*-[(1-methyl-2-nitroimidazol-5-yl)methylene]- 2.3.17  
 Morpholine, 4-[1-methyl-4-nitroimidazol-5-yl]sulfonyl- 2.4.14  
 Morpholine, 4-[1-methyl-4-nitroimidazol-5-yl]sulfonamidomethyl- 2.4.15  
 Morpholine, *N*-[1-methyl-5-nitroimidazol-4-yl]sulfonyl- 2.5.3  
 Morpholine, 4-[11-(2-nitroimidazol-1-yl)undecyl]- 2.3.53  
 Morpholine, 4-[2-(2-nitroimidazol-1-yl)ethyl]-, methiodide 2.3.46  
 Morpholine, 4-[2-(2-nitroimidazol-1-yl)ethyl]- 2.3.45  
 Morpholine, 4-[2-(4-nitroimidazol-1-yl)ethyl]- 2.4.40  
 Morpholine, 4-[2-(5-nitroimidazol-1-yl)ethyl]- 2.5.22  
 Morpholine, 4-[3-(2-nitroimidazol-1-yl)propyl]- 2.3.47  
 Morpholine, 4-[4-(2-nitroimidazol-1-yl)butyl]- 2.3.48  
 Morpholine, 4-[4-(2-nitroimidazol-1-yl)butyl]-, methiodide 2.3.49  
 Morpholine, 4-[5-(2-nitroimidazol-1-yl)pentyl]- 2.3.50  
 Morpholine, 4-[6-(2-nitroimidazol-1-yl)hexyl]- 2.3.51  
 Morpholine, 4-[8-(2-nitroimidazol-1-yl)octyl]- 2.3.52  
 4-Morpholineethanol,  $\alpha$ -[(2-nitroimidazol-1-yl)methyl]- 2.3.76  
 1-(4-*N*-Morpholinobutyl)-2-nitroimidazole 2.3.48  
 1-(4-*N*-Morpholinobutyl)-2-nitroimidazole methiodide 2.3.49  
 1-(2-*N*-Morpholinoethyl)-2-nitroimidazole 2.3.45  
 1-(2-*N*-Morpholinoethyl)-2-nitroimidazole methiodide 2.3.46  
 1-(2-*N*-Morpholinoethyl)-4-nitroimidazole 2.4.40  
 1-(2-*N*-Morpholinoethyl)-5-nitroimidazole 2.5.22  
 1-(5-*N*-Morpholinohexyl)-2-nitroimidazole 2.3.51  
 1-[3-(4-Morpholino)-2-hydroxypropyl]-2-nitroimidazole 2.3.76  
 1-(8-*N*-Morpholinoethyl)-2-nitroimidazole 2.3.52  
 1-(5-*N*-Morpholinopentyl)-2-nitroimidazole 2.3.50  
 1-(11-*N*-Morpholinoundecyl)-2-nitroimidazole 2.3.53  
 1-[3-(4-Morpholinyl)propylaminocarbonylmethyl]-3-nitro-7-azaindole 2.6.5  
 1-[3-(4-Morpholinyl)propylaminocarbonylmethyl]-3-nitro-7-azaindole, protonated 2.6.8  
 7-[3-(4-Morpholinyl)propylaminocarbonylmethyl]-3-nitro-7-azaindole 2.6.7  
 Multergan 7.4.11  
 NSC 302653 2.3.49  
 NSC 309929 2.3.51  
 NSC 313391 2.3.48  
 NSC 313392 2.3.58  
 NSC 313393 2.3.53

- NSC 313394 2.3.52  
 NSC 313395 2.3.59  
 NSC 313396 2.3.50  
 NSC 313407 2.5.2  
 NSC 314919 2.3.55  
 NSC 321271 2.4.18  
 NSC 326151 2.4.14  
 NSC 326153 2.5.5  
 NSC 326154 2.4.26  
 NSC 326155 2.4.25  
 NSC 326156 2.4.21  
 NSC 326157 2.4.9  
 NSC 329113 2.4.6  
 NSC 329114 2.5.6  
 NSC 329115 2.5.3  
 NSC 329116 2.4.4  
 NSC 329117 2.5.1  
 NSC 38075 2.4.8  
 NSC 38083 2.4.11  
 NSC 38086 2.4.20  
 NSC 38087 2.4.19  
 NSC 38088 2.4.22  
 NSC 38090 2.4.30  
 NSC 46506 2.4.15  
 NSC 46509 2.4.12  
 NSC 46510 2.4.13  
 NSC 46511 2.4.24  
 NSC 46512 2.4.27  
 NSC 46513 2.4.23  
 NSC 46514 2.4.31  
 5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-hexopyranosyloxy)-tetrahydro-6,8,11-trihydroxy-1-methoxy]- 1.5.5  
 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy- $\alpha$ -L-lyxo-hexopyranosyloxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8]- 1.5.4  
 Naphthalene, 1,4-dihydroxy-2-methyl- 8.1.3  
 Naphthazarin 1.2.4  
 1,4-Naphthoquinone, 2-[(acetyloxy)methyl]- 1.2.9  
 1,4-Naphthoquinone, 6-[(acetyloxy)methyl]- 1.2.13  
 1,4-Naphthoquinone, 6-(bromomethyl)- 1.2.11  
 1,4-Naphthoquinone, 1-[[[(1-chloroethyl)amino]carbonyloxy]methyl]- 1.2.10  
 1,4-Naphthoquinone, 6-(chloromethyl)- 1.2.12  
 1,4-Naphthoquinone, 5,8-dihydroxy- 1.2.4  
 1,4-Naphthoquinone, 2,3-dimethyl- 1.2.15  
 1,4-Naphthoquinone, 1-(S-glutathionyl)-2-methyl- 1.2.16  
 1,4-Naphthoquinone, 2-hydroxymethyl- 1.2.7  
 1,4-Naphthoquinone, 2-(methoxymethyl)- 1.2.8  
 1,4-Naphthoquinone, 2-methyl- 1.2.6  
 1,4-Naphthoquinone, 6-[[[(methylamino)carbonyloxy]methyl]- 1.2.14  
 1,4-Naphthoquinone, 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)- 1.2.17, 8.1.4  
 1,2-Naphthoquinone 1.2.1  
 1,4-Naphthoquinone 1.2.2  
 1,4-Naphthoquinone-2-sulfonate ion 1.2.5  
 Nicotinamide adenine dinucleotide 4.4.6  
 Nicotinamide adenine dinucleotide, reduced 8.2.1  
 Nifuroxime 2.2.2  
 Nifurpipone 2.2.6  
 Nimorazole 2.4.40  
 Nitracrine 2.7.2  
 Nitrate ion 9.37.  
 Nitrite ion 9.36.  
 3-Nitroacetophenone 2.1.9  
 4-Nitroacetophenone 2.1.10  
*m*-Nitroacetophenone 2.1.9  
 Nitroakridin 3582 2.7.1  
 2-Nitrobenzaldehyde 2.1.12  
 4-Nitrobenzaldehyde 2.1.13  
*o*-Nitrobenzaldehyde 2.1.12  
*p*-Nitrobenzaldehyde 2.1.13  
 Nitrobenzene 2.1.11  
 2-Nitrobenzimidazole 2.8.1  
 2-Nitrobenzofuran 2.8.4  
 2-Nitrobenzoic acid 2.1.14  
 3-Nitrobenzoic acid 2.1.15  
 4-Nitrobenzoic acid 2.1.16  
*m*-Nitrobenzoic acid 2.1.15  
*o*-Nitrobenzoic acid 2.1.14  
 2-Nitrobenzotrile 2.1.17  
*o*-Nitrobenzotrile 2.1.17  
 4-Nitrobenzyl alcohol 2.1.18  
*p*-Nitrobenzyl alcohol 2.1.18  
 8-Nitrocaffeine 2.8.3  
 4-Nitro-(3'-dimethylamino)propiofenone 2.1.19  
 5-Nitro-2-furaldehyde semicarbazone 2.2.4  
*anti*-5-Nitro-2-furaldoxime 2.2.2  
 Nitrofurantoin 2.2.5  
 2-[2-(5-Nitro-2-furanyl)]ethenylquinoline 2.2.7  
 1-[(5-Nitro-2-furanyl)methylenc]amino]-2,4-imidazolidinedione 2.2.5  
 Nitrofurazone 2.2.4  
*N*-(5-Nitro-2-furfurylidene)-1-aminohydantoin 2.2.5  
 5-Nitro-2-furoic acid 2.2.1  
 Nitrogen dioxide 9.36.  
 Nitrogen trioxide 9.37.  
 2-Nitroimidazole 2.3.1  
 4-Nitroimidazole 2.4.1  
 2-Nitroimidazole-1-acetic acid 2.3.20

- 3-(2-Nitroimidazol-1-yl)-1,2-propanediol 2.3.29  
 1-(2-Nitroimidazol-1-yl)-2-propanone 2.3.24  
 2-Nitro-1-(2-oxopropyl)imidazole 2.3.24  
 3-Nitrophenothiazine 7.2.5  
 2-Nitro-1-(2-phenoxyethyl)imidazole 2.3.40  
 2-Nitro-1-(3-phenoxypropyl)imidazole 2.3.43  
 2-Nitro-1-(2-phenylsulfonyl)ethyl)imidazole 2.3.41  
 4-Nitropyridine 2.8.9  
 2-Nitro-1-[2-(2-pyridylethyl)]imidazole 2.3.60  
 5-Nitro-2,4-pyrimidinedione 2.8.11  
 5-Nitro-2-(2-quinolybutadienyl)furan 2.2.8  
 5-Nitro-2-(2-quinolyethenyl)furan 2.2.7  
 8-Nitrotheophylline 2.8.2  
 2-Nitrothiophene 2.8.10  
 5-Nitouracil 2.8.11  
 Norepinephrine 5.2.6  
 Octadecyl viologen 3.8.45  
 Ornidazole 2.5.16  
 Oxide radical ion 9.40.  
 Oxygen 9.41., 9.42.  
 Oxygen, lowest excited singlet state 9.43.  
 1-[3-(1-Oxypyridylmethylamino)carbonylmethyl]-4-nitroimidazole 2.4.41  
 Ozone 9.50., 9.51.  
 Ozonide ion 9.50.  
 Ozonide radical, protonated 9.51.  
 Paraquat 3.8.2  
 Penicillamine 8.3.2.3  
 Perazine 7.4.17  
 Perhydroxyl 9.42., 9.47., 9.48.  
 Peroxomonosulfate radical ion 9.64.  
 9,10-Phenanthrenequinone 1.5.3  
 1,10-Phenanthroline, conjugate diacid 3.6.1  
*o*-Phenanthroline, conjugate diacid 3.6.1  
 1,10-Phenanthroline 3.12.1, 4.4.9  
*o*-Phenanthroline 3.12.1, 4.4.9  
 1,10-Phenanthroline, 1,10-dimethyl- 3.6.2  
 1,9-Phenanthroline, 1,9-dimethyl- 3.12.2  
 2,7-Phenanthroline, 2,7-dimethyl- 3.12.4  
 2,8-Phenanthroline, 2,8-dimethyl- 3.12.3  
 3,7-Phenanthroline, 3,7-dimethyl- 3.12.6  
 3,8-Phenanthroline, 3,8-dimethyl- 3.12.5  
 4,7-Phenanthroline, 4,7-dimethyl- 3.12.7  
 1,10-Phenanthroline, 1,10-ethylene- 3.6.3  
 1,10-Phenanthroline, 1,10-propylene- 3.6.4  
 1,10-Phenanthroline, 1,10-tetramethylene- 3.6.9  
 1,10-Phenanthroline 3.6.1  
 Phenanthroline[4,5-*a*:6,7-*c*]diazepinedium 3.6.4  
 Phenanthroline[4,5-*a*:6,7-*c*]diazepinedium, 1,11-dimethyl- 3.6.7  
 Phenanthroline[4,5-*a*:6,7-*c*]diazocinedium 3.6.9  
 Phenanthroline[4,5-*a*:6,7-*c*]pyrazinedium 3.6.3  
 Phenazone 8.4.4  
 Phenethylamine, 3,4,5-trihydroxy- 5.5.2  
 Phenol 5.1.1  
 Phenol, 4-amino- 5.1.2  
 Phenol, 4-(dimethylamino)- 5.1.8  
 Phenol, 2,4-dinitro- 2.1.8  
 Phenol, 4-methoxy- 5.1.5  
 Phenol, 4-methyl- 5.1.4  
 Phenol, 4-(methylamino)- 5.1.6  
 Phenothiazine 7.1.1  
 Phenothiazine, 10-acetyl- 7.4.3  
 Phenothiazine, 2-acetyl-10-(3-dimethylaminopropyl)- 7.5.5  
 Phenothiazine, 10-benzoyl- 7.4.12  
 Phenothiazine, 3-bromo- 7.2.1  
 Phenothiazine, 3-chloro- 7.2.2  
 Phenothiazine, 2-chloro-10-dimethylaminopropyl- 7.5.1  
 Phenothiazine, 2-chloro-10-[3-(4-(2-hydroxyethyl)-1-piperazinyl)propyl]- 7.5.10  
 Phenothiazine, 2-chloro-7-methoxy- 7.3.1  
 Phenothiazine, 4-chloro-7-methoxy- 7.3.2  
 Phenothiazine, 2-chloro-10-[3-(4-methyl-1-piperazinyl)propyl]- 7.5.7  
 Phenothiazine, 3,7-dimethoxy- 7.3.4  
 Phenothiazine, 3,7-dimethyl- 7.3.3  
 Phenothiazine, 10-(3-dimethylaminopropyl)-2-trifluoromethyl- 7.5.2  
 Phenothiazine, 2-dimethylaminosulfonamido-10-[3-(4-methyl-1-piperazinyl)propyl]- 7.5.9  
 Phenothiazine, 5,5'-dioxide, 10-carbethoxy- 7.7.3  
 10*H*-Phenothiazine, 5,5'-dioxide 7.7.2  
 Phenothiazine, 1-ethoxy- 7.2.9  
 Phenothiazine, 3-ethoxy- 7.2.10  
 Phenothiazine, 3-fluoro- 7.2.3  
 Phenothiazine, 2-hydroxy-10-(3-dimethylaminopropyl)- 7.5.3  
 Phenothiazine, 10-[3-(4-(2-hydroxyethyl)-1-piperazinyl)propyl]- 7.4.18  
 Phenothiazine, 3-iodo- 7.2.4  
 Phenothiazine, 1-methoxy- 7.2.7  
 Phenothiazine, 3-methoxy- 7.2.8  
 Phenothiazine, 2-methoxy-10-(3-dimethylaminopropyl)- 7.5.4  
 Phenothiazine, 10-methyl- 7.4.2  
 Phenothiazine, 3-methyl- 7.2.6  
 Phenothiazine, 10-(2-methyl-2-diethylaminoethyl)- 7.4.14  
 Phenothiazine, 10-(*N*-methyl-3-piperidinyl)methyl- 7.4.13  
 Phenothiazine, 10-[3(4-methyl-1-piperazinyl)propyl]- 7.4.17



- Phenothiazine, 10-[3-(4-methyl-1-piperazinyl)propyl]-2-trifluoromethyl- 7.5.8
- Phenothiazine, 10-(2-methyl-2-trimethylammonioethyl)- 7.4.11
- Phenothiazine, 3-nitro- 7.2.5
- Phenothiazine, 3-phenyl- 7.2.11
- Phenothiazine, 10-(2-pyrrolidinyloethyl)- 7.4.8
- Phenothiazine, 10-(6-sulfonatohexyl)- 7.4.9
- 10-Phenothiazinecarboxaldehyde 7.4.1
- Phenothiazine-10-ethanamine, *N,N*-diethyl- 7.4.10
- Phenothiazine-10-ethanamine, *N,N*, $\alpha$ -trimethyl- 7.4.6
- Phenothiazine-10-ethanamine, *N,N*, $\beta$ -trimethyl- 7.4.7
- Phenothiazine-10-hexanamine, *N,N*-diethyl- 7.4.16
- 10*H*-Phenothiazine 5-oxide 7.7.1
- 10*H*-Phenothiazine-10-propanamine, 2-chloro-*N,N*-dimethyl- 7.5.1
- Phenothiazine-10-propanamine, 2-methoxy-*N,N*-dimethyl- 7.5.4
- Phenothiazine-10-propanamine, *N,N*-diethyl- 7.4.15
- Phenothiazine-10-propanamine, *N,N*-dimethyl- 7.4.5
- 10*H*-Phenothiazine sulfone 7.7.2
- 10*H*-Phenothiazine sulfoxide 7.7.1
- 5-Phenothiazinium, 3,7-bis(dimethylamino)- 4.5.2
- 1-Phenyl-2,3-dihydro-6-nitroimidazo[1,2-*a*]pyridinium 2.8.14
- 6-Phenyldipyrido[1,2-*a*:2',1'-*c*]pyrazinedium 3.2.3
- p*-Phenylenediamine, *N,N,N',N'*-tetramethyl- 6.1.5
- $\alpha$ -Phenylenediamine 6.1.3
- p*-Phenylenediamine 6.1.4
- 1,1'-(1-Phenylethylene)-2,2'-bipyridinium 3.3.19
- 3-Phenylphenothiazine 7.2.11
- Phenyl sulfone, (1-methyl-4-nitroimidazol-5-yl)- 2.4.18
- 1-Phenyl-2,3-trimethyleneisindole-4,7-dione 1.4.4
- Phthalazine-1,4-dione, 5-amino- 1.5.2
- Pimonidazole 2.3.74
- 1-Piperazinamine, *N*-[(1-methyl-2-nitroimidazol-5-yl)methylene]- 2.3.18
- Piperazine, 1-[3-(2-chloro-10-phenothiazinyl)propyl]-4-(2-hydroxyethyl)- 7.5.10
- 1-Piperazineacetic acid, 4-methyl-, [(5-nitro-2-furanyl)methylene]hydrazide 2.2.6
- 1-Piperazineethanol, 4-methyl- $\alpha$ -[2-nitroimidazol-1-yl)methyl]- 2.3.77
- 5-(*N*-Piperazinoiminomethyl)-1-methyl-2-nitroimidazole 2.3.18
- 1-Piperidinamine, *N*-[(1-methyl-2-nitroimidazol-5-yl)methylene]- 2.3.19
- Piperidine, 4-[2-hydroxy-3-(2-nitroimidazol-1-yl)propylamino]-2,2,6,6-tetramethyl- 2.3.72
- Piperidine, 1-[2-(2-nitroimidazol-1-yl)ethyl]- 2.3.56
- Piperidine, 1-[3-(2-nitroimidazol-1-yl)propyl]- 2.3.57
- Piperidine, 1-[4-(2-nitroimidazol-1-yl)butyl]- 2.3.58
- Piperidine, 1-[6-(2-nitroimidazol-1-yl)hexyl]- 2.3.59
- 1-Piperidineethanol, 3-hydroxy- $\alpha$ -[2-nitroimidazol-1-yl)methyl]- 2.3.75
- 1-Piperidineethanol,  $\alpha$ -[(2-nitroimidazol-1-yl)methyl]- 2.3.74
- Piperidine-1-oxy, 4-[2-hydroxy-3-(2-nitroimidazol-1-yl)propylamino]-2,2,6,6-tetramethyl- 2.3.71
- 1-(3-*N*-Piperidino-2-hydroxypropyl)-2-nitroimidazole 2.3.74
- 5-(*N*-Piperidinoiminomethyl)-1-methyl-2-nitroimidazole 2.3.19
- 1-(4-*N*-Piperidinylbutyl)-2-nitroimidazole 2.3.58
- 1-(2-Piperidinyloethyl)-2-nitroimidazole 2.3.56
- 1-(5-*N*-Piperidinylhexyl)-2-nitroimidazole 2.3.59
- 1-(3-*N*-Piperidinylpropyl)-2-nitroimidazole 2.3.57
- Prochlorperazine 7.5.7
- Promazine 7.4.5
- Promethazine 7.4.6
- 1,3-Propanediamine, *N,N*-dimethyl-*N'*-(4-chloro-1-nitro-9-acridinyl)- 2.7.3
- 1,3-Propanediamine, *N,N*-dimethyl-*N'*-(4-dimethylamino-1-nitro-9-acridinyl)- 2.7.8
- 1,3-Propanediamine, *N,N*-dimethyl-*N'*-[4-[di(2-acetoxyethyl)amino]-1-nitro-9-acridinyl]- 2.7.9
- 1,3-Propanediamine, *N,N*-dimethyl-*N'*-(4-fluoro-1-nitro-9-acridinyl)- 2.7.4
- 1,3-Propanediamine, *N,N*-dimethyl-*N'*-(4-methoxy-1-nitro-9-acridinyl)- 2.7.6
- 1,3-Propanediamine, *N,N*-dimethyl-*N'*-(4-methoxycarbonyl-1-nitro-9-acridinyl)- 2.7.7
- 1,3-Propanediamine, *N,N*-dimethyl-*N'*-(4-methyl-1-nitro-9-acridinyl)- 2.7.5
- 1,3-Propanediamine, *N,N*-dimethyl-*N'*-(1-nitro-9-acridinyl)- 2.7.2
- Propanedinitrile, [(1-methyl-2-nitroimidazol-5-yl)methylene]- 2.3.15
- 1,3-Propanediol, 3-(5-iodo-3-nitroimidazol-1-yl)- 2.4.36
- 1,2-Propanediol, 3-(2-nitroimidazol-1-yl)- 2.3.29
- 1,3-Propanediylbis(1'-methyl-4,4'-bipyridinium) 3.6.49
- 2-Propanol, 1-(diethylamino)-3-[(2,3-dimethoxy-6-nitro-9-acridinyl)amino]- 2.7.1
- 2-Propanol radical 4.1.6
- 1-Propanone, 3-dimethylamino-1-(4-nitrophenyl)- 2.1.19
- 2-Propanone, 1-(2-nitroimidazol-1-yl)- 2.3.24
- 5-Propoxy-1,1'-ethylene-2,2'-bipyridinium 3.3.16
- 1,1'-(1,2-Propylene)-2,2'-bipyridinium 3.3.6
- 1,1'-Propylene-2,2'-bipyridinium 3.4.1
- 1,10-Propylene-1,10-phenanthroline 3.6.4
- Protocatechuic acid 5.2.3
- Purine, [(3-amino-6-(2-methylpropyl))-1-(4-nitro-5-imidazolyl)- 2.4.29
- Purine, 3-amino-1-(4-nitro-5-imidazolyl)- 2.4.28
- Purine, 2,6,8-trihydroxy- 6.4.7

- Purine-2,6-dione, 3,7-dihydro- 6.4.6  
 Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-8-nitro- 2.8.2  
 Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl-8-nitro- 2.8.3  
 Purin-6-one, 2-amino-1,7-dihydro- 6.4.3  
 Purin-6(1*H*)-one 6.4.5  
 2-Pyrazolin-5-one, 3,4-dimethyl- 8.4.3  
 3-Pyrazolin-5-one, 2,3-dimethyl-1-phenyl- 8.4.4  
 2-Pyrazolin-5-one, 3-methyl- 8.4.1  
 2-Pyrazolin-5-one, 4-methyl- 8.4.2  
 1-[(1-Pyrazolyl)thiocarbonylmethyl]-1'-methyl-4,4'-bipyridinium 3.10.12  
 Pyridine, 4-nitro- 2.8.9  
 Pyridine-1-oxide, 3-[(methylcarbamyl)methyl-4-nitroimidazol-1-yl]- 2.4.41  
 Pyridinium, 4-aminocarbonyl-1-methyl- 4.4.2  
 Pyridinium, 4-cyano-1-ethyl- 4.4.5  
 Pyridinium, 1-ethyl-2,3-dihydro-6-nitroimidazo[1,2-*a*]- 2.8.13  
 Pyridinium, 1-phenyl-2,3-dihydro-6-nitroimidazo[1,2-*a*]- 2.8.14  
 Pyridinium ion, 3-aminocarbonyl-1-methyl- 4.4.1  
 4-Pyridyl-1,1'-ethylene-2,2'-bipyridinium 3.3.18  
 Pyrimidine, 5,6-dihydro-2,4,6-trihydroxy-5-methyl-5-nitro- 2.8.12  
 Pyrimidine, 2,4-dihydroxy-5-methyl- 6.3.3  
 Pyrimidine, 2,4,5-trihydroxy- 6.3.5  
 2,4-Pyrimidinedione, 5-nitro- 2.8.11  
 2,4(1*H*,3*H*)-Pyrimidinedione 6.3.1  
 2-Pyrimidinone, 4-amino- 6.3.6  
 2-Pyrimidinone, 4-amino-1-methyl- 6.3.7  
 Pyrocatechol 5.2.1  
 Pyrogallol 5.5.1  
 Pyrogallol 5.5.1  
 Pyrrolidine, 1-[2-(2-nitroimidazol-1-yl)ethyl]- 2.3.54  
 Pyrrolidine, 1-[4-(2-nitroimidazol-1-yl)butyl]- 2.3.55  
 1-(4-*N*-Pyrrolidinylbutyl)-2-nitroimidazole 2.3.55  
 1-[2-(*N*-Pyrrolidinyl)ethyl]-2-nitroimidazole 2.3.54  
 10-(2-Pyrrolidinylethyl)phenothiazine 7.4.8  
 1-(3-*N*-Pyrrolidinyl-2-hydroxypropyl)-2-nitroimidazole 2.3.73  
 1*H*-Pyrrolo[2,1,*a*]isoindole-6,9-dione, 2,3-dihydro-5-ethoxycarbonyl-7-methyl- 1.4.9  
 1*H*-Pyrrolo[2,1,*a*]isoindole-6,9-dione, 2,3-dihydro-5-ethoxycarbonyl-7-methyl-8-methoxy- 1.4.11  
 Pyrrolo[2,3-*b*]pyridine, 1-(2-bromoethyl)-3-nitro- 2.6.2  
 Pyrrolo[2,3-*b*]pyridine, 1-(2,3-dihydroxypropyl)-3-nitro 2.6.3  
 Pyrrolo[2,3-*b*]pyridine, 1-(ethoxycarbonylmethyl)-3-nitro- 2.6.6  
 Pyrrolo[2,3-*b*]pyridine, 1-[(2-hydroxyethyl)aminocarbonylmethyl]-3-nitro- 2.6.4  
 Pyrrolo[2,3-*b*]pyridine, 1-methyl-3-nitro- 2.6.1  
 Pyrrolo[2,3-*b*]pyridine, 1-[3-(4-morpholinyl)propylaminocarbonylmethyl]-3-nitro- 2.6.5  
 Pyrrolo[2,3-*b*]pyridine, 7-[3-(4-morpholinyl)propylaminocarbonylmethyl]-3-nitro- 2.6.7  
 Pyrrolo[2,3-*b*]pyridine, 7-[3-(4-morpholinyl)propylaminocarbonylmethyl]-3-nitro-, protonated 2.6.8  
 Pyrrolo[2,3-*f*]quinoline-2,7,9-tricarboxylic acid, 4,5-dihydro-4,5-dioxo- 1.5.10  
 Quercetin 8.1.9  
 Quinalizarin 8.1.5  
 Quinizarin-2-sulfonate ion 1.3.2  
 Quinizarin-6-sulfonate ion 1.3.3  
 Quinoline, 2-[2-(5-nitro-2-furanyl)]butadienyl- 2.2.8  
 Quinoline, 2-[2-(5-nitro-2-furanyl)]ethenyl- 2.2.7  
 Quinone 1.1.1  
 RGW-601 2.3.45  
 RGW-602 2.3.24  
 RGW-603 2.3.56  
 RGW-604 2.3.56  
 RGW-605 2.3.62  
 RGW-606 2.3.62  
 RGW-607 2.3.28  
 RGW-608 2.3.34  
 RGW-609 2.3.40  
 RGW-610 2.3.43  
 RGW-611 2.4.40  
 RGW-612 2.3.54  
 RGW-613 2.3.25  
 RGW-616 2.3.20  
 RGW-617 2.3.46  
 RGW-702 2.6.2  
 RGW-703 2.3.47  
 RGW-704 2.3.57  
 RGW-705 2.8.3  
 RGW-706 2.8.1  
 RGW-801 2.3.3  
 RGW-806 2.3.6  
 RGW-810 2.3.60  
 RGW-812 2.3.61  
 RSU 1005 2.3.46  
 RSU 1006 2.3.58  
 RSU 1007 2.3.49  
 RSU 1010 2.3.55  
 RSU 1017 2.3.51  
 RSU 1021 2.3.53

RSU 1022	2.3.52	Ro 03-9482	2.3.64
RSU 1031	2.3.59	Ro 03-9846	2.3.72
RSU 1032	2.3.50	Ro 03-9993	2.3.63
RSU 1069	2.3.63	Ro 05-9129	2.3.1
RSU 2096	2.4.34	Ro 05-9963	2.3.29
RSU 2097	2.5.8	Ro 07-0269	2.3.26
RSU 3021	2.5.2	Ro 07-0582	2.3.35
RSU 3025	2.4.6	Ro 07-0741	2.3.27
RSU 3045	2.4.44	Ro 07-1902	2.3.38
RSU 3046	2.4.18	Ro 11-3696	2.5.20
RSU 3047	2.5.12	Ro 12-5272	2.3.30
RSU 3050	2.4.14	Ro 12-5273	2.3.36
RSU 3052	2.4.35	Ro 12-5275	2.3.41
RSU 3053	2.5.5	Ro 31-0052	2.3.75
RSU 3054	2.4.26	Ro 31-0054	2.3.70
RSU 3056	2.4.25	Rubidomycin	1.5.5
RSU 3057	2.4.21	SK 21981	2.5.4
RSU 3059	2.4.9	SR-2508	2.3.32
RSU 3061	2.5.17	SR-2514	2.3.45
RSU 3062	2.5.6	SR-2530	2.3.37
RSU 3066	2.5.3	SR-2555	2.3.39
RSU 3067	2.5.7	Selenite(IV) ion	9.66.
RSU 3068	2.4.33	Selenite(V) ion	9.66., 9.67.
RSU 3069	2.4.4	Selenite radical ion	9.66., 9.67.
RSU 3071	2.5.1	Selenocyanate	9.68.
RSU 3084	2.4.32	Selenocyanide dimer, radical anion	9.68.
RSU 3100	2.4.16	Singlet oxygen	9.43.
RSU 3113	2.5.25	Skatole	6.2.5
RSU 3121	2.4.43	Sulfate(1-), dioxo-	9.58., 9.59.
RSU 3151	2.4.17	Sulfate(1-), pentaoxo-	9.64.
RSU 3162	2.4.36	Sulfate(1-), tetraoxo-	9.63.
Resorcinol	5.3.1	Sulfate(1-), trioxo-	9.60., 9.61., 9.62.
$\alpha$ -Resorcylic acid	5.3.3	Sulfate ion	9.62., 9.63.
Riboflavin, 8 $\alpha$ - <i>N</i> -imidazolyl-	4.6.4	Sulfate radical ion	9.63.
Riboflavin, 8 $\alpha$ -tetra- <i>O</i> -acetyl-( <i>N</i> -methyl- <i>N</i> -imidazolio)-	4.6.5	Sulfhydryl dimer radical	9.54.
Riboflavin 5'-(dihydrogen phosphate)	4.6.2	Sulfite ion	9.60.
Riboflavine	4.6.1	Sulfite radical ion	9.60., 9.61., 9.62.
Ro 03-0350	2.3.69	10-(6-Sulfonatohexyl)phenothiazine	7.4.9
Ro 03-5580	2.8.14	10-(3-Sulfonatopropyl)phenothiazine	7.4.4
Ro 03-5637	2.8.13	Sulfur	9.52.
Ro 03-8799	2.3.74	Sulfur dioxide	9.58.
Ro 03-8800	2.3.76	Sulfur dioxide radical anion	9.58., 9.59.
Ro 03-9041	2.3.44	Superoxide radical anion	9.41., 9.43., 9.44., 9.45., 9.46.
Ro 03-9309	2.3.68	3,3',5,5'-Tetrabromodiphenoquinone	1.5.8
Ro 03-9310	2.3.73	3,3',5,5'-Tetrachlorodiphenoquinone	1.5.9
Ro 03-9311	2.3.65	6,7,8,9-Tetrahydro-2,13-dimethyldipyrdo[1,2- <i>a</i> :2',1'- <i>c</i> ][1,4]diazocinediium	3.5.2
Ro 03-9330	2.3.77	6,7,8,9-Tetrahydrodipyrdo[1,2- <i>a</i> :2',1'- <i>c</i> ][1,4]diazocinediium	3.5.1
Ro 03-9340	2.3.67	6,7,8,9-Tetrahydro-2,3,12,13-tetramethyldipyrdo[1,2- <i>a</i> :2',1'- <i>c</i> ][1,4]diazocinediium	3.5.3
Ro 03-9349	2.3.66		
Ro 03-9454	2.3.71		

- 1,2,3,8-Tetrahydroxy-9,10-anthraquinone 8.1.5  
 2,3,7,8-Tetrahydroxy[1]benzopyrano[5,4,3-  
*cde*][1]benzopyran-5,7-dione 8.1.10  
 1,3,7,8-Tetramethylbenzo[*g*]pteridine-2,4-dione 4.6.9  
 Tetramethyl-1,4-benzoquinone 1.1.7  
 2,3,5,8-Tetramethylbenzoquinone 1.1.7  
 1,1',2,2'-Tetramethyl-4,4'-bipyridinium 3.9.5  
 1,1',3,3'-Tetramethyl-4,4'-bipyridinium 3.9.6  
 1,1'-Tetramethylene-2,2'-bipyridinium 3.5.1  
 1,10-Tetramethylene-1,10-phenanthroline 3.6.9  
 4,5,4',5'-Tetramethyl-1,1'-ethylene-2,2'-bipyridinium  
 3.3.17  
 Tetramethylhydroquinone 5.4.10  
 1-[3-[4-(2,2,5,5-Tetramethyl-1-oxypiperidinyl)amino]-2-  
 hydroxypropyl]-2-nitroimidazole 2.3.71  
*N,N,N',N'*-Tetramethyl-*p*-phenylenediamine 6.1.5  
 1,2,5,8-Tetramethyl-3-phenylisoindole-4,7-dione 1.4.8  
 1-[3-[4-(2,2,5,5-Tetramethylpiperidinyl)amino]-2-  
 hydroxypropyl]-2-nitroimidazole 2.3.72  
 4,5,4',5'-Tetramethyl-1,1'-tetramethylene-2,2'-  
 bipyridinium 3.5.3  
 4,5,4',5'-Tetramethyl-1,1'-trimethylene-2,2'-  
 bipyridinium 3.4.6  
 2,3,11,12-Tetramethyltriquat 3.4.6  
 Tetraquat 3.5.1  
 [1,2,5]Thiadiazolo[3,4-*b*]pyrazine, 5,6-di(2-furyl)- 4.8.3  
 [1,2,5]Thiadiazolo[3,4-*b*]pyrazine, 5,6-di-2-pyridinyl-  
 4.8.4  
 [1,2,5]Thiadiazolo[3,4-*b*]pyrazine, 5,6-di-2-pyridinyl-,  
*N*-oxide 4.8.5  
 Thiocyanate ion 9.55., 9.56.  
 Thiocyanogen 9.55.  
 Thiocyanogen 9.57.  
 Thioglycolic acid 8.3.2.2  
 Thionine 4.5.1  
 Thiophene, 2-nitro- 2.8.10  
 Thioproperazine 7.5.9  
 Thioridazine 7.5.6  
 Thiosulfate ion 9.65.  
 Thiosulfate radical ion 9.65.  
 Thymine 6.3.3  
 Tinidazole 2.5.21  
*p*-Toluquinone 1.1.2  
 Trichloromethylidoxo 8.5.2  
 Trichloromethylperoxy 8.5.2  
 Trifluoperazine 7.5.8  
 Triflupromazine 7.5.2  
 1,2,3-Trihydroxybenzene 5.5.1  
 1,2,4-Trihydroxybenzene 5.5.4  
 3,4,5-Trihydroxyphenethylamine 5.5.2  
 2,6,8-Trihydroxypurine 6.4.7  
 2,4,5-Trihydroxypyrimidine 6.3.5  
 1,7,8-Trimethylbenzo[*g*]pteridine-2,4-dione 4.6.7  
 3,7,8-Trimethylbenzo[*g*]pteridine-2,4-dione 4.6.8  
 2,3,5-Trimethyl-1,4-benzoquinone 1.1.6  
 1,1',2-Trimethyl-4,4'-bipyridinium 3.9.1  
 1,1'-Trimethylene-2,2'-bipyridinium 3.4.1  
 1,1'-Trimethylene-4,7-dimethyl-1,10-phenanthroline  
 3.6.7  
 1,1'-Trimethylene-5-methoxy-2,2'-bipyridinium 3.4.3  
 Trimethylhydroquinone 5.4.9  
 1,2,5-Trimethyl-3-phenylisoindole-4,7-dione 1.4.3  
 Triquat 3.4.1  
 Trolox C 6.1.6  
 Tryptamine 6.2.8  
 Tryptophan 6.2.9  
 L-Tryptophan, *N*-acetyl- 6.2.12  
 Tryptophan, 5-hydroxy- 6.2.10  
 DL-Tryptophanamide 6.2.11  
 L-Tryptophyl-L-alanine 6.2.13  
 L-Tyrosinamide, *N*-acetyl- 5.1.11  
 Tyrosine 5.1.9  
 DL-Tyrosine, methyl ester 5.1.10  
 Umbelliferone 8.1.2  
 Uracil 6.3.1  
 Uracil, *N*<sub>1</sub>-methyl- 6.3.2  
 Uric acid 6.4.7  
 Vitamin B<sub>2</sub> 4.6.1  
 Vitamin C 8.1.1  
 Vitamin K<sub>1</sub> 1.2.17, 8.1.4  
 Water 9.38.  
 Xanthine 6.4.6  
 1,1'-*o*-Xylylenebis-4,4'-bipyridinium 3.8.47  
 ZK-28943 2.5.9

## 15. Molecular Formula Index

Br	Bromine atom 9.2., 9.3.	$C_4H_4BrN_3O_2$	2-Bromo-1-methyl-4-nitroimidazole 2.4.32
$Br^-$	Bromide ion 9.2., 9.4., 9.5., 9.9.		4-Bromo-1-methyl-5-nitroimidazole 2.5.1
BrHO	Bromosyl hydride 9.5.		5-Bromo-1-methyl-4-nitroimidazole 2.4.4
	Hypobromous acid 9.3., 9.4.	$C_4H_4ClN_3O_2$	5-Chloro-1-methyl-4-nitroimidazole 2.4.5
BrHO <sub>2</sub>	Bromous acid 9.7.	$C_4H_4IN_3O_2$	2-Iodo-1-methyl-4-nitroimidazole 2.4.33
BrO <sub>2</sub>	Bromine dioxide 9.6., 9.7., 9.8.		2-Iodo-1-methyl-5-nitroimidazole 2.5.7
$BrO_2^-$	Bromite ion 9.6.		4-Iodo-1-methyl-5-nitroimidazole 2.5.2
$BrO_3^-$	Bromate ion 9.8.		5-Iodo-1-methyl-4-nitroimidazole 2.4.6
Br <sub>2</sub>	Bromine 9.10.	$C_4H_4N_2O_2$	Uracil 6.3.1
$Br_2^-$	Dibromine radical ion 9.9., 9.10.	$C_4H_4N_2O_3$	2,4,5-Trihydroxypyrimidine 6.3.5
CCl <sub>3</sub> O <sub>2</sub>	Trichloromethylperoxyl 8.5.2		Barbituric acid 6.3.4
CHO <sub>2</sub> <sup>-</sup>	Formate ion 9.14.	$C_4H_4N_4O_4$	1-Methyl-2,4-dinitroimidazole 2.4.34
CH <sub>2</sub> O	Formaldehyde 4.1.1, 4.1.2		1-Methyl-2,5-dinitroimidazole 2.5.8
CH <sub>2</sub> O <sup>-</sup>	Hydroxymethyl, conjugate base 4.1.1	$C_4H_5N_3O$	Cytosine 6.3.6
CH <sub>3</sub> O	Hydroxymethyl 4.1.2	$C_4H_5N_3O_2$	2-Methyl-4-nitroimidazole 2.4.3
CH <sub>3</sub> O <sub>2</sub>	Methylperoxyl 8.5.1	$C_4H_5N_3O_2S$	5-Mercapto-1-methyl-4-nitroimidazole 2.4.7
CH <sub>4</sub> N <sub>2</sub> O <sub>2</sub>	Hydroxyurea 4.3.1	$C_4H_5N_3O_3$	1-Methyl-4-nitroimidazol-5-one 2.4.42
CN	Cyanide radical 9.11.	$C_4H_6N_2O$	3-Methyl-2-pyrazolin-5-one 8.4.1
$CN^-$	Cyanide ion 9.11.		4-Methyl-2-pyrazolin-5-one 8.4.2
CNO <sup>-</sup>	Isocyanate ion 9.12.	$C_4H_6N_4O$	4(5)-Aminoimidazole-5(4)-carboxamide 4.3.2
CNS	Thiocyanogen 9.55.	$C_4H_6N_4O_4S$	1-Methyl-4-nitroimidazole-5-sulfonamide 2.4.8
CNS <sup>-</sup>	Thiocyanate ion 9.55., 9.56.		4-Aminosulfonyl-1-methyl-5- nitroimidazole 2.5.4
CNSE <sup>-</sup>	Selenocyanate 9.68.	$C_4H_{10}O_2S_2$	2-Hydroxyethyl disulfide 4.2.2
CO <sub>2</sub>	Carbon dioxide 9.13.		Dithioerythritol 8.3.4.4
CO <sub>2</sub> <sup>-</sup>	Carbon dioxide radical anion 9.13., 9.14.		Dithiothreitol 8.3.4.2
$C_2HN_2O_3^{2-}$	Cyanate radical anion 9.12.	$C_5H_3NO_5$	5-Nitro-2-furoic acid 2.2.1
$C_2H_2S_2$	Thiocyanogen 9.57.	$C_5H_4N_2O_2$	4-Nitropyridine 2.8.9
$C_2H_4O$	Acetaldehyde 4.1.3, 4.1.4	$C_5H_4N_2O_2S_2$	5 <i>H</i> ,7 <i>H</i> -2,3-Dioxa-2 <i>a</i> ,6-dithia(2 <i>a</i> -S <sup>IV</sup> )-1,4- diazacyclopent[ <i>c</i> , <i>d</i> -indene 4.7.1
$C_2H_4O^-$	1-Hydroxyethyl(1-) ion 4.1.3	$C_5H_4N_2O_3S_2$	5 <i>H</i> ,7 <i>II</i> -2,3-Dioxa-2 <i>a</i> ,6-dithia(2 <i>a</i> -S <sup>IV</sup> )-1,4- diazacyclopent[ <i>c</i> , <i>d</i> -indene 6-oxide 4.7.2
$C_2H_4O_2S$	Mercaptoacetic acid 8.3.2.2	$C_5H_4N_2O_4$	Nifuroxime 2.2.2
$C_2H_5O$	1-Hydroxyethyl 4.1.4	$C_5H_4N_2O_4S_2$	5 <i>H</i> ,7 <i>H</i> -2,3-Dioxa-2 <i>a</i> ,6-dithia(2 <i>a</i> -S <sup>IV</sup> )-1,4- diazacyclopent[ <i>c</i> , <i>d</i> -indene 6,6-dioxide 4.7.3
$C_2H_6OS$	2-Mercaptoethanol 8.3.1.2, 8.3.2.1, 8.3.4.1	$C_5H_4N_3O_4^-$	1-Methyl-2-nitroimidazole-5-carboxylate ion 2.3.5
$C_2H_6S_2$	Dimethyl disulfide 8.3.5.1	$C_5H_4N_4O$	Hypoxanthine 6.4.5
$C_2N_2S_2^-$	Di(thiocyanate) radical ion 9.56., 9.57.	$C_5H_4N_4O_2$	5-Cyano-1-methyl-2-nitroimidazole 2.3.3
$C_2N_2Se_2^-$	Selenocyanide dimer, radical anion 9.68.		Xanthine 6.4.6
$C_3H_2IN_3O_2$	4-Iodo-5-nitroimidazole 2.4.2	$C_5H_4N_4O_3$	Uric acid 6.4.7
$C_3H_2N_4O_4$	2,4-Dinitroimidazole 2.3.2	$C_5H_5N_3O_2S$	1,2-[Ethanediylthio]-5-nitroimidazole 2.5.24
$C_3H_3N_3O_2$	2-Nitroimidazole 2.3.1	$C_5H_5N_3O_3$	1-Methyl-2-nitroimidazole-5- carboxaldehyde 2.3.4
	4-Nitroimidazole 2.4.1		1-Methyl-5-nitroimidazole-2- carboxaldehyde 2.5.9
$C_3H_6O$	Acetone 4.1.5, 4.1.6	$C_5H_5N_3O_4$	1-(2-Carboxymethyl)-2-nitroimidazole 2.3.20
$C_3H_6O^-$	Acetone ketyl radical 4.1.5		
$C_3H_6O_2S$	3-Mercaptopropionic acid 8.3.2.4		
$C_3H_7NO_2S$	Cysteine 8.3.1.1, 8.3.3.1		
$C_3H_7O$	1-Hydroxy-1-methylethyl 4.1.6		
$C_4H_3NO_2S$	2-Nitrothiophene 2.8.10		
$C_4H_3N_3O_4$	5-Nitrouracil 2.8.11		

$C_6H_6N_3O_4S$	1,2-[Ethanediylsulfonyl]-5-nitroimidazole 2.5.25	$C_6H_7N_3O_4$	1-(Methoxycarbonylmethyl)-2-nitroimidazole 2.3.25
	3,4-[Ethanediylsulfonyl]-5-nitroimidazole 2.4.43		Methyl 1-methyl-2-nitroimidazole-5-carboxylate 2.3.9
$C_5H_5N_5$	Adenine 6.4.1	$C_6H_7N_3O_4S$	5-Carboxymethylthio-1-methyl-4-nitroimidazole 2.4.10
$C_5H_5N_5O$	Guanine 6.4.3	$C_6H_8ClN_3O_3$	1-(3-Chloro-2-hydroxypropyl)-2-nitroimidazole 2.3.26
$C_5H_6N_2O_2$	1-Methyluracil 6.3.2	$C_6H_8FN_3O_3$	1-(3-Fluoro-2-hydroxypropyl)-2-nitroimidazole 2.3.27
	Thymine 6.3.3	$C_6H_8IN_3O_4$	1-(2,3-Dihydroxypropyl)-5-iodo-4-nitroimidazole 2.4.36
$C_5H_6N_4O_3$	1-Methyl-2-nitroimidazole-5-carboxamide 2.3.6	$C_6H_8N_2$	<i>o</i> -Phenylenediamine 6.1.3
$C_5H_6N_4O_5$	1-(2-Hydroxyethyl)-2,4-dinitroimidazole 2.3.22		<i>p</i> -Phenylenediamine 6.1.4
$C_5H_7N_3O$	1-Methylcytosine 6.3.7	$C_6H_8N_3O_6P^{2-}$	2-Methyl-1-(2-phosphatoethyl)-4-nitroimidazole 2.5.14
$C_5H_7N_3O_2$	1,2-Dimethyl-5-nitroimidazole 2.5.10	$C_6H_8N_4O_3$	1-Methyl-5-[methyl(oxyamino)methylene]-2-nitroimidazole 2.3.10
$C_5H_7N_3O_3$	1-(2-Hydroxyethyl)-2-nitroimidazole 2.3.21	$C_6H_8O_6$	Ascorbic acid 8.1.1
	5-Hydroxymethyl-1-methyl-2-nitroimidazole 2.3.7	$C_6H_9N_3O_3$	1-(2-Hydroxyethyl)-2-methyl-5-nitroimidazole 2.5.15
$C_5H_7N_3O_3S$	1-Methyl-2-(methylsulfonyl)-5-nitroimidazole 2.5.11		1-(2-Hydroxyethyl)-5-methyl-2-nitroimidazole 2.3.23
$C_5H_7N_3O_4S$	1-Methyl-2-(methylsulfonyl)-4-nitroimidazole 2.4.35		1-(2-Methoxyethyl)-2-nitroimidazole 2.3.28
	1-Methyl-2-(methylsulfonyl)-5-nitroimidazole 2.5.12	$C_6H_9N_3O_4$	1-(2,3-Dihydroxypropyl)-2-nitroimidazole 2.3.29
	1-Methyl-5-(methylsulfonyl)-4-nitroimidazole 2.4.9		5-(1,2-Dihydroxyethyl)-1-methyl-2-nitroimidazole 2.3.11
$C_5H_7N_3O_5$	6-Hydroxy-5-nitrothymine 2.8.12	$C_6H_9N_3O_4S$	1-[2-(Methylsulfonyl)ethyl]-2-nitroimidazole 2.3.30
$C_5H_8N_2O$	3,4-Dimethyl-2-pyrazolin-5-one 8.4.3	$C_6H_9N_4O_5S$	5-Acetylaminosulfonyl-1-methyl-4-nitroimidazole 2.4.12
$C_5H_{11}NO_2S$	Penicillamine 8.3.2.3	$C_6H_{10}N_4O_4S$	5-(Dimethylaminosulfonyl)-1-methyl-4-nitroimidazole 2.4.11
$C_6H_4N_2O_4$	<i>m</i> -Dinitrobenzene 2.1.2	$C_6H_{10}N_6O$	5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide 4.3.3
	<i>o</i> -Dinitrobenzene 2.1.1	$C_6H_{12}N_2O_4S_2$	Cystine 4.2.1
	<i>p</i> -Dinitrobenzene 2.1.3	$C_7H_4N_2O_2$	2-Nitrobenzotrile 2.1.17
$C_6H_4N_2O_5$	2,4-Dinitrophenol 2.1.8	$C_7H_4N_2O_6$	2,4-Dinitrobenzoic acid 2.1.4
$C_6H_4O_2$	1,4-Benzoquinone 1.1.1		2,5-Dinitrobenzoic acid 2.1.5
$C_6H_4O_8S_2^{2-}$	1,4-Dihydroxybenzene-2,5-disulfonate ion 5.4.2		3,4-Dinitrobenzoic acid 2.1.6
$C_6H_5NO_2$	Nitrobenzene 2.1.11		3,5-Dinitrobenzoic acid 2.1.7
$C_6H_6N_2O_2S$	7,8-Dihydro-6 <i>H</i> [1,2,5]oxathiazolo[4,3,2- <i>h</i> ][2,1,3]benzoxathiazole-3- <i>S</i> <sup>IV</sup> 4.7.4	$C_7H_5NO_3$	<i>o</i> -Nitrobenzaldehyde 2.1.12
$C_6H_6N_4O_4$	5-Nitro-2-furaldehyde semicarbazone 2.2.4		<i>p</i> -Nitrobenzaldehyde 2.1.13
$C_6H_6O$	Phenol 5.1.1	$C_7H_5NO_4$	4-Nitrobenzoic acid 2.1.16
$C_6H_6O_2$	Catechol 5.2.1		<i>m</i> -Nitrobenzoic acid 2.1.15
	Hydroquinone 5.4.1		<i>o</i> -Nitrobenzoic acid 2.1.14
	Resorcinol 5.3.1	$C_7H_5N_3O_2$	2-Nitrobenzimidazole 2.8.1
$C_6H_6O_3$	1,2,4-Benzenetriol 5.5.4	$C_7H_6O_2$	Methyl-1,4-benzoquinone 1.1.2
	Pyrogallol 5.5.1	$C_7H_6O_3$	4-Hydroxybenzoic acid 5.1.3
$C_6H_7N$	Aniline 6.1.1		
$C_6H_7NO$	4-Aminophenol 5.1.2		
$C_6H_7NO_4$	2-Methoxymethyl-5-nitrofuran 2.2.3		
$C_6H_7N_3O_2$	5-Ethenyl-1-methyl-2-nitroimidazole 2.3.8		
$C_6H_7N_3O_3$	2-Nitro-1-(2-oxopropyl)imidazole 2.3.24		

$C_7H_6O_4$	2,3-Dihydroxybenzoic acid 5.2.2 2,5-Dihydroxybenzoic acid 5.3.2 3,4-Dihydroxybenzoic acid 5.2.3 3,5-Dihydroxybenzoic acid 5.3.3	$C_8H_8O_2$	2,3-Dimethyl-1,4-benzoquinone 1.1.3 2,5-Dimethyl-1,4-benzoquinone 1.1.4 2,6-Dimethyl-1,4-benzoquinone 1.1.5
$C_7H_7NO_3$	<i>p</i> -Nitrobenzyl alcohol 2.1.18	$C_8H_8O_3$	2,5-Dihydroxyacetophenone 5.4.5
$C_7H_7N_5O_4$	8-Nitrotheophylline 2.8.2	$C_8H_8O_4$	2,5-Dihydroxyphenylacetic acid 5.4.6 3,4-Dihydroxyphenylacetic acid 5.2.4
$C_7H_8IN_3O_4$	1-(Ethoxycarbonylmethyl)-4-iodo-5-nitroimidazole 2.5.17 Ethyl 5-iodo-4-nitroimidazole-1-acetate 2.4.37	$C_8H_9NO_2$	Acetaminophen 5.1.7
$C_7H_8N_4O_5$	5-Amino-2,4-dinitrobenzamide 2.1.24	$C_8H_9N_2^+$	4-Cyano-1-ethylpyridinium 4.4.5
$C_7H_8O$	4-Methylphenol 5.1.4	$C_8H_9N_5O_4$	8-Nitrocaffeine 2.8.3
$C_7H_8O_2$	4-Methoxyphenol 5.1.5 Methylhydroquinone 5.4.3	$C_8H_{10}NO^+$	<i>N</i> -Methyl-4-acetylpyridinium 4.4.3
$C_7H_8O_3$	Methoxyhydroquinone 5.4.4	$C_8H_{10}NO_2^+$	<i>N</i> -Methyl-4-(methoxycarbonyl)pyridinium 4.4.4
$C_7H_9NO$	4-(Methylamino)phenol 5.1.6	$C_8H_{10}O_2$	1,4-Benzenediol, 2,5-dimethyl- 5.4.8 1,4-Dihydroxy-2,3-dimethylbenzene 5.4.7
$C_7H_9N_2O^+$	1-Methylisonicotinamide 4.4.2 1-Methylnicotinamide 4.4.1	$C_8H_{11}N$	<i>N,N</i> -Dimethylaniline 6.1.2
$C_7H_9N_3O_5$	1-(2-Methylcarbonyloxyethyl)-2-nitroimidazole 2.3.31	$C_8H_{11}NO$	4-( <i>N,N</i> -Dimethylamino)phenol 5.1.8
$C_7H_{10}ClN_3O_3$	$\alpha$ -(Chloromethyl)-2-methyl-5-nitroimidazole-1-ethanol 2.5.16	$C_8H_{11}NO_2$	3,4-Dihydroxyphenethylamine 5.2.5
$C_7H_{10}IN_3O_4$	1-(2-Hydroxy-3-methoxypropyl)-5-iodo-4-nitroimidazole 2.4.38, 2.5.18	$C_8H_{11}NO_3$	5-Hydroxydopamine 5.5.2 Norepinephrine 5.2.6
$C_7H_{10}N_4O_4$	1-(2-Hydroxyethyl)aminocarbonylmethyl-2-nitroimidazole 2.3.32	$C_8H_{12}N_4O_3S$	1-[2-(Methoxythiocarbonylamino)ethyl]-2-methyl-5-nitroimidazole 2.5.19
$C_7H_{11}N_3O_2$	1-Methyl-5-(1-methylethyl)-2-nitroimidazole 2.3.12	$C_8H_{12}N_4O_5$	1-(2,3-Dihydroxypropyl)aminocarbonylmethyl-2-nitroimidazole 2.3.37
$C_7H_{11}N_3O_3$	1-(2-Ethoxyethyl)-2-nitroimidazole 2.3.34 5-(1-Hydroxy-1-methylethyl)-1-methyl-2-nitroimidazole 2.3.13	$C_8H_{12}N_4O_5S$	1-Methyl-4-( <i>N</i> -morpholinosulfonyl)-5-nitroimidazole 2.5.3 1-Methyl-5-( <i>N</i> -morpholinosulfonyl)-4-nitroimidazole 2.4.14
$C_7H_{11}N_3O_4$	1-(2-Hydroxy-3-methoxypropyl)-2-nitroimidazole 2.3.35	$C_8H_{13}N_3O_4$	$\alpha$ -(Methoxymethyl)-2-methyl-5-nitroimidazole-1-ethanol 2.5.20 1-(2-Hydroxy-3-methoxypropyl)-2-methyl-4-nitroimidazole 2.4.39
$C_7H_{11}N_3O_4S$	1-[(2-Ethylsulfonyl)ethyl]-2-nitroimidazole 2.3.36	$C_8H_{13}N_3O_4S$	1-(2-Ethylsulfonyl)ethyl-2-methyl-5-nitroimidazole 2.5.21
$C_7H_{11}N_5O_2$	5-(Dimethylaminoiminomethyl)-1-methyl-2-nitroimidazole 2.3.14	$C_8H_{14}N_4O_3$	1-(3-Dimethylamino-2-hydroxypropyl)-2-nitroimidazole 2.3.64
$C_7H_{13}N_5O_4S$	5-[[Dimethylaminomethyl)aminosulfonyl]-1-methyl-4-nitroimidazole 2.4.13	$C_8H_{14}O_2S_2$	Lipoic acid 8.3.5.2
$C_8H_2N_4S$	2,1,3-Benzothiadiazole-4,7-dicarbonitrile 4.8.2	$C_8H_{15}NOS_2$	Lipoamide 4.2.3, 6.3.4.3
$C_8H_5NO_3$	2-Nitrobenzofuran 2.8.4	$C_9H_6O_3$	7-Hydroxycoumarin 8.1.2
$C_8H_5NO_4$	5-Hydroxy-2-nitrobenzofuran 2.8.7 7-Hydroxy-2-nitrobenzofuran 2.8.5	$C_9H_7NO_4$	5-Methoxy-2-nitrobenzofuran 2.8.8 7-Methoxy-2-nitrobenzofuran 2.8.6
$C_8H_5N_3O_2$	5-Aminophthalazine-1,4-dione 1.5.2	$C_9H_8BrN_3O_2$	1-(2-Bromoethyl)-3-nitro-7-azaindole 2.6.2
$C_8H_5N_5O_2$	5-(2,2-Dicyanoethenyl)-1-methyl-2-nitroimidazole 2.3.15	$C_9H_8N_4O_5$	5-Aziridinyl-2,4-dinitrobenzamide 2.1.20
$C_8H_6N_4O_5$	Furadantin 2.2.5	$C_9H_8O_4$	( <i>E</i> )-3,4-Dihydroxycinnamic acid 5.2.7
$C_8H_7N$	Indole 6.2.1	$C_9H_9N$	1-Methylindole 6.2.3 2-Methylindole 6.2.4 3-Methylindole 6.2.5
$C_8H_7NO$	5-Hydroxyindole 6.2.2	$C_9H_9NO_3$	Adrenochrome 1.5.1
$C_8H_7NO_3$	4-Nitroacetophenone 2.1.10 <i>m</i> -Nitroacetophenone 2.1.9	$C_9H_9N_6O_2S$	5-(3-Aminopurinyl)-1-methyl-4-nitroimidazole 2.4.28
$C_8H_7N_3O_2$	1-Methyl-3-nitro-7-azaindole 2.6.1		

- $C_9H_{10}N_4O_3$  2-Amino-5-aziridinyl-4-nitrobenzamide 2.1.26  
 4-Amino-5-aziridinyl-2-nitrobenzamide 2.1.27  
 $C_9H_{10}O_2$  2,3,5-Trimethyl-1,4-benzoquinone 1.1.6  
 $C_9H_{10}O_5$  Ethyl gallate 5.5.3  
 $C_9H_{11}NO_3$  Adrenalone 5.2.8  
 Tyrosine 5.1.9  
 $C_9H_{11}NO_4$  DL-DOPA 5.2.9  
 $C_9H_{11}N_3O_6$  5-[Bis(methylcarbonyloxy)methyl]-1-methyl-2-nitroimidazole 2.3.16  
 $C_9H_{12}N_2O_4$  *N*-Butyl-5-nitro-2-furamide 2.2.11  
 $C_9H_{12}N_3O_2^+$  1-Ethyl-2,3-dihydro-6-nitroimidazo[1,2-*c*]pyridinium 2.8.13  
 $C_9H_{12}N_4O_5$  5-(Dimethylamino)-2,4-dinitrobenzamide 2.1.25  
 $C_9H_{12}O_2$  Trimethylhydroquinone 5.4.9  
 $C_9H_{13}N_3O_4$   $\alpha$ -(Allyloxymethyl)-2-nitroimidazole-1-ethanol 2.3.38  
 Ethyl 5-ethyl-2-nitroimidazole-1-acetate 2.3.33  
 $C_9H_{13}N_5O_3$  1-Methyl-5-(*N*-morpholinoiminomethyl)-2-nitroimidazole 2.3.17  
 $C_9H_{14}N_4O_2$  1-[2-(*N*-Pyrrolidinyl)ethyl]-2-nitroimidazole 2.3.54  
 $C_9H_{14}N_4O_3$  1-(2-*N*-Morpholinoethyl)-2-nitroimidazole 2.3.45  
 1-(2-*N*-Morpholinoethyl)-4-nitroimidazole 2.4.40  
 1-(2-*N*-Morpholinoethyl)-5-nitroimidazole 2.5.22  
 $C_9H_{14}N_4O_5$  1-[Bis(2-hydroxyethyl)]aminocarbonylmethyl-2-nitroimidazole 2.3.39  
 $C_9H_{14}N_6O_2$  5-(*N*-Piperazinoiminomethyl)-1-methyl-2-nitroimidazole 2.3.18  
 $C_9H_{15}N_5O_5S$  1-Methyl-5-[(*N*-morpholinomethylamino)sulfonyl]-4-nitroimidazole 2.4.15  
 $C_{10}H_5O_5S^-$  1,4-Naphthoquinone-2-sulfonate ion 1.2.5  
 $C_{10}H_6O_2$  1,2-Naphthoquinone 1.2.1  
 1,4-Naphthoquinone 1.2.2  
 $C_{10}H_6O_3$  5-Hydroxy-1,4-naphthoquinone 1.2.3  
 $C_{10}H_6O_4$  5,8-Dihydroxy-1,4-naphthoquinone 1.2.4  
 $C_{10}H_8ClN_3O_5S$  1-Methyl-5-(4-chlorophenoxy)sulfonyl-4-nitroimidazole 2.4.20  
 $C_{10}H_8N_2$  2,2'-Bipyridine 4.4.7  
 4,4'-Bipyridine 3.8.1  
 $C_{10}H_8N_4O_7S$  1-Methyl-5-(4-nitrophenoxy)sulfonyl-4-nitroimidazole 2.4.21  
 $C_{10}H_9ClN_4O_4S$  1-Methyl-5-(2-chlorophenyl)aminosulfonyl-4-nitroimidazole 2.4.23  
 $C_{10}H_9NO_2$  Indole-3-acetic acid 6.2.6  
 $C_{10}H_9N_3O_2S$  1-Methyl-4-nitro-5-(phenylthio)imidazole 2.4.44  
 $C_{10}H_9N_3O_3$  1-Methyl-4-nitro-5-phenoxyimidazole 2.4.16  
 $C_{10}H_9N_3O_4$  1-Methyl-4-nitro-5-(*p*-hydroxyphenoxy)imidazole 2.4.17  
 $C_{10}H_9N_3O_4S$  1-Methyl-5-nitro-4-phenylsulfonylimidazole 2.5.5  
 1-Methyl-5-phenylsulfonyl-4-nitroimidazole 2.4.18  
 $C_{10}H_9N_3O_5S$  1-Methyl-5-nitro-4-phenylsulfonyloxyimidazole 2.5.6  
 1-Methyl-5-phenoxy-sulfonyl-4-nitroimidazole 2.4.19  
 $C_{10}H_{10}N_2^{2+}$  2,2'-Bipyridinium 3.1.1  
 $C_{10}H_{10}N_4O_2$  2-Nitro-1-[2-(2-pyridylethyl)]imidazole 2.3.60  
 $C_{10}H_{10}N_4O_4S$  1-Methyl-5-phenylaminosulfonyl-4-nitroimidazole 2.4.22  
 $C_{10}H_{10}N_4O_5$  5-Aziridinyl-*N*-methyl-2,4-dinitrobenzamide 2.1.21  
 $C_{10}H_{11}N$  2,3-Dimethylindole 6.2.7  
 $C_{10}H_{11}N_3O_4$  1-(2,3-Dihydroxypropyl)-3-nitro-7-azaindole 2.6.3  
 $C_{10}H_{12}N_2$  Tryptamine 6.2.8  
 $C_{10}H_{12}O_2$  Duroquinone 1.1.7  
 $C_{10}H_{13}NO_3$  DL-Tyrosine, methyl ester 5.1.10  
 $C_{10}H_{13}N_5O_4$  Adenosine 6.4.2  
 $C_{10}H_{13}N_5O_5$  Guanosine 6.4.4  
 $C_{10}H_{14}O_2$  Durohydroquinone 5.4.10  
 $C_{10}H_{15}N_5O_2$  5-(*N*-Piperidinoiminomethyl)-1-methyl-2-nitroimidazole 2.3.19  
 $C_{10}H_{16}N_2$  *N,N,N',N'*-Tetramethyl-*p*-phenylenediamine 6.1.5  
 $C_{10}H_{16}N_4O_2$  1-(2-Piperidylethyl)-2-nitroimidazole 2.3.56  
 $C_{10}H_{16}N_4O_3$  1-(3-*N*-Morphinopropyl)-2-nitroimidazole 2.3.47  
 1-(3-*N*-Pyrrolidinyl-2-hydroxypropyl)-2-nitroimidazole 2.3.73  
 $C_{10}H_{16}N_4O_4$  1-[3-(4-Morpholino)-2-hydroxypropyl]-2-nitroimidazole 2.3.76  
 $C_{10}H_{17}N_4O_3$  1-(2-*N*-Morpholinoethyl)-2-nitroimidazole methiodide 2.3.46  
 $C_{10}H_{17}N_5O_3$  1-[2-(1-Aziridinoethyl)amino-2-hydroxypropyl]-2-nitroimidazole 2.3.63  
 $C_{10}H_{18}N_4O_3$  1-(3-Diethylamino-2-hydroxypropyl)-2-nitroimidazole 2.3.65  
 1-[3-(*tert*-Butylamino)-2-hydroxypropyl]-2-nitroimidazole 2.3.67  
 $C_{10}H_{18}N_4O_5$  1-[3-Bis(2-hydroxyethylamino)-2-hydroxypropyl]-2-nitroimidazole 2.3.66



$C_{11}H_7BrO_2$	6-(Bromomethyl)-1,4-naphthoquinone 1.2.11	$C_{11}H_{18}N_4O_3$	1-(3- <i>N</i> -Piperidino-2-hydroxypropyl)-2-nitroimidazole 2.3.74
$C_{11}H_7ClO_2$	6-(Chloromethyl)-1,4-naphthoquinone 1.2.12		1-(4- <i>N</i> -Morpholinobutyl)-2-nitroimidazole 2.3.48
$C_{11}H_8N_2O_5$	( <i>E</i> )-2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide 2.2.10 ( <i>Z</i> )-2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide 2.2.9	$C_{11}H_{18}N_4O_4$	1-[3- <i>N</i> -(3-Hydroxypiperidino)-2-hydroxypropyl]-2-nitroimidazole 2.3.75
$C_{11}H_8O_2$	2-Methyl-1,4-naphthoquinone 1.2.6	$C_{11}H_{19}N_5O_3$	1-[3- <i>N</i> -(4-Methylpiperazino)-2-hydroxypropyl]-2-nitroimidazole 2.3.77
$C_{11}H_8O_3$	2-Hydroxymethyl-1,4-naphthoquinone 1.2.7	$C_{11}H_{20}N_4O_2$	1-[2,2-Bis(isopropyl)aminoethyl]-2-nitroimidazole 2.3.62
$C_{11}H_{10}IN_5O_3$	4-Iodo-5-nitro-1-(3-pyridylmethylaminocarbonylmethyl)imidazole 2.5.23	$C_{12}H_4Br_4O_2$	3,3',5,5'-Tetrabromodiphenoquinone 1.5.8
$C_{11}H_{10}O_2$	2-Methyl-1,4-naphthoquinol 8.1.3	$C_{12}H_4Cl_4O_2$	3,3',5,5'-Tetrachlorodiphenoquinone 1.5.9
$C_{11}H_{11}N_3O_3$	2-Nitro-1-(2-phenoxyethyl)imidazole 2.3.40	$C_{12}H_6N_4O_2S$	5,8-Di(2-furyl)-[1,2,5]thiadiazolo[3,4- <i>b</i> ]pyrazine 4.8.3
$C_{11}H_{11}N_3O_4$	7-(Ethoxycarbonylmethyl)-3-nitro-7-azaindole 2.6.6	$C_{12}H_8BrNS$	3-Bromophenothiazine 7.2.1
$C_{11}H_{11}N_3O_4S_2$	2-Nitro-1-(2-phenylsulfonyl-ethyl)imidazole 2.3.41	$C_{12}H_8ClNS$	3-Chlorophenothiazine 7.2.2
$C_{11}H_{11}N_3O_6S_1$	Methyl-5-(2-methoxyphenoxy)sulfonyl-4-nitroimidazole 2.4.25 1-Methyl-5-(4-methoxyphenoxy)sulfonyl-4-nitroimidazole 2.4.26	$C_{12}H_8FNS$	3-Fluorophenothiazine 7.2.3
$C_{11}H_{11}N_5O_4$	1-[3-(1-Oxypyridylmethylamino)carbonylmethyl]-4-nitroimidazole 2.4.41	$C_{12}H_8INS$	3-Iodophenothiazine 7.2.4
$C_{11}H_{12}N_2O$	2,3-Dimethyl-1-phenyl-3-pyrazolin-5-one 8.4.4	$C_{12}H_8N_2$	1,10-Phenanthroline 3.12.1, 4.4.9
$C_{11}H_{12}N_2O^+$	1-Methyl-4,4'-bipyridinium-1'-oxide 3.10.1	$C_{12}H_8N_2O_2S$	3-Nitrophenothiazine 7.2.5
$C_{11}H_{12}N_2O_2$	Tryptophan 6.2.9	$C_{12}H_9N^{2+}$	1,10-Phenanthroline 3.6.1
$C_{11}H_{12}N_2O_3$	5-Hydroxytryptophan 6.2.10	$C_{12}H_9NOS$	10 <i>H</i> -Phenothiazine sulfoxide 7.7.1
$C_{11}H_{12}N_4O_2$	1-(2-Anilinoethyl)-2-nitroimidazole 2.3.61	$C_{12}H_9NO_2S$	10 <i>H</i> -Phenothiazine sulfone 7.7.2
$C_{11}H_{12}N_4O_4$	1-[(2-Hydroxyethyl)aminocarbonylmethyl]-3-nitro-7-azaindole 2.6.4	$C_{12}H_9NS$	Phenothiazine 7.1.1
$C_{11}H_{12}N_4O_4S_1$	Methyl-5-(2-methylphenyl)aminosulfonyl-4-nitroimidazole 2.4.24	$C_{12}H_{10}ClN_3S$	Thionine 4.5.1
$C_{11}H_{12}N_4O_5$	5-Aziridinyl- <i>N,N</i> -dimethyl-2,4-dinitrobenzamide 2.1.22	$C_{12}H_{10}N_2^{2+}$	Dipyrido[1,2- <i>a</i> :2',1'- <i>c</i> ]pyrazinediium 3.2.1
$C_{11}H_{12}N_4O_5S_1$	Methyl-2-methoxyphenylaminosulfonyl-4-nitroimidazole 2.4.27	$C_{12}H_{10}N_4O_2$	Lumichrome 4.6.6
$C_{11}H_{13}N_3O$	DL-Tryptophanamide 6.2.11	$C_{12}H_{10}O_2$	2,3-Dimethyl-1,4-naphthoquinone 1.2.15
$C_{11}H_{14}N_2O_3$	4-Nitro-(3'-dimethylamino)propiophenone 2.1.19 <i>N</i> -Acetyl- <i>L</i> -tyrosinamide 5.1.11	$C_{12}H_{10}O_3$	2-(Methoxymethyl)-1,4-naphthoquinone 1.2.8
$C_{11}H_{18}N_4O_2$	1-(3- <i>N</i> -Piperidylpropyl)-2-nitroimidazole 2.3.57 1-(4- <i>N</i> -Pyrrolidinylbutyl)-2-nitroimidazole 2.3.55	$C_{12}H_{11}BrN_2^{2+}$	6-Bromo-1,1'-ethylene-2,2'-bipyridinium 3.3.2
		$C_{12}H_{11}NO_2$	1-Methyl-2,3-trimethyleneisindole-4,7-dione 1.4.6 5-Methyl-1,2-trimethyleneisindole-4,7-dione 1.4.2
		$C_{12}H_{12}N_2$	4,4'-Dimethyl-2,2'-bipyridine 4.4.8
		$C_{12}H_{12}N_2^{2+}$	1,1'-Ethylene-2,2'-bipyridinium 3.3.1
		$C_{12}H_{12}N_2O^{2+}$	1,1'-Hydroxyethylene-2,2'-bipyridinium 3.3.3
		$C_{12}H_{12}N_4O_3$	1-(Benzylcarbonylmethyl)-2-nitroimidazole 2.3.42
		$C_{12}H_{13}N_2O_3S_2$	[(4-Carboxyphenoxy)ethyl]thio-1-methyl-5-nitroimidazole 2.5.13
		$C_{12}H_{13}N_3O_3$	2-Nitro-1-(3-phenoxypropyl)imidazole 2.3.43

- $C_{12}H_{14}N_2^{2+}$  1,1'-Dimethyl-2,2'-bipyridinium 3.1.2  
 1,1'-Dimethyl-2,4'-bipyridinium 3.7.1  
 1,1'-Dimethyl-4,4'-bipyridinium 3.8.2  
 4,4'-Dimethyl-2,2'-bipyridinium 3.1.4  
 $C_{12}H_{14}N_2O_2^{2+}$  1,1'-Dimethoxy-4,4'-bipyridinium 3.8.3  
 $C_{12}H_{16}N_2O_4$  L-Alanyl-L-tyrosine 5.1.12  
 $C_{12}H_{17}N_5O_4$  Nifurpipone 2.2.6  
 $C_{12}H_{20}ClN_3O_5$  1-[3-[(1-Chloromethyl-2-isopropoxy)ethoxy]-2-hydroxypropyl]-2-nitroimidazole 2.3.44  
 $C_{12}H_{20}N_4O_2$  1-(4-N-Piperidinylbutyl)-2-nitroimidazole 2.3.58  
 $C_{12}H_{20}N_4O_3$  1-(5-N-Morpholinopentyl)-2-nitroimidazole 2.3.50  
 $C_{12}H_{21}N_4O_3$  1-(4-N-Morpholinobutyl)-2-nitroimidazole methiodide 2.3.49  
 $C_{13}H_9NOS$  10-Phenothiazinecarboxaldehyde 7.4.1  
 $C_{13}H_{10}ClNOS$  2-Chloro-7-methoxyphenothiazine 7.3.1  
 4-Chloro-7-methoxyphenothiazine 7.3.2  
 $C_{13}H_{10}O_4$  2-[(Acetyloxy)methyl]-1,4-naphthoquinone 1.2.9  
 6-[(Acetyloxy)methyl]-1,4-naphthoquinone 1.2.13  
 $C_{13}H_{11}NOS$  1-Methoxyphenothiazine 7.2.7  
 3-Methoxyphenothiazine 7.2.8  
 $C_{13}H_{11}NO_4$  6-[[[(Methylamino)carbonyl]oxy]methyl]-1,4-naphthoquinone 1.2.14  
 $C_{13}H_{11}NS$  10-Methylphenothiazine 7.4.2  
 3-Methylphenothiazine 7.2.6  
 $C_{13}H_{11}N_3^{2+}$  5-Cyano-1,1'-ethylene-2,2'-bipyridinium 3.3.4  
 $C_{13}H_{12}N_2^{2+}$  6-Methyl-dipyrido[1,2- $\alpha$ :2',1'-c]pyrazinediium 3.2.2  
 $C_{13}H_{12}N_3O_2^+$  1-Phenyl-2,3-dihydro-6-nitroimidazo[1,2-a]pyridinium 2.8.14  
 $C_{13}H_{12}N_4O_2$  1-Methylumichrome 4.6.7  
 3-Methylumichrome 4.6.8  
 $C_{13}H_{14}N_2^{2+}$  1,1'-(1,2-Propylene)-2,2'-bipyridinium 3.3.6  
 1,1'-Trimethylene-2,2'-bipyridinium 3.4.1  
 6,7-Dihydro-4-methyldipyrido[1,2- $\alpha$ :2',1'-c]pyrazinediium 3.3.5  
 $C_{13}H_{14}N_2O^{2+}$  6,7-Dihydro-3-methoxydipyrido[1,2- $\alpha$ :2',1'-c]pyrazinediium 3.3.7  
 $C_{13}H_{14}N_2O_3$  N-Acetyl-L-tryptophan 6.2.12  
 $C_{13}H_{15}N_3^{2+}$  1-Methyl-1'-cyanomethyl-4,4'-bipyridinium 3.10.2  
 $C_{13}H_{16}N_2^{2+}$  1,1',2-Trimethyl-4,4'-bipyridinium 3.9.1  
 $C_{13}H_{16}N_2O^{2+}$  1-Methyl-1'-(2-hydroxyethyl)-4,4'-bipyridinium 3.10.4  
 $C_{13}H_{16}N_4O_3$  1-[3-(Benzylamino)-2-hydroxypropyl]-2-nitroimidazole 2.3.68  
 $C_{13}H_{16}N_4O_4$  1-[3-(4-Methoxyphenylamino)-2-hydroxypropyl]-2-nitroimidazole 2.3.69  
 $C_{13}H_{16}N_4O_7$  5-Aziridinyl-N-[(2,2-dimethoxy)ethyl]-2,4-dinitrobenzamide 2.1.23  
 $C_{13}H_{17}N_3O^{2+}$  1-Methyl-1'-carbamylmethyl-4,4'-bipyridinium 3.10.3  
 $C_{13}H_{17}N_6O_2S_5$  [3-Amino-6-(2-methylpropyl)purinyl]-1-methyl-4-nitroimidazole 2.4.29  
 $C_{13}H_{22}N_4O_3$  1-(5-N-Morpholinohexyl)-2-nitroimidazole 2.3.51  
 $C_{14}H_6N_2O_8$  Methoxatine 1.5.10  
 $C_{14}H_6O_8$  Ellagic acid 8.1.10  
 $C_{14}H_7O_5S^-$  9,10-Anthraquinone-2-sulfonate ion 1.3.1  
 $C_{14}H_7O_7S^-$  1,4-Dihydroxy-9,10-anthraquinone-2-sulfonate ion 1.3.2  
 1,4-Dihydroxy-9,10-anthraquinone-6-sulfonate ion 1.3.3  
 $C_{14}H_8N_6OS$  5,6-Di(2-pyridinyl)-[1,2,5]thiadiazolo[3,4-b]pyrazine N-oxide 4.8.5  
 $C_{14}H_8N_6S$  5,6-Di(2-pyridinyl)-[1,2,5]thiadiazolo[3,4-b]pyrazine 4.8.4  
 $C_{14}H_8O_2$  9,10-Phenanthrenequinone 1.5.3  
 $C_{14}H_8O_6$  Quinalizarin 8.1.5  
 $C_{14}H_{11}NOS$  10-Acetylphenothiazine 7.4.3  
 $C_{14}H_{11}N_3O_5S$  1-Methyl-5-(1-naphthylloxy)sulfonyl-4-nitroimidazole 2.4.30  
 $C_{14}H_{12}ClNO_4$  2-[[[(2-Chloroethyl)amino]carbonyl]oxy]methyl]-1,4-naphthoquinone 1.2.10  
 $C_{14}H_{12}N_2^{2+}$  Phenanthroline[4,5- $\alpha$ :6,7- $c$ ]pyrazinediium 3.6.3  
 $C_{14}H_{12}N_4^{2+}$  1,1'-Bis(cyanomethyl)-4,4'-bipyridinium 3.8.4  
 $C_{14}H_{12}N_4O_4S$  1-Methyl-5-(1-naphthylamino)sulfonyl-4-nitroimidazole 2.4.31  
 $C_{14}H_{13}NOS$  1-Ethoxyphenothiazine 7.2.9  
 3-Ethoxyphenothiazine 7.2.10  
 $C_{14}H_{13}NO_2S$  3,7-Dimethoxyphenothiazine 7.3.4  
 $C_{14}H_{13}NS$  3,7-Dimethylphenothiazine 7.3.3  
 $C_{14}H_{14}Cl_4N_2^{2+}$  1,1'-Bis(1,2-dichloroethyl)-4,4'-bipyridinium 3.8.14

$C_{14}H_{14}N_2^{2+}$	1,10-Dimethyl-1,10-phenanthroline 3.6.2	$C_{14}H_{18}N_2^{2+}$	1,1',2,2'-Tetramethyl-4,4'-bipyridinium 3.9.5
	1,9-Dimethyl-1,9-phenanthroline 3.12.2		1,1',3,3'-Tetramethyl-4,4'-bipyridinium 3.9.6
	2,7-Dimethyl-2,7-phenanthroline 3.12.4		1,1'-Diethyl-2-methyl-4,4'-bipyridinium 3.9.2
	2,8-Dimethyl-2,8-phenanthroline 3.12.3		1,1'-Diethyl-4,4'-bipyridinium 3.8.10
	3,7-Dimethyl-3,7-phenanthroline 3.12.6	$C_{14}H_{18}N_2O_2^{2+}$	1,1'-Bis(2-hydroxyethyl)-4,4'- bipyridinium 3.8.11
	3,8-Dimethyl-3,8-phenanthroline 3.12.5	$C_{14}H_{18}N_4O_4$	1-[3-(4-Methoxybenzylamino)-2- hydroxypropyl]-2-nitroimidazole 2.3.70
	4,7-Dimethyl-4,7-phenanthroline 3.12.7	$C_{14}H_{18}O_4$	6-Hydroxy-2,5,7,8-tetramethylchroman-2- carboxylic acid 8.1.6
$C_{14}H_{14}N_2O^{2+}$	5-Methoxycarbonyl-1,1'-ethylene-2,2'- bipyridinium 3.3.8	$C_{14}H_{20}N_4^{2+}$	1,1'-Bis(2-aminoethyl)-4,4'-bipyridinium 3.8.12
$C_{14}H_{14}N_2O_4^{2+}$	1,1'-Bis(carboxymethyl)-4,4'- bipyridinium 3.8.5	$C_{14}H_{20}N_4O_4$	2,5-Diaziridinyl-3,6-bis(2- hydroxyethylamino)-1,4-benzoquinone 1.1.8
$C_{14}H_{14}N_4^{2+}$	2,2'-Dicyano-1,1'-dimethyl-4,4'- bipyridinium 3.9.4	$C_{14}H_{24}N_4O_2$	1-(5-N-Piperidinyloxy)-2-nitroimidazole 2.3.59
$C_{14}H_{14}N_4O_2$	1,3-Dimethylumichrome 4.6.9	$C_{15}H_{10}N_2O_3$	5-Nitro-2-(2-quinolyloxy)furan 2.2.7
$C_{14}H_{16}O_2N_2^{2+}$	1,1'-Bis(2-chloroethyl)-4,4'- bipyridinium 3.8.7	$C_{15}H_{10}O_7$	Quercetin 8.1.9
$C_{14}H_{16}N_2^{2+}$	1,1'-(1,1-Dimethylethylene)-2,2'- bipyridinium 3.3.15	$C_{15}H_{12}NO_2$	2-Methyl-3-phenylisoindole-4,7-dione 1.4.5
	1,1'-Ethylene-4,4'-dimethyl-2,2'- bipyridinium 3.3.12	$C_{15}H_{13}ClN_2^{2+}$	1-Chlorophenanthroline[4,5-a:6,7- c]diazepinedium 3.6.5
	1,1'-Tetramethylene-2,2'-bipyridinium 3.5.1	$C_{15}H_{13}NO_4S$	10-Carboxyphenothiazine sulfone 7.7.3
	1-Methyl-1'-allyl-4,4'-bipyridinium 3.10.5	$C_{15}H_{14}NO_3S_2$	10-(3-Sulfonatopropyl)phenothiazine 7.4.4
	5,5'-Dimethyl-1,1'-ethylene-2,2'- bipyridinium 3.3.13	$C_{15}H_{14}N_2^{2+}$	Phenanthroline[4,5-a:6,7- c]diazepinedium 3.6.4
	6,7-Dihydro-1,12-dimethyldipyrro[1,2- a:2',1'-c]pyrazinedium 3.3.11	$C_{15}H_{14}O_6$	Catechin 8.1.7
	6,7-Dihydro-4,9-dimethyldipyrro[1,2- a:2',1'-c]pyrazinedium 3.3.14		l-Epicatechin 8.1.8
	6-Ethyl-1,1'-ethylene-2,2'-bipyridinium 3.3.9	$C_{15}H_{15}NO_4$	1-Ethoxycarbonyl-5-methyl-2,3- trimethyleneisoindole-4,7-dione 1.4.9
	8-Methyl-1,1'-trimethylene-2,2'- bipyridinium 3.4.2	$C_{15}H_{15}N_3^{2+}$	1-Methyl-1'-(3-cyano-2-propenyl)-4,4'- bipyridinium 3.10.7
$C_{14}H_{16}N_2O^{2+}$	1-Methyl-1'-(acetyl)-4,4'-bipyridinium 3.10.6	$C_{15}H_{16}N_2O_2^{2+}$	1-Allyl-1'-carboxymethyl-4,4'- bipyridinium 3.11.4
	5-Ethoxy-1,1'-ethylene-2,2'-bipyridinium 3.3.10		1-Methyl-1'-ethoxycarbonylmethyl-4,4'- bipyridinium 3.10.9
	7,8-Dihydro-3-methoxydipyrro[1,2- a:2',1'-c]diazepinedium 3.4.3	$C_{15}H_{18}N_2^{2+}$	1-Allyl-1'-ethyl-4,4'-bipyridinium 3.11.5
$C_{14}H_{16}N_2O_6S_2$	1,1'-Bis(2-sulfonatoethyl)-4,4'- bipyridinium 3.8.6		4,4'-Dimethyl-1,1'-trimethylene-2,2'- bipyridinium 3.4.4
$C_{14}H_{16}N_4O_2^{2+}$	1,1'-Bis(2-hydroxyiminoethyl)-4,4'- bipyridinium 3.8.9		5,5'-Dimethyl-1,1'-trimethylene-2,2'- bipyridinium 3.4.5
	1,1'-Bis(carbamylmethyl)-4,4'- bipyridinium 3.8.8	$C_{15}H_{18}N_2O^{2+}$	5-Propoxy-1,1'-ethylene-2,2'- bipyridinium 3.3.16
$C_{14}H_{17}N_3O_3$	L-Tryptophyl-L-alanine 6.2.13	$C_{15}H_{18}N_2S_2^{2+}$	1-Methyl-1'-[2-bis(methylthio)ethyl]- 4,4'-bipyridinium 3.10.8
		$C_{15}H_{18}N_4O_5$	Mitomycin C 1.5.7
		$C_{15}H_{26}N_4O_3$	1-(8-N-Morpholinoethyl)-2-nitroimidazole 2.3.52

- $C_{15}H_{26}N_5O_4$  1-[3-[4-(2,2,5,5-Tetramethyl-1-oxypiperidinyloxy)propyl]-2-nitroimidazole-2.3.71
- $C_{15}H_{27}N_5O_3$  1-[3-[4-(2,2,5,5-Tetramethylpiperidinyloxy)propyl]-2-nitroimidazole-2.3.72
- $C_{16}H_8N_2O_8S_2^{2-}$  Indigodisulfonate ion 1.5.6
- $C_{16}H_{11}NS$  12*H*-Benzo[*a*]phenothiazine 7.6.1  
7*H*-Benzo[*c*]phenothiazine 7.6.2
- $C_{16}H_{13}NO_2$  1,2-Dimethyl-3-phenylisoindole-4,7-dione 1.4.1
- $C_{16}H_{14}N_2^{2+}$  1,1'-Bis(2-propynyl)-4,4'-bipyridinium 3.8.13
- $C_{16}H_{14}N_2O_4$  1,1'-Bis(2-carboxyethyl)-4,4'-bipyridinium 3.8.17
- $C_{16}H_{16}N_2^{2+}$  1-Methylphenanthroline[4,5-*a*:6,7-*c*]diazepinedium 3.6.6  
Phenanthroline[4,5-*a*:6,7-*c*]diazocinedium 3.6.9
- $C_{16}H_{16}N_2O_2^{2+}$  1-Methyl-1'-[3-(methoxycarbonyl)-2-propenyl]-4,4'-bipyridinium 3.10.11
- $C_{16}H_{16}N_3O_2^{2+}$  1-Methyl-1'-[cyano(ethoxycarbonyl)methyl]-4,4'-bipyridinium 3.10.10
- $C_{16}H_{16}N_4^{2+}$  1,1'-Bis(cyanomethyl)-2,2'-dimethyl-4,4'-bipyridinium 3.9.10
- $C_{16}H_{18}ClN_3S$  Methylene Blue 4.5.2
- $C_{16}H_{18}N_2^{2+}$  1,1'-Diallyl-4,4'-bipyridinium 3.8.15  
2-Methyl-1,1'-dipropyl-4,4'-bipyridinium 3.9.3
- $C_{16}H_{18}N_2O_2^{2+}$  1,1'-Bis(2-oxopropyl)-4,4'-bipyridinium 3.8.16
- $C_{16}H_{19}N_3O^{2+}$  1-(Carbamylmethyl)-1'-(2-methyl-2-propenyl)-4,4'-bipyridinium 3.11.10
- $C_{16}H_{20}Cl_2N_2^{2+}$  1,1'-Bis(2-chloroethyl)-2,2'-dimethyl-4,4'-bipyridinium 3.9.11
- $C_{16}H_{20}N_2^{2+}$  4,4'-Dimethyl-1,1'-tetramethylene-2,2'-bipyridinium 3.5.2  
4,5,4',5'-Tetramethyl-1,1'-ethylene-2,2'-bipyridinium 3.3.17
- $C_{16}H_{20}N_2O_6S_2^{1-}$  1'-Bis(3-sulfonato-1-propyl)-2,2'-bipyridinium 3.1.3  
1,1'-Bis(3-sulfonatopropyl)-4,4'-bipyridinium 3.8.18
- $C_{16}H_{21}N_5O_4$  1-[3-(4-Morpholinyl)propylaminocarbonylmethyl]-3-nitro-7-azaindole 2.6.5  
7-[3-(4-Morpholinyl)propylaminocarbonylmethyl]-3-nitro-7-azaindole 2.6.7
- $C_{16}H_{22}N_2^{2+}$  1,1',2,2',6,6'-Hexamethyl-4,4'-bipyridinium 3.9.7
- $C_{16}H_{22}N_2^{2+}$  1,1'-Bis(1-methylethyl)-4,4'-bipyridinium 3.8.20  
1,1'-Dipropyl-4,4'-bipyridinium 3.8.19
- $C_{16}H_{22}N_2O_2^{2+}$  1,1'-Bis(2-hydroxyethyl)-2,2'-dimethyl-4,4'-bipyridinium 3.9.12
- $C_{16}H_{22}N_2S_2^{2+}$  1,1'-Bis(ethylthiomethyl)-4,4'-bipyridinium 3.8.21
- $C_{16}H_{22}N_5O_4^{+}$  1-[3-(4-Morpholinyl)propylaminocarbonylmethyl]-3-nitro-7-azaindole, protonated 2.6.8
- $C_{16}H_{24}N_2S^{2+}$  1-Ethyl-1'-(2-ethylthioethyl)-4,4'-bipyridinium 3.11.1
- $C_{16}N_{17}NO_5$  1-Ethoxycarbonyl-6-methoxy-5-methyl-2,3-trimethyleneisoindole-4,7-dione 1.4.11
- $C_{17}H_{12}N_2O_3$  5-Nitro-2-(2-quinolybutadienyl)furan 2.2.8
- $C_{17}H_{13}NO_2$  1-Phenyl-2,3-trimethyleneisoindole-4,7-dione 1.4.4
- $C_{17}H_{15}NO_2$  1,2,5-Trimethyl-3-phenylisoindole-4,7-dione 1.4.3
- $C_{17}H_{16}N_3^{2+}$  6-Pyridyl-1,1'-ethylene-2,2'-bipyridinium 3.3.18
- $C_{17}H_{18}N_2^{2+}$  1,11-Dimethylphenanthroline[4,5-*a*:6,7-*c*]diazepinedium 3.6.7
- $C_{17}H_{18}N_4S^{2+}$  1-Methyl-1'-[(1-pyrazolyl)thiocarbonylmethyl]-4,4'-bipyridinium 3.10.12
- $C_{17}H_{19}ClN_2S$  Chlorpromazine 7.5.1
- $C_{17}H_{19}N_3^{2+}$  1-Allyl-1'-(3-cyanopropyl)-4,4'-bipyridinium 3.11.6
- $C_{17}H_{20}N_2OS$  2-Hydroxy-10-(3-dimethylaminopropyl)phenothiazine 7.5.3
- $C_{17}H_{20}N_2S$  10-(3-Dimethylaminopropyl)phenothiazine 7.4.5  
Isopromethazine 7.4.7  
Promethazine 7.4.6
- $C_{17}H_{20}N_4O_6$  Riboflavin 4.6.1
- $C_{17}H_{21}ClN_2O^{2+}$  1-(3-Chloro-2-butenyl)-1'-(2-methoxyethyl)-4,4'-bipyridinium 3.11.12
- $C_{17}H_{21}FN_2^{2+}$  1-(2-Butenyl)-1'-(3-fluoropropyl)-4,4'-bipyridinium 3.11.9
- $C_{17}H_{22}N_2^{2+}$  4,5,4',5'-Tetramethyl-1,1'-trimethylene-2,2'-bipyridinium 3.4.6
- $C_{17}H_{22}N_2O_2^{2+}$  1-(2-Methoxycarbonylethyl)-1'-propyl-4,4'-bipyridinium 3.11.2
- $C_{17}H_{24}N_2O^{2+}$  1-(2-Hydroxyethyl)-1'-pentyl-4,4'-bipyridinium 3.11.3
- $C_{17}H_{24}N_2S$  10-[3-(Diethylamino)propyl]phenothiazine 7.4.15
- $C_{18}H_{13}NS$  3-Phenylphenothiazine 7.2.11

- $C_{18}H_{14}N_2^{2+}$  6-Phenyldipyrido[1,2-*a*:2',1'-*c*]pyrazinedium 3.2.3  
 $C_{18}H_{16}N_2^{2+}$  1,1'-(1-Phenylethylene)-2,2'-bipyridinium 3.3.19  
 $C_{18}H_{17}NO_2$  1,2,5,6-Tetramethyl-3-phenylisindole-4,7-dione 1.4.8  
 $C_{18}H_{18}N_2^{2+}$  1-Methyl-1'-benzyl-4,4'-bipyridinium 3.10.13  
 $C_{18}H_{19}ClN_4O_2$  9-[3-(*N,N*-Dimethylamino)propyl]amino-4-chloro-1-nitroacridine 2.7.3  
 $C_{18}H_{19}FN_4O_2$  9-[3-(*N,N*-Dimethylamino)propyl]amino-4-fluoro-1-nitroacridine 2.7.4  
 $C_{18}H_{19}N_3S^{2+}$  1-Methyl-1'-[anilino(thiocarbonylmethyl)]-4,4'-bipyridinium 3.10.14  
 $C_{18}H_{20}F_3N_2S$  10-(3-Dimethylaminopropyl)-2-trifluoromethylphenothiazine 7.5.2  
 $C_{18}H_{20}NO_3S_2^-$  10-(6-Sulfonatohexyl)phenothiazine 7.4.9  
 $C_{18}H_{20}N_2S$  10-(2-Pyrrolidinyloethyl)phenothiazine 7.4.8  
 $C_{18}H_{20}N_4^{2+}$  1,1'-Bis(3-cyanopropyl)-4,4'-bipyridinium 3.8.22  
 $C_{18}H_{20}N_4O_2$  Nitracrine 2.7.2  
 $C_{18}H_{21}N_3^{2+}$  1-(3-Butenyl)-1'-(3-cyanopropyl)-4,4'-bipyridinium 3.11.8  
 $C_{18}H_{22}N_2OS$  Methoxypromazine 7.5.4  
 $C_{18}H_{22}N_2O_2^{2+}$  1,1'-Bis(2-oxopropyl)-2,2'-dimethyl-4,4'-bipyridinium 3.9.13  
 $C_{18}H_{22}N_2O_4^{2+}$  1,1'-Bis(ethoxycarbonylmethyl)-4,4'-bipyridinium 3.8.23  
 $C_{18}H_{22}N_2S$  Diethazine 7.4.10  
 $C_{18}H_{23}N_2S^+$  10-(2-Methyl-2-trimethylammonioethyl)phenothiazine 7.4.11  
 $C_{18}H_{24}N_2^{2+}$  4,5,4',5'-Tetramethyl-1,1'-tetramethylene-2,2'-bipyridinium 3.5.3  
 $C_{18}H_{24}N_2O_2^{2+}$  1-(2-Ethyl-2-propenyl)-1'-(2-methoxyethyl)-4,4'-bipyridinium 3.11.11  
 $C_{18}H_{24}N_2O_6S_2$  1,1'-Bis(3-sulfonatopropyl)-3,3'-dimethyl-4,4'-bipyridinium 3.9.15  
 $C_{18}H_{24}N_2O_6S_2$  1,1'-Bis(3-sulfonatopropyl)-2,2'-dimethyl-4,4'-bipyridinium 3.9.16  
 $C_{18}H_{24}N_4O_2^{2+}$  1,1'-Bis(dimethylaminocarbonylmethyl)-4,4'-bipyridinium 3.8.24  
 $C_{18}H_{26}N_2O_2^{2+}$  1,1'-Bis(2-ethoxyethyl)-4,4'-bipyridinium 3.8.25  
 $C_{18}H_{32}N_4O_3$  1-(11-*N*-Morpholinoundecyl)-2-nitroimidazole 2.3.53  
 $C_{19}H_{13}NOS$  10-Benzoylphenothiazine 7.4.12  
 $C_{19}H_{17}NO_2$  5,6-Dimethyl-3-phenyl-1,2-trimethyleneisindole-4,7-dione 1.4.7  
 $C_{19}H_{17}NO_4$  1-Ethoxycarbonyl-2,5-dimethyl-3-phenylisindole-4,7-dione 1.4.10  
 $C_{19}H_{22}N_2S$  Mepazine 7.4.13  
 $C_{19}H_{22}N_4O_2$  9-[3-(*N,N*-Dimethylamino)propyl]amino-4-methyl-1-nitroacridine 2.7.5  
 $C_{19}H_{22}N_4O_3$  9-[3-(*N,N*-Dimethylamino)propyl]amino-4-methoxy-1-nitroacridine 2.7.6  
 $C_{19}H_{23}N_2OS$  2-Acetyl-10-(3-dimethylaminopropyl)phenothiazine 7.5.5  
 $C_{19}H_{24}N_2S$  10-(2-Methyl-2-diethylaminoethyl)phenothiazine 7.4.14  
 $C_{19}H_{25}N_3O_2^{2+}$  1-Methyl-1'-[2-(3,5-dimethyl-4-oxoethyl)-4,4'-bipyridinium 3.10.15  
 $C_{20}H_{13}NS$  13*H*-Dibenzo[*a,j*]phenothiazine 7.6.3  
 $C_{20}H_{13}NS$  7*H*-Dibenzo[*c,h*]phenothiazine 7.6.4  
 $C_{20}H_{18}N_2^{2+}$  1,1'-Dimethyl-2,2'-biquinolinium 3.6.10  
 $C_{20}H_{22}N_4O_4$  9-[3-(*N,N*-Dimethylamino)propyl]amino-4-methoxycarbonyl-1-nitroacridine 2.7.7  
 $C_{20}H_{22}N_4O_6$  8 $\alpha$ -*N*-Imidazolylriboflavin 4.6.4  
 $C_{20}H_{24}ClN_3S_2$  Chloro-10-[3-(4-methyl-1-piperazinyl)propyl]phenothiazine 7.5.7  
 $C_{20}H_{25}N_3S$  Perazine 7.4.17  
 $C_{20}H_{25}N_5O_2$  9-[3-(*N,N*-Dimethylamino)propyl]amino-4-dimethylamino-1-nitroacridine 2.7.8  
 $C_{20}H_{26}N_2O_4^{2+}$  1,1'-Bis(ethoxycarbonylmethyl)-2,2'-dimethyl-4,4'-bipyridinium 3.9.14  
 $C_{20}H_{26}N_2O_4^{2+}$  1,1'-Bis[2-(ethoxycarbonyl)ethyl]-4,4'-bipyridinium 3.8.26  
 $C_{20}H_{26}N_2S_2$  2-Methylthio-10-[2-(*N*-methyl-2-piperidinyloethyl)]phenothiazine 7.5.6  
 $C_{20}H_{27}N_3O_2^{2+}$  1-Allyl-1'-[2-(diethylaminocarbonyl)ethyl]-4,4'-bipyridinium 3.11.7  
 $C_{20}H_{28}N_2O_6S_2$  1,1'-Bis(3-sulfonatopropyl)-2,2',6,6'-tetramethyl-4,4'-bipyridinium 3.9.17  
 $C_{20}H_{28}N_4O_2^{2+}$  1,1'-Bis[2-(dimethylaminocarbonyl)ethyl]-4,4'-bipyridinium 3.8.27  
 $C_{20}H_{30}N_2S$  10-[6-(Diethylamino)hexyl]phenothiazine 7.4.16  
 $C_{20}H_{34}N_4^{4+}$  1,1'-Bis[2-(trimethylammonio)ethyl]-4,4'-bipyridinium 3.8.29  
 $C_{21}H_{16}N_3O_3SN^+$  (Acridinyl)-*N*<sup>4</sup>-methylsulfonyl-2-methoxycyclohexa-2,5-diene-1',4 1.5.12  
 $C_{21}H_{20}N_3O_3S^+$  9-(2-Methoxy-4-methylsulfonylaminoanilino)acridinium 4.8.1  
 $C_{21}H_{22}ClN_3OS_2$  Chloro-10-[3-(4-(2-hydroxyethyl)-1-piperazinyl)propyl]phenothiazine 7.5.10

- $C_{21}H_{23}N_3O_8S_3$  (*S*-Glutathionyl)-2-methyl-1,4-naphthoquinone 1.2.16
- $C_{21}H_{24}F_3N_3S_{10}$  [3-(4-Methyl-1-piperazinyl)propyl]-2-trifluoromethylphenothiazine 7.5.8
- $C_{21}H_{26}N_7O_{13}P_2^+$  Nicotinamide adenine dinucleotide 4.4.6
- $C_{21}H_{27}N_3OS$  10-[3-(4-(2-Hydroxyethyl)-1-piperazinyl)propyl]phenothiazine 7.4.18
- $C_{21}H_{29}N_7O_{14}P$  Nicotinamide adenine dinucleotide, reduced 8.2.1
- $C_{22}H_{14}N_2^{2+}$  Benzo[1,2-*b*:3,4-*b'*]diquinolizium 3.12.8  
Benzo[1,2-*b*:3,4-*g'*]diquinolizium 3.12.10  
Benzo[1,2-*b*:5,6-*b'*]diquinolizium 3.12.9
- $C_{22}H_{16}N_4O_4^{2+}$  1,1'-Bis(4-nitrophenyl)-4,4'-bipyridinium 3.8.30
- $C_{22}H_{18}N_2^{2+}$  1,1'-Diphenyl-4,4'-bipyridinium 3.8.31
- $C_{22}H_{18}N_4O_2SN^1$ -(Acridinyl)-*N*<sup>4</sup>-methylsulfonyl-2-dimethylaminocyclohexa-2,5-diene-1 1.5.13
- $C_{22}H_{20}N_4^{2+}$  1,1'-Bis(2-pyridylmethyl)-4,4'-bipyridinium 3.8.32
- $C_{22}H_{20}N_4O_2S_2$  2-Dimethylaminosulfonamido-10-[3-(4-methyl-1-piperazinyl)propyl]phenothiazine 7.5.9
- $C_{22}H_{27}N_5O_4$  7-Hydroxy-2-[2-(2-hydroxyethyl)aminoethyl]-5-[[2-(2-hydroxyethyl)aminoethyl]amino]-anthra[1,9-*cd*]pyrazol-6-on 1.5.11
- $C_{22}H_{28}N_4O_6$  1,4-Dihydroxy-5,8-bis[(2-hydroxyethylamino)ethyl]amino-9,10-anthraquinone 1.3.4
- $C_{22}H_{28}N_4O_{10}2,5$ -Diaziridinyl-3,6-bis(carbethoxyamino)-1,4-benzoquinone 1.1.9
- $C_{22}H_{30}N_2O_4^{2+}$  1,1'-Bis[3-(ethoxycarbonyl)propyl]-4,4'-bipyridinium 3.8.28
- $C_{22}H_{32}N_4O_2^{2+}$  1,1'-Bis(diethylaminocarbonylmethyl)-4,4'-bipyridinium 3.8.33  
1,1'-Bis[3-(dimethylaminocarbonyl)propyl]-4,4'-bipyridinium 3.8.34
- $C_{22}H_{34}N_2^{2+}$  1,1'-Dihexyl-4,4'-bipyridinium 3.8.35
- $C_{22}H_{34}N_2O_4^{2+}$  1,1'-Bis(2,2-diethoxyethyl)-4,4'-bipyridinium 3.8.36
- $C_{22}H_{38}N_4^{4+}$  1,1'-Bis[3-(trimethylammonio)propyl]-4,4'-bipyridinium 3.8.37
- $C_{23}H_{28}N_4O_5$  Nitroakridin 3582 2.7.1
- $C_{24}H_{22}N_2^{2+}$  1,1'-Dibenzyl-4,4'-bipyridinium 3.8.39  
1,1'-Dimethyl-2,2'-diphenyl-4,4'-bipyridinium 3.9.8
- $C_{24}H_{26}N_4^{4+}$  1,2-Ethanedylbis(1'-methyl-4,4'-bipyridinium) 3.8.48
- $C_{24}H_{38}N_2^{2+}$  1,1'-Diheptyl-4,4'-bipyridinium 3.8.40
- $C_{24}H_{42}N_4^{4+}$  1,1'-Bis[4-(trimethylammonio)butyl]-4,4'-bipyridinium 3.8.41
- $C_{26}H_{28}N_4^{4+}$  1,3-Propanediylbis(1'-methyl-4,4'-bipyridinium) 3.8.49
- $C_{26}H_{20}N_2^{2+}$  1,11-Diphenylphenanthrolino[4,5-*a*:6,7-*c*]diazepinedium 3.6.8
- $C_{26}H_{20}N_4^{2+}$  1,1'-Bis( $\alpha$ -cyanobenzyl)-4,4'-bipyridinium 3.8.38, 3.8.42
- $C_{26}H_{26}N_2^{2+}$  1,1'-Dimethyl-2,2'-bis(4-methylphenyl)-4,4'-bipyridinium 3.9.9
- $C_{26}H_{30}N_4^{4+}$  1,4-Butanediylbis(1'-methyl-4,4'-bipyridinium) 3.8.50
- $C_{26}H_{32}N_4O_6$  1,4-Bis[(2-hydroxyethylamino)ethyl]amino-9,10-anthraquinone diacetate 1.3.5
- $C_{26}H_{33}N_5O_6$  9-[3-(*N,N*-Dimethylamino)propyl]amino-[4-(di(2-acetoxyethyl)amino)-1-nitroacridine 2.7.9
- $C_{26}H_{36}N_4O_4^{2+}$  1,1'-Bis[2-(3,5-dimethyl-4-morpholinyl)-2-oxoethyl]-4,4'-bipyridinium 3.8.43
- $C_{26}H_{42}N_2^{2+}$  1,1'-Dioctyl-4,4'-bipyridinium 3.8.44
- $C_{27}H_{29}NO_{10}$  Daunomycin 1.5.5
- $C_{27}H_{29}NO_{11}$  Adriamycin 1.5.4
- $C_{27}H_{33}N_9O_5P_2$  Flavine mononucleotide 4.6.2
- $C_{27}H_{33}N_9O_{15}P_2$  Flavine adenine dinucleotide 4.6.3
- $C_{29}H_{33}N_4O_{10}8\alpha$ -(*N*-Methyl-*N*-imidazolium)tetra-*O*-acetylriboflavin 4.6.5
- $C_{30}H_{30}N_2O_2^{2+}$  1,1'-Bis[ethoxycarbonyl(phenyl)methyl]-4,4'-bipyridinium 3.8.46
- $C_{31}H_{46}O_2$  Vitamin K<sub>1</sub> 1.2.17, 8.1.4
- $C_{36}H_{32}N_4^{4+}$  1,1'-*o*-Xylylenebis-4,4'-bipyridinium 3.8.47
- $C_{46}H_{82}N_2^{2+}$  1,1'-Dioctadecyl-4,4'-bipyridinium 3.8.45
- Cl Chlorine atom 9.15., 9.16.
- Cl<sup>-</sup> Chloride ion 9.15., 9.17., 9.18., 9.22., 9.26.
- ClHO Chlorosyl hydride 9.18.  
Hypochlorous acid 9.16., 9.17.
- ClHO<sub>2</sub> Chlorous acid 9.20.
- ClO<sub>2</sub> Chlorine dioxide 9.19., 9.20., 9.21.
- ClO<sub>2</sub><sup>-</sup> Chlorite ion 9.19.
- ClO<sub>3</sub><sup>-</sup> Chlorate ion 9.21.
- Cl<sub>2</sub> Chlorine 9.23.
- Cl<sub>2</sub><sup>-</sup> Dichlorine radical ion 9.22., 9.23.
- Cl<sub>2</sub>I<sup>-</sup> Iodine dichloride dianion 9.26.
- F Fluorine atom 9.24.
- F<sup>-</sup> Fluoride ion 9.24.
- HIO Hypoiodous acid 9.27., 9.28.
- HIO<sub>2</sub> Iodous acid 9.31.
- HO Hydroxyl 9.4., 9.17., 9.28., 9.38., 9.39., 9.49.
- HO<sup>-</sup> Hydroxide ion 9.39., 9.40.
- HO<sub>2</sub> Perhydroxyl 9.42., 9.47., 9.48.

$\text{HO}_2^-$	Hydroperoxide ion 9.44., 9.48.	$\text{NO}_3^-$	Nitrate ion 9.37.
$\text{HO}_3$	Ozonide radical, protonated 9.51.	$\text{N}_3$	Azide radical 9.33.
$\text{HO}_3\text{S}^-$	Hydrogen sulfite ion 9.59., 9.61.	$\text{N}_3^-$	Azide ion 9.33., 9.34.
$\text{HO}_3\text{Se}^-$	Hydrogen selenite(IV) ion 9.67.	$\text{N}_6^-$	Azide dimer radical anion 9.34.
$\text{HO}_5\text{S}^-$	Hydrogen peroxomonosulfate ion 9.64.	$\text{O}^-$	Oxide radical ion 9.40.
HS	Mercapto 9.52., 9.53.	$\text{O}_2$	Oxygen 9.41., 9.42.
$\text{HS}^-$	Bisulfide ion 9.53., 9.54.	$\text{O}_2^-$	Superoxide radical anion 9.41., 9.43., 9.44., 9.45., 9.46.
$\text{H}_2$	Hydrogen 9.1.	$\text{O}_2\text{S}$	Sulfur dioxide 9.58.
$\text{H}_2\text{O}$	Water 9.38.	$\text{O}_2\text{S}^-$	Sulfur dioxide radical anion 9.58., 9.59.
$\text{H}_2\text{O}_2$	Hydrogen peroxide 9.45., 9.46., 9.47., 9.49.	$\text{O}_3$	Ozone 9.50., 9.51.
$\text{H}_2\text{S}_2$	Sulfhydryl dimer radical 9.54.	$\text{O}_3^-$	Ozonide ion 9.50.
$\text{H}_4\text{N}_2$	Hydrazine 9.35.	$\text{O}_3\text{S}^-$	Sulfite radical ion 9.60., 9.61., 9.62.
$\text{H}_4\text{N}_2^+$	Hydrazine radical cation 9.35.	$\text{O}_3\text{S}_2^-$	Sulfite ion 9.60.
I	Iodine atom 9.25., 9.27.	$\text{O}_3\text{S}_2^-$	Thiosulfate radical ion 9.65.
$\text{I}^-$	Iodide ion 9.25., 9.28., 9.29.	$\text{O}_3\text{S}_2^{2-}$	Thiosulfate ion 9.65.
$\text{IO}_2$	Iodine dioxide 9.31., 9.32.	$\text{O}_3\text{Se}^-$	Selenite(V) ion 9.66., 9.67.
$\text{IO}_3^-$	Iodate ion 9.32.	$\text{O}_3\text{Se}^{2-}$	Selenite(IV) ion 9.66.
$\text{I}_2$	Iodine 9.26., 9.30.	$\text{O}_4\text{S}^-$	Sulfate radical ion 9.63.
$\text{I}_2^-$	Diiodine radical ion 9.29., 9.30.	$\text{O}_4\text{S}_2^-$	Sulfate ion 9.62., 9.63.
$\text{NO}_2$	Nitrogen dioxide 9.36.	$\text{O}_5\text{S}^-$	Peroxomonosulfate radical ion 9.64.
$\text{NO}_2^-$	Nitrite ion 9.36.	S	Sulfur 9.52.
$\text{NO}_3$	Nitrogen trioxide 9.37.		